UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. 1)
Filed by the
Registrant
x
Filed by
a Party other than the Registrant
¨
Check the appropriate box:
|
|
|
x
|
|
Preliminary Proxy Statement
|
|
|
¨
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
¨
|
|
Definitive Proxy Statement
|
|
|
¨
|
|
Definitive Additional Materials
|
|
|
¨
|
|
Soliciting Material Pursuant to § 240.14a-11(c) or § 240.14a-12
|
FIRST PHYSICIANS CAPITAL GROUP, INC.
(Name of Registrant as Specified in Its Charter)
Not Applicable
(Name of
Person(s) Filing Proxy Statement, if Other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
x
|
|
No fee required.
|
|
|
¨
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5)
|
|
Total fee paid:
|
|
|
¨
|
|
Fee paid previously with preliminary materials.
|
|
|
¨
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
|
|
|
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing Party:
|
|
|
(4)
|
|
Date Filed:
|
PRELIMINARY COPY
FIRST PHYSICIANS CAPITAL GROUP, INC.
433 North Camden Drive # 810
Beverly Hills, California 90210
(310) 860-2501
NOTICE
OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held
, 2014
To our Stockholders:
You are cordially invited to attend the Annual Meeting of Stockholders of First Physicians Capital Group, Inc., a Delaware corporation (the
Company), to be held at 2727 North Harwood Street, Dallas, Texas 75201, on , 2014, at 9:00 a.m., local time, in order
to:
1.
|
approve an amendment to the Companys Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of 1-for-2,000 shares (the Reverse Stock Split);
|
As described in more detail in the accompanying Proxy Statement, in the event the Reverse Stock Split is approved by stockholders at the
Annual Meeting, any stockholder owning fewer than 2,000 shares of our common stock will be cashed out. The intended effect of the Reverse Stock Split is to reduce the number of record holders of our common stock to fewer than 300 holders, so we will
be eligible to deregister our common stock with the Securities and Exchange Commission (the SEC). In such case, we would no longer be required to file periodic reports with the SEC.
2.
|
elect William A. Houlihan, Sean Kirrane, Brian Potiker, Robert N. Schwartz, Ph.D., and Richardson E. Sells as directors;
|
3.
|
hold a non-binding, advisory vote on the frequency of non-binding, advisory votes on executive compensation;
|
4.
|
hold a non-binding, advisory vote to approve executive compensation; and
|
5.
|
ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ended September 30, 2014.
|
Further, we will transact such other business as may properly come before the meeting or any postponement or adjournment thereof.
Please read the accompanying Proxy Statement carefully. Copies of our Annual Report on Form 10-K for the fiscal year ended September 30, 2013 and our
Quarterly Report on Form 10-Q for the period ended March 31, 2014 are included as Annex B and C, respectively, to the Proxy Statement. We encourage you to read our Annual Report and our Quarterly Report. They include our financial statements
and information about our business and operations.
The Board of Directors has fixed the close of business on
, 2014 as the record date for the meeting. Only stockholders of record at such time will be entitled to notice of and to vote at
the meeting or any postponement or adjournment thereof. A list of the stockholders entitled to vote at the meeting will be open to the examination of any stockholder for any purpose germane to the meeting during ordinary business hours for a period
of 10 days prior to the date of the meeting at the Companys headquarters and at the place of the meeting.
Your vote is important. Whether or not
you plan to attend the meeting, we encourage you to vote by internet, telephone or mail, so your shares may be represented. In the event you attend the meeting, you may withdraw your proxy and vote in person.
By order of the Board of Directors,
Sean Kirrane
President and Chief Executive Officer
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be
held on , 2014: The Proxy Statement, Annual Report to Stockholders and other proxy materials are available at
www.edocumentview.com/FPCG.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE
REVERSE STOCK SPLIT, PASSED UPON THE MERITS OR FAIRNESS OF THE REVERSE STOCK SPLIT, OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PROXY STATEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
IMPORTANT
Whether or not you plan to attend the meeting in person, please vote using the internet or telephone
procedures described on the proxy card or by signing, dating, and promptly returning the enclosed proxy card in the pre-addressed, postage-paid envelope.
Table of Contents
i
PRELIMINARY COPY
FIRST PHYSICIANS CAPITAL GROUP, INC.
433 North Camden Drive # 810
Beverly Hills, California 90210
(310) 860-2501
Proxy
Statement
for Annual Meeting of Stockholders to be held on
, 2014
This
Proxy Statement is furnished in connection with the solicitation by the Board of Directors (the Board) of First Physicians Capital Group, Inc., a Delaware corporation (the Company), of proxies to be voted at an Annual Meeting
of Stockholders of the Company to be held on , 2014, or at any postponement or adjournment thereof (the Meeting), for
the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders. This Proxy Statement and accompanying proxy are first being mailed to stockholders on or about
, 2014. We encourage you to read the entire Proxy Statement and the documents attached as annexes to this Proxy Statement
carefully.
Summary Term Sheet
In Proposal 1 below, you are being asked to vote on an amendment to our Certificate of Incorporation (the Certificate of
Amendment) to effect a reverse stock split (the Reverse Stock Split) of our common stock, par value $0.01 (the Common Stock). If approved, the Reverse Stock Split will become effective upon the filing of the Certificate
of Amendment (the Effective Date).
The Board has authorized a 1-for-2,000 Reverse Stock Split, subject to stockholder
approval at the Meeting. An affirmative vote of the holders of a majority of the votes eligible to be cast at the Meeting by the holders of shares of Common Stock voting as a separate class and by the holders of our outstanding shares of Common
Stock and Preferred Stock (defined below) voting on an as converted basis, voting together as a separate class, is required to approve the Certificate of Amendment to effect the Reverse Stock Split. The Board has determined that the Reverse Stock
Split is fair to and in the best interest of all of our unaffiliated stockholders, including those stockholders who will be cashed out pursuant to the Reverse Stock Split and those stockholders who will retain an equity interest in the Company
subsequent to the Reverse Stock Split. See the information under the captions Special Factors Reasons for and Purposes of the Reverse Stock Split, Recommendation of the Board and Special Factors
Fairness of the Reverse Stock Split in this Proxy Statement.
Each of our directors and executive officers intends to vote the
Voting Shares (defined below) that each beneficially owns in favor of the Reverse Stock Split. The shares of Common Stock held by our directors and executive officers represent approximately 3.0% of the Common Stock votes eligible to be cast at the
Meeting. The shares of Common Stock held by our directors and executive officers, plus the votes afforded to them as holders of Preferred Stock (defined below), represent approximately 2.1% of the votes eligible to be cast at the Meeting. Further,
SMP Investments I, LLC (SMP) and Ciabattoni Living Trust dated August 17, 2000 (Ciabattoni Trust), two of our significant stockholders, have informed management that they intend to vote the Voting Shares they
beneficially own in favor of the Reverse Stock Split. The shares of Common Stock held by SMP and Ciabattoni Trust represent approximately 30.6% and 18.1% of the Common Stock votes eligible to be cast at the Meeting. The shares of Common Stock held
by SMP and Ciabattoni Trust, plus the votes afforded to them as holders of Preferred Stock, represent approximately 20.4% and 13.0%, respectively, of the votes eligible to be cast at the Meeting.
Holders of 10,076,392 shares of Common Stock, or approximately 51.3% of the Common Stock votes eligible to be cast at the Meeting have advised
the Company that they intend to vote in favor of the Reverse
1
Stock Split. The votes afforded to the shares of Common Stock held by those stockholders, plus the votes afforded to them as holders of Preferred Stock, represent 22,972,392 votes, or
approximately 35.4% of the votes eligible to be cast at the Meeting.
As a result of the Reverse Stock Split, stockholders owning
fewer than 2,000 shares of our Common Stock will be cashed out at a price of $0.55 per pre-split share. Additionally, as the Company will not issue fractional shares, you will also receive a cash payment of $0.55 per pre-split share for any number
of pre-split shares that will not result in the issuance of a whole post-split share. For example, assuming you own 2,500 pre-split shares, you will be issued one share of Common Stock and $0.55 for each pre-split share that otherwise would have
resulted in a fractional share, or $275.
As soon as practicable after the Reverse Stock Split is effected, you will be notified in
writing and asked to surrender your stock certificates to the exchange agent. Upon receipt of your stock certificates by the exchange agent, you will receive any cash payment to which you are entitled and a certificate for post-split shares (if
any). See the information under the caption Description of the Reverse Stock Split Exchange of Certificates for Cash Payment or Shares in this Proxy Statement.
If the Reverse Stock Split is effected, we will be eligible to deregister our Common Stock. In such case, we would no longer be required to
file periodic reports with the Securities and Exchange Commission (the SEC). Except for the anticipated cost savings associated with no longer being a public company, the Reverse Stock Split is not expected to affect our current business
plan or operations. For additional information about the Reverse Stock Split, see Special Factors Reasons for and Purposes of the Reverse Stock Split, Special Factors Termination of Exchange Act
Registration, Recommendation of the Board and Special Factors Fairness of the Reverse Stock Split.
Neither the Company, the Board, nor any committee of the Board has solicited or obtained any appraisal, report or opinion by any outside party
regarding the fairness of the Reverse Stock Split. The Board chose not to retain the services of an independent advisor to provide advice regarding the fairness of the Reverse Stock Split because it believes the cost of doing so would be excessive
given the relative size and cost of the Reverse Stock Split. However, the Board did evaluate and consider a number of factors in determining that the Reverse Stock Split is fair to the Company and our stockholders, including a valuation of the
Common Stock by Cabrillo Advisors, LLC (Cabrillo Advisors). See the information under the caption Information about the Meeting and the Reverse Stock Split, Special Factors Fairness of the Reverse Stock
Split, Special Factors Third Party Valuation and Special Factors Absence of a Fairness Opinion in this Proxy Statement.
For those stockholders who receive a cash payment in the Reverse Stock Split and cease to hold, either directly or indirectly, shares of
post-split Common Stock, you will need to recognize a gain or loss for federal income tax purposes for the difference between the amount of cash received and the aggregate tax basis in your shares of Common Stock. For those stockholders who continue
to hold shares of Common Stock after the Reverse Stock Split, you will only recognize a gain or loss for federal income tax purposes to the extent that you receive a cash payment in lieu of a fractional share. You are urged to consult your tax
advisor regarding the tax consequences of the Reverse Stock Split in light of your own particular circumstances. See the information under the caption Special Factors Federal Income Tax Consequences of the Reverse Stock Split
in this Proxy Statement.
You will not be entitled to appraisal rights under our Certificate of Incorporation or Delaware law since the
matter to be voted on does not involve a merger or consolidation. For additional information about appraisal rights, see Description of the Reverse Stock Split Appraisal Rights.
We currently anticipate having the financial resources to complete the Reverse Stock Split, the costs of which we estimate to be $505,000. The
estimated costs include $225,000, which is the approximate cost to satisfy the Companys obligation to pay cash for each fractional share resulting from the Reverse Stock Split. The payments to holders who receive cash in lieu of fractional
shares will be paid out of cash on hand. As of June 20, 2014, we had approximately $2.0 million of cash on hand.
2
Solicitation and Revocation of Proxies; Quorum; Voting
If the accompanying proxy is properly executed and returned, the shares represented by the proxy will be voted as directed at the Meeting. You
cannot vote your shares unless you are present at the Meeting or you have properly executed your proxy. You can vote by proxy in one of three convenient ways:
|
|
|
by internet: visit the website shown on your proxy card and follow the instructions;
|
|
|
|
by telephone: dial the toll-free number shown on your proxy card and follow the instructions; or
|
|
|
|
in writing: sign, date, and return the enclosed proxy card in the enclosed pre-addressed, postage paid envelope.
|
Stockholders holding their shares of Common Stock through a broker, bank, or other record holder should follow the instructions provided to them by the record
holders to vote their shares. A stockholder may revoke his or her proxy by giving written notice of revocation to the Secretary of the Company at any time before the Meeting, by executing another valid proxy bearing a later date and delivering such
proxy to the Secretary of the Company prior to or at the Meeting, or by voting in person at the Meeting.
The presence in person or by
proxy of the holders of a majority of the Common Stock will constitute a quorum for purposes of the separate vote of the Common Stock on Proposal No. 1 regarding an amendment to the Certificate of Incorporation to effect the Reverse Stock
Split. The presence in person or by proxy of the holders of a majority of the Eligible Votes (defined below) will constitute a quorum for all other purposes. If the organization that holds your shares does not receive instructions from you on how to
vote your shares, the organization that holds your shares will inform us that it does not have the authority to vote on these matters with respect to your shares. This is generally referred to as a broker non-vote. Broker non-votes will
be considered as present for purposes of determining a quorum but will not otherwise affect voting results.
The inspector of election at
the Meeting will count votes as follows:
|
|
|
|
|
|
|
Proposal
|
|
Vote Necessary to
Approve Proposal
|
|
Broker
Discretionary
Voting
Allowed?
|
|
Treatment of Abstentions
and Broker Non-Votes
|
No. 1 Amendment of the Certificate of Incorporation to effect the Reverse Stock Split
|
|
Affirmative vote of a majority of the Common Stock and a majority of the Eligible Votes
|
|
No
|
|
Abstentions and broker non-votes will have the same effect as a vote AGAINST the proposal
|
|
|
|
|
No. 2 Election of Directors
|
|
Plurality (the largest number) of the Eligible Votes cast
|
|
No
|
|
No effect on voting results
|
|
|
|
|
No. 3 Advisory Vote on Frequency of Executive Compensation
|
|
Affirmative vote of a majority of the Eligible Votes cast
|
|
No
|
|
No effect on voting results
|
|
|
|
|
No. 4 Advisory Vote on Executive Compensation
|
|
Affirmative vote of a majority of the Eligible Votes cast
|
|
No
|
|
No effect on voting results
|
|
|
|
|
No. 5 Ratification of the appointment of Whitley Penn LLP
|
|
Affirmative vote of a majority of Eligible Votes cast
|
|
Yes
|
|
No effect on voting results
|
The Company will bear the expenses of this proxy solicitation, including the cost of preparing and mailing
this Proxy Statement and accompanying proxy. This includes the charges and expenses of banks, brokerage firms, and other custodians, nominees or fiduciaries for forwarding solicitation material regarding the Meeting to beneficial owners of the
Companys Voting Shares. Our directors, officers, and employees may solicit proxies by mail, telephone, personal interviews, or by other means. They will not be compensated for these activities but may be reimbursed for their out-of-pocket
expenses.
3
Stockholders Entitled to Vote
Stockholders of record at the close of business on
, 2014 (the Record Date) will be entitled to vote at the Meeting. As of the Record Date, there were 19,659,507 shares
of the Companys issued and outstanding Common Stock. The holders of Common Stock are entitled to one vote per share. In addition, as of the Record Date, there are four series of convertible preferred stock (collectively, the Preferred
Stock) outstanding and entitled to vote at the Meeting: Series 1-A Convertible Preferred Stock (Series 1-A), Series 2-A Convertible Preferred Stock (Series 2-A), Series 5-A Convertible Preferred Stock (Series
5-A), and Series 6-A Convertible Preferred Stock (Series 6-A). The Preferred Stock is entitled to one vote per share of Common Stock into which the Preferred Stock is convertible. These series of Preferred Stock, the number of
votes each share of Preferred Stock is entitled to cast at the Meeting and the aggregate number of votes of each series of Preferred Stock that are eligible to be cast at the Meeting are described below. Together, the votes of holders of outstanding
Common Stock plus the eligible votes of holders of outstanding Preferred Stock equals 64,882,753 votes (the Eligible Votes). The Common Stock and the Preferred Stock together are referred to herein as the Voting Shares.
The table below summarizes the Eligible Votes of the holders of our outstanding shares of Common Stock and Preferred Stock entitled to vote at
the Meeting.
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Capital Stock
|
|
Outstanding
Shares of Class
|
|
|
Conversion Rate/
Votes Per Share
|
|
|
Aggregate
Vote Per Class
|
|
Common Stock
|
|
|
19,659,507
|
|
|
|
1.0
|
|
|
|
19,659,507
|
|
Series 1-A
|
|
|
67,600
|
|
|
|
9.7
|
|
|
|
654,292
|
|
Series 2-A
|
|
|
3,900
|
|
|
|
43.3
|
|
|
|
168,954
|
|
Series 5-A
|
|
|
9,000
|
|
|
|
3,200.0
|
|
|
|
28,800,000
|
|
Series 6-A
|
|
|
4,875
|
|
|
|
3,200.0
|
|
|
|
15,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
64,882,753
|
|
On all matters, the holders of the Common Stock, together with the holders of all classes of Preferred
Stock, will vote together as a class at the Meeting. Further, the holders of the Common Stock will vote separately on Proposal 1 regarding an amendment to the Certificate of Incorporation to effect the Reverse Stock Split. The vote on Proposal 1 has
not been structured to require separate approval of the Companys unaffiliated stockholders.
Shares may not be voted
cumulatively for the election of directors. Fractional shares are not be entitled to a vote.
4
Proposal 1 Amendment to Certificate of Incorporation to
Effect the Reverse Stock Split
You are being asked to vote on an amendment to our Certificate of Incorporation to effect a Reverse
Stock Split of our Common Stock. The intended effect of the Reverse Stock Split is to reduce the number of record holders of our Common Stock to fewer than 300, so we will be eligible to terminate the registration of our Common Stock under the
Securities Exchange Act of 1934 (the Exchange Act). If the Reverse Stock Split is approved by stockholders, we will take action to deregister our Common Stock with the SEC, and our Common Stock will no longer be eligible for trading on
the
Over-the-Counter
Bulletin Board (the OTCBB). In such case, we will no longer be required to file periodic reports with the SEC. However, our Common Stock
may be quoted on the OTC Pink Marketplace, or the Pink Sheets.
We intend for the Reverse Stock Split to treat stockholders
holding Common Stock in street name through a nominee (such as a bank or broker) in the same manner as stockholders whose shares are registered in their names. Nominees will be instructed to effect the Reverse Stock Split for their beneficial
holders. However, nominees may have different procedures, and stockholders holding shares in street name should contact their nominees.
As soon as practicable after the Reverse Stock Split, our exchange agent will send each stockholder with the right to receive a
certificate for post-split shares and/or cash payment a letter to be used to transmit Common Stock certificates to the exchange agent. After properly completing, executing and returning the transmittal letter and accompanying stock certificates to
the exchange agent, these stockholders will receive a certificate for post-split shares and/or a check for their cashed out shares. Nominees (such as a bank or broker) may have required procedures, and stockholders holding Common Stock in street
name should contact their nominees to determine how the Reverse Stock Split will affect them. See the information under the caption Information About the Reverse Stock Split Exchange of Certificates for Cash Payment or Shares
in this Proxy Statement. In the event we are unable to locate a stockholder or if a stockholder fails properly to complete, execute, and return the transmittal letter and accompanying stock certificates to the exchange agent, any funds payable to
that holder pursuant to the Reverse Stock Split will be held in escrow until a proper claim is made, subject to applicable abandoned property laws.
Please do not return your stock certificates with your proxy.
The Board recommends that stockholders vote FOR
the Certificate of Amendment to effect the Reverse Stock Split.
5
Information about the Meeting and the Reverse Stock Split
The following questions and answers briefly address some commonly asked questions about the Meeting and the Reverse Stock Split that are not
addressed in the Summary Term Sheet. These questions and answers may not include all the information that is important to you. We urge you to read carefully this entire Proxy Statement, including our financial statements and annexes.
Q:
|
What vote is required for the Companys stockholders to approve the Reverse Stock Split?
|
A:
|
An affirmative vote of the holders of a majority of the votes eligible to be cast at the Meeting by the holders of shares of Common Stock voting as a separate class and by the holders of our outstanding shares of Common
Stock and Preferred Stock voting on an as converted basis, voting together as a separate class, is required to approve the Certificate of Amendment to effect the Reverse Stock Split. The holders of outstanding shares of Common Stock and Preferred
Stock on , 2014 will be eligible to vote at the Meeting. A failure to vote in person or by proxy or an abstention has the same
effect as a vote AGAINST the Certificate of Amendment.
|
Q:
|
What are the advantages of the Reverse Stock Split?
|
A:
|
Our Board believes that the Reverse Stock Split will have the following advantages:
|
|
|
|
We will terminate the registration of our Common Stock under the Exchange Act, which will eliminate the significant costs of being a public company, with estimated savings of $370,000 to $410,000 annually;
|
|
|
|
Our senior management will be able to focus their time and efforts on operations without having the burden of addressing issues related to being a public company;
|
|
|
|
We estimate that the Reverse Stock Split will reduce the number of record holders by approximately 80% and the number of beneficial holders by approximately 95% while reducing the number of outstanding Common Stock by
less than 1.5%. We will be able to reduce the expense associated with maintaining stockholder accounts for numerous stockholders with small accounts;
|
|
|
|
We will be able to cost-effectively implement the Reverse Stock Split without negatively affecting our business operations;
|
|
|
|
Our affiliated stockholders will be treated no differently than our unaffiliated stockholders. The sole determining factor as to whether a stockholder will continue as a stockholder after the Reverse Stock Split is the
number of shares of Common Stock that they own at the effective time of the Reverse Stock Split; and
|
|
|
|
We will be able to provide liquidity and a predictable exit for the large number of unaffiliated stockholders holding relatively small positions. These stockholders have had limited liquidity as our stock is thinly
traded and, until recently, our stock price has been extremely low over the last 12 months. We will be able to provide this liquidity through a transaction in which such unaffiliated stockholders generally may be eligible to receive capital
gains tax treatment for their proceeds and avoid paying brokerage commissions and fees.
|
Q:
|
What are the disadvantages of the Reverse Stock Split?
|
A:
|
Our Board believes that the Reverse Stock Split will have the following disadvantages:
|
|
|
|
Stockholders owning fewer than 2,000 shares of our Common Stock will not have an opportunity to liquidate their shares at a time and for a price of their choosing. Instead, they will be cashed out, will no longer be
stockholders of our Company, and will not have the opportunity to participate in or benefit from any future potential appreciation in the value of our Common Stock;
|
|
|
|
The public market for shares of our Common Stock, which has been limited to date, will cease to exist;
|
|
|
|
Stockholders holding our Common Stock following the Reverse Stock Split will no longer have ongoing access to recent information regarding our operations and results that is required by the SEC;
|
6
|
|
|
Eliminating the trading market for our Common Stock may result in less flexibility when attracting and retaining executives and employees since equity-based incentives tend to be less valuable in private companies; and
|
|
|
|
It will be more difficult to access the public equity markets in the future, should we decide to do so.
|
Q:
|
What are the factors that the Board considered when approving the Reverse Stock Split?
|
A:
|
In addition to the advantages and disadvantages discussed above, and under the captions Special Factors Strategic Alternatives Considered, Special Factors Background of the
Reverse Stock Split and Special Factors Effects of the Reverse Stock Split in this Proxy Statement, the Board also considered the following:
|
|
|
|
The fairness of the price to be paid to stockholders owning fewer than 2,000 shares of our Common Stock;
|
|
|
|
The projected tangible and intangible cost savings to us by terminating our status as a public company;
|
|
|
|
The valuation of our Common Stock presented by Cabrillo Advisors in its report and at Board meetings;
|
|
|
|
Liquidating shares in the public trading market would be difficult due to the low daily trading volume of our Common Stock on the OTCBB. Only a small number of shares could be sold on the OTCBB without risking a
significant decrease in the trading price;
|
|
|
|
The Reverse Stock Split affords stockholders with fewer than 2,000 shares an opportunity to liquidate their holdings without paying brokerage commissions and fees;
|
|
|
|
The Company has been unable to use broad-based equity awards as a significant incentive to attract and retain employees due to the low trading price, limited trading volume, and public float of our Common Stock; and
|
|
|
|
Terminating our status as a public company will allow management to focus on operations more than it is currently able.
|
Q:
|
Did the Board obtain a fairness opinion or engage an independent financial advisor before approving the Reverse Stock Split?
|
A:
|
The Board engaged Cabrillo Advisors, an independent advisor, to assist the Company in evaluating the fair market value of our Common Stock. The Board did not obtain or request an opinion from Cabrillo Advisors regarding
the fairness of the Reverse Stock Split. This valuation cost approximately $26,500 plus expenses. The Board also did not want to rely exclusively on recent trading prices due to the recent low volume trading activity of our Common Stock. The total
anticipated cost of the Reverse Stock Split is approximately $505,000 (including the fractional share payments of approximately $225,000).
|
The Board chose not to retain the services of an independent advisor to evaluate and prepare an opinion regarding the fairness of the Reverse
Stock Split because it believes the cost of these services would be excessive given the relative size and cost of the Reverse Stock Split. The total expected payment to be made for fractional shares cashed out in connection with the Reverse Stock
Split is approximately $225,000. In comparison, a fairness opinion was expected to cost approximately $100,000.
Q:
|
What are the interests of our directors, executive officers and significant stockholders in the Reverse Stock Split?
|
A:
|
As a result of the Reverse Stock Split, the aggregate Common Stock ownership of our directors, executive officers and significant stockholders will
not materially increase. Prior to the Reverse Stock Split, our directors and executive officers beneficially own approximately 12.1% of our Common Stock. After the Reverse Stock Split, they will beneficially own approximately 12.3% of our Common
Stock. The shares of Common Stock held by our directors and executive officers represent approximately 3.0% of the Common
|
7
|
Stock votes eligible to be cast at the Meeting. The shares of Common Stock held by our directors and executive officers, plus the votes afforded to them as holders of Preferred Stock, represent
approximately 2.1% of the votes eligible to be cast at the Meeting.
|
Prior to the Reverse Stock Split, SMP and Ciabattoni
Trust, two of our significant stockholders, beneficially own approximately 54.1% and 39.0%, respectively, of our Common Stock. After the Reverse Stock Split, SMP and Ciabattoni Trust will beneficially own approximately 54.8% and 39.5%, respectively,
of our Common Stock. The shares of Common Stock held by SMP and Ciabattoni Trust represent approximately 30.6% and 18.1% of the Common Stock votes eligible to be cast at the Meeting. The shares of Common Stock held by SMP and Ciabattoni Trust, plus
the votes afforded to them as holders of Preferred Stock, represent approximately 20.4% and 13.0%, respectively, of the votes eligible to be cast at the Meeting.
Each of our directors, executive officers, SMP and Ciabattoni Trust intend to vote the Voting Shares that each beneficially owns in favor of
the Reverse Stock Split. See the information under the captions Special Factors Effects of the Reverse Stock Split, Special Factors Potential Disadvantages of the Reverse Stock Split to Stockholders,
Special Factors Financial Effect of the Reverse Stock Split and Special Factors Costs of the Reverse Stock Split in this Proxy Statement.
Q:
|
How will I be affected if I own more than 2,000 shares of Common Stock?
|
A:
|
You will receive one share of Common Stock for each 2,000 shares you own, and $0.55 for each pre-split share that otherwise would have resulted in a fractional
post-split
share.
For example, if you own 5,000 shares of Common Stock, you would receive two shares of Common Stock upon consummation of the Reverse Stock Split and $550, representing the value of 1,000 pre-split shares times $0.55 per pre-split share.
|
Q:
|
How will I be affected if I own Preferred Stock?
|
A:
|
The number of shares of Common Stock into which each share of Preferred Stock is convertible will be adjusted to reflect the Reverse Stock Split. Correspondingly, the number of votes to which each share of Preferred
Stock is entitled will also be adjusted to reflect the Reverse Stock Split. Shares of our Series 1-A, Series 2-A, Series 5-A and Series 6-A are currently outstanding. You will retain all of your shares of Preferred Stock and will not receive any
compensation. For example, if you own 100 shares of Series
5-A,
after the Reverse Stock Split you would be entitled to 1.6 votes per share of Series
5-A,
for a total of
approximately 160 votes, and to convert each share of Series
5-A
into 1.6 shares of Common Stock. Upon conversion of your Preferred Stock, the Company will pay you the fair market value (as determined under
the applicable Certificate of Designation for the Preferred Stock) of any fractional share of Common Stock to which you are entitled. The table below summarizes the Eligible Votes of the holders of our outstanding shares of Common Stock and
Preferred Stock before and after the Reverse Stock Split.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of
Capital Stock
|
|
Outstanding
Shares of Class
|
|
|
Conversion Rate/
Votes Per Share
|
|
|
Aggregate
Vote Per Class
|
|
|
|
Pre-Split
|
|
|
Post-Split
|
|
|
Pre-Split
|
|
|
Post-Split
|
|
|
Pre-Split
|
|
|
Post-Split
|
|
Common Stock
|
|
|
19,659,507
|
|
|
|
9,636
|
|
|
|
1.0
|
|
|
|
1.0
|
|
|
|
19,659,507
|
|
|
|
9,636
|
|
Series 1-A
|
|
|
67,600
|
|
|
|
67,600
|
|
|
|
9.7
|
|
|
|
0.005
|
|
|
|
654,292
|
|
|
|
325
|
|
Series 2-A
|
|
|
3,900
|
|
|
|
3,900
|
|
|
|
43.3
|
|
|
|
0.022
|
|
|
|
168,954
|
|
|
|
84
|
|
Series 5-A
|
|
|
9,000
|
|
|
|
9,000
|
|
|
|
3,200.0
|
|
|
|
1.6
|
|
|
|
28,800,000
|
|
|
|
14,398
|
|
Series 6-A
|
|
|
4,875
|
|
|
|
4,875
|
|
|
|
3,200.0
|
|
|
|
1.6
|
|
|
|
15,600,000
|
|
|
|
7,799
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
64,882,753
|
|
|
|
32,242
|
|
Q:
|
How will I be affected if I have exercised my right to participate in the Series 7-A Exchange?
|
A:
|
During the fiscal year ended September 30, 2011, we entered into bridge financing transactions (the 2011 Bridge Notes) in which we
entered into ten promissory notes in the aggregate principal amount of $2,034,000 with various investors (the 2011 Bridge Lenders). As part of the consideration for entering into the 2011 Bridge Notes, each of the 2011 Bridge Lenders was
granted the option to exchange (the Series 7-A Exchange) their current holdings, if any, of Series 5-A, Series 6-A and Common Stock (collectively the Exchanged Securities) for shares of our Series 7-A Convertible Preferred
Stock
|
8
|
(Series 7-A). Upon election to exchange, each lender would receive the number of Series 7-A equal to the initial consideration paid for their Exchanged Securities divided by $1,000.
In connection with the exchange, each 2011 Bridge Lender would receive warrants to purchase a number of shares of Common Stock of the Company in an amount equal to 1,120 multiplied by the aggregate number of shares of Series 7-A issued at an
exercise price of $0.3125 per share. The Company expects each of the 2011 Bridge Lenders to convert their holdings of Exchanged Securities to Series 7-A, which will result in the issuance of an aggregate of 5,998 shares of Series 7-A and warrants to
purchase up to 6,717,760 shares of Common Stock.
|
Because the number of shares of Series 7-A to be issued to the 2011
Bridge Lenders is based on the consideration paid for the Exchanged Securities, the Company does not expect the Reverse Stock Split to have an effect on the 2011 Bridge Lenders. The number of shares of Series 7-A that each 2011 Bridge Lender will
receive will not be adjusted. However, as with our other series of Preferred Stock, the total number of shares of Common Stock into which each share of Series 7-A is convertible and the number of votes to which each share of Series 7-A is entitled
will be adjusted on the Effective Date to reflect the Reverse Stock Split. No shares of Series 7-A are currently outstanding.
Each of
William Houlihan, SMP and Ciabattoni Trust is a 2011 Bridge Lender and is eligible to participate in the Series 7-A Exchange. The Company expects to consummate the Series 7-A Exchange within the next year but anticipates that the Series 7-A Exchange
will not occur until after the Meeting. Consequently, the Series 7-A Exchange will not affect the beneficial ownership or the voting rights of William Houlihan, SMP or Ciabattoni Trust at the Meeting. If the Reverse Stock Split is approved, the
Board intends to adjust the number of shares of Common Stock issuable upon exercise of and the exercise price of any warrants issued in relation to the Series 7-A Exchange to reflect the Reverse Stock Split.
As of the date of this Proxy Statement, William Houlihan, SMP and Ciabattoni Trust beneficially owned 10.6%, 54.1% and 39.0% of the
Companys Common Stock, respectively. Assuming that the Companys stockholders do not approve the Reverse Stock Split, following the Series 7-A Exchange, they will beneficially own 13.8%, 61.0%, and 46.2% of the Companys Common
Stock, respectively. The table below summarizes the voting rights of William Houlihan, SMP and Ciabattoni Trust before and after the completion of the Series 7-A Exchange assuming the Companys stockholders do not approve the Reverse Stock
Split.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before Series 7-A Exchange
|
|
|
After Series 7-A Exchange
|
|
|
|
Percentage of
Common
Stock Vote
|
|
|
Percentage of
Eligible
Votes
|
|
|
Percentage of
Common
Stock Vote
|
|
|
Percentage of
Eligible
Votes
|
|
William Houlihan
|
|
|
1.5
|
%
|
|
|
1.7
|
%
|
|
|
|
|
|
|
1.8
|
%
|
SMP
|
|
|
30.6
|
%
|
|
|
20.4
|
%
|
|
|
28.5
|
%
|
|
|
20.9
|
%
|
Ciabattoni
|
|
|
18.1
|
%
|
|
|
13.0
|
%
|
|
|
20.0
|
%
|
|
|
13.0
|
%
|
Q:
|
How will I be affected if I own stock options or warrants to purchase Common Stock?
|
A:
|
Your stock options and warrants will remain outstanding after the Reverse Stock Split. The number of shares of Common Stock and the exercise or strike price of your stock options and warrants will be adjusted to reflect
the Reverse Stock Split. Before and after the adjustment to reflect the Reverse Stock Split, the aggregate number of shares of Common Stock underlying the Companys outstanding stock options and warrants are 6,520,879 and 3,256, respectively.
Upon exercise of your stock options or warrants, the Company will pay you the fair market value (as determined under the applicable stock option or warrant agreement) of any fractional share of Common Stock to which you are entitled.
|
Q:
|
Does the Company have net operating loss carry-forwards and how will the Reverse Stock Split affect the Companys and its stockholders ability to benefit from those net operating loss carry-forwards?
|
A:
|
As of September 30, 2013, we had net operating loss carry-forwards of approximately $19.9 million, available to offset future taxable income, if any.
A change of ownership of more than 50% occurred on June 22, 2001. According to applicable U.S. tax laws, losses that occurred before that date are limited to $0.3 million per year for up to 20 years, totaling approximately $6.5 million of the $19.9
million of net operating loss carry-forwards. The balance of the Companys net operating loss carry-forwards are not subject to any annual
|
9
|
limitation. The Companys net operating loss carry-forwards will expire between 2012 and 2030. To the extent that the Company has future regular, alternative minimum and foreign taxable
income, the Company and its stockholders, including its affiliates, may benefit from the use of the Companys net operating loss carry-forwards. Stockholders owning fewer than 2,000 shares of Common Stock will be cashed out and will not have
the opportunity to benefit from the use of the Companys net operating loss carry-forwards.
|
Q:
|
What do I need to do now?
|
A:
|
We urge you to read the Proxy Statement carefully, including the annexes, and to consider how the Reverse Stock Split affects you. If you are a stockholder of record, you can ensure your shares are voted at the Meeting
by completing, signing, dating, and mailing the enclosed proxy card or following the instructions on the proxy card to vote by Internet or phone. Even if you plan to attend the Meeting, we encourage you to return the enclosed proxy card or to vote
by Internet or phone. If you hold your shares in street name, you can ensure that your shares are voted at the Meeting by instructing your broker or nominee how to vote.
Please do not return your stock certificate(s) with your proxy.
|
Q:
|
What happens if I sell my shares before the Meeting?
|
A:
|
If you transfer your shares of Common Stock after the Record Date but before the Meeting, you will retain your right to vote at the Meeting but will have transferred the right to receive any consideration for fractional
shares that will be cashed out in connection with the Reverse Stock Split. In order to receive consideration for fractional shares that will be cashed out, you must hold your shares through the Effective Date.
|
Q:
|
Will I be entitled to appraisal rights if I object to the Reverse Stock Split?
|
A:
|
No. You are not entitled to appraisal rights under either our Certificate of Incorporation or Delaware law. See the additional information under the caption Description of the Reverse Stock Split
Appraisal Rights in this Proxy Statement.
|
Special Factors
Reasons for and Purposes of the Reverse Stock Split
The primary purpose of the Reverse Stock Split is to reduce the number of record holders of our Common Stock to fewer than 300 holders, so we
can terminate the registration of our Common Stock under the Exchange Act. The Reverse Stock Split is expected to eliminate expenses related to our disclosure and reporting requirements under the Exchange Act and to decrease administrative expenses
we incur by servicing record stockholders who own a relatively small number of shares of our Common Stock.
As discussed further in
this Proxy Statement under the caption Special Factors Background of the Reverse Stock Split, the Board began informally reviewing a going private transaction in early 2011. The Board began serious consideration of a going
private transaction in March 2014 and, as a result, engaged Cabrillo Advisors to assist the Company in evaluating the fair market value of the Common Stock. The Board began more detailed discussions of a going private transaction at the Board
meeting held on May 23, 2014, which was the first Board meeting after the Company became current in its SEC reporting obligations. Management expressed concern about the expense of remaining a public company, the Companys inability in the past
to comply with the periodic reporting requirements of the Exchange Act, the significant commitment of management time and resources, and the burden of continuing to be subject to periodic reporting requirements. As a result of these concerns and the
factors discussed further in this Proxy Statement under the caption Special Factors Background of the Reverse Stock Split, the Board believes that any material benefit derived from continued registration under the Exchange
Act is outweighed by the cost and burdens and that continuing our public company status is not in the best interest of the Company or our stockholders.
Further, we have had difficulty maintaining internal controls over financial reporting. We have reported in our periodic reports for all
periods ending after December 31, 2010 that we have material weaknesses in our internal control over financial reporting. Management believes that it would be difficult and expensive for the Company to
10
remedy the material weaknesses in its internal controls to conform to the internal control requirements for public companies and such an undertaking would require a commitment of a significant
amount of time from management.
In the Boards view, our status as a public company does not materially benefit our stockholders and
places significant financial burden on the Company. To prepare and file our delinquent filings for the periods ending after December 31, 2010, we spent approximately $850,000 in audit, legal, printing, filing and other fees. To continue as a
public company, we would need to incur a number of costs associated with compliance with the SECs filing and reporting requirements imposed on public companies. To comply with the public company requirements, we estimate we would incur
$543,000 annually in related expenses, as follows:
|
|
|
|
|
Audit fees
|
|
$
|
150,000
|
|
Internal control compliance
|
|
|
150,000
|
|
Transfer agent/stockholder expenses
|
|
|
8,000
|
|
Legal fees
|
|
|
175,000
|
|
Printing and mailing costs
|
|
|
45,000
|
|
Other
|
|
|
15,000
|
|
|
|
|
|
|
Total estimated expenses
|
|
$
|
543,000
|
|
|
|
|
|
|
The estimates set forth above are only estimates. These costs would not all be eliminated entirely if the
Company terminated its obligations under the Exchange Act. However, these expenses are anticipated to substantially decrease after the Reverse Stock Split and related deregistration. We estimate that the actual annual savings will approximate
$370,000 to $410,000, as the Company will continue to incur audit and related fees to prepare its financial statements. The actual savings may be higher or lower than this estimate. The Board believes that it is in our best interests and the best
interests of our stockholders to eliminate the administrative, financial, and additional auditing burdens associated with being a public company by going forward with the Reverse Stock Split and related deregistration.
The principal benefits of being an SEC registrant, including access to the public markets for capital raising and liquidity for our
stockholders, have largely been unavailable to the Company. The Company has only received financing due to continued investment from our major stockholders. Given the current state of the capital markets and the current economic environment, the
Board does not believe that we are in a position to use our status as a public company to raise capital through a public offering of equity or debt securities. Further, the Company does not currently have plans to raise capital in the public market.
However, the Company intends to satisfy its future capital requirements using cash flow from operations and may seek bank financing or issue debt securities, if necessary.
Our Common Stocks low price has impaired our smaller stockholders ability to sell their shares, as doing so in the public market
is cost prohibitive. In addition, the limited trading volume of our Common Stock and minimal public float could impair our larger stockholders ability to sell their shares, which could prevent them from realizing the full benefits of holding
publicly traded stock. Our small market capitalization has resulted in limited interest from market makers and financial analysts who might report on our activity to the investment community. Our stock has been thinly traded, and the price of our
Common Stock has been low. As a result, entering into a large purchase or sale could significantly impact the market price of our Common Stock. In addition, our Common Stocks limited trading volume and public float has limited our ability to
use our Common Stock as acquisition currency or to attract and retain employees. The Board believes that it is unlikely that our market capitalization and trading liquidity will increase significantly in the foreseeable future.
As a result of going private, we believe management will have more time to further our business objectives and the interests of our
stockholders. If the Company does not go private, the time and resources required of management for compliance with SEC reporting requirements may require us to hire additional personnel. Further, remaining public may make it difficult for us to
attract and retain additional executives and independent directors without increasing director compensation and obtaining additional directors and officers liability insurance.
11
The Board determined to proceed with the Reverse Stock Split at this time because it recently
filed its delinquent SEC reports and because of the burden of continued compliance with SEC reporting obligations. The benefits of remaining a public company are far outweighed by the direct and indirect costs associated with remaining a public
company. See also information under the caption Special Factors Strategic Alternatives Considered in this Proxy Statement for an additional description of the reasons why our Board approved the Reverse Stock Split instead of
another alternative transaction structure.
The Reverse Stock Split will terminate the equity interests of approximately 287 record
holders of Common Stock. The Reverse Stock Split will treat stockholders holding Common Stock in street name through a nominee (such as a bank or broker) in the same manner as record holders. Nominees will be instructed to effect the Reverse Stock
Split for their beneficial holders. Nominees may have different procedures, and stockholders holding shares in street name should contact their nominees.
We presently have approximately 354 record holders and 3,759 beneficial holders of our Common Stock, of which we believe approximately 287
record holders and 3,567 beneficial holders own less than 2,000 shares. We estimate that the shares held by these small holders of less than 2,000 shares comprise less than 1.5% of our outstanding shares of Common Stock before the Reverse Stock
Split. Further, 242 of the record holders that will be cashed out in the Reverse Stock split own less than 100 shares of Common Stock. The Reverse Stock Split will provide small stockholders a mechanism to liquidate their equity interest without
having to pay brokerage commissions. The Reverse Stock Split will eliminate much of the administrative burden and cost of maintaining records for numerous small accounts and the associated cost of preparing, printing, and mailing information to
them.
When the Reverse Stock Split is consummated, stockholders owning fewer than 2,000 shares of Common Stock will no longer have
any equity interest in the Company and will not participate in our future earnings, any increased value of our assets or operations or any benefit derived from our net operating loss carry-forwards. Only continuing stockholders will benefit from any
future increase in our earnings. The stockholders who continue to hold an equity interest in the Company after the Reverse Stock Split will own a security with limited liquidity. See also information under the captions Recommendation of the
Board and Fairness of the Reverse Stock Split in this Proxy Statement.
Strategic Alternatives Considered
The Board considered alternatives to effect deregistration of the Common Stock when evaluating the Reverse Stock Split. After evaluating the
risks and benefits of each alternative, the Board determined that the Reverse Stock Split would be the simplest and most cost-effective means to achieve the purposes described above. The alternatives considered were:
|
|
|
Odd lot tender offer.
The Board considered purchasing shares in an odd lot tender offer. Unlike a traditional issuer tender offer, an odd lot tender offer would be offered only to stockholders owning a set number
of shares of our Common Stock (or fewer). Because the tender of shares would be at the option of the stockholder, there could be no assurance that enough stockholders would participate so as to reduce the number of record holders to fewer than 300.
While the time frame for completing an odd lot tender offer is shorter than that of a reverse stock split and could also be less expensive, our Board opted for the Reverse Stock Split because it is uncertain that an odd lot tender offer would
produce the intended result.
|
|
|
|
Purchase of shares in the open market.
The Board also considered purchasing our shares in the open market in order to reduce the number of our record stockholders to fewer than 300. However, given the low daily
trading volume of our Common Stock, there was no assurance that purchasing shares in isolated transactions would reduce the number of stockholders sufficiently to permit us to deregister and terminate our public reporting requirements in a
reasonable period of time without substantially increasing the price of the shares to the Company, given the low daily trading volume.
|
|
|
|
Self-tender offer.
The Board considered a self-tender offer, by which we would offer to repurchase shares of our outstanding Common Stock. The
results of an issuer tender offer would be unpredictable,
|
12
|
however, due to its voluntary nature. The Board was uncertain whether this alternative would result in shares being tendered by a sufficient number of record stockholders to reduce the number of
record stockholders below 300, which would allow us to terminate our public reporting requirements. The Board believed it unlikely that many holders of small numbers of shares would tender their shares, especially given that many of our smaller
stockholders have had no contact with us or our transfer agent in a number of years. In addition, the Board considered that the estimated transaction costs of completing a tender offer would be similar to or greater than the costs of the Reverse
Stock Split transaction, and these costs could be significant in relation to the value of the shares purchased since there could be no certainty that stockholders would tender a significant number of shares.
|
|
|
|
Maintaining the status quo
. The Board also considered taking no action to reduce the number of our stockholders. However, due to the significant and increasing costs of being a public company, the Board believed
that maintaining the status quo would be detrimental to all stockholders. We would continue to incur the expenses of being a public company without realizing the benefits.
|
The Board also considered pursuing a sale of the Company. The Board concluded that they did not believe that a sale was in the best interests
of the Company or its stockholders given the small scale of its operations and the concentration of its customer base. Further, the Board did not believe that a majority of the stockholders would support a sale.
In selecting the method by which to take the Company private, the Board did not consider the existence or lack of appraisal rights. Section
262 of Delaware General Corporation Law provides for appraisal rights in transactions structured as, among other things, mergers, consolidations and sales involving all or substantially all of a corporations assets. Other than pursuing a sale
of the Company, none of the strategic alternatives considered would have provided the Companys stockholders with appraisal rights under Delaware law.
Background of the Reverse Stock Split
During the fiscal year ended September 30, 2010, we shifted our strategy from majority ownership in healthcare delivery companies to a
focus on providing management, financial, and ancillary healthcare and information technology services to rural and community hospitals. We expect to maintain and/or acquire minority ownership in selected healthcare delivery companies that
complement our management services and financing activities. We may also invest in, acquire, or partner with other companies that provide similar services in our markets.
In pursuit of this reorganization, we undertook to divest underperforming facilities and reduce or outsource administrative functions to
better manage costs. As a result of the initiative, during the fiscal year ended September 30, 2011, we successfully divested our majority owned hospitals and obtained contracts to provide healthcare management services to two hospital clients.
We currently have four operating subsidiaries:
|
|
|
First Physicians Business Solutions, LLC (Solutions)
|
|
|
|
First Physicians Resources, LLC (Resources)
|
|
|
|
First Physicians Services, LLC (Services); and
|
|
|
|
First Physicians Realty Group, LLC (Realty Group).
|
Solutions provides an array of
management services, including hospital operations management, revenue cycle management, IT, finance and human resources. Services provides ancillary service oversight and management solutions for lab, pharmacy, and emergency departments in rural
hospital settings. Resources provides medical and back office staffing solutions to our hospital clientele. Realty Group is our real estate subsidiary that owns healthcare-related properties and leases them to clients. We currently have contracts to
provide financial and administrative services to two hospital clients. As of September 30, 2013 and 2012, 100% of our accounts receivable were derived from our management services contract with one customer.
13
During the reorganization, the Company experienced significant management turnover. It was
difficult to recruit talent with the necessary public company experience to manage our operations and public reporting process. Further, the Company did not use the public markets to raise the capital that it needed during this time period and had
successfully obtained funding from its existing stockholders, including SMP and Ciabattoni Trust.
In early 2011, David Hirschhorn, the
Companys then current Chief Executive Officer, recommended that the Board consider a going private transaction. As a result, the Board began informally reviewing the costs and benefits to the Company of remaining a public company or,
alternatively, taking the Company private. The Board did not engage any third-party advisors at this time. Mr. Hirschhorn also discussed the idea of a going private transaction with Brian Potiker of SMP and Anthony Ciabattoni of Ciabattoni Trust.
Mr. Potiker and Mr. Ciabattoni agreed that it would be appropriate to consider a going private transaction and that they would consider any proposal approved by the Board.
Prior to the reorganization, the Company had experienced sustained losses and had an accumulated deficit of approximately $95.5 million as of
September 30, 2010. The Company funded its losses through the issuance of Preferred Stock, the issuance of promissory notes, and cash from operations. During and since the reorganization, the Company has not utilized the public markets to raise
capital to fund operations and management does not anticipate that it will need to do so in the near future. Further, the Company was not eligible to utilize the public markets for capital raising during this period because the Company was not
current in filing its periodic reports with the SEC.
Following the reorganization, the Company had net income from continuing
operations of $5.6 million and $5.8 million in the fiscal years ended September 30, 2012 and 2013, respectively. While the Company had returned to profitability, management expressed concerns that the Companys size and anticipated capital
needs did not justify the costs of remaining a public company.
In 2011, the Company ceased filing periodic reports with the SEC as a
result of time and resource constraints on management and significant management turnover. From time to time since 2011, management, members of the Board, Mr. Potiker and Mr. Ciabattoni had informal discussions regarding the advisability
of and the reasons for undertaking a going private transaction. The Board members understood that the Company would be unable to pursue a going private transaction until the Company was current in its public reporting obligations with the SEC. As a
result, the Board members determined that they would defer consideration of undertaking a going private transaction until the Company had stabilized management and provided current public disclosure.
On August 5, 2013, the Company received a letter from the SEC requesting that the Company file all required reports to avoid SEC
administrative proceedings to revoke our Exchange Act registration. Prior to April 4, 2014, the last periodic report of the Company filed with the SEC was the Form 10-Q for the fiscal quarter ended December 31, 2010, which was filed on
February 22, 2011. In order to become current with all required quarterly and annual reports under the Exchange Act, the Company filed Form 10-Ks for the fiscal years ended September 30, 2011, 2012, and 2013 concurrently with Form
10-Qs for the fiscal quarters ended March 31, 2011, June 30, 2011, December 31, 2011, March 31, 2012, June 30, 2012, December 31, 2012, March 31, 2013, June 30, 2013, and December 31, 2013 (collectively,
the Reports).
Mr. Potiker and Mr. Ciabattoni were invited to participate as observers in Board meetings on behalf of SMP
and Ciabattoni Trust following the closing in November 2013 of the 2013 bridge financing in which SMP and Ciabattoni Trust participated. SMP and Ciabattoni Trust were already significant stockholders at the time. As Board observers, Messrs. Potiker
and Ciabattoni receive all notices and agendas for Board meetings and have the right to attend Board meetings.
14
While preparing the Reports in January 2014, Mr. Kirrane had informal discussions with Board
members, recommending that the Board consider a going private transaction following the Company becoming current with its SEC reporting obligations. At the request of the Board, management engaged outside legal counsel to consider the process and
costs of taking the Company private. The Board members and management determined that it was the appropriate time to analyze the advisability of terminating the Companys SEC reporting obligations following the filing of the Reports. Management
has continued to consult with counsel periodically regarding these matters. In late January 2014, Mr. Kirrane informed Mr. Potiker and Mr. Ciabattoni that the Board had started to consider a going private transaction. Each of Mr. Potiker and Mr.
Ciabattoni informed Mr. Kirrane that they intended to support a going private transaction, assuming the Board approved terms they considered fair to stockholders.
While preparing the Reports, Mr. Kirrane, the Companys current President and Chief Executive Officer, concluded that the Company did not
maintain effective internal control over financial reporting. Specifically, the Company has material weaknesses in its internal controls related to the effectiveness of managements controls over the closing process for financial reporting.
These controls specifically related to adequate oversight by management, adequate segregation of duties, adequate review and approval of journal entries and adequate review and approval of consolidating financial statements. Management informed the
Board that it believes that it would be difficult and expensive for the Company to remedy the material weaknesses in its internal controls to conform to the internal control requirements for public companies and such an undertaking would require a
commitment of a significant amount of time from management.
In January 2014, the Board had informal discussions regarding engaging an
independent financial advisor to give an opinion regarding the fairness of the Reverse Stock Split and to assist in the evaluation of strategic alternatives available to the Company. The Board asked management to review the anticipated cost of an
independent financial advisor. Management informed the Board that the cost to retain an independent financial advisor to provide a fairness opinion was expected to exceed $100,000 and they did not believe it would provide a benefit commensurate with
the anticipated cost. Given the current financial condition of the Company, management believed that retaining an independent financial advisor to provide an opinion regarding fairness would not be a prudent use of the Companys limited
financial resources. However, in March 2014, the Board began serious consideration of a going private transaction and, as a result, engaged Cabrillo Advisors, an independent advisor, to assist the Company in evaluating the fair market value of our
Common Stock. The Board selected Cabrillo Advisors following discussions with several valuation firms. Following those discussions and the receipt of cost estimates from several firms, the Board selected Cabrillo Advisors based on their valuation
experience, understanding of the Companys industry and reasonable cost estimate. The Board did not obtain or request an opinion from Cabrillo Advisors regarding the fairness of the Reverse Stock Split. This valuation cost approximately $26,500
plus expenses. The payment to Cabrillo Advisors was not contingent on any result. The Board also believed that a third party valuation was necessary because the trading price was not a reliable indicator of fair market value because of the lack of
consistent trading in the Companys Common Stock prior to the filing of the Reports and significant fluctuation in the price of our Common Stock following the filing of the Reports.
In January 2014, counsel suggested that the Board consider whether a special committee should be formed to consider the Companys
strategic alternatives and the terms of any going private transaction. Establishing a special committee would have created another protection of procedural fairness for any going private transaction. However, the Board determined that, in view of
the small size of the Board, the independence of all the Board members and the cost of retaining separate independent counsel for a special committee, a special committee was not necessary.
In February 2014, following informal discussion of the various alternatives for taking the Company private, the Board members generally agreed
that the Reverse Stock Split would be the most desirable alternative to pursue, given the relative certainty of the outcome and cost of completion, provided that it was effected at a price and on terms fair to all of our stockholders. The Board
instructed management to make a recommendation
15
regarding the terms of the Reverse Stock Split, including the specific ratio for the reverse stock split and the pre-split share price to be paid for fractional shares. Management was also
directed to engage counsel and prepare the necessary documents to comply with the reporting and disclosure requirements of the Exchange Act. Concurrently, management prepared an analysis of the potential reverse stock split ratios.
Following the Boards discussion, Mr. Kirrane informed Mr. Potiker that the Board had asked management to prepare an analysis of a
potential reverse stock split and expected to formally begin to consider a going private transaction in the near future. Mr. Potiker and Mr. Ciabattoni determined that they would not exercise their observation rights with respect to Board meetings
at which the Board considered a going private transaction and related alternatives in order to allow the Board members, each of which is independent, to consider the transaction without any input or influence from Mr. Potiker or Mr. Ciabattoni.
In determining the appropriate ratios, management reviewed the list of record owners provided by the transfer agent and ran calculations to
determine the minimum ratio necessary to achieve the Companys primary objective of reducing the number of stockholders to below 300. In preparing the analysis, management used a range of split ratios that would allow the Company to achieve a
number of record holders below 300 after the anticipated conversion of a portion of beneficial owners holding shares of the Companys Common Stock through nominees or brokers to record ownership.
On April 8, 2014, management provided Cabrillo Advisors with historical financial statements and cash flow information. Further, during early
April, management and Cabrillo Advisors representatives had discussions regarding the prospects for the Companys operations. Using that information, Cabrillo Advisors developed projected financial statements and worked with management to
refine the calculations and assumptions used in the forecast. On May 29, 2014, the Board reviewed and approved the financial forecast.
On
May 21, 2014, management called a Board meeting to be held on May 23, 2014 and informed the Board, legal counsel, Mr. Potiker and Mr. Ciabattoni. The agenda for the meeting included, among other matters, a discussion of the valuation process, the
preliminary proxy statement and potential Board nominees for the Meeting.
On May 23, 2014, the Board held a meeting with
representatives from Cabrillo Advisors, management and legal counsel to discuss the valuation process undertaken by Cabrillo Advisors and begin more detailed discussions regarding the process and timeline for a going private transaction. Mr. Potiker
and Mr. Ciabattoni did not attend the meeting. Mr. Houlihan requested that management send the valuation presentation to the Board when it was ready and that they subsequently schedule a meeting to review the presentation.
On May 28, 2014, management called a Board meeting to be held on May 29, 2014 and sent the draft of the valuation presentation, the stock
split ratio analysis and the public company cost estimates to the Board, legal counsel, representatives of Cabrillo Advisors, Mr. Potiker and Mr. Ciabattoni for their review. The agenda for the meeting included a review of the terms of the proposed
going private transaction and the preparation of the preliminary proxy statement.
On May 29, 2014, the Board held a meeting with
representatives from Cabrillo Advisors, management and legal counsel to review the materials sent to the Board. Mr. Potiker and Mr. Ciabattoni did not attend the meeting. At the meeting, representatives of Cabrillo Advisors reviewed a draft of the
valuation presentation and the range of the fair market value of the Common Stock with the Board. Mr. Houlihan asked questions regarding the comparability of the companies and transactions used in the analysis, and representatives from Cabrillo
reviewed the comparability factors. The Board discussed and asked questions regarding the analysis, including the assumptions used in the valuation. In particular, the Board discussed the number of shares of Common Stock used in the valuation
analysis, which was adjusted for 4.25 million shares of Common Stock acquired by the Company that were being cancelled and the changes to the Companys Common Stock, Series 5-A and Series 6-A as a result of the Series 7-A Exchange that the
Company expects to consummate within the next year. Mr. Sells asked about the treatment of the Companys outstanding options and warrants in the analysis. Representatives from Cabrillo Advisors confirmed that their analysis assumed the
conversion of all outstanding options and warrants.
16
Management also reviewed its stock split analysis with the Board. The stock split analysis set
forth stock split ratios between 1-for-1,000 and 1-for-100,000. Management and the Board members discussed the composition of the Companys stockholder base and the estimated impact of each ratio on the number of record holders, the number of
fractional shares to be purchased and the cost to purchase the fractional shares. They further discussed the need to reduce the number of record stockholders below 300 stockholders to make sure that beneficial owners that convert from street name
positions to record positions do not cause the Company to have more than 300 record holders.
The Board members then discussed the
alternatives to a going private transaction, including pursuing a sale of the Company and maintaining the status quo. The Board concluded that they did not think that a sale was in the best interests of the Company or its stockholders given the
small scale of its operations and the concentration of its customer base. Further, the Board did not believe that a majority of the stockholders would support a sale. The Board members and management agreed that the Company was still in the process
of stabilizing operations and personnel and developing a more stable operating history. Further, management believed that a sale process would be disruptive and would distract management from operating the business. Mr. Kirrane confirmed that this
reasoning was consistent with his previous informal discussions with Mr. Potiker and Mr. Ciabattoni. The Board also concluded that remaining public was undesirable because the benefits of remaining a public company are outweighed by the costs
associated with remaining a public company and the commitment of management time and resources necessary to comply with public reporting requirement. Following the discussion, the Board members determined that they should reconvene the following
week to consider the fair market value of the Companys Common Stock.
On June 2, 2014, management called a Board meeting to be held
on June 3, 2014 and informed the Board, legal counsel, Mr. Potiker and Mr. Ciabattoni. The agenda included, among other matters, a review of the terms of the going private transaction.
At a meeting of the Board on June 3, 2014, the Board members, management and legal counsel further discussed the potential going
private transaction and reviewed the various alternatives for going private, including a self-tender offer, an odd lot tender offer, purchases of shares in the open market and a reverse stock split. Mr. Potiker and Mr. Ciabattoni did not attend the
meeting. The Board members continued to believe that the Reverse Stock Split was the appropriate going private method for the Company due the relative cost and greater certainty of completion. The Board members also discussed the size of the Reverse
Stock Split and the price per pre-split share
.
They emphasized the need to select a stock split ratio that was large enough to meet their goal of going private with an appropriate margin for stockholders
that may convert their holdings
to be held of record. In evaluating the price per pre-split share to be paid to stockholders, they discussed the range for the fair market value of the Common Stock indicated by the draft of the valuation presentation by Cabrillo Advisors, the
recent trading prices and related volumes, the Companys cash position and the need to maintain a cash cushion for purposes of their operations. The Board did not give significant weight to the Companys projected financial results because
results from operation had remained fairly consistent recently.
The Board considered the Companys reliance on one
customer for a majority of its revenue. Based on these considerations, the Board focused its discussion on stock split ratios from 1-for-1,000 to 1-for-2,500. The Board members determined that they would reconvene after further analysis of the
potential terms of the going private transaction.
Subsequent to the June 3, 2014 Board meeting, Mr. Kirrane discussed the status
of the Boards evaluation of the going private transaction with Mr. Potiker. Mr. Kirrane told Mr. Potiker to expect a preliminary draft of a proxy statement to be distributed shortly thereafter. Mr. Potiker agreed to review the draft proxy
statement when received and to discuss with Mr. Ciabattoni of the status of the transaction.
On June 16, 2014, at the request of
management, legal counsel distributed drafts of the preliminary proxy statement, the Rule
13E-3
Transaction Statement and the final valuation report, including the final valuation presentation, to the Board,
representatives of Cabrillo Advisors, Mr. Potiker and Mr. Ciabattoni for their review.
17
On June 17, 2014, management called a Board meeting to be held on June 18, 2014 and informed
the Board, legal counsel, representatives of Cabrillo Advisors, Mr. Potiker and Mr. Ciabattoni. The primary agenda item was the consideration of the filing of the preliminary proxy statement.
Following the distribution of the draft preliminary proxy statement to Mr. Potiker and Mr. Ciabattoni neither indicated that they had any
substantive comments to the draft proxy statement.
On June 18, 2014, the Board held a meeting to further discuss going private and the
filing of the preliminary proxy statement. Management and legal counsel also attended. Mr. Potiker and Mr. Ciabattoni did not attend the meeting. The final valuation presentation presented to the Board reflected an adjustment to the conversion rate
for the Series 1-A and Series 2-A, which increased the shares of Common Stock issuable upon conversion of the series by 787,496 shares. This increase resulted in a higher number of total diluted shares being used as the denominator in determining
the per share value of the Common Stock from the total equity value. The increase in total diluted shares resulted in a $0.01 decrease in the top end of the range of fair market value from $0.65 to $0.64 per share. There were no other changes from
the draft to the final valuation presentation.
The Board discussed the draft of the preliminary proxy statement, which incorporated the
information from the final valuation report. The Board reviewed managements analysis of the costs and benefits of proceeding with a going-private transaction. Mr. Houlihan noted managements assessment that a large percentage of the
Companys shares of Common Stock are held by a relatively small number of stockholders and that the Reverse Stock Split would cash out a significant number of small stockholders that held few shares of Common Stock while only eliminating a
small percentage of the outstanding shares of Common Stock. The Board members then discussed that the stockholders with relatively small accounts had very little or no liquidity as a practical matter since the fees associated with trading their
shares would significantly reduce or exceed the proceeds from the sale of their stock. They then reviewed the costs to the Company of maintaining its public company status, including the costs associated with the audit and internal control
compliance. The Board believed that these costs were excessive given the Companys resources and operations.
The Board
members agreed that a reverse stock split continued to be the appropriate approach
.
Management emphasized its belief that the cost and commitment of managements time required to remain public was likely
not justified since the
Company did not anticipate using the public markets to raise capital and the market for the Companys Common Stock was not providing significant liquidity to stockholders.
Management then revisited the stock split analysis and the composition of the Companys stockholder base with the Board. After further
discussion, the Board determined that a ratio of 1-for-2,000 was appropriate to achieve the Companys primary objective of reducing the number of record holders to fewer than 300 holders so that the Company can terminate the registration of the
Companys Common Stock under the Exchange Act while also maintaining an adequate cash position and allowing for a portion of the Companys stockholders to convert from street name positions to record positions.
The Board then considered the fairness of cashing out pre-split shares at various prices. The Board considered the price of the Common Stock
as traded on the OTCBB, including the one-month, three-month, six-month and twelve-month average closing prices of $0.54, $0.30, $0.15 and $0.08, respectively, and the 52-week range of $0.01 $0.60 per share as one factor in determining
the price to be paid for fractional post-split shares. In determining the proposed price per pre-split share, the Board considered the increase in the Companys trading price following the filing of the Reports by reviewing the one-month and
three-month average closing prices, which periods followed the filing of the Reports. The Board did not consider the increase in the Companys trading price in determining whether to pursue a going private transaction at this time. The Board
decided to give more weight to the range of fair market value of $0.54 $0.64 per per-split share in the Cabrillo Advisors final valuation presentation because of the lack of consistent trading in the Companys Common Stock
prior to the filing of the Reports and the significant fluctuation in the price of the Companys Common Stock following the filing of the Reports. In determining the pre-split price per share within the range of fair market value determined by
Cabrillo Advisors, the Board considered that the Cabrillo Advisors range of fair market value did not fully reflect the lack of
18
liquidity in the trading market for the Companys Common Stock, the impact of the brokerage fees and commissions associated with selling a small number of shares or certain risk factors such
as customer concentration and collections rates. As a result, the Board believed that it was appropriate and fair to all stockholders to pay a pre-split price per share at the lower end of the range. In the subjective judgment of the directors,
$0.55 per pre-split share represented fair consideration, in light of the historical market prices, while also being within the valuation range provided by Cabrillo Advisors.
On the basis of managements recommendations, the Boards independent analysis, the subjective judgment of the Board members and the
factors described elsewhere in this Proxy Statement in the sections entitled Special Factors Reasons for and Purposes of the Reverse Stock Split, Special Factors Strategic Alternatives Considered,
Special Factors Third Party Valuation and Special Factors Fairness of the Reverse Stock Split, on June 18, 2014, the Board approved a 1-for-2,000 Reverse Stock Split, with a purchase price of
$0.55 per pre-split share to be paid to persons that would otherwise be entitled to receive a fractional post-split share of Common Stock. Our directors unanimously approved the Reverse Stock Split. No director dissented or abstained from voting on
the Reverse Stock Split. The Board further resolved that the Reverse Stock Split was substantively and procedurally fair to all unaffiliated stockholders, including those whose shares would be cashed out pursuant to the Reverse Stock Split and those
who would retain an equity interest in the Company subsequent to the consummation of the Reverse Stock Split. The Board approved the amendment to the Certificate of Incorporation and authorized management to file the necessary documentation with the
SEC.
Subsequent to the June 18, 2014 Board meeting, Mr. Kirrane relayed the Boards decision regarding the terms of the Reverse
Stock Split with Mr. Potiker and Mr. Ciabattoni.
On June 19, 2014, Mr. Potiker and Mr. Ciabattoni confirmed to Mr. Kirrane that they
intended to vote the shares of Common Stock and Preferred Stock held by SMP and Ciabattoni Trust, respectively, in favor of the Reverse Stock Split. Their intent to vote their shares in favor of the Reverse Stock Split is also disclosed in their
respective Schedule 13D filings.
Third Party Valuation
On March 14, 2014, the Board retained Cabrillo Advisors, a third-party independent advisor with extensive experience in performing
valuations of businesses and stock, to determine a range of fair market value of the Companys Common Stock. On May 30, 2014, the Board held a meeting with Cabrillo Advisors and reviewed the draft of the valuation presentation dated as of
May 27, 2014. On June 20, 2014, the Board reviewed the final valuation report, including the final valuation presentation dated as of May 27, 2014, which reflected updates to the conversion rates of the Series 1-A and Series 2-A as a
result of changes in the Companys capital structure. The valuation was considered by the Board in connection with its decision regarding the price per pre-split share of Common Stock to be paid to our stockholders in the Reverse Stock Split
and the fairness of that price to the Companys stockholders.
The Board did not limit Cabrillo Advisors in any manner concerning
the scope or methodology to be employed in conducting the valuation. The Company paid Cabrillo Advisors a fee of $26,500 plus expenses for the valuation, which payment was not contingent on Cabrillo Advisors conclusions or the consummation of
any transaction. The Company has agreed to indemnify and hold harmless Cabrillo Advisors and its affiliates and their respective directors, officers, agents and employees against and from all liabilities arising out of or in connection with the
advice or services to be rendered by them in connection with this engagement. No person or entity employed by or associated with Cabrillo Advisors owns the stock of, or trades the securities of, or has any financial interest in, the Company or any
related entities. Other than with respect to the current engagement, during the past two years no material relationship has existed, nor is one mutually understood to be contemplated, and no compensation was received or is to be received as a result
of any relationship between Cabrillo Advisors, its affiliates, and/or unaffiliated representatives and the Company or its affiliates. Cabrillo Advisors may in the future seek to provide services to the Company for which Cabrillo Advisors would
expect to receive customary compensation.
19
The full text of Cabrillo Advisors final valuation report, which includes the final
valuation presentation dated as of May 27, 2014 attached as an exhibit thereto, is attached as Annex D to this Proxy Statement and should be read carefully in its entirety. Cabrillo Advisors valuation report has been provided in this
Proxy Statement with the express written permission of Cabrillo Advisors. The valuation report is directed to the Board, relates only to the fair market value of the shares of the Common Stock and does not address any other aspect of the Reverse
Stock Split or any related transaction and does not constitute a recommendation to the Board or any stockholder with respect to the Reverse Stock Split or any other matter being voted upon by the stockholders. The valuation report and its analyses
must be considered as a whole. Selecting portions of the valuation report and Cabrillo Advisors analyses and factors considered by it, without considering all of its analyses and factors, or attempting to ascribe relative weights to some or
all its analyses and factors, could create an incomplete view of the evaluation process underlying the valuation.
In the course of
preparing the valuation report, representatives of Cabrillo Advisors made such reviews, analyses and inquiries as it deemed necessary and appropriate under the circumstances. Among other things, Cabrillo Advisors:
|
|
|
had discussions with the Companys management concerning the Companys operations, financial condition, future prospects and financial forecast;
|
|
|
|
reviewed the Companys Annual Reports on Form
10-K
and related financial information for the years ended September 30, 2010, 2011, 2012 and 2013 as filed with the SEC;
|
|
|
|
reviewed the Companys Quarterly Reports on Form
10-Q
and the related unaudited financial information for the periods ended March 31, 2013 and March 31, 2014 as
filed with the SEC;
|
|
|
|
reviewed the reported current and historical market prices and trading activity of the Companys publicly traded securities;
|
|
|
|
analyzed the Company, its financial and operating history, the nature of its offerings, and its competitive position;
|
|
|
|
reviewed the industry in which the Company competes and the state of development of the Companys target markets;
|
|
|
|
reviewed the current economic conditions and outlook for the U.S. economy;
|
|
|
|
reviewed prior transactions in the Companys Common Stock by related parties;
|
|
|
|
reviewed and analyzed certain publicly-available information, including information from Capital IQ and analyst reports regarding the guideline public companies, and information from Capital IQ regarding transactions of
comparable companies for which financial data was disclosed; and
|
|
|
|
conducted such other financial studies, analyses and investigations and considered such other historical information as it deemed necessary or appropriate for purposes of its presentation.
|
Cabrillo Advisors valuation is based on a number of key considerations, including the following:
|
|
|
The Companys historical and projected financial performance;
|
|
|
|
The Companys size (including number of facilities);
|
|
|
|
The Companys operating risk (including payor mix and customer concentration risk);
|
|
|
|
Rights and privileges of the Companys classes of preferred stock, including an estimate of the Companys time to liquidity; and
|
|
|
|
Anticipated changes in the Companys outstanding Common Stock as a result of the anticipated Series 7-A Exchange and cancellation of 4.25 million shares of Common Stock acquired from a stockholder in 2011.
|
20
None of the information provided by the Company was verified by Cabrillo Advisors as part of its
engagement. The valuation report and related analysis reflect Cabrillo Advisors best judgment in light of the information available at the time.
Based on its experience and professional judgment after considering the result of its analyses taken as a whole, Cabrillo Advisors estimates
that the fair market value of the pre-split shares of Common Stock to be purchased in connection with the Reverse Stock Split is in the range of $0.54 to $0.64 per pre-split share.
Set forth below is a summary of the valuation presentation included in the valuation report. The summary set forth below does not purport to
be a complete description of the analyses performed or the presentation made by Cabrillo Advisors to the Board and is qualified by reference to the valuation presentation included in Annex D to this Proxy Statement.
General.
Cabrillo Advisors was engaged to provide a calculation of a range of fair market value per share of the Companys Common Stock. For
purposes of its report fair market value means the price, expressed in terms of cash equivalents, at which such property would change hands between a hypothetical willing and able buyer and a hypothetical willing and able seller, acting
at arms length in an open and unrestricted market, when neither is
under compulsion to buy or to sell, and when both have reasonable knowledge of relevant facts. The best evidence of fair market value would be the market price in
an active market
.
However, over the past several years, trading in the Companys Common Stock has been sporadic and at relatively low volumes primarily as a result of the lack of current information about the Company. Even after filing
the Reports, trading volumes have remained low and the stock price has been volatile. As a result, Cabrillo Advisors has calculated the fair market value of the Company through taking into consideration the best information available, using
generally accepted valuation techniques.
Valuation Methods.
Cabrillo Advisors considered three valuation methods in preparing the valuation
presentation:
|
|
|
guideline public company method;
|
|
|
|
guideline transaction method; and
|
|
|
|
discounted cash flow method.
|
Guideline Public Company Method
In order to assess how the public market values companies with similar characteristics to the Company, Cabrillo Advisors reviewed and compared
specific financial and operating data relating to the Company with the following ten selected,
publicly-traded
companies that Cabrillo Advisors deemed appropriate:
|
|
|
AmSurg Corp.
|
|
Providence Service Corp.
|
|
|
First Choice Healthcare Solutions, Inc.
|
|
SunLink Health Systems Inc.
|
|
|
Foundation Healthcare, Inc.
|
|
Surgical Care Affiliates, Inc.
|
|
|
IPC The Hospitalist Company, Inc.
|
|
Team Health Holdings, Inc.
|
|
|
Northstar Healthcare Inc.
|
|
USMD Holdings, Inc.
|
Cabrillo Advisors chose these public companies based on their general similarity of industry and operating
model to the Company. Cabrillo Advisors noted that many of these companies are significantly larger than the Company. As of the date of the valuation presentation, the last twelve month (LTM) revenue, enterprise value and number of
facilities of all but one of the 10 comparable companies was greater than that of the Company. Cabrillo Advisors also took into consideration factors such as the Companys current and projected operating margins, growth rate, customer
concentration risk, and payor mix, among other relevant factors.
21
Due to the inherent differences between the business, operations and prospects of the Company and
the business, operations and prospects of each of the companies included in the analysis, Cabrillo Advisors believed that it was inappropriate to, and therefore did not, rely solely on the quantitative results of the guideline public company
analysis. Accordingly, Cabrillo Advisors also made qualitative judgments concerning differences between the financial and operating characteristics and prospects of the Company and the companies included in the guideline public company analysis that
would affect the public trading values of each. Cabrillo Advisors reviewed multiples of enterprise value to earnings before interest, taxes, depreciation and amortization adjusted for certain non-recurring items (Adjusted EBITDA) and
enterprise value to revenue. The following table shows the share price, equity market value, enterprise value, enterprise value to Adjusted EBITDA multiple and enterprise value to revenue multiple for each guideline public company.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EV to Adjusted EBITDA
|
|
|
EV to Revenue
|
|
Guideline Company
|
|
Share
Price
|
|
|
Equity
Market
Value
1
|
|
|
Enterprise
Value
2
|
|
|
FYE
(2013)
|
|
|
LTM
|
|
|
NFY
(2014)
|
|
|
NFY+1
(2015)
|
|
|
FYE
(2013)
|
|
|
LTM
|
|
|
NFY
(2014)
|
|
|
NFY+1
(2015)
|
|
AmSurg Corp.
|
|
$
|
42.96
|
|
|
$
|
1,382.6
|
|
|
$
|
2,461.6
|
|
|
|
6.7x
|
|
|
|
6.8x
|
|
|
|
6.4x
|
|
|
|
5.7x
|
|
|
|
2.28x
|
|
|
|
2.27x
|
|
|
|
2.17x
|
|
|
|
1.99x
|
|
First Choice Healthcare Solutions, Inc.
|
|
|
1.74
|
|
|
|
29.7
|
|
|
|
42.2
|
|
|
|
NMF
|
|
|
|
NMF
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
6.48x
|
*
|
|
|
5.72x
|
*
|
|
|
NA
|
|
|
|
NA
|
|
Foundation Healthcare, Inc.
|
|
|
0.31
|
|
|
|
53.1
|
|
|
|
81.7
|
|
|
|
NMF
|
|
|
|
25.8x
|
|
|
|
11.6x
|
|
|
|
7.2x
|
|
|
|
0.94x
|
|
|
|
0.90x
|
|
|
|
0.83x
|
|
|
|
0.78x
|
|
IPC The Hospital Company, Inc.
|
|
|
44.23
|
|
|
|
780.4
|
|
|
|
842.2
|
|
|
|
12.7x
|
|
|
|
12.5x
|
|
|
|
11.0x
|
|
|
|
9.8x
|
|
|
|
1.38x
|
|
|
|
1.34x
|
|
|
|
1.18x
|
|
|
|
1.07x
|
|
Northstar Healthcare Inc.
|
|
|
1.05
|
|
|
|
45.6
|
|
|
|
49.3
|
|
|
|
9.5x
|
|
|
|
7.8x
|
|
|
|
5.2x
|
|
|
|
2.4x
|
*
|
|
|
1.58x
|
|
|
|
1.26x
|
|
|
|
1.00x
|
|
|
|
0.54x
|
|
Providence Service Corp.
|
|
|
39.97
|
|
|
|
616.3
|
|
|
|
640.9
|
|
|
|
11.9x
|
|
|
|
11.6x
|
|
|
|
9.6x
|
|
|
|
8.1x
|
|
|
|
0.57x
|
|
|
|
0.57x
|
|
|
|
0.51x
|
|
|
|
0.46x
|
|
SunLink Health Systems Inc.
|
|
|
1.16
|
|
|
|
11.0
|
|
|
|
24.8
|
|
|
|
6.6x
|
|
|
|
5.7x
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
0.23x
|
*
|
|
|
0.23x
|
*
|
|
|
NA
|
|
|
|
NA
|
|
Surgical Care Affiliates, Inc.
|
|
|
29.04
|
|
|
|
1,159.5
|
|
|
|
1,981.2
|
|
|
|
14.6x
|
|
|
|
14.8x
|
|
|
|
12.9x
|
|
|
|
11.4x
|
|
|
|
2.52x
|
|
|
|
2.51x
|
|
|
|
2.37x
|
|
|
|
2.29x
|
|
Team Health Holdings, Inc.
|
|
|
49.71
|
|
|
|
3,570.7
|
|
|
|
4,013.2
|
|
|
|
17.0x
|
|
|
|
16.2x
|
|
|
|
14.0x
|
|
|
|
12.1x
|
|
|
|
1.68x
|
|
|
|
1.64x
|
|
|
|
1.50x
|
|
|
|
1.36x
|
|
USMD Holdings, Inc.
|
|
|
11.93
|
|
|
|
121.0
|
|
|
|
158.6
|
|
|
|
15.0x
|
|
|
|
NMF
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
0.68x
|
|
|
|
0.65x
|
|
|
|
NA
|
|
|
|
NA
|
|
Low
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.6x
|
|
|
|
5.7x
|
|
|
|
5.2x
|
|
|
|
5.7x
|
|
|
|
0.57x
|
|
|
|
0.57x
|
|
|
|
0.51x
|
|
|
|
0.46x
|
|
High
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.0x
|
|
|
|
25.8x
|
|
|
|
14.0x
|
|
|
|
12.1x
|
|
|
|
2.52x
|
|
|
|
2.51x
|
|
|
|
2.37x
|
|
|
|
2.29x
|
|
Median
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.3x
|
|
|
|
12.1x
|
|
|
|
11.0x
|
|
|
|
8.9x
|
|
|
|
1.38x
|
|
|
|
1.26x
|
|
|
|
1.09x
|
|
|
|
0.93x
|
|
Mean
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.7x
|
|
|
|
12.6x
|
|
|
|
10.1x
|
|
|
|
9.0x
|
|
|
|
1.42x
|
|
|
|
1.36x
|
|
|
|
1.34x
|
|
|
|
1.19x
|
|
1.
|
Based on reported diluted shares.
|
2.
|
Enterprise value calculated as equity market value + debt outstanding + preferred stock cash and cash equivalents.
|
*
|
Excluded from high, low, mean and median data.
|
NA refers to not available; NMF refers to not meaningful
figure.
FYE refers to the most recently complete fiscal year end (FYE), latest twelve months (LTM) or next fiscal year (NFY) for which financial
information has been made public.
Based on the analysis of the guideline public companies, Cabrillo Advisors selected multiple ranges of
2.0x 2.5x LTM revenue for the LTM period ended March 31, 2014, 2.0x 2.5x NFY 2014 projected revenue, 6.0x 7.0x LTM Adjusted EBITDA for the LTM period ended March 31, 2014 and 5.5x 6.5x 2014
NFY projected Adjusted EBITDA to determine an enterprise value range for the Company.
The guideline public company method indicated an
enterprise value range for the Company of $43.0 $52.0 million.
Guideline Transaction Method
Cabrillo Advisors reviewed the purchase prices and multiples paid in the following select mergers and acquisitions involving publicly-traded
target companies. The transactions were selected because the target companies in the transactions were outsourced medical service providers and hospital and other medical facility operators, and the transactions occurred between May 2011 and the
date of the valuation. Cabrillo Advisors reviewed transactions involving public companies not only because of the Companys status as a public company but also because of the greater availability and reliability of the financial information,
valuation multiples and other data relating to the companies involved and the transaction terms.
22
Cabrillo Advisors noted that the comparability of these selected transactions to any
potential transaction in which the Company would be involved was limited due to the relative size of the Company as compared to the companies involved in the selected transactions. Additionally, Cabrillo Advisors noted that the relevance of these
historical transactions to the current valuation is limited due to the recent and current market conditions. Since late 2011, there were only two transactions involving outsourced medical service providers for which implied EBITDA multiples were
available. Additionally, there were only four transactions involving medical facility operators for which EBITDA multiples were available over the same time period. Given the many developments in the Affordable Care Act since the end of 2011, as
well as significant movements in the broader stock market, Cabrillo Advisors reliance on transactions prior to 2011 was limited.
Based on its analysis of the guideline transactions, Cabrillo Advisors applied a multiple of
6.0x - 7.0x
to the Companys earnings before interest, taxes, depreciation and amortization (EBITDA) for the LTM period ended March 31, 2014, which it adjusted for a 20%
minority interest discount and the Companys interest-bearing debt to determine an implied enterprise value range for the Company. The multiple range was based on the multiples of EBITDA for the LTM period for the selected transactions. The
tables below summarizes the transaction value, revenue, EBITDA, transaction value to revenue multiple and transaction value to EBITDA multiple for each guideline transaction.
Outsourced Medical Providers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($ in millions)
|
|
|
|
|
|
|
Target
|
|
Transaction
Value
1
|
|
|
Revenue
|
|
|
EBITDA
|
|
|
Transaction
Value /
Revenue
2
|
|
|
Transaction
Value /
EBITDA
2
|
|
Allied Healthcare Staffing Division
|
|
$
|
28.7
|
|
|
$
|
39.5
|
|
|
|
NA
|
|
|
|
0.73x
|
|
|
|
NA
|
|
Novia Care Clinics, LLC
|
|
|
13.5
|
|
|
|
15.0
|
|
|
|
NA
|
|
|
|
0.90x
|
|
|
|
NA
|
|
TherEX, Inc.
|
|
|
14.0
|
|
|
|
20.0
|
|
|
|
NA
|
|
|
|
0.70x
|
|
|
|
NA
|
|
Health Inventures, LLC
|
|
|
18.5
|
|
|
|
41.5
|
|
|
|
4.3
|
|
|
|
0.45x
|
|
|
|
4.27x
|
|
Conmed Healthcare Management, Inc.
|
|
|
59.5
|
|
|
|
75.1
|
|
|
|
4.6
|
|
|
|
0.79x
|
|
|
|
13.02x
|
|
American Dental Partners, Inc.
|
|
|
396.2
|
|
|
|
289.3
|
|
|
|
48.9
|
|
|
|
1.37x
|
|
|
|
8.10x
|
|
Healthcare Partners, Inc.
|
|
|
19.4
|
|
|
|
20.0
|
|
|
|
NA
|
|
|
|
0.97x
|
|
|
|
NA
|
|
Allied Healthcare International Inc.
|
|
|
180.5
|
|
|
|
283.6
|
|
|
|
18.2
|
|
|
|
0.64x
|
|
|
|
9.91x
|
|
Low
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.45x
|
|
|
|
4.3x
|
|
High
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.37x
|
|
|
|
13.0x
|
|
Median
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.76x
|
|
|
|
9.0x
|
|
Mean
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.82x
|
|
|
|
8.8x
|
|
23
Hospital and Other Medical Facilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($ in millions)
|
|
|
|
|
|
|
|
|
|
|
|
Transaction
Value
1
|
|
|
Revenue
|
|
|
EBITDA
|
|
|
Transaction
Value /
Revenue
2
|
|
|
Transaction
Value /
EBITDA
2
|
|
Casa Grande Community Hospital
|
|
$
|
87.0
|
|
|
$
|
138.6
|
|
|
|
NA
|
|
|
|
0.63x
|
*
|
|
|
NA
|
|
Ambulatory Surgery Center in Great Falls
|
|
|
4.0
|
|
|
|
0.3
|
|
|
|
NA
|
|
|
|
11.76x
|
*
|
|
|
NA
|
|
Crescent City Surgical Centre, LLC
|
|
|
37.5
|
|
|
|
2.3
|
|
|
|
NA
|
|
|
|
16.45x
|
*
|
|
|
NA
|
|
GRMC, MVMC and Southeast Texas Hospital
|
|
|
283.3
|
|
|
|
2,400.0
|
|
|
|
NA
|
|
|
|
0.12x
|
*
|
|
|
NA
|
|
Health Management Associates, Inc.
|
|
|
7,715.9
|
|
|
|
5,868.3
|
|
|
|
880.1
|
|
|
|
1.31x
|
|
|
|
8.77x
|
|
Wilson Medical Center, Inc.
|
|
|
56.0
|
|
|
|
150.0
|
|
|
|
NA
|
|
|
|
0.37x
|
*
|
|
|
NA
|
|
Vanguard Health Systems Inc.
|
|
|
4,818.4
|
|
|
|
5,936.7
|
|
|
|
523.9
|
|
|
|
0.81x
|
|
|
|
9.20x
|
|
Cleveland County Healthcare System
|
|
|
100.0
|
|
|
|
243.5
|
|
|
|
NA
|
|
|
|
0.41x
|
*
|
|
|
NA
|
|
North Valley Orthopedic Surgery
|
|
|
9.0
|
|
|
|
0.8
|
|
|
|
NA
|
|
|
|
11.39x
|
*
|
|
|
NA
|
|
LifeCare Holdings, Inc.
|
|
|
801.4
|
|
|
|
483.2
|
|
|
|
59.7
|
|
|
|
1.66x
|
|
|
|
13.42x
|
|
Arkansas Surgical Hospital LLC
|
|
|
39.0
|
|
|
|
53.8
|
|
|
|
9.9
|
|
|
|
0.72x
|
|
|
|
3.93x
|
|
Woods Memorial Hospital, LLC
|
|
|
17.7
|
|
|
|
74.3
|
|
|
|
NA
|
|
|
|
0.24x
|
*
|
|
|
NA
|
|
Univ. of Maryland St. Joseph Medical Center LLC
|
|
|
158.1
|
|
|
|
409.2
|
|
|
|
NA
|
|
|
|
0.39x
|
*
|
|
|
NA
|
|
Cheboygan Memorial Hospital
|
|
|
5.0
|
|
|
|
44.1
|
|
|
|
NA
|
|
|
|
0.11x
|
*
|
|
|
NA
|
|
Tennova Healthcare
|
|
|
532.4
|
|
|
|
600.0
|
|
|
|
NA
|
|
|
|
0.89x
|
*
|
|
|
NA
|
|
Continucare Corp.
|
|
|
413.2
|
|
|
|
324.2
|
|
|
|
42.7
|
|
|
|
1.27x
|
|
|
|
9.68x
|
|
Smith of Georgia, LLC
|
|
|
55.0
|
|
|
|
52.0
|
|
|
|
NA
|
|
|
|
1.06x
|
*
|
|
|
NA
|
|
Low
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.72x
|
|
|
|
3.9x
|
|
High
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.66x
|
|
|
|
13.4x
|
|
Median
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.27x
|
|
|
|
9.2x
|
|
Mean
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.16x
|
|
|
|
9.0x
|
|
*
|
Excluded from high, low, mean and median data.
|
1.
|
Transaction Value refers to the implied enterprise value of target company, based on the announced transaction price and other public information available.
|
2.
|
Based on reported metric for the most recent LTM period prior to the announcement of the transaction.
|
NA
refers to not available.
Transaction study based on announced and completed, controlling interest acquisitions greater than $1.0 million
No company used in this analysis for comparative purposes is identical to the Company.
The guideline transaction method indicated an enterprise value range for the Company of $39.0 $45.0 million.
Discounted Cash Flow Method
A discounted
cash flow analysis is a valuation methodology used to derive a valuation of an asset by calculating the present value of estimated future cash flows of the asset. Present value refers to the current value of future cash flows
and is obtained by discounting those future cash flows by a discount rate that takes into account macro-economic assumptions and estimates of risk, the opportunity cost of capital, expected returns and other appropriate factors.
Cabrillo Advisors performed a discounted cash flow analysis by adding the present value of projected free cash flows for the
Company for the fiscal years 2014 through 2020 to the present value of the terminal value for the Companys projected free cash flow for 2021
.
Free cash flow is defined as cash that is available to either reinvest
or to distribute to security holders and terminal value refers to the value of all future cash flows from an asset at a particular point in time
.
The projected free cash flows that Cabrillo Advisors used in its analysis were based
on financial projections and estimates prepared based on discussions with the management of the Company.
24
Below is a summary of the financial forecast used in the discounted cash flow method, which was
prepared by Cabrillo Advisors based on discussions with management.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($ in millions)
|
|
Projected FYE September 30,
|
|
|
|
2014
1
|
|
|
2015
|
|
|
2016
|
|
|
2017
|
|
|
2018
|
|
|
2019
|
|
|
2020
|
|
Revenue (net)
|
|
$
|
12.566
|
|
|
$
|
22.005
|
|
|
$
|
23.008
|
|
|
$
|
24.052
|
|
|
$
|
25.138
|
|
|
$
|
26.144
|
|
|
$
|
27.189
|
|
Adjusted EBIT
|
|
|
4.703
|
|
|
|
8.303
|
|
|
|
8.841
|
|
|
|
9.404
|
|
|
|
9.994
|
|
|
|
10.339
|
|
|
|
10.711
|
|
Unlevered Earnings
|
|
|
2.822
|
|
|
|
4.982
|
|
|
|
5.305
|
|
|
|
5.643
|
|
|
|
5.997
|
|
|
|
6.204
|
|
|
|
6.427
|
|
Net Unlevered Cash Flows
|
|
|
2.667
|
|
|
|
4.561
|
|
|
|
4.919
|
|
|
|
5.294
|
|
|
|
5.687
|
|
|
|
5.955
|
|
|
|
6.210
|
|
Present Value of Net Unlevered Cash Flows
|
|
|
2.551
|
|
|
|
3.876
|
|
|
|
3.603
|
|
|
|
3.343
|
|
|
|
3.096
|
|
|
|
2.795
|
|
|
|
2.512
|
|
(1)
|
Represents a 7.2-month stub period.
|
The financial forecast was developed by Cabrillo
Advisors using the Companys historical financial statements and related cash flow information provided by management. Further, management and Cabrillo Advisors representatives had discussions regarding the Companys operations and
prospects. Using that information, Cabrillo Advisors developed projected financial statements and worked with management to refine the calculations and assumptions used in the forecast. The Board then reviewed and approved the financial forecast.
Gross revenue was projected to grow at a rate of 3.0%, with slight improvement in the Companys bad debt allowance rate each year.
Additionally, operating expenses were projected to increase at a rate consistent with gross revenue, and capital expenditures were expected to remain consistent at 1.5% of revenue annually.
Cabrillo Advisors discounted the projected free cash flows and the terminal value of the Company using a discount rate of 16.0%. Cabrillo
Advisors calculated a terminal value for the Company by dividing projected 2021 cash flow by 12.0% (which reflects the discount rate of 16.0% less the projected perpetual growth rate of 4.0%).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Perpetual Growth Rate
|
|
Discount Rate
|
|
3.0%
|
|
|
4.0%
|
|
|
5.0%
|
|
15.0%
|
|
$
|
45.084
|
|
|
$
|
47.392
|
|
|
$
|
50.160
|
|
16.0%
|
|
|
41.682
|
|
|
|
43.550
|
|
|
|
45.758
|
|
17.0%
|
|
|
38.768
|
|
|
|
40.301
|
|
|
|
42.089
|
|
The discount rate was determined based on Cabrillo Advisors estimate of the Companys weighted
average cost of capital. The WACC was calculated by applying the capital asset pricing model to the Companys estimated cost of debt and equity. The estimated cost of equity was calculated by reviewing inputs such as comparable companies
equity beta, the current risk free interest rate and market risk and size premiums as provided by Ibbotson & Associates and Duff & Phelps.
Cabrillo Advisors also performed a sensitivity analysis using discount rates ranging from 15.0% to 17.0% and perpetual growth rates from 3.0%
to 5.0% to determine an implied enterprise value range as summarized in the table below. Cabrillo Advisors further adjusted the implied enterprise value range to account for a minority interest discount and the Companys interest-bearing debt.
The discounted cash flow method indicated an enterprise value range for the Company of $32.0 $41.0 million.
Valuation Summary
Cabrillo Advisors
presented a combined analysis of its valuation methods based on the weightings given to the guideline public company method (30.0%,), guideline transaction method (25.0%) and discounted cash flow method (45.0%). Cabrillo Advisors placed a
greater degree of weight on the discounted cash flow method
25
(45%) given the relative lack of highly comparable companies and transactions in the guideline public company and guideline transaction methods. Cabrillo Advisors weighted the guideline
company method at 30% versus the similar transaction method at 25% given the higher relevance of comparable companies in the guideline company method relative to the guideline transaction method. The combined analysis implied an enterprise value
range for the Company of $37.1 $45.3 million. Cabrillo Advisors adjusted the implied enterprise value range for the Companys net debt, which included the anticipated impact of certain deferred Medicare and Medicaid payments and net
operating losses, to determine an implied equity value range of $40.0 $48.0 million. Based on the equity value range and the capital structure of the Company as adjusted for certain anticipated transactions, Cabrillo Advisors calculated that
the range for the fair market value of the Companys Common Stock was $0.54 $0.64 per share.
Effects of the Reverse Stock Split
If effected, based on information available to us, the Reverse Stock Split is estimated to reduce the number of record stockholders of
our Common Stock from 354 to 67. This reduction in the number of our stockholders will enable us to terminate registration of our Common Stock under the Exchange Act. Additionally, certain provisions of the Exchange Act will no longer apply, such as
the short-swing profit recovery provisions of Section 16(b).
For estimated expenditures by the Company of $280,000 in transaction
costs (including legal, financial, accounting, printing, mailing and other fees and costs) and estimated costs of $225,000 for fractional post-split shares, we estimate we will realize $370,000 to $410,000 in cost savings on an annual basis by
terminating our public company status. We intend to apply for termination of registration of our Common Stock under the Exchange Act as soon as practicable following completion of the Reverse Stock Split.
The effect of the Reverse Stock Split on each stockholder will depend on the number of shares that such stockholder owns. Registered
stockholders and stockholders holding shares of Common Stock in street name through a nominee (
e.g
., a broker or a bank) holding fewer than 2,000 shares of Common Stock will have their shares converted into the right to receive a cash amount
equal to $0.55 per pre-split share.
Prior to the Reverse Stock Split, SMP and Ciabattoni Trust, two of our significant
stockholders, beneficially own approximately 54.1% and 39.0%, respectively, of our Common Stock. After the Reverse Stock Split, SMP and Ciabattoni Trust will beneficially own approximately 54.8% and 39.5%, respectively, of our Common Stock. Further,
prior to the Reverse Stock Split, SMP and Ciabattoni Trust beneficially own 13.9% and 6.7%, respectively, of our Series 5-A and 20.5% and 19.1%, respectively, of our Series 6-A. After the Reverse Stock Split, the percentage of Series 5-A and Series
6-A beneficially owned by SMP and Ciabattoni Trust will not change.
As of September 30, 2013, we had net operating loss
carry-forwards of approximately $19.9 million, available to offset future taxable income, if any. A change of ownership of more than 50% occurred on June 22, 2001. According to applicable U.S. tax laws, losses that occurred before that date are
limited to $0.3 million per year for up to 20 years, totaling approximately $6.5 million of the $19.9 million in net operating loss carry-forwards. The balance of the Companys net operating loss carry-forwards are not subject to an annual
limitation. These net operating loss carry-forwards will expire between 2012 and 2030. To the extent that the Company has future regular, alternative minimum and foreign taxable income, the Company and its stockholders, including its affiliates, may
benefit from the use of the Companys net operating loss carry-forwards. Stockholders owning fewer than 2,000 shares of Common Stock will be cashed out and will not have the opportunity to benefit from the use of the Companys net
operating loss carry-forwards.
The fractional shares acquired in the Reverse Stock Split will be restored to the status of
authorized but unissued shares.
Potential Disadvantages of the Reverse Stock Split to Stockholders
Stockholders owning fewer than 2,000 shares of Common Stock immediately prior to the effective time of the Reverse Stock Split will no longer
have any equity interest in the Company after the Reverse Stock Split.
26
They will not participate in any future potential earnings or growth. Approximately 287 holders of record are currently expected to be fully cashed out in the Reverse Stock Split. It will not be
possible for cashed out stockholders to re-acquire an equity interest in the Company unless they purchase an interest from the remaining stockholders.
The Reverse Stock Split will require stockholders who own fewer than 2,000 shares of Common Stock to involuntarily surrender their shares for
cash. These stockholders will not have the ability to continue to hold their shares. The ownership interest of these stockholders will terminate as a result of the Reverse Stock Split. The Board believes the Reverse Stock Split will benefit these
stockholders because of the liquidity provided by the transaction at a price that is fair to these stockholders and the Company.
The
percentage of Common Stock beneficially owned by our officers, directors, and significant stockholders of the Company will not materially increase as a result of the Reverse Stock Split. Based on an assumed cash-out of approximately 407,753 shares,
the percentage ownership of each holder remaining after the Reverse Stock Split will not increase materially. For example, if a holder owns 10% of the outstanding Common Stock prior to the Reverse Stock Split, such holder would hold approximately
10.2% after the Reverse Stock Split.
Disadvantages to our stockholders who will remain as stockholders after the Reverse Stock Split
include less access to information and decreased liquidity as a result of deregistration of our Common Stock under the Exchange Act. As a result of deregistration, we will not have periodic reporting requirements under the Exchange Act.
Effect of the Reverse Stock Split on Option and Warrant Holders
Regardless of whether an outstanding stock option provides a right to purchase fewer than, equal to or greater than 2,000 shares, the exercise
price and the number of shares underlying each such outstanding stock option granted by the Company under its stock option plan will be automatically adjusted to reflect the Reverse Stock Split on the Effective Date.
Similarly, the exercise price and the number of shares underlying our outstanding warrants will be adjusted to reflect the Reverse Stock
Split.
Before and after the adjustment to reflect the Reverse Stock Split, the aggregate number of shares of Common Stock underlying the
Companys outstanding stock options and warrants are 6,370,879 and 3,256, respectively. Upon exercise of stock options or warrants, the Company will pay the holder the fair market value (as determined under the applicable stock option or
warrant agreement) of any fractional share of Common Stock to which the holder is entitled.
Effect of the Reverse Stock Split on our Preferred
Stockholders
The total number of shares of Common Stock into which each of share our outstanding Preferred Stock can be converted will
be adjusted on the Effective Date to reflect the Reverse Stock Split. Correspondingly, the number of votes to which each share of Preferred Stock is entitled will also be adjusted to reflect the Reverse Stock Split. Upon conversion of Preferred
Stock, the Company will pay the holder the fair market value (as determined under the applicable Certificate of Designation for the Preferred Stock) of any fractional share of Common Stock to which the holder is entitled. For additional information
about the adjustment, see Stockholders Entitled to Vote in this Proxy Statement.
Effect of the Reverse Stock Split on Participants in
Series 7-A Exchange
During the fiscal year ended September 30, 2011, we entered into the 2011 Bridge Notes with the 2011 Bridge
Lenders. As part of the consideration for entering into the 2011 Bridge Notes, each of the 2011 Bridge Lenders was granted the option to exchange their current holdings, if any, of Series 5-A, Series 6-A and Common
27
Stock (collectively the Exchanged Securities) for shares of our Series 7-A. Upon election to exchange, each lender would receive the number of Series 7-A equal to the initial
consideration paid for their Exchanged Securities divided by $1,000. In connection with the exchange, each 2011 Bridge Lender would receive warrants to purchase a number of shares of Common Stock of the Company in an amount equal to 1,120 multiplied
by the aggregate number of shares of Series 7-A issued at an exercise price of $0.3125 per share. The Company expects each of the 2011 Bridge Lenders to convert their holdings of Exchanged Securities to Series 7-A, which will result in the issuance
of an aggregate of 5,998 shares of Series 7-A and warrants to purchase up to 6,717,760 shares of Common Stock.
Because the number of
shares of Series 7-A to be issued to the 2011 Bridge Lenders is based on the consideration paid for the Exchanged Securities, the Company does not expect the Reverse Stock Split to have an effect on the 2011 Bridge Lenders. The number of shares of
Series 7-A that each 2011 Bridge Lender will receive will not be adjusted. However, as with our other series of Preferred Stock, the total number of shares of Common Stock into which each share of Series 7-A is convertible and the number of votes to
which each share of Series 7-A is entitled will be adjusted on the Effective Date to reflect the Reverse Stock Split. No shares of Series 7-A are currently outstanding.
Each of William Houlihan, SMP and Ciabattoni Trust is a 2011 Bridge Lender and is eligible to participate in the Series 7-A Exchange. The
Company expects to consummate the Series 7-A Exchange within the next year but anticipates that the Series 7-A Exchange will not occur until after the Meeting. Consequently, the Series 7-A Exchange will not affect the beneficial ownership or the
voting rights of William Houlihan, SMP or Ciabattoni Trust at the Meeting. If the Reverse Stock Split is approved, the Board intends to adjust the number of shares of Common Stock issuable upon exercise of and the exercise price of any warrants
issued in relation to the Series 7-A Exchange to reflect the Reverse Stock Split.
As of the date of this Proxy Statement, William
Houlihan, SMP and Ciabattoni Trust beneficially owned 10.6%, 54.1% and 39.0% of the Companys Common Stock, respectively. Assuming that the Companys stockholders do not approve the Reverse Stock Split, following the Series 7-A Exchange,
they will beneficially own 13.8%, 61.0%, and 46.2% of the Companys Common Stock, respectively. The table below summarizes the voting rights of William Houlihan, SMP and Ciabattoni Trust before and after the completion of the Series 7-A
Exchange assuming the Companys stockholders do not approve the Reverse Stock Split.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before Series 7-A Exchange
|
|
|
After Series 7-A Exchange
|
|
|
|
Percentage of
Common
Stock Vote
|
|
|
Percentage of
Eligible
Votes
|
|
|
Percentage of
Common
Stock Vote
|
|
|
Percentage of
Eligible
Votes
|
|
William Houlihan
|
|
|
1.5
|
%
|
|
|
1.7
|
%
|
|
|
|
|
|
|
1.8
|
%
|
SMP
|
|
|
30.6
|
%
|
|
|
20.4
|
%
|
|
|
28.5
|
%
|
|
|
20.9
|
%
|
Ciabattoni
|
|
|
18.1
|
%
|
|
|
13.0
|
%
|
|
|
20.0
|
%
|
|
|
13.0
|
%
|
28
Effect of the Reverse Stock Split on Affiliates
The following table summarizes the effect of the Reverse Stock Split on each affiliates interest in the net book value and net earnings
of the Company in dollar amounts and percentages, assuming that 407,753 shares of Common Stock are cashed out in the Reverse Stock Split.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage
Common
Stock
Ownership
before
Reverse
Stock Split
|
|
|
Percentage
Common
Stock
Ownership
after
Reverse
Stock Split
|
|
|
Net book
value as of
March 31,
2014,
before
Reverse
Stock Split
|
|
|
Pro
Forma net
book
value as of
March 31,
2014,
after
Reverse
Stock
Split
|
|
|
Change
in net
book
value
|
|
|
Percent
change
in net
book
value
|
|
|
Net
income
for the six
months
ending
March 31,
2014,
before
Reverse
Stock
Split
|
|
|
Pro forma
net
income
for the six
months
ending
March 31,
2014,
after
Reverse
Stock Split
|
|
|
Change
in net
income
|
|
|
Percent
change
in net
income
|
|
SMP Investments I, LLC(1)
|
|
|
30.6
|
%
|
|
|
31.2
|
%
|
|
$
|
4,549,969
|
|
|
$
|
4,641,253
|
|
|
|
91,284
|
|
|
|
2.01
|
%
|
|
$
|
1,680,732
|
|
|
$
|
1,714,452
|
|
|
$
|
33,720
|
|
|
|
2.01
|
%
|
Ciabattoni Living Trust(2)
|
|
|
18.1
|
%
|
|
|
18.5
|
%
|
|
|
2,693,236
|
|
|
|
2,747,399
|
|
|
|
54,163
|
|
|
|
2.01
|
%
|
|
|
994,866
|
|
|
|
1,014,873
|
|
|
|
20,008
|
|
|
|
2.01
|
%
|
Richardson E. Sells
|
|
|
1.0
|
%
|
|
|
1.0
|
%
|
|
|
151,305
|
|
|
|
154,348
|
|
|
|
3,043
|
|
|
|
2.01
|
%
|
|
|
55,891
|
|
|
|
57,015
|
|
|
|
1,124
|
|
|
|
2.01
|
%
|
Robert N. Schwartz(3)
|
|
|
*
|
|
|
|
*
|
|
|
|
1,594
|
|
|
|
1,543
|
|
|
|
(51
|
)
|
|
|
-3.17
|
%
|
|
|
589
|
|
|
|
570
|
|
|
|
(19
|
)
|
|
|
-3.17
|
%
|
William Houlihan
|
|
|
1.5
|
%
|
|
|
1.6
|
%
|
|
|
226,958
|
|
|
|
231,522
|
|
|
|
4,564
|
|
|
|
2.01
|
%
|
|
|
83,837
|
|
|
|
85,523
|
|
|
|
1,686
|
|
|
|
2.01
|
%
|
Sean Kirrane
|
|
|
*
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
|
Adrian Reeder
|
|
|
*
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
|
*
|
Indicates less than 1%.
|
(1)
|
Brian Potiker, in his capacity as a manager of SMP, may be deemed to beneficially own the shares held by SMP.
|
(2)
|
Anthony J. Ciabattoni and Jane G. Ciabattoni, in their capacity as trustees of Ciabattoni Living Trust, may be deemed to beneficially own the shares held by Ciabattoni Living Trust.
|
(3)
|
Mr. Schwartz currently owns 2,107 shares of Common Stock. The reduction in his interest in the net book value and net earnings of the Company results from the fact that a portion of his Common Stock will be cashed out
in the Reverse Stock Split.
|
Financial Effect of the Reverse Stock Split
We estimate that completion of the Reverse Stock Split will require $505,000, which includes $280,000 for estimated expenses, including legal,
financial, accounting, printing, mailing, and other fees and costs. As a result, we will have decreased working capital following the Reverse Stock Split. The payments to holders who receive cash in lieu of a fractional post-split share will be paid
from our available cash.
Based upon analysis of the stock ownership among holders of Common Stock, the Board limited the scope of the
Reverse Stock Split to 1-for-1,000 to 1-for-2,500 in light of the Companys continuing working capital needs. See also the information under the caption Financing the Reverse Stock Split in this Proxy Statement.
Fairness of the Reverse Stock Split
The
Board determined that the Reverse Stock Split, including the proposed cash payment of $0.55 per pre-split share to stockholders whose shares would be cashed out, is substantively and procedurally fair to all of our unaffiliated stockholders,
including those whose shares will be cashed out and those who will continue as stockholders of the Company.
The Board considered, among
other things, the following factors related to the substantive fairness of the Reverse Stock Split for unaffiliated stockholders:
|
|
|
Cash Payment.
Those stockholders who own less than 2,000 shares of our pre-split Common Stock will receive a cash payment of $0.55 per pre-split share. They will not pay commissions that stockholders would
have to pay if they attempted to sell their shares in the open market. The Board also considered that the Reverse Stock Split provided our stockholders with an opportunity to obtain liquidity in a limited trading market.
|
|
|
|
Valuation.
The Board evaluated and considered a valuation of the Common Stock by Cabrillo Advisors in determining the price per
pre-split share to be paid to stockholders. The Board chose not to retain the services of an independent advisor to evaluate and prepare an opinion regarding the fairness of the
|
29
|
Reverse Stock Split because it believes the cost of these services would be excessive given the relative size and cost of the Reverse Stock Split
.
For additional information about the
valuation and the Boards consideration of the valuation, see Special Factors Background of the Reverse Stock Split and Special Factors Third Party Valuation in this Proxy Statement.
|
|
|
|
Current and Historical Market Prices for our Common Stock.
The proposed transaction price of $0.55 per pre-split share of Common Stock compares favorably to the one-month, three-month, six-month and
twelve-month average price of the Common Stock, as well as to the
52-week
range of $0.01 $0.60 per share. In determining the proposed price per pre-split share, the Board also considered the
increase in the Companys trading price following the filing of the Reports by reviewing the one-month and three-month average closing prices of $0.54 and $0.30, respectively, which periods followed the filing of the Reports.
|
|
|
|
Company Financial Position.
The completion of the Reverse Stock Split will require approximately $505,000 in cash, which the Company expects to pay from cash on hand. The Board considered the level of cash
on hand necessary to continue to operate its business following the Reverse Stock Split and preserve the value in the business for stockholders that will continue to hold an interest in the Company.
|
|
|
|
Undiscounted Price.
The Board considered the valuation of Cabrillo Advisors and the current and historical market prices and trading volumes of our Common Stock when evaluating the fairness of the
pre-split share value to our unaffiliated stockholders. The Board determined not to apply any discount for the lack of marketability of the shares of our Common Stock when determining the price per pre-split share.
|
|
|
|
Net Book Value and Liquidation Value.
The Board did not consider the Companys net book value or liquidation value of the Common Stock in its deliberations regarding the fairness of the Reverse Stock
Split. The Board determined that the Companys net book value was not a reliable indicator of market value of the Companys Common Stock because net book value is an accounting concept based on historical costs and the fact that the
Company is primarily a services company with few marketable assets
.
In addition, the Board did not consider the liquidation value of the Common Stock because the Board believed that the range of fair market value represented by the valuation
analysis by Cabrillo Advisors would exceed any liquidation value.
|
|
|
|
Going Concern Value
. In determining the proposed transaction price, the Board considered the range of fair market value from the valuation of the Company prepared by Cabrillo Advisors, which values the Company
based on the assumption that the Company will continue as a going concern.
|
|
|
|
Equal Treatment of Affiliated and Unaffiliated Holders.
The Reverse Stock Split will not affect holders of our Common Stock differently on the basis of affiliate status. The sole determining factor in
whether a stockholder will be cashed-out Common Stock or be a continuing holder of our Common Stock as a result of the Reverse Stock Split is the number of shares of our Common Stock held by the stockholder immediately prior to the Reverse Stock
Split.
|
|
|
|
Purchases to Continue Stock Ownership.
Depending on the availability of shares for purchase and the number of shares they currently hold, stockholders may elect to remain stockholders of the Company by
acquiring sufficient additional shares so that they will hold at least 2,000 shares of Common Stock in their account immediately prior to the Reverse Stock Split. Stockholders can control whether they remain stockholders after the Reverse Stock
Split is effected or receive cash in connection with the Reverse Stock Split.
|
|
|
|
Sales or Transfers to Discontinue Stock Ownership.
Stockholders who would otherwise retain an equity interest in the Company after the Reverse Stock Split may have some control as to whether they will
retain an interest in the Company by selling or transferring shares of Common Stock prior to the Reverse Stock Split, depending on the demand for their shares. They can reduce their equity interest to below 2,000 shares and, as a result, cash out
pursuant to the Reverse Stock Split.
|
30
|
|
|
No Firm Offers to Acquire Control of the Company.
During the past two years, we have not received any firm offers for the merger or consolidation of the Company with or into another company, or vice versa,
the sale or transfer of all or substantially all of our assets to another company, or a purchase of our securities by another person that would involve a change in control of the Company.
|
|
|
|
Stockholder Rights.
The Reverse Stock Split will not materially change the rights, preferences or limitations of stockholders who will retain an interest in the Company subsequent to the Reverse Stock
Split.
|
The Board considered, among other things, the following factors related to the procedural fairness of the
Reverse Stock Split for unaffiliated stockholders:
|
|
|
Purchases or Sales by Stockholders
. Before the Reverse Stock Split becomes effective, all stockholders may seek to buy enough shares so that they will not be cashed out or to sell enough shares so that they will
no longer be a stockholder.
|
|
|
|
Separate Vote of Unaffiliated Stockholders
. The Reverse Stock Split has not been structured to require the separate approval of stockholders unaffiliated with the Company because the Board concluded that the
interests of unaffiliated stockholders were sufficiently represented by the Board. The Board noted that affiliated and unaffiliated stockholders will be treated equally in the Reverse Stock Split. If separate approval of unaffiliated stockholders
were required, the Companys affiliated stockholders would receive lesser voting rights than unaffiliated stockholders solely on the basis of their affiliate status. Further, the separate approval by the Companys unaffiliated stockholders
is not required by Delaware law.
|
|
|
|
Special Committee/Independent Advisor
. The Board did not create a special committee to approve the Reverse Stock Split, nor did it hire an independent advisor to advise the Board on the fairness of the Reverse
Stock Split. The Board decided it was not necessary to form a special committee because the Board was composed of three independent directors. However, the Board did consider the valuation by Cabrillo Advisors in determining the fairness of the
price per pre-split share. See Special Factors Background of the Reverse Stock Split in this Proxy Statement. The Board believed that the unaffiliated stockholders option to buy or sell shares of Common Stock protects their
interests.
|
|
|
|
Board Approval
. Board approval was required for the Reverse Stock Split. The Board, which is entirely independent, unanimously approved the Reverse Stock Split and determined that the Reverse Stock Split was fair
to unaffiliated stockholders.
|
|
|
|
Corporate Records
. The Board did not provide stockholders access to our corporate files, except as provided under Delaware law. The Board determined that this Proxy Statement, together with our other filings with
the SEC, provide adequate information for all of the Companys stockholders.
|
|
|
|
Unaffiliated Representatives
. None of the Companys non-employee directors has retained an unaffiliated representative to act solely on behalf of unaffiliated stockholders for purposes of negotiating the
terms of the Reverse Stock Split or to prepare a report concerning the fairness of the transaction. The Board did not believe that it was necessary to appoint an unaffiliated representative because all three members of the Board are independent and
because the Board believed that they could represent the interests of the unaffiliated stockholders.
|
Based on the factors
above, the Board determined that the Reverse Stock Split is procedurally and substantively fair to all unaffiliated stockholders. Because of the wide variety of factors the Board considered in rendering the substantive and procedural fairness of the
Reverse Stock Split, the Board did not find it practicable to assign relative weights to factors it considered in deciding that the transaction is fair and in the best interests of unaffiliated stockholders.
31
Fairness Determination by Sean Kirrane, Adrian Reeder, SMP, Brian Potiker, Ciabattoni Trust, A. Ciabattoni
and J. Ciabattoni
Each of Sean Kirrane, Adrian Reeder, SMP, Brian Potiker, Ciabattoni Trust, A. Ciabattoni and J. Ciabattoni, being
those persons and entities deemed a filing person for purposes of Schedule 13E-3, has determined that the Reverse Stock Split is procedurally and substantively fair to unaffiliated stockholders, including both unaffiliated stockholders
who will be cashed-out in the Reverse Stock Split and those who continue as stockholders following the Reverse Stock Split. In reaching this determination, these persons relied upon the factors considered by, and the analyses of, our Board and
adopted such factors and analyses as their own. See Special Factors Fairness of the Reverse Stock Split.
Absence of a Fairness
Opinion
Neither the Company, the Board, nor any committee of the Board has solicited or obtained any appraisal, report or opinion by
any outside party regarding the fairness of the Reverse Stock Split. The Board chose not to retain the services of an independent advisor to provide advice regarding the fairness of the Reverse Stock Split because it believes the cost of doing so
would be excessive relative to the size and cost of the Reverse Stock Split. The total estimated payment to be made for all fractional shares cashed out in connection with the Reverse Stock Split is $225,000. In addition, the total estimated cost of
the Reverse Stock Split is approximately $505,000 (including the payment amount of $0.55 per pre-split share). Based on managements estimates, the cost of a fairness opinion was estimated to be $100,000. In light of the relative costs, the
Board did not seek a fairness opinion.
However, the Board engaged Cabrillo Advisors, an independent advisor, to assist the Company in
evaluating the fair market value of our Common Stock. The Board did not obtain or request an opinion from Cabrillo Advisors regarding the fairness of the Reverse Stock Split. This valuation cost approximately $26,500 plus expenses.
Termination of Exchange Act Registration
Our Common Stock is currently registered under the Exchange Act and trades on the OTCBB. We are permitted to terminate the Exchange Act
registration if there are fewer than 300 record holders of our outstanding shares of Common Stock. As of June 20, 2014, we had 354 record holders of our Common Stock. Upon the effectiveness of the Reverse Stock Split, we expect to have 67
record holders of our Common Stock. We intend to terminate the registration of our Common Stock under the Exchange Act as promptly as possible after the Effective Date. Following deregistration, our Common Stock will no longer be eligible for
trading on the OTCBB. Our Common Stock may be quoted on the Pink Sheets.
Terminating our registration under the Exchange Act will
substantially reduce the information we will be required to furnish to our stockholders. After we are no longer an SEC reporting company, our stockholders will have access to our corporate books and records to the extent provided by the Delaware law
and to any additional disclosures required by our directors and officers fiduciary duties.
Deregistering will make many of
the provisions of the Exchange Act inapplicable to us. These Exchange Act provisions include the short-swing profit provisions of Section 16, the proxy solicitation rules under Section 14 and the stock ownership reporting rules under
Section 13. Affiliated stockholders will be permitted to dispose of their Common Stock under Rule 144 promulgated under the Securities Act of 1933. There will no longer be a public market for our Common Stock. Market makers on the OTCBB will not be
able to make a market in our Common Stock.
We estimate that termination of registration of our Common Stock under the Exchange Act will
save us between $370,000 and $410,000 per year in legal, accounting, printing and other expenses. Deregistration will also enable our management to devote more time to our operations. See also information under the caption Special
Factors Reasons for and Purposes of the Reverse Stock Split in this Proxy Statement.
32
Quotation of Common Stock
Our Common Stock is currently quoted on the OTCBB. Following the Reverse Stock Split, our shares may be quoted on the Pink Sheets at
http://www.otcmarkets.com, an electronic interdealer quotation service. The Pink Sheets are not a stock exchange, and we do not have the ability to list on or control whether our shares are quoted on the Pink Sheets. The price may be more or less
than the current price on the OTCBB. In addition, the spread between the bid and ask prices of our Common Stock may be wider than on the OTCBB, and the liquidity of our shares may be lower. There is no assurance, however, that there will be any Pink
Sheets quotations after the Reverse Stock Split or that, if such quotations begin, they will continue for any length of time.
Federal Income Tax
Consequences of the Reverse Stock Split
The following is a summary of the material federal income tax consequences of the Reverse
Stock Split to holders of Common Stock and to the Company. This summary is based on the Internal Revenue Code of 1986, as amended (the Code), regulations, rulings and judicial decisions currently in effect, all of which are subject to
change. This summary does not address all aspects of federal income taxation that may apply to a stockholder because of his particular circumstances. This summary does not discuss any special rules that may be applicable to some investors (for
example, estates, trusts, individuals who are not citizens or residents of the United States, foreign corporations, insurance companies, regulated investment companies, tax-exempt organizations and dealers in securities). The discussion assumes that
stockholders have held shares of the Companys Common Stock subject to the Reverse Stock Split as capital assets at all relevant times. This summary does not cover the applicability and effect of any state, local or foreign tax laws. Investors
should accordingly consult their own tax advisors for information about the state, local and foreign tax consequences of the transaction.
The following discussion summarizes material federal tax consequences and is based on current law. Stockholders should consult their own
tax advisors as to the federal, state, local and foreign tax effects of the Reverse Stock Split in light of their individual circumstances.
The Reverse Stock Split will be a tax-free recapitalization to the Company under the Internal Revenue Code. The Company will not recognize any
gain or loss as a result of the Reverse Stock Split. There will not be any other material tax consequences to the Company from the transaction.
Stockholders who receive only Common Stock in exchange for their existing shares, and do not receive payment for any fractional shares, will
not recognize gain or loss. Their adjusted tax basis of their new Common Stock will be the same as their adjusted tax basis of their existing Common Stock. The holding period of new Common Stock received as a result of the Reverse Stock Split will
be the same as the holding period for the stockholders existing Common Stock.
Stockholders who receive cash in lieu of a fractional
share of Common Stock and who do not own any of our new Common Stock following the Reverse Stock Split (because they have fewer than 2,000 pre-split shares) will be treated as receiving the cash as payment in exchange for their fractional shares of
new Common Stock. They will recognize capital gain or loss equal to the difference between the amount of cash received and the adjusted basis of the pre-split shares surrendered for cash. For these purposes, however, stockholders who do not own any
of our new Common Stock following the Reverse Stock Split may be treated as owning some such stock by reason of attribution from family members or entities of which they are owners.
Stockholders who receive a cash payment in lieu of a fractional share but who own some of our new Common Stock (or are treated as owning such
stock by attribution rules) following the Reverse Stock Split will either be treated as having sold the fractional shares for the cash or as having received a distribution from the Company in the amount of the cash. Such stockholders are encouraged
to consult with their own tax advisors concerning the income tax treatment of the receipt of cash.
If the receipt of cash either is
not essentially equivalent to a dividend or constitutes a substantially disproportionate redemption of stock under rules described below, the stockholder will be treated as having sold
33
the fractional shares for the cash, and thus will recognize gain or loss to the extent the cash received is greater or less than the portion of the stockholders tax basis in his old Common
Stock allocable to the shares for which the cash payment is received.
Not Essentially Equivalent to a Dividend.
The receipt of
cash is not essentially equivalent to a dividend if the reduction in the stockholders proportionate interest in the Company resulting from the Reverse Stock Split (taking into account shares attributed to the stockholder) is
considered a meaningful reduction given your particular facts and circumstances. For a minority stockholder whose relative stock interest is minimal and who exercises no control over the affairs of a corporation, the Internal Revenue
Service has ruled that even a very small reduction can satisfy this test.
Substantially Disproportionate Redemption of Stock.
The
receipt of cash will be a substantially disproportionate redemption of stock if (a) the stockholder owns less than 50% of the total combined voting power of all classes of stock entitled to vote, and (b) the percentage of
voting stock owned immediately after the Reverse Stock Split is less than 80% of the percentage of shares of voting stock owned immediately before the Reverse Stock Split. For purposes of this test, again a stockholder may be treated as owning stock
under attribution rules.
If the receipt of cash in lieu of fractional shares is not treated as a sale of the corresponding stock under
either of the tests, it will be treated as a distribution by the Company to the stockholder. Such as distribution will be treated first as ordinary dividend income to the extent of the stockholders ratable share of the Companys current
and accumulated earnings and profits, then as a tax-free return of capital to the extent of the stockholders aggregate adjusted tax basis in all shares, and any remaining amount will be treated as capital gain.
Capital gain or loss recognized will be long-term if a stockholders holding period with respect to the shares surrendered is more than
one year. Individuals generally are taxed at a reduced rate on long term capital gains and at the same reduced rate on dividends.
Financing the
Reverse Stock Split
Completion of the Reverse Stock Split will require approximately $505,000 in cash, which includes, in addition to
the cost to cash out fractional post-split shares of Common Stock, advisory, legal, financial, accounting, printing, mailing and other fees and costs. These costs and related fees and expenses will be paid from the Companys available cash. You
should read the discussion under the caption Costs of the Reverse Stock Split below for a description of the fees and expenses we expect to incur in connection with the transaction.
Costs of the Reverse Stock Split
The
following estimates the costs incurred or expected to be incurred in connection with the Reverse Stock Split. Final costs of the transaction may be more or less than the estimates shown below. We will be responsible for paying these costs. Please
note that the following estimate of costs does not include the cost of cashing out fractional shares of Common Stock pursuant to the Reverse Stock Split.
|
|
|
|
|
Legal fees
|
|
$
|
200,000
|
|
Valuation costs
|
|
|
30,000
|
|
Transfer and exchange agent fees
|
|
|
18,000
|
|
Printing, mailing and filing fee costs
|
|
|
20,000
|
|
Other
|
|
|
12,000
|
|
|
|
|
|
|
Total
|
|
$
|
280,000
|
|
|
|
|
|
|
34
Conduct of the Companys Business After the Reverse Stock Split
We expect our business and operations to continue as usual and, except as disclosed in this Proxy Statement, we do not anticipate the Reverse
Stock Split will have any effect upon our business. We expect time and cost savings as a result of no longer being a public company. When the Reverse Stock Split is completed, persons owning fewer than 2,000 shares of Common Stock will no longer
have any equity interest in, and will not be stockholders of, the Company. These stockholders will not participate in our future earnings and growth.
When the Reverse Stock Split is effected, we estimate that, based on our stockholder records, 67 record holders will remain as record holders
of Common Stock. Stockholders who currently beneficially own approximately 98.9% of our Common Stock will beneficially own 100% of our Common Stock after the Reverse Stock Split. See also information under the caption Security Ownership
in this Proxy Statement. When the Reverse Stock Split is effected, our directors and executive officers will beneficially own approximately 12.3% of our Common Stock. Further, following the Reverse Stock Split, SMP and Ciabattoni Trust will
beneficially own approximately 54.8% and 39.5%, respectively, of our Common Stock.
Following the consummation of the Reverse Stock Split,
we will become a privately held company. The registration of our Common Stock under the Exchange Act will be terminated, and our Common Stock will no longer be eligible for trading on the OTCBB. Because our Common Stock will no longer be publicly
held, we will no longer need to comply with the proxy rules of Regulation 14A under Section 14 of the Exchange Act. Our officers, directors and stockholders owning more than 10% of our Common Stock will no longer have stock ownership reporting
requirements and short swing trading restrictions under Section 16 of the Exchange Act. We will no longer be subject to the periodic reporting requirements of the Exchange Act and will cease filing information with the SEC. Among
other things, this change will enable us to realize time and cost savings from not having to comply with the requirements of the Exchange Act.
Other than as described in this Proxy Statement, neither we nor our management has any current plans or proposals to (a) effect any
extraordinary corporate transaction, such as a merger, reorganization or liquidation; (b) sell or transfer any material amount of our assets; (c) change our Board or management; (d) materially change our indebtedness or
capitalization; or (e) otherwise to effect any material change in our corporate structure or business.
Recommendation of the Board
The Board believes that the Reverse Stock Split is fair to our stockholders. The Board believes the transaction is fair to those whose
interests are being cashed out pursuant to the Reverse Stock Split and those who will retain an equity interest in the Company subsequent to the Reverse Stock Split. The discussion in this Proxy Statement under the captions Special
Factors Reasons for and Purposes of the Reverse Stock Split, Special Factors Strategic Alternatives Considered, Special Factors Background of the Reverse Stock Split and Special
Factors Effects of the Reverse Stock Split summarizes the material factors considered by the Board in reaching its fairness determination. For the reasons described above under the caption Special Factors Fairness
of the Reverse Stock Split, the Board also believes that the process is fair to all unaffiliated stockholders, including those whose interests are being cashed out pursuant to the Reverse Stock Split and those who will retain an equity
interest in the Company subsequent to the Reverse Stock Split.
In consideration of the factors discussed under Special
Factors Reasons for and Purposes of the Reverse Stock Split, Special Factors Strategic Alternatives Considered, Special Factors Background of the Reverse Stock Split, Special
Factors Effects of the Reverse Stock Split, Recommendation of the Board and Fairness of the Reverse Stock Split in this Proxy Statement, the Board unanimously approved the Reverse Stock Split and unanimously
recommends that stockholders vote FOR the Certificate of Amendment to effect the Reverse Stock Split.
If the Reverse Stock Split is
effected, each of the members of our Board and each of our executive officers will continue to be stockholders in the Company. All of the companys officers and directors intend to vote their shares FOR the Certificate of Amendment to effect
the Reverse Stock Split.
35
Description of the Reverse Stock Split
Amendment and Restatement of Certificate of Incorporation to Effect the Reverse Stock Split
The Board determined that it is advisable to amend and restate our Certificate of Incorporation to effect a
1-for-2,000
Reverse Stock Split of Common Stock and to provide for the cash payment of $0.55 per pre-split share in lieu of fractional shares of Common Stock that would otherwise be issued following the
Reverse Stock Split. As a result, the Board recommends that stockholders vote FOR the proposed Certificate of Amendment.
The proposed
Certificate of Amendment is attached as Annex A to this Proxy Statement. The Reverse Stock Split will become effective upon the filing of the proposed Certificate of Amendment with the Office of the Secretary of State of Delaware.
Regulatory Approvals
Except for
stockholder approval of the Certificate of Amendment, the amendment is not subject to any regulatory approvals.
Holders as of Effective Date; Net
Effect After Reverse Stock Split
Stockholders holding fewer than 2,000 pre-split shares of Common Stock will be cashed out at a price
of $0.55 per pre-split share. The holdings of all other stockholders will be reduced on a 1-for-2,000 basis. Any stockholders whose shares are cashed out will have no continuing equity interest in the Company.
Nominees and brokers are expected to deliver to the exchange agent the beneficial ownership positions they hold. However, if you are a
beneficial owner of Common Stock who is not the record holder of those shares and wish to ensure that your ownership position is accurately delivered to the Companys exchange agent, you should instruct your broker or nominee to transfer your
shares into a record account in your name. Nominees and brokers may have required procedures. Holders should contact their nominees and brokers to determine how to effect the transfer in a timely manner prior to the Reverse Stock Split.
Appraisal Rights
You will not be
entitled to appraisal rights under our Certificate of Incorporation or Delaware law since the matter to be voted on does not involve a merger or consolidation. Stockholders holding fewer than 2,000 pre-split shares who want to remain stockholders of
the Company may purchase a sufficient number of additional shares on the open market in order to hold at least 2,000 pre-split shares prior to the Effective Date. Those stockholders who do not desire to remain stockholders of the Company may sell a
sufficient number of shares so that they hold fewer than 2,000 pre-split shares in order to be cashed out in the Reverse Stock Split. The Company is not aware of any other right or relief that may be available to stockholders in law or in equity.
Exchange of Certificates for Cash Payment or Shares
If the Reverse Stock Split is approved, we will file the Certificate of Amendment with the Secretary of State of Delaware and effect the
amendment set forth in Annex A to this Proxy Statement. The Reverse Stock Split will become effective at the time set forth in the Certificate of Amendment. Promptly following the Effective Date, you will be notified by our exchange agent, who will
provide instructions to carry out the exchange of certificates for cash.
As soon as practicable after the Effective Date, record holders
that are entitled to cash in lieu of fractional shares will be asked to surrender their certificates representing shares of Common Stock to the exchange agent. These record holders will receive in exchange a cash payment in the amount of $0.55 per
pre-split share.
36
Record holders owning shares after the Reverse Stock Split must exchange their stock certificates
for a new stock certificates that will bear a new CUSIP number. The Companys transfer agent will furnish stockholders with the necessary materials and instructions to effect the surrender promptly following the Reverse Stock Split. The letter
of transmittal will direct how old certificates are to be surrendered for new certificates. Stockholders must complete and sign the letter of transmittal and return it with their stock certificates to the transfer agent in accordance with the
instructions set forth in the transmittal letter before they can receive their new stock certificates for those shares. The letter of transmittal will also contain instructions in the event that your certificates has been lost, destroyed or
mutilated. Do not send your stock certificates to us, and do not send them to the transfer agent until you have received a transmittal letter and have followed the instructions in the letter of transmittal.
If the Reverse Stock Split is effected, any stockholder owning fewer than 2,000 shares of the currently outstanding Common Stock will cease to
have any rights with respect to our Common Stock, except to be paid in cash. No interest will be paid or accrued on the cash payable to stockholders after the Reverse Stock Split.
No service charges will be payable by stockholders in connection with the exchange of certificates for cash. All such expenses will be borne
by the Company.
Nominees (such as a bank or broker) may have required procedures, and stockholders holding Common Stock in street name
should contact their nominees to determine how the Reverse Stock Split will affect them. The exchange agent appointed by us to carry out the exchange has informed us that nominees are expected to provide beneficial ownership positions so that
beneficial owners may be treated appropriately in effecting the Reverse Stock Split. However, if you are a beneficial owner of fewer than 2,000 shares of Common Stock, you should instruct your nominee to transfer your shares into a record account in
your name in a timely manner to ensure that you will be considered a holder of record prior to the Effective Date, which is anticipated to be promptly following the approval by stockholders of the Certificate of Amendment. A stockholder holding
fewer than 2,000 shares of Common Stock in street name who does not transfer shares into a record account in a timely manner may not have his or her shares cashed out in connection with the Reverse Stock Split. For example, such stockholders
shares may not be cashed out if such stockholders nominee is a record holder of an aggregate of 2,000 or more shares of Common Stock, holds shares for multiple stockholders in street name and does not provide such beneficial ownership
positions in a timely manner to the exchange agent.
In the event that any certificate representing shares of Common Stock is not
presented for cash upon request by us, the cash payment will be administered in accordance with the relevant state abandoned property laws. Until the cash payments have been delivered to the appropriate public official pursuant to the abandoned
property laws, such payments will be paid to the holder thereof or to his or her designee, without interest, when the shares of Common Stock are properly presented for exchange.
37
Information about the Company and Filing Persons
Name and Address of the Company
The
Companys principal executive office is located at 433 North Camden Drive # 810, Beverly Hills, California 90210, and its telephone number is (310) 860-2501.
Price Range of Common Stock and Dividends
Our Common Stock trades on the OTCBB under the symbol FPCG. The following is a schedule of the reported high and low closing bid
quotations (rounded to the nearest cent) per share for our Common Stock for the fiscal years ended September 30, 2012, 2013 and 2014. All quotations represent prices between dealers, do not include retail mark-up, mark-down or commission and
may not necessarily represent actual transactions:
|
|
|
|
|
|
|
|
|
|
|
High
|
|
|
Low
|
|
Fiscal Year Ended September 30, 2014
|
|
|
|
|
|
|
|
|
Third Quarter (through July 29, 2014)(1)
|
|
$
|
0.60
|
|
|
$
|
0.02
|
|
Second Quarter
|
|
|
0.02
|
|
|
|
0.02
|
|
First Quarter
|
|
|
0.02
|
|
|
|
0.02
|
|
|
|
|
Fiscal Year Ended September 30, 2013
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
|
0.00
|
|
|
|
0.00
|
|
Third Quarter
|
|
|
0.01
|
|
|
|
0.00
|
|
Second Quarter
|
|
|
0.10
|
|
|
|
0.01
|
|
First Quarter
|
|
|
0.07
|
|
|
|
0.01
|
|
|
|
|
Fiscal Year Ended September 30, 2012
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
|
0.01
|
|
|
|
0.01
|
|
Third Quarter
|
|
|
0.08
|
|
|
|
0.01
|
|
Second Quarter
|
|
|
0.10
|
|
|
|
0.01
|
|
First Quarter
|
|
|
0.10
|
|
|
|
0.01
|
|
(1)
|
The Reports were filed on April 4, 2014.
|
The source of the foregoing quotations was the
Financial Industry Regulatory Composite Feed or other qualified inter dealer quotation medium, as provided by OTC Market Group Inc.
We
have not paid any cash dividends in the last two years. Any future declaration and payment of cash dividends will be subject to the discretion of the Board and will depend upon our results of operations, financial condition, cash requirements,
future prospects, changes in tax legislation, debt covenant restrictions and other factors deemed relevant by the Board.
On
July 29, 2014, our Common Stocks closing price per share was $0.50. On , 2014, the last practicable trading day prior
to the date this Proxy Statement was mailed to stockholders, our Common Stocks closing price was $ .
Identity and Background of Filing Persons
The Company, William Houlihan (Houlihan), Robert N. Schwartz, Ph.D. (Schwartz), Richardson E. Sells
(Sells), Sean Kirrane (Kirrane), Adrian Reeder (Reeder), SMP, Brian Potiker (Potiker), Ciabattoni Trust, Anthony J. Ciabattoni (A. Ciabattoni) and Jane G. Ciabattoni (J.
Ciabattoni) (collectively, the Filing Persons) listed below are filing a Schedule 13E-3 concurrently with this Proxy Statement. If the Reverse Stock Split is approved, the Company and other Filing Persons intend to deregister the
Companys Common Stock. The names, addresses, business and background of the Filing Persons (other than the Company) are set forth below.
38
Unless otherwise stated, the business address of each director and officer is 433 North Camden Drive # 810, Beverly Hills, California 90210, and the business telephone number for each officer and
director is (310) 860-2501.
Houlihan, Schwartz, Sells, Kirrane, Potiker, A. Ciabattoni, and J. Ciabattoni are citizens of the United
States. Reeder is a citizen of New Zealand.
None of the Filing Persons has been (a) convicted in a criminal proceeding during the
past five years (excluding traffic violations or similar misdemeanors) or (b) a party to any judicial or administrative proceeding during the past five years (except for matters that were dismissed without sanction or settlement) that resulted
in a judgment, decree or final order enjoining such person from future violations of, or prohibition activities subject to, federal or state securities laws.
Directors
The directors
of the Company are Houlihan, Schwartz, and Sells. For the additional information about the Companys directors, see Proposal 2 Election of Directors in this Proxy Statement.
Houlihan is a Filing Person and an affiliate of the Company because he is a director of the Company. The business address for Houlihan is 92
Bonnie Way, Allendale, New Jersey 07401 and the business telephone number is (201) 819-5046.
Schwartz is a Filing Person and an
affiliate of the Company because he is a director of the Company. The business address for Schwartz is the University of California, Los Angeles, California 90095-1594, and the business telephone number is (310) 317-5672.
Sells is a Filing Person and an affiliate of the Company because he is a director of the Company. The business address for Sells is 18 Audubon
Pond Road, Sea Pines, Hilton Head Island, South Carolina 29928, and the business telephone number is (843) 290-9993.
Executive
Officers
The executive officers of the Company are Kirrane and Reeder. For additional information about the Companys executive
officers, see Executive Officers in this Proxy Statement.
Kirrane is a Filing Person and an affiliate of the Company because
he is President and Chief Executive Officer of the Company.
Reeder is a Filing Person and an affiliate of the Company because he is Chief
Financial Officer and Executive Vice President of the Company.
Significant Stockholders
SMP, a Michigan limited liability company, is a Filing Person and an affiliate of the Company because it beneficially owns approximately 54.1%
of the Common Stock, which represents 30.6% of the Common Stock votes eligible to be cast at the Meeting. The shares of Common Stock held by SMP, plus the votes afforded to it as a holder of the Preferred Stock, represent approximately 20.4% of the
Eligible Votes with respect to the Meeting. Potiker is the manager of SMP, has the sole power to vote and dispose of the shares held by SMP and is a Filing Person. For additional information about Potiker, see Proposal 2 Election
of Directors in this Proxy Statement. SMPs primary business is investing in securities for its own account. The business address for SMP and Potiker is 433 N. Camden Drive, Suite 810, Beverly Hills, California 90210, and the business
telephone number is (310) 271-4381.
39
Ciabattoni Trust, a trust formed under the laws of California, is a Filing Person and an
affiliate of the Company because it beneficially owns approximately 39.0% of the Common Stock, which represents 18.1% of the Common Stock votes eligible to be cast at the Meeting. The shares of Common Stock held by SMP, plus the votes afforded to it
as a holder of the Preferred Stock, represent approximately 13.0% of the Eligible Votes with respect to the Meeting. A. Ciabattoni is the spouse of J. Ciabattoni and serves as a trustee of the Ciabattoni Trust. A. Ciabattoni has shared power to vote
and dispose of the shares held by the Ciabattoni Trust and is a Filing Person. J. Ciabattoni is the spouse of A. Ciabattoni and serves as a trustee of the Ciabattoni Trust. J. Ciabattoni has shared power to vote and dispose of the shares held by the
Ciabattoni Trust and is a Filing Person. For the past five years the primary business activity of each of Ciabattoni Trust and A. Ciabattoni is investment in various public and private business ventures. J. Ciabattoni is not presently and for the
past five years has not been employed. The business address for A. Ciabattoni, J. Ciabattoni and Ciabattoni Trust is 16 Lagunita Drive, Laguna Beach, California 92561, and the business telephone number is (949) 497-4344.
40
Proposal 2 Election of Directors
The Board has established the size of the Board immediately after the Meeting to be five directors and has nominated the five director
nominees listed below for election at the Meeting. Three of the five director nominees are standing for re-election at the Meeting. Directors are elected for a one-year term and serve until the next annual meeting in which their successors are
elected, or, if earlier, until their retirement, resignation or removal.
We have no reason to believe that any of the nominees will be
unable or unwilling to serve if elected. If any nominee should become unable or unwilling to serve for any reason, proxies may be voted for another person nominated as a substitute by the Board, or the Board may reduce the number of directors. There
are no family relationships between any of our director nominees and our executive officers.
The following table and biographies set
forth the names, ages and certain information regarding each of the five director nominees.
|
|
|
|
|
|
|
Name
|
|
Age
|
|
|
Position
|
William A. Houlihan
|
|
|
58
|
|
|
Chairman of the Board and Director
|
Sean Kirrane
|
|
|
36
|
|
|
President, Chief Executive Officer and Director nominee
|
Brian Potiker
|
|
|
48
|
|
|
Director nominee
|
Robert N. Schwartz, PhD.
|
|
|
74
|
|
|
Director
|
Richardson E. Sells
|
|
|
67
|
|
|
Lead Independent Director
|
William A. Houlihan.
Mr. Houlihan has served on our Board since September 2009 and has served
as the non-executive Chairman of our Board since August 2013 and Chairman of our Audit Committee since September 2009. Mr. Houlihan has more than 30 years of business and financial experience. Mr. Houlihan has served as Chief
Financial Officer for Amalgamated Bank, a privately owned company, from March 2013 to February 2014, Sixth Gear, Inc., a financial services company, from October 2007 to November 2008, Sedgwick Claims Management Services, a financial
services company, from August 2006 until January 2007, Metris Companies, a financial services company, from August 2004 to January 2006, and Hudson United Bancorp, a financial services company, from January 2001 to
November 2003. Mr. Houlihan has served on the Board of Directors of Five Oaks Investment Corp., a real estate investment trust, since 2013 and has also served on the Board of Directors of Tiptree Financial Inc., a publically traded
financial services holding company, as its lead independent director and chairman of the audit committee since July 2013 and on the board of directors of Care Investment Trust, a publically traded healthcare REIT, which merged with Tiptree
Financial, from August 2010 to July 2013, and SNL Financial, a privately owned financial information company, from 2003 to 2010. He was an investment banker with UBS from June 2007 to September 2007, with J.P. Morgan Securities from
November 2003 to July 2004, with KBW, Inc. from October 1996 to January 2001, with Bear, Stearns & Co., Inc. from April 1991 to October 1996, and with Goldman Sachs & Co. from June 1981 to
April 1991. For the periods from February 2006 to July 2006, February 2007 to May 2007 and December 2008 through present, Mr. Houlihan was a private investor. From 1998 to 2012, he was a director and shareholder of
a family-owned commercial real estate investment partnership. Mr. Houlihan received a B.S. in Accounting in 1977 from Manhattan College, became licensed as a C.P.A. in 1979, and received his M.B.A. in Finance in 1983 from New York University
Graduate School of Business. Based upon Mr. Houlihans prior experience as an executive officer in a variety of industries and his financial expertise, the Company believes that Mr. Houlihan has the requisite skill set to serve as a
Board member of the Company.
Sean Kirrane, Chief Executive Officer.
Mr. Kirrane, 36, has served as the Companys Chief
Executive Officer since November 2013. From November 2013 to April 2014, he served as the Companys Chief Financial Officer. He has also served as the Companys Vice President of Finance and Controller and Principal Accounting Officer
since June 14, 2010. Mr. Kirrane brings over 10 years of experience in senior finance and accounting roles for large publicly traded companies. From September 2007 to March 2010, Mr. Kirrane served as Assistant
41
Vice President, Head of Global Treasury for Endurance Specialty Holdings, Ltd. From March 2004 to March 2007, Mr. Kirrane served in various finance and investment roles at New York
Mortgage Trust, Inc. He assisted New York Mortgage Trust through a successful IPO in June 2004 and was eventually appointed Vice President and Treasurer in 2005. From January 2000 to March 2004, Mr. Kirrane held various positions
in the accounting and treasury departments of Hudson United Bancorp. Mr. Kirrane received a B.S. in Finance in 2000 from St. Josephs University. Based on Mr. Kirranes experience as an executive of the Company and his unique
knowledge of Companys industry and operations, the Company believes that Mr. Kirrane has the requisite skill set to serve as a Board member of the Company.
Brian Potiker, J.D., LL.M (Taxation)
. Mr. Potiker has served on the Companys advisory board since May 2007 and is manager of
SMP Investments I, LLC, the Companys largest shareholder. He is the Chief Investment Officer and a Manager of HSP Group, LLC, a private investment business that he co-founded in 1992 to manage interests in real estate, energy, private equity,
and other alternative investments. Mr. Potiker is also Vice Chairman and a co-founder of ARF Financial, LLC, a leading provider of short-term working capital loans to merchants and retailers nationwide, and serves on a number of other
management boards, including HSP-EPI Acquisition LLC dba Entertainment
®
. Mr. Potiker also serves as a member of the Board of Trustees, Board Treasurer and Chair of the Audit Committee for
The Center for Early Education. Mr. Potiker received a Bachelor of General Studies from the University of Michigan in 1987, a J.D from the Pepperdine University School of Law in 1990, and an LL.M in taxation from Golden Gate University in 1999.
Based on Mr. Potikers experience as a board member and executive, his familiarity with the Company and his financial and transactional experience, the Company believes that Mr. Potiker has the requisite skill set to serve as a Board
member of the Company.
Robert N. Schwartz, Ph.D.
Dr. Schwartz has served on our Board since January 1998 and
has served as a member of our Compensation Committee since 2005. Dr. Schwartz has been associated with the University of California, Los Angeles since 1979 as a visiting professor; since 2009, as a Western Institute of Nanoelectronics
(Department of Electrical Engineering) Research Scientist/Principal Investigator; and since December 2000, the owner of Channel Islands Scientific Consulting, a scientific consulting company. From 1981 to 2000, Dr. Schwartz was a Senior
Research Scientist at HRL Laboratories, LLC, a research laboratory. Prior to joining HRL Laboratories, he was a Professor of Physical Chemistry at the University of Illinois, Chicago from 1968 until 1981. Since 2006, Dr. Schwartz has served as
a Senior Scientist at the Aerospace Corporation, an advanced physical science and engineering laboratory. He has a B.A. in Mathematics, Chemistry and Physics, an M.S. in Chemical Physics from the University of Connecticut and a Ph.D. in Chemical
Physics from the University of Colorado. Based on Dr. Schwartzs technical expertise and prior executive management experience, the Company believes that Dr. Schwartz has the requisite skill set to serve as a Board member of the
Company.
Richardson E. Sells.
Mr. Sells has served on our Board of Directors since April 2005 and as our lead
independent director since August 2013. Mr. Sells has also served as the Chairman of the Compensation Committee since 2005 and on the Audit Committee since 2005. Mr. Sells is currently the Managing Partner of Transition Management, LLC, a
turnaround related consulting firm. Mr. Sells served as Vice President Global Sales, Cargo, of Northwest Airlines, Inc. from January 29, 2001 until his retirement in 2007. Prior to joining Northwest Airlines, Mr. Sells was Managing
Director, Hong Kong and China, for CV Transportation Services, LDC, a logistics company, from 1995 through December 2000. Mr. Sells has a B.S. in Business Management from East Tennessee State University. Based on Mr. Sells
operational, corporate governance, financial and transactional experience, the Company believes that Mr. Sells has the requisite skill set to serve as a Board member of the Company.
The Board recommends you vote FOR
the election of each of the director nominees named above.
42
Corporate Governance
Board Leadership Structure and Role in Risk Oversight
We do not have a policy requiring that the positions of Chairman of the Board and Chief Executive Officer be held by different individuals or
by the same individual. Currently, these roles are separate, with Mr. Houlihan, a non-employee director, serving as Chairman of our Board and Mr. Kirrane serving as our Chief Executive Officer.
Our Board recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position. We believe having a
separate Chairman allows our Chief Executive Officer to focus on the day-to-day operations of our business while allowing the Chairman of the Board to focus on his role of leading the Board and, together with the other directors, advising and
overseeing management.
Our Board has appointed Mr. Sells as our lead independent director. His responsibilities include advising
management as to the quality, quantity and timeliness of the information provided to the Board, confirming the agendas for Board meetings, serving as the principal liaison between the independent directors and management on sensitive issues and
performing such other duties as the Board delegates to the lead independent director.
While our management team is responsible for the
day-to-day management of the risks we face, our Board is responsible for overseeing managements risk assessment and risk management functions. The Audit Committee further assists the Board in fulfilling its oversight responsibility in the
areas of financial reporting and by meeting periodically with management to review financial risk exposures and discuss the Companys policies and guidelines concerning risk assessment and risk management. The Compensation Committee also
assists the Board with this function by assessing risks associated with our compensation programs.
Director Independence
Our Common Stock is not listed on a national securities exchange. We use the independence standards of the NYSE Amex (formerly known as the
American Stock Exchange or AMEX). The Board has determined that Richardson E. Sells, Robert N. Schwartz and William Houlihan are independent directors under the rules of the NYSE Amex.
Board Meetings
The Board met
telephonically nine times during the fiscal year ended September 30, 2013. In 2010, our Board transitioned to monthly and twice-monthly board and committee calls in response to the volume of transactions, financings and operational changes
being considered by the Company. This approach proved more efficient and obtained more input and leverage from the Board and timelier dialog given the sheer volume of project and negotiations in process simultaneously.
Board Committees
The Audit Committee
assists in the Boards oversight of our financial statements and compliance with legal and regulatory requirements and the qualifications and performance of our independent auditor. The Audit Committee currently has two members:
Mr. Houlihan and Mr. Sells. Mr. Houlihan is the Chairman of the Audit Committee. Each of Mr. Houlihan and Mr. Sells satisfies the independence requirements for audit committee members under SEC rules. Neither
Mr. Houlihan nor Mr. Sells is considered an audit committee financial expert, as defined under SEC rules. The Audit Committee does not have an audit committee financial expert because it has not been able to
identify a qualified candidate. The Audit Committee held one meeting during the fiscal year ended September 30, 2013.
The
Compensation Committee has two members: Dr. Schwartz and Mr. Sells. Mr. Sells is the Chairman of the Compensation Committee. Each of Dr. Schwartz and Mr. Sells satisfies the independence requirements for
43
compensation committee members under SEC rules. The primary purpose of the Compensation Committee is to determine, or recommend to the Board for its determination, the compensation of our
executive officers. The Compensation Committee ensures that our executive officers are fairly compensated based upon their performance and contribution to the Company. The Compensation Committee, held one meeting during the fiscal year ended
September 30, 2013.
We do not currently have a nominating committee or a committee performing the functions of a nominating
committee. Our Board fulfills the roles of this committee. The Board believes it is appropriate not to have a separate nominating committee in light of our size and level of operations. Moreover, we are not required to have a nominating committee
since we are not listed on a national stock exchange.
In selecting director nominees, we consider, among other things, recommendations of
the independent directors, the candidates relevant business skills and experience, commitment to enhancing stockholder value and professional ethics and values. We do not currently consider director nominations from stockholders.
Stockholder Communications with the Board
Our stockholders may communicate with the Board by writing directly to the Board or specific directors at the following address:
First Physicians Capital Group, Inc.
Attn: Chairman
433 North Camden
Drive # 810
Beverly Hills, California 90210
Our Chairman will deliver stockholder communications to the specified individual director, if so addressed, or to a director who can address
the matter.
Code of Ethics
The
Company adopted a Corporate Code of Business Conduct and Ethics (Code of Ethics) that applies to all directors, executive officers and employees. Any amendments to or waivers from the Code of Ethics regarding our executive officers will
be disclosed on our website (www.firstphysicianscapitalgroup.com). The Code of Ethics was previously filed as an exhibit to the Form 10-K for the fiscal year ended September 30, 2008.
Certain Relationships and Related Transactions
We require disclosure of any potential transaction with related persons, conflict of interest or the taking of a corporate opportunity (as
those terms are defined in our Code of Ethics). If a director or executive officer believes that a transaction or a situation may be a related party transaction, a conflict of interest or the taking of a corporate opportunity, the matter must be
brought to the attention of the Board for a determination as to whether such matter violates the intent and purpose of the Code of Ethics. If an employee believes that a transaction or a situation may be a related party transaction, conflict of
interest or the taking of a corporate opportunity, the matter must be disclosed to his or her immediate supervisor for a determination as to whether such matter violates the intent and purpose of the Code of Ethics. In reviewing a matter, the
reviewing party may report it to the next level of management and to our outside counsel, or, where appropriate, to the Board. If the individual or individuals to whom such information is conveyed are not responsive, or if there is reason to believe
that reporting to such individuals is inappropriate in particular cases, then the executive officer, director or employee may contact our outside counsel. Any failure to timely and accurately report any such transaction or matter is a violation of
our Code of Ethics.
In addition to indemnification provisions for the Companys officers and directors in the Companys bylaws
and Certificate of Incorporation, indemnification provisions are included in Kirranes and Reeders employment
44
agreements with the Company. Their employment agreements provide that we will indemnify them to the fullest extent permitted by law for claims arising in their capacity as our director or
officer.
During the fiscal year ended September 30, 2009, we entered into a bridge financing transaction and issued associated notes
(the 2009 Bridge Notes). SMP and Ciabattoni Trust were lenders under the 2009 Bridge Notes. The Company exercised its option to extend the date of the 2009 Bridge Notes. As part of the 2009 Bridge Notes extensions, in January 2014, the
Company issued warrants to SMP for the purchase of up to 8,500,000 shares of Common Stock at an initial exercise price of $0.01 per share. These warrants were exercisable for a period of five years from the date of issuance. In March 2014, SMP
exercised its warrant to purchase 8,500,000 shares of Common Stock for an aggregate purchase price of $85,000. On July 6, 2011, Ciabattoni Trust acquired an additional $100,000 of 2009 Bridge Notes from individual investors. During the fiscal
year ended September 30, 2012, $750,000 of the original 2009 Bridge Notes was repaid. Of the $750,000 paid, $75,000 and $175,000 was paid to SMP and Ciabattoni Trust, respectively. On April 7, 2014, the Company paid $429,425 and $934,630
to SMP and Ciabattoni Trust, respectively, which represents all outstanding principal and accrued interest on these notes.
The 2011
Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the fiscal year ended September 31, 2013, in installments of $420,000 and $1,614,000, respectively. SMP, Ciabattoni Trust, and Houlihan are 2011
Bridge Lenders and received $759,000, $380,000, and $420,000, respectively, of the 2013 payments. On April 7, 2014, we paid $55,324, $31,225 and $33,680 to SMP, Ciabattoni Trust and Houlihan, respectively, which represented the remaining
accumulated interest on the 2011 Bridge Notes.
The 2011 Bridge Lenders also received warrants to purchase an aggregate of 2,278,079
shares of our Common Stock with an exercise price of $0.3125, expiring five years from date of issuance. These warrants were issued January 1, 2014. Three of the 2011 Bridge Lenders, SMP, Ciabattoni Trust, and Houlihan, received 850,080,
425,600, and 470,400, respectively, of these warrants.
During the fiscal year ended September 30, 2012, we entered into bridge
financing transactions in the aggregate principal amount of $1,279,000 (the 2012 Bridge Notes). The three lenders, SMP, Ciabattoni Trust, and Houlihan, held $620,000, $434,000, and $225,000, respectively, of the 2012 Bridge Notes. The
2012 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the fiscal year ended September 31, 2013 in installments of $225,000 and $1,054,000. The lenders under the 2012 Bridge Notes received warrants
to purchase an aggregate of 4,092,800 shares of our Common Stock with an exercise price of $0.3125. These warrants were issued January 1, 2014 and expire five years from date of issuance. SMP, Ciabattoni Trust, and Houlihan, received 1,984,000,
1,388,800, and 720,000 warrants, respectively. On April 7, 2014, we paid $142,144, $98,214 and $55,135 to SMP, Ciabattoni Trust and Houlihan, respectively, which represented the remaining accumulated interest on the 2012 Bridge Notes.
In November 2013, we entered into bridge financing transactions in the aggregate principal amount of $650,000 (the 2013 Bridge
Notes). The four lenders, SMP, Ciabattoni Trust, Houlihan, and Blue Ridge Investments, LLC, a limited liability company wholly owned by Sells, held $300,000, $125,000, $125,000, and $100,000 respectively, of the 2013 Bridge Notes. On
April 7, 2014, we paid $303,167, $126,319, $126,319 and $101,056 to SMP, Ciabattoni Trust, Houlihan, and Blue Ridge Investments, LLC, respectively, which represented all outstanding and accrued interest and principal on the 2013 Bridge Notes.
On December 5, 2013, the Board approved the Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred
Stock (Series 7-A) and authorized the issuance of up to 7,000 shares of Series 7-A. As part of the consideration for entering into the 2011 Bridge Financing, all of the 2011 Bridge Lenders were granted the option to convert their current
holdings, if any, of Series 5-A, Series 6-A and Common Stock (collectively the Exchanged Securities) into Series 7-A. Upon election to convert, each lender would receive the number of Series 7-A equal to the initial consideration paid
for their Exchanged Securities divided by $1,000. In connection with the conversion, each 2011 Bridge Lender will receive warrants to purchase a number of
45
shares of Common Stock of the Company in an amount equal to 1,120 multiplied by the aggregate number of shares of Series 7-A issued at an exercise price of $0.3125 per share. The warrants will
have an exercise price of $0.3125 and will expire five years from date of issuance. The Company has received notification from all the 2011 Bridge Lenders of their intent to convert their holdings of Exchanged Securities to Series 7-A, which will
result in the issuance of an aggregate of 5,998 shares of Series 7-A and warrants to purchase up to 6,717,760 shares of Common Stock. SMP, Ciabattoni Trust, and Houlihan are 2011 Bridge Lenders.
The Company expects to consummate the Series 7-A Exchange within the next year but anticipates that the Series 7-A Exchange will not occur
until after the Meeting. Consequently, the Series 7-A Exchange will not affect the beneficial ownership or the voting rights of SMP, Ciabattoni Trust or Houlihan at the Meeting. If the Reverse Stock Split is approved, the Board intends to adjust the
number of shares of Common Stock issuable upon exercise of and the exercise price of any warrants issued in relation to the Series 7-A Exchange to reflect the Reverse Stock Split.
SMP, Ciabattoni Trust and Houlihan are Filing Persons and are considered related parties because each holds more than five percent of one or
more classes of the Companys voting securities. See also the information under the caption Information about the Company and Filing Persons Identity and Background of Filing Persons in this Proxy Statement.
Director Compensation
The non-employee
members of our Board did not receive any compensation for their service on the Board or any committee during the fiscal years ended September 30, 2013 and 2012.
Mr. Hirschhorn was the only director who served as a full-time employee of the Company as of September 30, 2013. He received no
additional compensation for serving as a director. Mr. Hirschhorn resigned from the Board effective November 18, 2013.
46
Proposal 3 Advisory Vote on the Frequency of the Advisory
Vote on Executive Compensation
Pursuant to Section 14A of the Exchange Act, our stockholders have an opportunity to vote on
the frequency with which stockholders vote on executive compensation: every year, every other year, or every three years. The Board recommends that you vote for every three years so as to avoid the additional cost of including the materials to vote
more frequently.
Though this vote is non-binding and advisory in nature, we value the opinions of our stockholders and will consider
the outcome of this vote determining how frequently future advisory votes to approve executive compensation will occur. However, if Proposal 1 regarding the Reverse Stock Split is approved, the Company will not hold advisory stockholder votes on
executive compensation in the future.
The Board recommends you vote EVERY THREE YEARS for the frequency
with which our stockholders have an advisory vote on executive compensation.
47
Proposal 4 Advisory Vote to Approve Executive
Compensation
Pursuant to Section 14A of the Exchange Act, our stockholders have an opportunity to approve the compensation
we paid to our named executive officers during the fiscal year ended September 30, 2013. Accordingly, our proposal is set forth in the following resolution:
RESOLVED: That the compensation paid to the Companys named executive officers, as disclosed pursuant to Item 402 of SEC Regulation
S-K, including the executive compensation tables and narrative discussion included in this Proxy Statement, is hereby approved.
Though
this vote is non-binding and advisory in nature, we value the opinions of our stockholders and will consider the outcome of this vote when considering future executive compensation decisions. However, if Proposal 1 regarding the Reverse Stock Split
is approved, the Company will not hold advisory stockholder votes on executive compensation in the future.
The Board recommends you
vote FOR
the resolution approving the compensation of our named executive officers.
48
Executive Officers
The following section provides the principal positions and business experience for our current named executive officers:
Sean Kirrane, President and Chief Executive Officer.
Mr. Kirrane, 36, has served as the Companys Chief Executive Officer
since November 2013. See the information under the caption Proposal 2 Election of Directors in this Proxy Statement for additional information about Mr. Kirrane.
Adrian Reeder, Chief Financial Officer.
Mr. Reeder, 40, has served as the Companys Executive Vice President and Chief
Financial Officer since April 10, 2014. Mr. Reeder brings over 14 years of experience in finance and accounting. Since 2013, Mr. Reeder served as a senior consultant for NowCFO, a professional services firm providing outsourced CFO
services and provided advisory and consulting services to the Company prior to his appointment as the Companys Chief Financial Officer. From 2010 until 2013, Mr. Reeder served as audit manager and consultant for Kezos & Dunlavy,
LLC, an accounting firm. Prior to 2010, Mr. Reeder was involved in several ventures, including founding Old Cobblestone Road, LLC, an online retail company, and serving as director of finance for Elim Valley Planning & Development,
LLC, a 2,400 acre master planned real estate development. Mr. Reeder began his career with KPMG, LLP and held the position of manager at his departure. Mr. Reeder received a B.S. and Masters in Accountancy in 2000 from Brigham Young
University and is a Certified Public Accountant.
49
Executive Compensation
Employment Agreements
Sean
Kirrane, President and Chief Executive Officer.
Prior to his appointment as Chief Executive Officer, Mr. Kirrane and the Company entered into a consulting agreement, pursuant to which Mr. Kirrane is entitled to receive $20,000 per
month. Under the consulting agreement, Mr. Kirrane is eligible to receive a bonus of $250,000 for filing documents with the SEC. Upon meeting certain performance milestones, Mr. Kirrane may also receive bonuses totaling $475,000. On
March 21, 2014, the Board approved an addendum to the consulting agreement which amended criteria related to his bonus. In return for past services rendered and upon the occurrence of certain events, Mr. Kirrane may also receive two earned
bonus payments in the amount of $177,500 each.
On May 27, 2014, the Company entered into an employment agreement with
Mr. Kirrane, the Companys President and Chief Executive Officer, which will be effective as of July 1, 2014. On the effective date, the Employment Agreement will supersede the consulting agreement currently in place between
Mr. Kirrane and the Company. The term of the employment agreement is one year and commences on the effective date. The employment agreement provides that, among other things, during the term, Mr. Kirrane will (1) receive a base salary
of no less than $360,000, (2) be eligible to participate in the Companys management equity incentive plan as determined in the sole discretion of the Board, (3) be eligible to receive a cash bonus of up to 100% of his base salary
upon achievement of certain strategic goals and objectives to be established by the Board, (4) be entitled to participate in the Companys medical, life insurance, retirement and other benefit plans, and (5) accrue four weeks of
vacation annually. He will also be eligible to receive additional bonuses at the discretion of the Board. In the event that Mr. Kirrane is terminated without cause (as defined in the employment agreement) by the Company during the term, he will
be entitled to receive (1) base salary accrued to the date of termination and during the termination notice period, (2) a severance payment equal to 50% of his base salary, (3) any earned but unpaid bonuses, (4) health benefits
until the earlier of six months from the date of termination and his eligibility to participate in a similar health plan, and (5) payment of any unreimbursed expenses and accrued but unused paid time off. In the event that Mr. Kirrane is
terminated with cause (as defined in the employment agreement) during the term, elects to terminate his employment, or is terminated as a result of permanent incapacity (as defined in the employment agreement, he will be entitled to receive
(1) base salary accrued to the date of termination, (2) payment of any unreimbursed expenses and accrued but unused vacation, and (3) any earned but unpaid bonuses. The employment agreement contains customary non-compete,
non-solicitation, and confidentiality provisions.
Adrian Reeder, Chief Financial Officer.
The Board appointed Mr. Reeder
to the position of Executive Vice President and Chief Financial Officer and approved an employment agreement effective April 10, 2014. The term of the employment agreement is two years and commenced on the effective date. The employment
agreement provides that Mr. Reeder will (1) receive an annual base salary of $185,000, (2) be eligible to participate in the Companys employee benefit plans and other benefits, (3) be eligible to receive a cash bonus with a
payment equal to 50% of his base salary upon achievement of strategic goals and objectives, (4) be entitled to participate in the Companys medical, life insurance, retirement, and other benefit plans, and (5) accrue three weeks of
vacation annually. He will also be eligible to receive additional discretionary bonuses and to participate in any executive equity compensation plan. If Mr. Reeder is terminated without cause during the first two years of his employment with
the Company, he will be entitled to receive (1) base salary accrued to the date of termination, during the first two years of his employment with the Company, he will be entitled to receive (2) a severance pay equal to 50% of his base
salary, (3) any earned but unpaid bonuses, (4) health benefits until the earlier of six months from the date of termination and his eligibility to participate in a similar health plan, and (5) payment of any unreimbursed expenses and
accrued but unused paid time off. The Company will also reimburse up to $10,000 of Mr. Reeders relocation expenses for his move from Salt Lake City, Utah to Dallas, Texas. In the event that Mr. Reeder is terminated with cause (as
defined in the employment agreement) during the term, elects to terminate his employment, or is terminated as a result of permanent incapacity (as defined in the employment
50
agreement, he will be entitled to receive (1) base salary accrued to the date of termination, (2) payment of any unreimbursed expenses and accrued but unused vacation, and (3) any
earned but unpaid bonuses. The employment agreement contains customary non-compete, non-solicitation, and confidentiality provisions.
David Hirschhorn, former Chief Executive Officer.
Mr. Hirschhorn was party to an employment agreement with the Company dated
July 1, 2008. Under the employment agreement, Mr. Hirschhorn was entitled to receive an annual base salary of not less than $480,000. Mr. Hirschhorn was eligible for an annual incentive bonus not to exceed three times his base salary
for that fiscal year or 10% of our EBITDA for the immediately preceding fiscal year. He was also entitled to certain insurance benefits. Mr. Hirschhorns employment agreement was extended from July 2013 through October 2013. He received a
base salary of $30,000 monthly during the extension. Mr. Hirschhorns vested stock options expired three months after his departure from the Company on November 18, 2013. His unvested options were forfeited.
Summary of Compensation Table
The
following table provides information regarding the compensation of our executive officers for the fiscal years ended September 30, 2013 and 2012.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
|
Salary
($)
|
|
|
Bonus
|
|
|
All Other
Compensation
|
|
|
Total
($)
|
|
Sean Kirrane
|
|
|
2013
|
|
|
$
|
202,500
|
|
|
$
|
480,000
|
|
|
$
|
16,350
|
(2)
|
|
$
|
698,850
|
|
Chief Executive Officer(1)
|
|
|
2012
|
|
|
$
|
165,000
|
|
|
|
|
|
|
|
|
|
|
$
|
165,000
|
|
|
|
|
|
|
|
David Hirschhorn
|
|
|
2013
|
|
|
$
|
661,500
|
|
|
|
|
|
|
|
|
|
|
$
|
661,500
|
|
Former Chief Executive Officer(3)
|
|
|
2012
|
|
|
$
|
630,000
|
|
|
|
|
|
|
|
|
|
|
$
|
630,000
|
|
(1)
|
Mr. Kirrane was appointed Chief Financial Officer in June 2013 and Chief Executive Officer in November 2013.
|
(2)
|
Represents $9,900 in health insurance premiums and $6,450 paid into Mr. Kirranes healthcare spending account.
|
(3)
|
Mr. Hirschhorns employment agreement terminated in July 2013. The agreement was extended for three months, with a base salary of $30,000 monthly, or $360,000 annually. Mr. Hirschhorns employment
terminated in November 2013.
|
Outstanding Equity Awards at Fiscal Year End
The following table summarizes information with respect to our outstanding equity awards held by executive officers at September 30, 2013.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
|
|
Number of
Securities
Unexercised
Options
Unexercisable
|
|
|
Option
Exercise
Price
|
|
|
Option
Expiration
Date
|
|
Sean Kirrane,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer(1)
|
|
|
93,750
|
|
|
|
56,250
|
|
|
$
|
0.625
|
|
|
|
6/14/2017
|
|
|
|
|
|
|
David Hirschhorn
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Former Chief Executive Officer(2)
|
|
|
3,750,000
|
|
|
|
2,500,000
|
|
|
$
|
0.625
|
|
|
|
7/1/2015
|
|
(1)
|
On June 14, 2010, our Compensation Committee approved the issuance of options to purchase 150,000 shares of our Common Stock to Mr. Kirrane pursuant to the 2001 Plan. These options are exercisable for a period
of seven years at an exercise price of $0.625 per share.
|
(2)
|
On July 1, 2008, our Compensation Committee approved the issuance of options to purchase 6,250,000 shares of our Common Stock to
Mr. Hirschhorn pursuant to the 2001 Plan. These options were exercisable
|
51
|
for seven years at an exercise price of $0.625 per share. Mr. Hirschhorns employment with the Company terminated on November 18, 2013. The stock options that had not vested prior
to his resignation were forfeited. The vested stock options were no longer exercisable three months after his termination date. None of these options were exercised.
|
Potential Payments Upon Termination or Change in Control
In the event that Mr. Kirranes employment with the Company had been terminated without cause on September 30, 2013, the Company
would have been required to pay Mr. Kirrane 12-months salary, or $202,500, and health benefits of no more than approximately $5,596. In the event that Mr. Kirranes employment with the Company had been terminated for cause or
Mr. Kirrane had voluntarily terminated his employment on September 30, 2013, the Company would have been required to pay Mr. Kirrane any earned but unpaid salary.
52
Proposal 5 Ratification of Appointment of Whitley Penn
as the Companys Independent Registered Public Accounting Firm
The Audit Committee has appointed Whitley Penn as the
Companys independent registered public accountant for the fiscal year ended September 30, 2014. The Board is asking stockholders to ratify this appointment.
Representatives of Whitley Penn are expected to be present at the Meeting and are expected to be available to respond to appropriate questions
at the Meeting. Representatives of Whitley Penn will have the opportunity to make a statement if they desire to do so.
If our
stockholders do not ratify the appointment, the Audit Committee will consider the reasons the ratification failed and whether the committee should select a different firm. However, the committee is not required to do so. Even if the appointment is
ratified, the Audit Committee, in its discretion, may select a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and our
stockholders.
Fees
Aggregate fees
for professional services rendered by Whitley Penn for the fiscal years ended September 30, 2013 and 2012, respectively, were:
|
|
|
|
|
|
|
|
|
|
|
Year Ended
September 30,
2013
|
|
|
Year Ended
September 30,
2012
|
|
Audit Fees
|
|
$
|
110,126
|
|
|
$
|
141,070
|
|
Audit-related fees
|
|
|
|
|
|
|
|
|
Tax fees
|
|
|
30,000
|
|
|
|
32,450
|
|
All other fees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
140,126
|
|
|
$
|
173,520
|
|
|
|
|
|
|
|
|
|
|
Audit Fees.
Audit fees for the fiscal years ended September 30, 2013 and 2012 were for
professional services for the audits of our consolidated financial statements, reviews of certain subsidiary companies and the quarterly reviews of the financial statements included in our Form 10-Qs.
Audit-Related Fees
. Audit-related fees for the fiscal years ended September 30, 2013 and 2012 would have been for accounting
consultations, capital issuances and review of responses to various SEC comment letters. There were no audit-related fees for the fiscal years ended September 30, 2013 and 2012.
Tax Fees.
Tax fees for the fiscal years ended September 30, 2013 and 2012 were for services related to tax compliance and advisory
services, including assistance with review of tax returns, advice on goods and services taxes and duties in various jurisdictions and ad hoc corporate tax planning and advice.
All Other Fees.
We had no other fees for professional services rendered by our independent auditors during the fiscal years ended
September 30, 2013 and 2012.
Audit Committee Pre-Approval Policies and Procedures
Our Audit Committee pre-approves audit and non-audit services provided by our independent auditors at its quarterly meetings. Our Audit
Committee approved all of the services described above.
The Board recommends you vote FOR the ratification
of Whitley Penn LLP as the Companys independent registered public accounting firm.
53
Security Ownership
The following tables set forth information regarding the beneficial ownership of our voting securities as of July 29, 2014 for:
|
|
|
each person who is known to beneficially own more than 5.0% of our outstanding voting securities;
|
|
|
|
each of our named executive officers, directors and director nominees; and
|
|
|
|
all of our executive officers and directors as a group.
|
The tables below list the
percentages of shares beneficially owned based on 19,659,507 shares of Common Stock, 67,600 shares of Series 1-A Preferred Stock, 3,900 shares of Series 2-A Preferred Stock, 9,000 shares of Series 5-A Preferred Stock and 4,875 shares of Series 6-A
Preferred Stock outstanding as of July 29, 2014. Unless otherwise indicated below, to the Companys knowledge, all persons and entities listed below have sole voting and investment power over their voting securities. Unless otherwise noted
below, the address of the persons and entities listed in the tables below is c/o First Physicians Capital Group, Inc., 433 North Camden Drive # 810, Beverly Hills, California 90210.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock(1)
|
|
|
|
|
Name of Beneficial Owner
|
|
Number of
Shares
Beneficially
Owned
|
|
|
Percentage
of Common
Stock
Beneficially
Owned
|
|
|
Percentage of
Common
Stock Vote(2)
|
|
|
Percentage
of Eligible
Votes(3)
|
|
5% Holders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SMP Investments I, LLC(4)
|
|
|
16,048,365
|
|
|
|
54.1
|
%
|
|
|
30.6
|
%
|
|
|
20.4
|
%
|
Ciabattoni Living Trust(5)
|
|
|
10,270,400
|
|
|
|
39.0
|
%
|
|
|
18.1
|
%
|
|
|
13.0
|
%
|
The Kupfer Family Trust UTD May 3, 2009(6)
|
|
|
2,384,250
|
|
|
|
12.1
|
%
|
|
|
12.1
|
%
|
|
|
3.7
|
%
|
William Houlihan(7)
|
|
|
2,290,400
|
|
|
|
10.6
|
%
|
|
|
1.5
|
%
|
|
|
1.7
|
%
|
Gerlach & Company(8)
|
|
|
2,000,000
|
|
|
|
9.2
|
%
|
|
|
*
|
|
|
|
3.1
|
%
|
Integral Investors Waveland LLC(9)
|
|
|
1,920,000
|
|
|
|
8.9
|
%
|
|
|
*
|
|
|
|
3.0
|
%
|
David Hirschhorn(10)
|
|
|
1,729,200
|
|
|
|
8.6
|
%
|
|
|
6.7
|
%
|
|
|
2.7
|
%
|
James Chao(11)
|
|
|
1,704,000
|
|
|
|
8.1
|
%
|
|
|
1.8
|
%
|
|
|
2.3
|
%
|
Darras Revocable Trust dated 9/2/94(12)
|
|
|
1,600,000
|
|
|
|
7.5
|
%
|
|
|
*
|
|
|
|
2.5
|
%
|
South Bay Capital LLC(13)
|
|
|
1,600,000
|
|
|
|
7.5
|
%
|
|
|
*
|
|
|
|
2.5
|
%
|
William J. And Mary Ann McGrath(14)
|
|
|
1,075,800
|
|
|
|
5.3
|
%
|
|
|
1.2
|
%
|
|
|
1.5
|
%
|
Named Executive Officers, Directors and Director Nominees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William Houlihan(7)
|
|
|
2,290,400
|
|
|
|
10.6
|
%
|
|
|
1.5
|
%
|
|
|
1.7
|
%
|
Sean Kirrane(15)
|
|
|
150,000
|
|
|
|
*
|
|
|
|
*
|
|
|
|
*
|
|
Brian Potiker(4)
|
|
|
16,048,365
|
|
|
|
54.1
|
%
|
|
|
30.6
|
%
|
|
|
20.4
|
%
|
Adrian Reeder
|
|
|
|
|
|
|
*
|
|
|
|
*
|
|
|
|
*
|
|
Robert N. Schwartz, Ph.D.(16)
|
|
|
2,107
|
|
|
|
*
|
|
|
|
*
|
|
|
|
*
|
|
Richardson E. Sells(17)
|
|
|
200,000
|
|
|
|
1.0
|
%
|
|
|
1.0
|
%
|
|
|
*
|
|
David Hirschhorn(10)
|
|
|
1,729,200
|
|
|
|
8.6
|
%
|
|
|
2.0
|
%
|
|
|
2.7
|
%
|
Current Executive Officers and Directors as a group (5 persons)
|
|
|
2,642,507
|
|
|
|
12.1
|
%
|
|
|
2.6
|
%
|
|
|
2.0
|
%
|
*
|
Indicates ownership of less than 1%.
|
(1)
|
The number of shares of Common Stock shown as beneficially owned by any person or entity includes all Preferred Stock, options and warrants other than
the Series 7-A Exchange rights that are currently exercisable by that person or entity within 60 days of July 29, 2014. The percentages of beneficial ownership of Common Stock shown assume the exercise or conversion of all Preferred Stock,
options and warrants (other than the Series 7-A Exchange rights) that are convertible into Common Stock held by such person or entity currently exercisable within 60 days of July 29, 2014, but not the exercise or conversion of
|
54
|
Preferred Stock, options, warrants, or Series 7-A Exchange rights held by other holders of such securities. The number of shares of Common Stock includes shares held directly as well as shares
held jointly with family members, held in retirement accounts, held in a fiduciary capacity, held by certain of the group members families, or held by trusts of which the group member is a trustee or substantial beneficiary.
|
(2)
|
Represents the percentage of the 19,659,507 Common Stock votes eligible to be cast at the Meeting. For additional information about the voting rights of the holders of the Common Stock, see Stockholders Entitled
to Vote.
|
(3)
|
Represents the percentage of the 64,882,753 Eligible Votes with respect to the Meeting. Eligible Votes include the votes of holders of outstanding Common Stock plus the eligible vote of holders of outstanding Preferred
Stock, on an as converted basis. For additional information about the Eligible Votes and voting rights of each class of Voting Shares, see Stockholders Entitled to Vote.
|
(4)
|
Based on a Schedule 13D/A filed with the SEC by SMP on June 20, 2014. Beneficial ownership consists of (a) 6,014,285 shares of Common Stock; (b) 1,250 shares of Series 5-A, which are convertible into
4,000,000 shares of Common Stock; (c) 1,000 shares of Series 6-A, which are convertible into 3,200,000 shares of Common Stock; and (d) warrants to purchase 2,834,000 shares of Common Stock. The address for SMP is c/o HSP Group, LLC, 875
Prospect Street, Suite 220, La Jolla, CA 92037. Brian Potiker, in his capacity as a manager of SMP, may be deemed to beneficially own the shares held by SMP and has the sole power to vote or to direct the vote of 16,048,365 shares of Common Stock,
and the sole power to dispose of or to direct the disposition of 16,048,365 shares of Common Stock. Mr. Potiker is a director nominee.
|
(5)
|
Based on a Schedule 13D/A filed with the SEC by Ciabattoni Trust on June 20, 2014. Beneficial ownership consists of (a) 3,560,000 shares of Common Stock; (b) 600 shares of Series 5-A, which are
convertible into 1,920,000 shares of Common Stock; (c) 930 shares of Series 6-A, which are convertible into 2,976,000 shares of Common Stock; and (d) warrants to purchase 1,814,400 shares of Common Stock. The address for Ciabattoni Trust
is 16 Lagunita Drive, Laguna Beach, CA 92561. Anthony J. Ciabattoni and Jane G. Ciabattoni, in their capacity as trustees of Ciabattoni Living Trust, may be deemed to beneficially own the shares held by Ciabattoni Living Trust and have shared voting
and dispositive power of 10,270,400 shares of Common Stock.
|
(6)
|
The address for The Kupfer Family Trust UTD May 3, 2009 is P.O. Box 9330, Rancho Santa Fe, CA 92067.
|
(7)
|
Consists of (a) 300,000 shares of Common Stock, (b) 250 shares of Series 5-A, which are convertible into 800,000 shares of Common Stock and (c) warrants to purchase 1,190,400 shares of Common Stock.
|
(8)
|
Consists of 625 shares of Series 5-A, which are convertible into 2,000,000 shares of Common Stock. The address for Gerlach & Co. is P.O. Box 7247-7057, Philadelphia, PA 19170.
|
(9)
|
Consists of 600 shares of Series 5-A, which are convertible into 1,920,000 shares of Common Stock. The address for Integral Investors Waveland LLC is 19800 MacArthur Blvd., Suite 650, Irvine, CA 92612.
|
(10)
|
Consists of (a) 1,250,000 shares of Common Stock owned outright; (b) 470,000 shares beneficially owned by Hirschhorn in his capacity as President of Hope & Abel Investments, LLC, which directly holds
125 shares of Series 5-A, which are convertible into 400,000 shares of Common Stock, and 60,000 shares of Common Stock; and (c) 6 shares of Series 5-A owned by Hirschhorn individually, which are convertible into 19,200 shares of Common
Stock. The address for Mr. Hirschhorn is 4312 Park Verdi, Calabasas, CA 91302. Mr. Hirschhorn resigned from the Company effective November 18, 2013.
|
(11)
|
Consists of (a) 360,000 shares of Common Stock owned outright; (b) 350 shares of Series 6-A, which are convertible into 1,120,000 shares of Common Stock; and (c) warrants to purchase 224,000 shares of
Common Stock. The address for James Chao is 5471 Kearny Villa Road, #200, San Diego, CA 92123.
|
(12)
|
Consists of (a) 250 shares of Series 5-A, which are convertible into 800,000 shares of Common Stock; and (b) 250 shares of Series 6-A, which are convertible into 800,000 shares of Common Stock. The address for
the Darras Revocable Trust dated 9/2/94 is 600 South Indian Hill Boulevard, Claremont, CA 91711.
|
(13)
|
Consists of 500 shares of Series 5-A, which are convertible into 1,600,000 shares of Common Stock. The address for South Bay Capital LLC is c/o Keith Lehman, Managing Member, 960 Third Street, Apt. 204, Santa Monica, CA
90403.
|
(14)
|
Consists of (a) 239,000 shares of Common Stock owned outright; (b) 230 shares of Series 5-A, which are convertible into 736,000 shares of Common Stock. The address for William J. and Mary Ann McGrath is 943
Edgemere Ct., Evanston, IL 60202.
|
55
(15)
|
Consists of options to purchase 150,000 shares of Common Stock.
|
(16)
|
Consists of (a) 982 shares of Common Stock owned outright; and (b) 1,125 shares of Common Stock owned in Schwartzs IRA.
|
(17)
|
Consists of 200,000 shares of Common Stock owned outright.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock(1)
|
|
Name of Beneficial Owner
|
|
Number of
Shares
Beneficially
Owned
|
|
|
Percentage of
Outstanding
Shares of the
Series
|
|
|
Percentage
of Eligible
Votes(2)
|
|
5% Holders of Series 1-A
|
|
|
|
|
|
|
|
|
|
|
|
|
Ron Soderling(3)
|
|
|
40,000
|
|
|
|
59.2
|
%
|
|
|
*
|
|
First Clearing Corporation(4)
|
|
|
20,000
|
|
|
|
29.6
|
%
|
|
|
*
|
|
Steven Tingey Jt Ten(5)
|
|
|
7,600
|
|
|
|
11.2
|
%
|
|
|
*
|
|
5% Holders of Series 2-A
|
|
|
|
|
|
|
|
|
|
|
|
|
Gretchen K. Musey(6)
|
|
|
3,900
|
|
|
|
100.0
|
%
|
|
|
*
|
|
5% Holders of Series 5-A
|
|
|
|
|
|
|
|
|
|
|
|
|
SMP Investments I, LLC(7)
|
|
|
1,250
|
|
|
|
13.9
|
%
|
|
|
20.4
|
%
|
Gerlach & Company(8)
|
|
|
625
|
|
|
|
6.9
|
%
|
|
|
3.1
|
%
|
Ciabattoni Living Trust(9)
|
|
|
600
|
|
|
|
6.7
|
%
|
|
|
13.0
|
%
|
Integral Investors Waveland LLC(10)
|
|
|
600
|
|
|
|
6.7
|
%
|
|
|
3.0
|
%
|
South Bay Capital LLC(11)
|
|
|
500
|
|
|
|
5.6
|
%
|
|
|
2.5
|
%
|
Named Executive Officers, Directors and Director Nominees Holding Series 5-A
|
|
|
|
|
|
|
|
|
|
|
|
|
William Houlihan
|
|
|
250
|
|
|
|
2.8
|
%
|
|
|
1.7
|
%
|
David Hirschhorn(12)
|
|
|
131
|
|
|
|
1.5
|
%
|
|
|
*
|
|
Brian Potiker(7)
|
|
|
1,250
|
|
|
|
13.9
|
%
|
|
|
20.4
|
%
|
Current Executive Officers and Directors as a group (1 person)
|
|
|
250
|
|
|
|
2.8
|
%
|
|
|
1.7
|
%
|
5% Holders of Series 6-A
|
|
|
|
|
|
|
|
|
|
|
|
|
SMP Investments I, LLC(7)
|
|
|
1,000
|
|
|
|
20.5
|
%
|
|
|
20.4
|
%
|
Ciabattoni Living Trust(9)
|
|
|
930
|
|
|
|
19.1
|
%
|
|
|
13.0
|
%
|
James Chao(13)
|
|
|
350
|
|
|
|
7.2
|
%
|
|
|
2.3
|
%
|
Hector S. Torres(14)
|
|
|
300
|
|
|
|
6.2
|
%
|
|
|
1.5
|
%
|
Darras Revocable Trust dated 9/2/94(15)
|
|
|
250
|
|
|
|
5.1
|
%
|
|
|
2.5
|
%
|
Named Executive Officers, Directors and Director Nominees Holding Series 6-A
|
|
|
|
|
|
|
|
|
|
|
|
|
Brian Potiker(7)
|
|
|
1,000
|
|
|
|
20.5
|
%
|
|
|
20.4
|
%
|
*
|
Indicates ownership of less than 1%.
|
(1)
|
Excludes the effect of the Series 7-A Exchange.
|
(2)
|
Represents the percentage of the 64,882,753 Eligible Votes with respect to the Meeting. Eligible Votes include the votes of holders of outstanding Common Stock plus the eligible vote of holders of outstanding Preferred
Stock, on an as converted basis. For additional information about the Eligible Votes and voting rights of each class of Voting Shares, see Stockholders Entitled to Vote.
|
(3)
|
The address for Ron Soderling is 901 Dove Street, Suite 270, Newport Beach, CA 92660.
|
(4)
|
The address for First Clearing Corporation is P.O. Box 6570, Glen Allen, VA 23058.
|
(5)
|
The address for Steven Tingey Jt Ten is c/o Jeffries & Co. Inc., 650 California Street, San Francisco, CA 94108.
|
(6)
|
The address for Gretchen K. Musey is 2312 Naples, Newport Beach, CA 92660.
|
(7)
|
Based on a Schedule 13D/A filed with the SEC by SMP on June 20, 2014. The address for SMP is c/o HSP Group, LLC, 875 Prospect Street, Suite 220,
La Jolla, CA 92037. Brian Potiker, in his capacity as a manager of SMP, may be deemed to beneficially own the shares held by SMP and has the sole power to vote or to
|
56
|
direct the vote of 16,048,365 shares of Common Stock, and the sole power to dispose of or to direct the disposition of 16,048,365 shares of Common Stock. Mr. Potiker is a director nominee.
|
(8)
|
The address for Gerlach & Co. is P.O. Box 7247-7057, Philadelphia, PA 19170.
|
(9)
|
Based on a Schedule 13D/A filed with the SEC by Ciabattoni Trust on June 20, 2014. The address for Ciabattoni Trust is 16 Lagunita Drive, Laguna Beach, CA 92561. Anthony J. Ciabattoni and Jane G. Ciabattoni, in
their capacity as trustees of Ciabattoni Living Trust, may be deemed to beneficially own the shares held by Ciabattoni Living Trust and have shared voting and dispositive power of 10,270,400 shares of Common Stock.
|
(10)
|
The address for Integral Investors Waveland LLC is 19800 MacArthur Blvd., Suite 650, Irvine, CA 92612.
|
(11)
|
The address for South Bay Capital LLC is c/o Keith Lehman, Managing Member, 960 Third Street, Apt. 204, Santa Monica, CA 90403.
|
(12)
|
The address for Mr. Hirschhorn is 4312 Park Verdi, Calabasas, CA 91302.
|
(13)
|
The address for James Chao is 5471 Kearny Villa Road, #200, San Diego, CA 92123.
|
(14)
|
The address for Hector S. Torres is c/o Joseph Apuzzo, CPA, 150 Airport Road, Suite 1000, Lakewood, NJ 08701.
|
(15)
|
The address for the Darras Revocable Trust dated 9/2/94 is 600 South Indian Hill Boulevard, Claremont, CA 91711.
|
57
Financial Information
First Physicians Capital Group, Inc.
Earnings to Fixed Charges
(Dollars in Thousands, Except Ratio Data)
The following table sets forth the ratio of earnings to fixed charges for the six months ended March 31, 2014 and the twelve months ended
September 30, 2013 and September 30, 2012. For the purposes of computing the ratio of earnings to fixed charges, earnings consist of income before income taxes plus fixed charges. Fixed charges consist of interest expense on all indebtedness and the
portion of rental expenses that management believes is representative of the interest factor.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six
months ended
March 31,
2014
|
|
|
Twelve
months ended
September 30,
2013
|
|
|
Twelve
months ended
September 30,
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-tax income
|
|
$
|
5,608
|
|
|
$
|
5,571
|
|
|
$
|
5,649
|
|
Fixed charges
|
|
|
313
|
|
|
|
882
|
|
|
|
1,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income available to cover fixed charges
|
|
$
|
5,921
|
|
|
$
|
6,453
|
|
|
$
|
6,797
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed Charges
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
303
|
|
|
|
866
|
|
|
|
1,126
|
|
Interest portion of rental expense
|
|
|
10
|
|
|
|
16
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total fixed charges
|
|
$
|
313
|
|
|
$
|
882
|
|
|
$
|
1,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio of earnings to fixed charges
|
|
|
18.9x
|
|
|
|
7.3x
|
|
|
|
5.9x
|
|
The book value per share at March 31, 2014 was $0.14.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors and officers and persons who beneficially own more than 10% of our Common Stock
(collectively, Section 16(a) Filers) to file with the SEC reports of beneficial ownership on Forms 3 and changes in beneficial ownership on Form 4 or Forms 5. SEC regulations require all Section 16(a) Filers to furnish us with
copies of all Section 16(a) forms they file. Based solely on a review of the copies of such forms furnished to the Company, the Company believes that during the fiscal year ended September 30, 2013 all Section 16(a) filing
requirements applicable to the Section 16(a) Filers were in compliance with Section 16(a), except that Ciabattoni Trust was late in filing one Form 4s relating to one transaction.
Stockholder Proposals
Any stockholder who wishes to have a qualified proposal included in our proxy statement for our 2015 Annual Meeting must send notice of the
proposal to our Secretary at our principal executive office no later than . If you make such a proposal, you must provide your
name, address, the number of shares of Common Stock you hold of record or beneficially, the date or dates on which such Common Stock was acquired and documentary support for any claim of beneficial ownership. Any stockholder proposal submitted
outside the process of Rule 14a-8 under the Exchange Act for the 2015 Annual Meeting will be considered untimely pursuant to Rule 14a-4(c)(1) if notice thereof is not received by
.
58
If the Company changes the date of the 2015 Annual Meeting by more than 30 days from the date of
the Meeting, the deadline for submitting proposals is a reasonable time before the Company begins to print and send 2015 proxy materials. If Proposal 1 regarding the Reverse Stock Split is approved, the Company will not be subject to the proxy rules
under the Exchange Act and does not expect to print and send proxy materials to stockholders prior to the 2015 Annual Meeting.
59
Forward-Looking Statements
This Proxy Statement contains forward-looking statements. The words believe, expect, anticipate,
estimate, project, and similar expressions identify forward-looking statements, which speak only as of the date of this Proxy Statement. Forward-looking statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified. Future events and actual results could differ materially from those made in, contemplated by, or underlying the forward-looking statements. For these reasons, you should not place undue reliance on any
forward-looking statements included in this Proxy Statement.
Any statement contained in a document incorporated by reference herein shall
be deemed to be modified or superseded for purposes of this Proxy Statement to the extent that a statement contained herein (or in any other subsequently filed documents which also is deemed to be incorporated by reference herein) modifies or
supersedes the statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Proxy Statement.
Available Information
We are subject to the informational requirements of the Exchange Act and, in accordance with the Exchange Act, file reports, proxy statements
and other information with the SEC. These reports, proxy statements, and other information can be inspected and copied at the public reference facilities of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Copies of this Proxy Statement can
also be obtained at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. In addition, these reports, proxy statements, and other information are available from the EDGAR filings
obtained through the SECs website (http://www.sec.gov).
Our financial statements incorporated herein by reference may be viewed
over the Internet at the SECs website (http://www.sec.gov) or, if you request them in writing, we will send them to you. Please address any request to the Companys Secretary, at the following address: First Physicians Capital Group,
Inc., 433 North Camden Drive # 810, Beverly Hills, California 90210.
60
Incorporation of Certain Documents by Reference
The following documents that we filed with the SEC are incorporated by reference in this Proxy Statement, except for any discussion therein of
the safe harbor protections for forward-looking statements provided under The Private Securities Litigation Reform Act of 1995: (i) the Annual Report on Form 10-K for the fiscal year ended September 30, 2013 and (ii) the
Quarterly Reports on Form 10-Q for the fiscal quarters ended December 31, 2013 and March 31, 2014.
All documents and reports
that we filed with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this Proxy Statement are not incorporated by reference into this Proxy Statement. New material information, if any, will be provided in an
amended Proxy Statement.
THIS PROXY STATEMENT DOES NOT CONSTITUTE THE SOLICITATION OF A PROXY IN ANY JURISDICTION TO OR FROM ANY PERSON
TO WHOM OR FROM WHOM IT IS UNLAWFUL TO MAKE SUCH PROXY SOLICITATION IN THAT JURISDICTION. YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROXY STATEMENT TO VOTE YOUR SHARES AT THE MEETING. WE HAVE NOT
AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT FROM WHAT IS CONTAINED IN THIS PROXY STATEMENT. THIS PROXY STATEMENT IS DATED
, 2014. YOU SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED IN THIS PROXY STATEMENT IS ACCURATE AS OF ANY DATE OTHER THAN THAT
DATE, AND THE MAILING OF THIS PROXY STATEMENT TO STOCKHOLDERS DOES NOT CREATE ANY IMPLICATION TO THE CONTRARY.
By order
of the Board of Directors,
Sean Kirrane
Chief Executive Officer
, 2014
61
Annex A
CERTIFICATE OF AMENDMENT TO
AMENDED CERTIFICATE OF INCORPORATION
OF
FIRST PHYSICIANS
CAPITAL GROUP, INC.,
a Delaware corporation
First Physicians Capital Group, Inc., a Delaware corporation (the
Corporation
) organized and existing under and by virtue
of the Delaware General Corporation Law (the
DGCL
), does hereby certify:
FIRST: That resolutions were adopted in
accordance with Section 242 of the DGCL setting forth the following amendment to the Certificate of Incorporation of the Corporation, as amended (the
Certificate
), declaring said amendment to be advisable and directing said
amendment to be submitted to the stockholders of the Corporation for consideration thereof. The resolutions setting forth the proposed amendment are as follows:
RESOLVED, that Article 4 of the Certificate is hereby amended to add the following paragraph B immediately subsequent
to paragraph A. The newly added paragraph B will read as follows:
B. Effective immediately following the
effectiveness of the amendment to this Certificate of Incorporation, as amended, adding paragraph B to Article IV, and without regard to any other provision contained herein, each 2,000 shares of Common Stock either issued and outstanding
or held by the Corporation as treasury stock (and including each fractional share) immediately prior to the time this amendment becomes effective shall automatically and without any action on the part of the respective holders thereof or the
Corporation, be reclassified and changed into 1 fully-paid and nonassessable share of Common Stock (or, with respect to such fractional shares and interests, such lesser number of shares or interests as may be applicable based on such 2,000 to 1
ratio), without increasing or decreasing the amount of stated capital or paid-in surplus of the Corporation (the Reverse Stock Split). No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who
otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash (without interest or deduction) from the Corporations transfer agent in lieu of such fractional share interests upon the submission of a
transmittal letter by a stockholder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of the stockholders certificates, in an amount of $0.55 per share.
RESOLVED FURTHER, that Article 4 of the Certificate is hereby amended to cause the current paragraph B to be
relettered to be paragraph C and the current paragraph C to be relettered to be paragraph D.
SECOND: That thereafter,
pursuant to a resolution of the Board of Directors, the Annual Meeting of the Stockholders of the Corporation was called and held, upon notice in accordance with Section 222 of the DGCL, at which meeting the necessary number of shares as
required by statute were voted in favor of the amendment of the Certificate.
THIRD: That said amendment was adopted in accordance with
the provisions of Section 242 of the DGCL.
[Signature Page Follows]
A-1
IN WITNESS WHEREOF, First Physicians Capital Group, Inc. has caused this certificate to be signed
by Adrian Reeder, its authorized officer, this day of , 2014.
A-2
Annex B
U.S. SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 10-K
(MARK ONE)
x
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the Fiscal Year Ended September 30, 2013
OR
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the Transition Period from
to
Commission file number: 000-30326
FIRST
PHYSICIANS CAPITAL GROUP, INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
DELAWARE
|
|
77-0557617
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
433 North Camden Drive #810
Beverly Hills, California
|
|
90210
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(310) 860-2501
SECURITIES REGISTERED PURSUANT TO SECTION 12 (b) OF THE ACT: NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12 (g) OF THE ACT:
COMMON STOCK, PAR VALUE $0.01 PER SHARE
Indicate by check mark whether
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.
¨
Yes
x
No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
¨
Yes
x
No
Indicate
by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
¨
Yes
x
No
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the
registrant was required to submit and post such files).
x
Yes
¨
No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
¨
|
|
|
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).
¨
Yes
x
No
The aggregate market value of common stock of the registrant held by non-affiliates of the registrant on March 31, 2013 was $115,181 computed upon the
basis of the closing price on that date.
|
|
|
Number of shares of common stock outstanding as of March 28, 2014
|
|
23,909,507
|
B-1
EXPLANATORY NOTE
The last periodic report of First Physicians Capital Group, Inc. (the Registrant) filed with the Securities and Exchange Commission was the Form
10-Q for the Fiscal Quarter Ended December 31, 2010, filed February 22, 2011. In order to become current with all required quarterly and annual reports under the Securities Exchange Act of 1934, the Registrant is filing this Form 10-K for
the Fiscal Period Ended September 30, 2013 concurrently with Form 10-Qs for the Fiscal Quarters Ended March 31, 2011, June 30, 2011, December 31, 2011, March 31, 2012, June 30,
2012, December 31, 2012, March 31, 2013, June 30, 2013 and December 31, 2013, and
Form 10-Ks
for the Fiscal Years Ended September 30, 2011 and
September 30, 2012.
B-2
FIRST PHYSICIANS CAPITAL GROUP, INC.
FORM 10-K ANNUAL REPORT
FOR THE
FISCAL YEAR ENDED SEPTEMBER 30, 2013
TABLE OF CONTENTS
B-3
PART I
FORWARD LOOKING STATEMENTS
The discussion
in this Form 10-K contains forward-looking statements that may be subject to protection under the Private Securities Litigation Reform Act of 1995 and such statements should not be unduly relied upon. Forward-looking statements can be identified by
the use of words such as may, will, could, should, anticipates, believes, estimates, expects, intends, plans and variations
thereof or of similar expressions. All forward-looking statements included in this Form 10-K are based on information available to us on the date hereof. We assume no obligation to update any such forward-looking statements. Our actual results in
future periods could differ materially from those indicated in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to:
|
|
|
our ability to obtain ongoing financing, manage our cash resources, control expenses and continue as a going concern;
|
|
|
|
impact of our indebtedness on our ability to invest in the ongoing needs and growth of our business;
|
|
|
|
significant past operating losses, potential future losses and limited ongoing revenue;
|
|
|
|
changes in government regulation, particularly healthcare laws;
|
|
|
|
possession of significant voting control over us by the holders of our Series 5-A Preferred Stock and Series 6-A Convertible Preferred Stock;
|
|
|
|
increased competition in the industry, geography and the segments in which we compete;
|
|
|
|
our ability to attract and retain employees and key members of management;
|
|
|
|
changes in economic and industry conditions;
|
|
|
|
reliance on third parties to provide services critical to our operations;
|
|
|
|
potential dilution of existing stockholders if we raise capital by issuing additional capital stock;
|
|
|
|
availability of appropriate prospective acquisitions or investment opportunities;
|
|
|
|
significant costs and obligations as a result of being a public company;
|
|
|
|
continued positive relationships with our customers;
|
|
|
|
deterioration in the collectability of our accounts;
|
|
|
|
major man-made or natural disasters;
|
|
|
|
compliance with applicable laws and regulations and cost of potential legal actions such as litigation or investigations;
|
|
|
|
inadequacy of our insurance coverage and fluctuating insurance requirements and costs;
|
|
|
|
impact of a potential requirement to record asset impairment charges in the future;
|
|
|
|
failure of our information technology system or the breach of our network security;
|
|
|
|
impact on our disclosure of use the scaled disclosure option available to smaller reporting companies; and
|
|
|
|
volatility in the price of our common stock.
|
References to we, us, our,
TIGroup, FPCG or the Company refers to First Physicians Capital Group, Inc. (f/k/a Tri-Isthmus Group, Inc.) and its subsidiaries. We maintain our executive offices at 433 North Camden Drive, #810, Beverly Hills,
California 90210. Our telephone number is +1 (310) 860-2501, and our website is at www.firstphysicianscapitalgroup.com.
B-4
This Form 10-K report covers the twelve-month period ended September 30, 2013 and the
twelve-month period ended September 30, 2012, with additional information on other fiscal years, as required by SEC rules and regulations.
Information in this Form 10-K is current as of March 28, 2014 unless otherwise specified.
Current Operations
During the Fiscal
Year Ended September 30, 2010, we shifted our strategy away from majority ownership in healthcare delivery companies to a focus on the provision of management, financial, and ancillary healthcare and IT services to the rural and community
hospital market. We expect to maintain and/or acquire minority ownership in selected healthcare delivery companies that complement our management services and financing activities. We may also invest in, acquire or partner with other companies that
provide similar services in our markets.
In pursuit of this reorganization, we undertook an initiative to divest ourselves of
underperforming facilities and reduce or outsource administrative functions to better align cost structures and business volume. As a result of the initiative, during the Fiscal Year Ended September 30, 2011, we successfully divested ourselves
of our majority owned hospitals, and obtained contracts to provide the healthcare management services to two hospital clients.
We
currently have 4 operating subsidiaries which are First Physicians Business Solutions, LLC, First Physicians Resources, LLC, First Physicians Services, LLC and First Physicians Realty Group. First Physicians Business Solutions, LLC provides an
array of management services to include hospital operations management, revenue cycle management, IT, finance and human resources. First Physicians Services provides ancillary service oversight and management solutions for lab, pharmacy, and
emergency departments in rural hospital settings. First Physicians Resources, LLC provides medical and back office staffing solutions to our hospital clientele. First Physicians Realty Group is our real estate subsidiary that owns
healthcare related properties and leases them to clients. We currently have contracts to provide financial and back office services to two hospital clients.
COMPANY BACKGROUND
We were originally
incorporated in Nevada in October 1980 and re-incorporated in Delaware in November 2000.
During the fiscal year ended
January 31, 2007 (the Fiscal Year Ended January 31, 2007), we resumed active operations following the acquisition of two ambulatory surgical centers located in Southern California. On December 2, 2005, through newly
created indirect subsidiaries, we entered into two separate purchase agreements to acquire from Surgical Ventures, Inc., a California corporation, a controlling interest in two separate outpatient surgical centers in San Diego, California, Point
Loma Surgical Center, L.P. and Outpatient Surgery of Del Mar, L.P., and we completed these acquisitions on November 16, 2006.
On
October 29, 2007, we acquired 51% of the issued and outstanding membership units of Rural Hospital Acquisition, LLC, an Oklahoma limited liability company (RHA). Based in Oklahoma City, RHA owned and operated three critical access
hospitals, one medical clinic and an ancillary support services unit, which were focused on the delivery of healthcare services to rural communities in Oklahoma. On May 1, 2008, RHA Anadarko, LLC, a wholly owned subsidiary of RHA, purchased
100% of the issued and outstanding membership interests of Southern Plains Medical Center (SPMC). Founded in 1915, SPMC is one of the oldest continuously operating multi-specialty physician practices in the United States. Beginning
November 18, 2008, RHA began operating under the trade name Southern Plains Medical Group. On December 11, 2008, we acquired the remaining 49% of the issued and outstanding membership units of RHA, making RHA an indirect wholly-owned
subsidiary of ours.
B-5
On December 12, 2008, we and certain of our subsidiaries entered into three loan agreements,
effective November 6, 2008, with two Oklahoma lenders, Bank of Commerce and Valliance Bank, resulting in an aggregate debt financing of $8.4 million. We obtained the financing to purchase the building and real property of the Stroud
Regional Medical Center Hospital and clinics, refinance existing loans totaling $4.6 million, upgrade facilities at the Johnston Memorial Hospital and improve the consolidated balance sheet and maintain general working capital. The loans were
evidenced by promissory notes issued by RHA Anadarko, LLC, RHA Stroud, LLC and RHA Tishomingo, LLC, two of which mature on November 6, 2028 and one of which matures on November 6, 2024.
On May 1, 2009, we purchased The Chandler Clinic (TCC), a family medical practice located in Chandler, Oklahoma. On
December 1, 2010, we sold the operations of The Chandler Clinic to the physician group from which it was originally purchased. The Company has no further obligations or interests in this facility and the buyer assumed the liabilities and leases
related to this facility in the transaction. The Company received no consideration at closing.
On September 29, 2009, at our Annual
Meeting of Stockholders, our stockholders voted to amend our Certificate of Incorporation to change our legal name from Tri-Isthmus Group, Inc. to First Physicians Capital Group, Inc. We became First Physicians Capital Group,
Inc. on September 29, 2009.
On January 13, 2010, SPMC entered into a sale/leaseback transaction pursuant to an asset purchase
agreement dated January 13, 2010 whereby SPMC sold certain property to Southern Plains Associates, LLC (SPA). First Physicians Realty Group, LLC, owned 50% of SPA and Capital Investors of Oklahoma, LLC, owned the other 50%. The
purchase price for the sale/leaseback transaction was paid to SPMC as follows: (i) $1,500,000 was paid in the form of a promissory note, dated January 13, 2010, and (ii) $4,500,000 was paid in cash at the closing. The $4,500,000 in
cash proceeds was used to pay off short-term debt associated with the property sold in the amount of $3,700,942, plus related interest. SPMC received net proceeds of $732,221 after retirement of the debt and other associated closing costs.
Restricted cash on deposit with the debt holder and pledged as a security on the debt in the amount of $1,524,091 was released and returned to us. In connection with the transaction, SPMC leased back from SPA the property sold, pursuant to a lease
agreement dated December 16, 2009. The lease agreement provided for a 20-year term with an automatic 10-year renewal.
On
January 10, 2011, RHA Tishomingo, LLC, an indirect subsidiary of ours, entered into an asset purchase agreement to sell the hospital operations of Johnson Memorial Hospital in Tishomingo, Oklahoma to Mercy Tishomingo Hospital Corporation. Also
on January 10, 2011, we entered into an agreement for purchase and sale of real property to sell the real estate and equipment of Johnson Memorial Hospital to RSE Enterprises, Inc., (together with the sale to Mercy Tishomingo Hospital
Corporation, the Tishomingo Transaction).
As part of the Tishomingo Transaction, the $1.13 million in USDA mortgage debt
related to the facility was retired. The gross proceeds in the transaction were $1,687,000, consisting of $1,630,000 purchase price, $500,000 in cash and an additional $57,000 for medical supplies.
On January 31, 2011, RHA, and our wholly-owned subsidiaries, sold its owned hospital buildings and land in Stroud and Anadarko, Oklahoma
to First Physicians Realty Group, LLC LLC, a wholly owned subsidiary of the Company, for $10,324,000. As payment for the purchase, First Physicians Realty Group assumed the existing first mortgage debt of $6,625,000 and executed $3,699,000 of
promissory notes payable to RHA.
Simultaneously with the sale of the land and buildings, RHA and its wholly-owned subsidiaries executed a
twenty (20) year lease for the hospital facilities. The leases have been accounted by First Physicians Realty Group as direct financing leases and reflected as notes receivable in the accompanying Consolidated Balance Sheet subsequent to the
April 1, 2011 sale of the owned hospitals.
On May 4, 2011, RHA entered into that certain Stock Purchase Agreement, dated
May 4, 2011 (the Cura SPA), by and between RHA and with One Cura Wellness Inc. (One Cura) for the sale of RHA Anadarko, LLC,
B-6
and RHA Stroud, LLC to One Cura (the Cura Transaction). Upon closing, RHA received two notes totaling $12,000,000 as consideration for the purchase. The notes have a term of ten
(10) years and bear interest at a rate of ten percent (10%).
In conjunction with the Cura SPA, First Physicians Business Solutions,
LLC (FPBS) a wholly owned direct subsidiary of the Company entered into management services agreements with RHA Anadarko and RHA Stroud to provide management services for an initial period of six and one half (6.5) years. Further,
First Physicians Resources, LLC (FPR) and wholly owned direct subsidiary of the registrant entered into staff leasing agreements to provide staffing to RHA Anadarko and RHA Stroud for an initial term of one (1) year. Finally, First
Physicians Realty Group, LLC (FPRG) a wholly owned direct subsidiary of the registrant entered into an Amended and Restated lease with RHA Anadarko and RHA Stroud to continue the lease of real property associated with the hospitals owned
by RHA Anadarko and RHA Stroud.
On July 13, 2011, Rural Hospital Acquisition, LLC (RHA) entered into a Stock Purchase
Agreement, dated July 13, 2011 (the SPMC SPA), by and between RHA and Southern Plains Associates II, LLC (SPA II), and that certain Asset Purchase Agreement, dated July 13, 2011 (the SPMC APA), by and
between RHA and SPA II, for the sale of (i) SPMC and (ii) the medical records associated with SPMC, respectively. As consideration for the sale, RHA received two notes totaling $2,150,000. The notes have a term of ten (10) years and
bear interest at a rate of 5%. In addition, SPA II delivered to RHA a buyers Members guarantee and a company guarantee.
In
conjunction with the stock sale/purchase agreement, SPA and Capital Investors of Oklahoma, LLC entered into a Real Estate Purchase Agreement with the SPMC buyer for the purchase/sale of the SPMC real estate. As consideration for the purchase/sale of
the SPMC real estate the buyer assumed the existing mortgage on the property and caused the lender to release all guarantees of the mortgage by us. At closing the mortgage had a remaining principal balance of $4,560,982. The SPMC buyer also assumed
four equipment loans from the Company with a total remaining principal balance of $121,471 and bearing interest rates of 6.75%.
Following
the SPMC real estate sale, all assets of SPA were liquidated and SPA immediately ceased operations.
On September 15, 2011, First
Physicians Capital Group, Inc. (FPCG), entered into a Stock Purchase Agreement, dated September 15, 2011 (the DEL MAR SPA) by and between Del Mar Gen Par, Inc. (DGP), Del Mar Acquisition, Inc.
(DMA, and together with FPCG and DGP, the Seller), and Surgical Center Management, Inc. (the Management Company), IHM Del Mar, LLC (IHM), and several individuals (together with IHM, each a
Purchaser and collectively the Purchasers) for the sale of Outpatient Surgery of Del Mar, L.L.C. (DEL MAR). Prior to the sale, FPCG held 53.54% of the member units of DEL MAR. As consideration for the sale, FPCG
received two payments, consisting of $250,000, paid prior to closing as an initial deposit, and $500,000 paid at closing, for total consideration of $750,000. An additional earnout payment of $243,735, payable upon meeting certain
milestones, was not received.
Bridge Financing
During the Fiscal Year Ended September 30, 2009, we entered into a bridge financing transaction (the Bridge Financing) which
was consummated in three separate closings.
On February 11, 2009, we completed the first closing of the Bridge Financing, a
transaction in which we entered into the following two promissory notes, each dated as of February 6, 2009: (i) a convertible promissory note in the principal amount of $500,000 and (ii) a convertible promissory in the principal
amount of $1,000,000 (collectively, the Bridge Notes). On February 11, 2009, in addition to the issuance of the Bridge Notes, we issued four warrants to purchase Common Stock to the bridge lenders. See Note 6. Bridge
Financing in the accompanying notes to the financial statements in this Form 10-K.
B-7
On March 3, 2009, we completed the second closing of the Bridge Financing, a transaction in
which we entered into nine (9) promissory notes, each dated as of March 3, 2009, in the aggregate principal amount of $500,000 (the Second Bridge Notes), with various investors (the Second Bridge Lenders).
Subsequent to this second closing, Anthony J. Ciabattoni, holder of the $1,000,000 Bridge note from the first round of Bridge Financing, assumed three of the Second Bridge Notes, for a total of $100,000. See Note 6. Bridge Financing in
the accompanying notes to the financial statements in this Form 10-K.
On April 14, 2009, we completed the third closing of the
Bridge Financing, a transaction in which we entered into the following three (3) promissory notes: (i) a convertible promissory note, dated as of March 31, 2009 in the principal amount of $100,000; (ii) a convertible promissory
note, dated as of March 31, 2009, in the principal amount of $50,000 and (iii) a convertible promissory note, dated as of April 14, 2009, in the principal amount of $50,000. Of the total Bridge Financing, $1,600,000 was considered a
related party transaction. See Item 8, Note 6. Bridge Financing in the accompanying notes to the financial statements in this Form 10-K. Of the original Bridge Financing, $1,350,000 remained outstanding at September 30, 2013.
During the Fiscal Year Ended September 30, 2011, we entered into bridge financing transactions (the 2011 Bridge
Financing) where we entered into ten promissory notes, in the aggregate principal amount of $2,034,000 (the 2011 Bridge Notes), with various investors (the 2011 Lenders). We received the 2011 Bridge Financing in
multiple installments as follows: $674,400, $549,600, $360,000, and $100,000 in August, September, November and December of 2011 respectively and $350,000 in January 2012. Each bridge note has attached warrants to purchase an aggregate of 2,278,079
shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. Of the total 2011 Bridge Financing, $1,559,000 was considered a related party transaction. The warrants were issued January 1, 2014. See
Note 6. Bridge Financing in the accompanying notes to the financial statements in this Form 10-K.
Beginning in February 2012,
we entered into a staggered bridge financing transaction (the 2012 Bridge Financing) whereby we entered into three promissory notes, in the aggregate principal amount of $1,279,000 (the 2012 Bridge Notes), with three
investors (the 2012 Lenders) with maturity dates of June 30, 2014. The 2012 Bridge Loans funded as follows; $340,000, $320,000, $390,000 and $229,000 in February, March, April, and May of 2012 respectively. Each bridge note has
attached warrants to purchase an aggregate of 4,092,800 shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. The warrants were issued January 1, 2014. All of the 2012 Bridge Financing was
considered a related party transaction. The 2012 Bridge Notes were paid in full in the Fiscal Year Ended September 30, 2013.
Beginning in November 2013, we entered into a staggered bridge financing transaction (the 2013 Bridge Financing) whereby we
entered into four (4) promissory notes, with interest of 10% per annum, in the aggregate principal amount of $650,000 (the 2013 Bridge Notes), with 4 investors, each note maturing June 30, 2014. The 2013 Bridge Loans
funded as follows; $450,000 and $200,000 in November 2013 and January 2014, respectively. All of the 2013 Bridge Financing was considered a related party transaction.
INTELLECTUAL PROPERTY
We do not
currently have any patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, other than those that are incidental and customary to our business, such as licenses to use software applications.
EMPLOYEES
At September 30, 2013, we
had approximately 3 employees. As of March 28, 2014, we have two employees at the parent company level, including Sean Kirrane, Chief Executive Officer, and an administrative secretary. We consider our relations with employees to be good. None
of our employees are represented by a labor union or work under any collective bargaining agreement.
B-8
All employees employed by First Physicians Resources, LLC are part of a staff leasing/contract
labor operation and leased under staff leasing agreements to two hospital clients. At September 30, 2013, First Physicians Resources, LLC had approximately 174 employees. As of March 28, 2014 there were 170 employees employed by First
Physicians Resources LLC. None of these employees are represented by a labor union or work under any collective bargaining agreement.
GOVERNMENT
REGULATIONS
The United States healthcare industry is subject to extensive regulation by a number of governmental entities at the
federal, state and local level. Government regulation affects our business activities by controlling our growth, requiring licensure and certification of the facilities we manage, regulating the use of our properties and controlling reimbursement to
us for the services we provide.
Medicare-Medicaid Fraud and Abuse Provisions
Section 1128B(b) of the Social Security Act (the Federal Anti-Kickback Statute) prohibits the knowing or willful offering,
payment, solicitation or receipt or remuneration, directly or indirectly, overtly or covertly, in cash or in kind, for: (1) the referral of patients or arranging for the referral of patients to receive services for which payment may be made in
whole or in part under a federal or state healthcare program; or (2) the purchase, lease, order or arranging for the purchase, lease or order of any good, facility, service or item for which payment may be made under a federal or state
healthcare program. The Federal Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by case law or regulations. Violations may result in criminal penalties or fines of up to
$25,000, imprisonment for up to five years, or both. Violations of the Federal Anti-Kickback Statute may also result in substantial civil penalties, including penalties of up to $50,000 for each violation, plus three times the amount claimed and
exclusion from participation in the Medicare and Medicaid programs. Exclusion from these programs would result in significant reductions in revenue and would have a material adverse effect on our business.
As authorized by Congress, the Office of the Inspector General (OIG) promulgated safe harbor regulations that outline categories
of activities protected from prosecution under the Federal Anti-Kickback Statute. These safe harbors cover, among other things, investment interests, personal services and management contracts and employment arrangements. Although conduct or
business arrangements that do not fall within a safe harbor are not unlawful
per se
, noncompliant conduct or business arrangements risk increased scrutiny by governmental enforcement authorities.
In addition to the Federal Anti-Kickback Statute, the Health Insurance Portability and Accountability Act of 1996, or HIPAA,
provides for criminal penalties for healthcare fraud offenses that apply to all health benefit programs, including the payment of inducements to Medicare and Medicaid beneficiaries in order to influence those beneficiaries to order or receive
services from a particular provider or practitioner. Federal enforcement officials have numerous enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program and an incentive program under which individuals can receive
up to $1,000 for providing information on Medicare fraud and abuse that leads to the recovery of at least $100 of Medicare funds. In addition, federal enforcement officials have the ability to exclude from Medicare and Medicaid any investors,
officers and managing employees associated with business entities that have committed healthcare fraud.
Evolving interpretations of
current, or the adoption of new, federal or state laws or regulations could affect many of our arrangements. Law enforcement authorities, including the OIG, the courts and Congress, are increasing their scrutiny of arrangements between healthcare
providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to exchange remuneration for patient care referrals and opportunities. Investigators also have demonstrated a willingness to look behind the
formalities of a business transaction to determine the underlying purposes of payments between healthcare providers and potential referral sources.
B-9
The Federal False Claims Act and Similar Federal and State Laws
The False Claims Act (the FCA) prohibits any person from knowingly presenting or causing to be presented a false or fraudulent
claim, record or statement to obtain payment from the government or decrease any payments owed to the government. Governmental enforcement agencies or courts may impose fines up to three times the actual damages sustained by the government, plus
mandatory civil penalties of between $5,500 and $11,000 for each separate false claim.
Criminal false claims provisions apply to
(1) false claims or statements made knowingly or willfully to obtain benefits under Medicare or Medicaid or feign compliance with certification requirements, or (2) failure to refund, knowingly and with fraudulent intent, Medicare and
Medicaid funds not properly paid. Governmental enforcement agencies or courts may impose up to five years in prison, $25,000 in fines for each offense, or both.
FCA claims may be brought by governmental enforcement authorities or by individuals on the governments behalf under the FCAs
qui tam
, or whistleblower, provisions. Whistleblower provisions allow private individuals to bring actions on behalf of the government alleging that the defendant defrauded the federal government. Additionally, HIPAA established
(1) civil liability for up-coding and billing medically unnecessary items and services, and (2) federal criminal sanctions for healthcare fraud against a private, nongovernmental healthcare benefit program. Although we have implemented
policies and procedures to avoid violations of these laws, there can be no assurance that the conduct will not be reviewed and challenged by whistleblowers or governmental enforcement authorities. Any adverse determination could subject us to
criminal and civil liability.
A number of states have adopted their own false claims provisions as well as their own
qui tam
provisions whereby a private party may file a civil lawsuit in state court. We are currently not aware of any actions against us under any such state laws.
Healthcare Industry Investigations
Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing
investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral and billing practices.
From time to time, the OIG and the United States Department of Justice (the DOJ) have established national enforcement initiatives
that focus on specific billing practices or other suspected areas of abuse. Some of our activities could become the subject of governmental investigations or inquiries. In addition, our executives and managers, many of whom have worked at other
healthcare companies that are or may become the subject of federal and state investigations and private litigation could be included in governmental investigations or named as defendants in private litigation. We are not aware of any governmental
investigations involving any of our facilities, our executives or our managers. A future adverse investigation of us, our executives or our managers could result in significant expense to us, as well as adverse publicity.
Privacy Requirements and Administrative Simplification
Federal and state governmental enforcement authorities extensively regulate the confidentiality of patient health information. HIPAA privacy
regulations regulate the use and disclosure of patient health information, whether communicated electronically, on paper or orally. The regulations also provide patients with significant rights related to understanding and controlling how their
health information is used or disclosed. HIPAA security regulations require healthcare providers to implement administrative, physical and technical safeguards to protect the security of patient health information that is maintained or transmitted
electronically. Further, as required by HIPAA, US Department of Health and Safety has adopted regulations establishing electronic data transmission standards that all healthcare providers must use when submitting or receiving certain healthcare
transactions electronically.
B-10
The penalty for failure to comply with HIPAA privacy and security standards is a fine of up to
$100 for each violation, with a maximum penalty of $25,000 imposed for all violations of an identical requirement during a calendar year. Additionally, any person or entity who violates HIPAA privacy or security regulations may be fined up to
$250,000, imprisoned for not more than 10 years or both. We believe we comply in all material respects with all applicable federal and state laws, rules and regulations governing the privacy and security of patient health information. Because
of the complexity of these regulations, however, there can be no assurance that our privacy and security practices will not be reviewed and found not to be in compliance with these standards. An adverse determination by governmental enforcement
authorities could materially and adversely affect our business.
In addition, our clients will continue to remain subject to any state
laws that are more restrictive than the HIPAA privacy and security regulations. These statutes vary by state and could impose additional penalties.
Patient Protection and Affordable Care Act
On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act (the PPACA). The Healthcare
and Education Reconciliation Act of 2010 (the Reconciliation Act), which contains a number of amendments to the PPACA, was signed into law on March 30, 2010. Two primary goals of the PPACA, combined with the Reconciliation Act
(collectively referred to as the Health Reform Legislation), are to provide for increased access to coverage for healthcare and to reduce healthcare-related expenses.
On June 28, 2012, the United States Supreme Court upheld the constitutionality of the requirement in PPACA that individuals maintain
health insurance or pay a penalty under Congresss taxing power. The Supreme Court upheld the PPACA provision expanding Medicaid eligibility to new populations as constitutional, but only so long as the expansion of the Medicaid program is
optional for the states. States that choose not to expand their Medicaid programs to newly eligible populations in PPACA can only lose the new federal Medicaid funding in PPACA but not their eligibility for existing federal Medicaid matching
payments.
The Health Reform Legislation expands coverage of uninsured individuals and provides for significant reductions in the growth
of Medicare program payments, material decreases in Medicare and Medicaid disproportionate share hospital payments, and the establishment of programs where reimbursement is tied in part to patient outcomes. Based on Congressional Budget Office
estimates, the Health Reform Legislation, as enacted, is expected to expand health insurance coverage to approximately 32 to 34 million additional individuals through a combination of public program expansion and private sector health insurance
reforms.
Some of the most significant changes will expand the categories of individuals eligible for Medicaid coverage and permit
individuals with relatively higher incomes to qualify. The federal government reimburses the majority of a states Medicaid expenses, and it conditions its payment on the state meeting certain requirements. The federal government currently
requires that states provide coverage for only limited categories of low-income adults under 65 years old (e.g., women who are pregnant, and the blind or disabled). In addition, the income level required for individuals and families to qualify for
Medicaid varies widely from state to state. While the Health Reform Legislation will greatly expand the number of adults who are eligible for Medicaid, it may not impact our business as Medicaid generally does not reimburse for care provided to
adults treated in freestanding behavioral health facilities. As the direct impact of the Health Reform Legislation will be felt by our customers, we are unable to predict with any reasonable certainty the likely impact of the Health Reform on our
business model, financial condition or result of operations due to the laws complexity, lack of implementing regulations or interpretive guidance, gradual and partially delayed implementation, court challenges and possible amendment, repeal or
further implementation delays, as well as our inability to foresee how individuals, states and businesses will respond to the choices afforded them by the law.
B-11
Because we are a Smaller Reporting Company, we are not
required to disclose the information required by this item.
The following principal facilities are leased by us and are material to our
operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Facility
|
|
Address
|
|
Lease Term
|
|
Monthly Rent
|
|
|
Area (sq. ft.)
|
|
Office Sublease from HSP, Inc.
|
|
433 N. Camden,
Suite 810
Beverly Hills,
California 90210
|
|
Lease expires
1/31/2018
|
|
$
|
4,438
|
(1)
|
|
|
2,367
|
|
|
|
|
|
|
Office Sublease from Praxis Health Group, L.L.C
|
|
4323 N. W.
63
rd
Street
Suite 232,
Oklahoma City,
OK 73116
|
|
Month to month
|
|
$
|
2,700
|
|
|
|
Approx. 400
|
|
(1)
|
The lease agreement requires 3.0% annual increases beginning in 2014 through the term of the lease. See Note 9 in accompanying notes to the financial statements in this Form 10-K.
|
I
tem 3.
|
LEGAL PROCEEDINGS
|
The Company is party to various claims arising in the ordinary course
of business. The Company has accrued approximately $660,000 related to various claims based on managements assessment of the potential outcome. Actual settlement may be different from the accrued liability. However, in the
opinion of the Companys management, the ultimate liability in excess of the amounts accrued, if any, resulting from the disposition of these actions will not have a material effect on the consolidated financial position or results of
operations.
In June 2011, the Company vacated office space in Oklahoma City, Oklahoma prior to the expiration of the lease, at which time
the landlord proceeded with litigation to collect outstanding lease payments. In December of 2013, both parties entered into a settlement agreement under which the Company agreed to make a one-time payment of $65,000 in full satisfaction of all
amounts due under the lease terms.
In August 2011, the holder of the $1.5 million note payable (see Note 9 in footnotes to the financial
statements in this Form 10-K) and 4.25 million of the Companys outstanding common stock, filed a law suit for performance and repayment of the loan. In December 2011, in full settlement of the lawsuit and satisfaction of the $1.5 million
note payable, the lender accepted assignment and receipt of the $2.15 million notes receivable the Company had received in July 2011 as consideration for the sale of the SPMC medical records, and cash totaling $91,000. Additionally, as part of the
settlement, the lender agreed to transfer the 4.25 million common stock back to the Company.
Ite
m 4.
|
MINE SAFETY DISCLOSURES
|
Not applicable.
B-12
PAR
T II
Item 5.
|
MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER REPURCHASES OF EQUITY SECURITIES
|
MARKET INFORMATION
Our Common Stock is
traded in the over-the-counter market under the symbol FPCG.OB. The following table presents, for the periods indicated, the high and low bid prices per share of our Common Stock. The quotations reflect inter-dealer prices, without
retail mark-up, mark-down or commissions and may not represent actual transactions.
|
|
|
|
|
|
|
|
|
The Fiscal Year Ended September 30, 2013
|
|
High
|
|
|
Low
|
|
First Quarter
|
|
$
|
0.07
|
|
|
$
|
0.01
|
|
Second Quarter
|
|
|
0.10
|
|
|
|
0.01
|
|
Third Quarter
|
|
|
0.01
|
|
|
|
0.00
|
|
Fourth Quarter
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
|
The Fiscal Year Ended September 30, 2012
|
|
High
|
|
|
Low
|
|
First Quarter
|
|
$
|
0.10
|
|
|
$
|
0.01
|
|
Second Quarter
|
|
|
0.10
|
|
|
|
0.01
|
|
Third Quarter
|
|
|
0.08
|
|
|
|
0.01
|
|
Fourth Quarter
|
|
|
0.01
|
|
|
|
0.01
|
|
STOCKHOLDERS
As of March 28, 2014, to the best of our knowledge, there were approximately 353 stockholders of record of our Common Stock.
DIVIDENDS
We have never declared or paid
cash dividends on our Common Stock or preferred stock. Holders of our Series 1-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by the Board of Directors, of $0.20 per share annually. Holders of our
Series 2-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by the Board of Directors, in an amount equal to 8% of the price originally paid to us for each share of Series 2-A Convertible Preferred Stock.
Holders of our Series 5-A Convertible Preferred Stock, par value $0.01 per share (the 5-A Preferred) are entitled to non-cumulative dividends, if declared by the Board of Directors, of $40 per share annually. Holders of our 6-A
Preferred are entitled to non-cumulative dividends, if declared by the Board of Directors and
pari passu
with 5-A Preferred, of $40 per share annually. No dividend may be declared and paid upon shares of our Common Stock in any fiscal year
unless dividends on all such preferred stock have been paid or declared and set aside for payment to holders of our preferred stock for such fiscal year. We currently intend to retain all future earnings to finance future growth and therefore do not
anticipate declaring or paying any cash dividends in the foreseeable future.
B-13
EQUITY COMPENSATION PLAN INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of securities
to be issued upon
exercise of
Outstanding options,
warrants and rights
at Sep. 30, 2013
|
|
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
at Sep. 30, 2013
|
|
|
Number of securities
remaining available for
future issuance
under
equity compensation
plans (excluding
securities reflected in
column (a))
at Sep. 30, 2013
|
|
Plan category
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
Equity compensation plans approved by security holders(1)
|
|
|
7,120,000
|
|
|
$
|
0.61
|
|
|
|
4,802,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
7,120,000
|
|
|
$
|
0.61
|
|
|
|
4,802,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
In 2001, at our 2001 Annual Meeting, our stockholders approved two equity compensation plans: (a) our 2001 Stock Options/Stock Issuance Plan (the 2001 Plan) and (b) our Employee Stock Purchase Plan
(ESPP). The maximum number of shares of Common Stock that may be issued under the 2001 Plan cannot exceed 20% of the total shares of Common Stock outstanding at the time the calculation is made (including, on an as-converted basis, all
convertible preferred stock, convertible debt securities, warrants, options and other convertible securities that are exercisable), but in no event will the maximum number of shares of Common Stock which may be issued under the 2001 Plan as
incentive stock options exceed 20,000,000. As of September 30, 2013 based on the 20% calculation, the maximum number of shares issuable under the 2001 Plan was 11,922,614. As of September 30, 2013, we have discontinued offering the ESPP.
Since its inception, a total of 22,940 shares of Common Stock have been purchased pursuant to the ESPP.
|
I
tem 6.
|
SELECTED CONSOLIDATED FINANCIAL DATA
|
Because we are a Smaller Reporting
Company, we are not required to disclosure the information required by this item.
Item
7.
|
MANAGEMENTS DISCUSSION & ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial
statements and the related notes thereto appearing elsewhere in this Form 10-K.
FORWARD LOOKING STATEMENTS
The information set forth in this Item 7. Managements Discussion and Analysis of Financial Condition and Results of
Operations contains certain forward-looking statements. Please refer to FORWARD LOOKING STATEMENTS at the beginning of this Form 10-K for more information about forward-looking statements.
OVERVIEW
During the Fiscal Year Ended
September 30, 2010, we shifted our strategy away from majority ownership in healthcare delivery companies to a focus on the provision of management, financial, and ancillary healthcare and IT services to the rural and community hospital market.
Simultaneously, we embarked on initiatives to reorganize our operations. In pursuit of this reorganization, we undertook an initiative to divest ourselves of underperforming facilities and reduce or outsource administrative functions to better align
cost structures and business volume. For additional information about our divestments, see Item 1. Business in this Form 10-K.
B-14
CRITICAL ACCOUNTING POLICIES
We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America.
As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses during the periods presented. The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial
results include the following:
Accounts Receivable
The Company has contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed
revenues are then reduced by the Companys estimate of allowances based on expected collections, which includes the provision for doubtful accounts, to arrive at net revenues. Net revenues may not represent amounts ultimately collected.
Additions to the allowance for doubtful accounts are netted against revenue for the period See Revenue Recognition in Note
2 to the financial statements in this Form 10-K. We write off uncollectible accounts against the allowance for doubtful accounts after exhausting collection efforts and adding subsequent recoveries. Net accounts receivable include only those amounts
we estimate we will collect.
We perform an analysis of our historical cash collection patterns and consider the impact of any known
material events in determining the allowance for doubtful accounts. In performing our analysis, we considered the impact of any adverse changes in general economic conditions, business office operations, payor mix, or trends in federal or state
governmental healthcare coverage.
Revenue Recognition
The Company has contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed
revenues are then reduced by the Companys estimate of allowances, which includes the provision for doubtful accounts, to arrive at net service revenues. Net patient service revenues may not represent amounts ultimately collected. The Company
adjusts current period revenue for differences in estimated revenue recorded in prior periods and actual cash collections.
Income Taxes
The liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax
consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. We record a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized.
Accounting for Uncertainty in Income Taxes
Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 740 creates a single model to
address accounting for uncertainty in tax positions by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FASB ASC 740 also provides guidance on de-recognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated financial statements.
B-15
Stock-Based Compensation
The Company accounts for its stock options under the recognition and measurement principals of fair value set forth in FASB ASC Topic 718 Compensation
Stock Compensation. Our stock option plans are described in Note 11 to the financial statements contained in Item 8 of this Form 10-K.
Earnings
Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average shares of Common Stock
outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average shares of Common Stock and potential common shares outstanding during the year. Potential common shares outstanding consist of
dilutive shares issuable upon the conversion of our preferred stock to Common Stock as computed using the if-converted method and the exercise of outstanding options and warrants to purchase Common Stock, computed using the treasury stock method.
Fair Value of Financial Instruments
Carrying amounts of certain of our financial instruments, including cash equivalents, accounts receivable and accounts payable approximate fair
value due to their short maturities. Carrying value of notes payable and long-term debt approximate fair values as they bear market rates of interest. None of our financial instruments are held for trading purposes.
RESULTS OF OPERATIONS (All amounts in thousands)
|
|
|
|
|
|
|
|
|
|
|
Fiscal
Year
Ended
September 30,
2013
|
|
|
Fiscal
Year
Ended
September 30,
2012
|
|
Net revenue from services
|
|
$
|
19,392
|
|
|
$
|
16,194
|
|
Cost and expenses:
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
12,946
|
|
|
|
10,844
|
|
Depreciation and amortization
|
|
|
9
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
12,955
|
|
|
|
10,866
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
6,437
|
|
|
|
5,328
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(866
|
)
|
|
|
(1,126
|
)
|
Gain on retirement of note payable
|
|
|
|
|
|
|
1,447
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
(866
|
)
|
|
|
321
|
|
Net income from operations before taxation
|
|
|
5,571
|
|
|
|
5,649
|
|
Income tax
|
|
|
|
|
|
|
(212
|
)
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
|
5,571
|
|
|
|
5,437
|
|
Net income from discontinued operations, net of income taxes (including net gain on disposal of assets of $202 and $202, respectively.
See Note 3. Discontinued Operations)
|
|
|
202
|
|
|
|
181
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5,773
|
|
|
$
|
5,618
|
|
|
|
|
|
|
|
|
|
|
B-16
FISCAL YEAR ENDED SEPTEMBER 30, 2013 COMPARED TO FISCAL YEAR ENDED SEPTEMBER 30, 2012
Revenue
Net revenue of $19.4 million
was generated in the Fiscal Year Ended September 30, 2013 compared with $16.2 million in the Fiscal Year Ended September 30, 2012, an increase of 19.7%, primarily due to amendments to the service contracts secured in the Fiscal Year
Ended September 30, 2011 that increased the scope of services we provided and increases prices of the services we provided. The provision for doubtful accounts of $9.9 million is netted against revenues for the period ended September 30,
2013. See Note 2 in the footnotes to the financial statements in this Form 10-K.
Selling, General and Administrative Expenses
Selling, general and administrative expenses, consisted primarily of employee-related costs that are directly related to providing goods or
services, such as salaries and benefits of administrative and support personnel, rent, amortization of stock based compensation, insurance premiums and costs relating to other outside services.
Selling, general and administrative expenses totaled $12.9 million in the Fiscal Year Ended September 30, 2013 and $10.9 million in
the Fiscal Year Ended September 30, 2012, an increase of $2.0 million or 18.3%. This increase corresponds to the similar increase in revenue which was primarily the result of increased costs incurred in deliver more services to our customers.
Amortization of Stock-Based Compensation
Amortization of stock-based compensation consists of the expense incurred as the grant of options and warrants to purchase common stock vest
over the term of the grant agreements. Since 2006, we have granted to officers, employees and members of our Advisory Board options to purchase our common stock.
No options were granted during the Fiscal Year Ended September 30, 2013 and 2012. Amortization of stock-based compensation expense
decreased in Fiscal Year Ended September 30, 2013 to $574,000 compared to $766,000 during the Fiscal Year ended September 30, 2012. Amortization expense is included in selling, general and administrative expenses for presentation in the
financial statements in this Form 10-K.
See Note 11 in the accompanying notes to the financial statements in this Form 10-K, Stock
Options for a discussion of our stock option plans and stock-based compensation.
Operating Income
We had operating income in the Fiscal Year Ended September 30, 2013 of $6.4 million compared to operating income of $5.3 million in
the Fiscal Year Ended September 30, 2012, or an increase of 20.8%. This increase was primarily the result of the increase in price and scope of services we provide under our contracts to provide healthcare services management the Company
obtained in 2011.
Other Income
In
the Fiscal Year Ended September 30, 2012, we realized a $1.4 million net gain on the retirement of a note payable.
Interest Expense
We recorded interest expense of $0.9 million in the Fiscal Year Ended September 30, 2013 and $1.1 million in the Fiscal Year Ended
September 30, 2012, reflecting a decrease of $0.2 million or 18.2%. This decrease was
B-17
due primarily due to the $3.3 million repayment of the 2011 and 2012 Bridge Financing during the Fiscal Year Ended September 30, 2013.
LIQUIDITY AND CAPITAL RESOURCES
We have
funded operations primarily through cash flows from operations, short term bridge financing and the sales of certain of our businesses. We estimate that based on current plans and assumptions, our available cash and cash flows from operations will
be sufficient to satisfy our cash requirements under our present operating expectations, without further financing, for the next 12 months.
Our cash and cash equivalents totaled $1.0 million as of September 30, 2013, compared with $1.4 million as of
September 30, 2012, a decrease of 28.6%, primarily attributable to payments on long term financing of $3.7 million offset by $3.2 million cash provided by operating activities.
At September 30, 2013, we had working capital of $7.9 million as compared to working capital of $2.2 million at
September 30, 2012, an increase in working capital of $5.7 million. The increase was due primarily to a $3.2 million decrease in current portion of the long term debts and a $4.1 million increase in net accounts receivable, offset by a $1.0
million increase in accrued expenses.
At September 30, 2013, we had a stockholders deficit of $3.1 million, compared to a
stockholders deficit of $9.5 million at September 30, 2012, a decrease in the deficit of $6.4 million or 67.4%, primarily attributable to net income of $5.8 million for the Fiscal Year Ended September 30, 2013 and the
recognition of stock-based compensation of $0.6 million.
We have long-term liabilities of $21.2 million as of September 30,
2013, compared to $21.9 million as of September 30, 2012, a decrease of $0.7 million or 3.2%, primarily due to a $0.5 million decrease in the non-current portion of long-term debt and a reduction of $0.2 million in deferred gain on sale of
assets.
Net cash provided by operating activities totaled $3.2 million in the Fiscal Year Ended September 30, 2013, compared
with $0.2 million cash used in operating activities in the Fiscal Year Ended September 30, 2012. The $3.4 million increase in cash provided by operations during the Fiscal Year Ended September 30, 2013 compared to 2012 was primarily
the result of the increase in net income, increase in bad debt provision, and an increase in accrued expenses, offset by an increase in accounts receivable as of September 30, 2013. Also, in 2012, the Company recognized a gain on retirement of
note payable.
Net cash used in financing activities was $3.7 million in the Fiscal Year Ended September 30, 2013, compared with
$0.6 million provided by financing activities in the Fiscal Year Ended September 30, 2012. This decrease of $4.3 million was primarily due to increased payments on debt in the Fiscal Year Ended September 30, 2013 of $3.7 million
compared to payments on debt of $1.5 million and proceeds from debt of $2.1 million in the Fiscal Year Ended September 30, 2012.
At
September 30, 2013, we had total liabilities of $28.1 million, total assets of $37.3 million, current liabilities of $6.9 million, and current assets of $14.8 million.
FUNDING
We have an accumulated deficit
of approximately $84.7 million as of September 30, 2013, which has been funded primarily through the issuance of preferred stock, the issuance of promissory notes and cash generated from operations.
On February 11, 2009, we completed the first closing of the Bridge Financing, a transaction in which we entered into the following two
promissory notes, each dated as of February 6, 2009: (i) a convertible promissory
B-18
note in the principal amount of $500,000 and (ii) a convertible promissory in the principal amount of $1,000,000 (collectively, the Bridge Notes). On March 3, 2009, we
completed the second closing of the Bridge Financing, a transaction in which we entered into nine (9) promissory notes, each dated as of March 3, 2009, in the aggregate principal amount of $500,000 (the Second Bridge Notes),
with various investors (the Second Bridge Lenders). On April 14, 2009, we completed the third closing of the Bridge Financing, a transaction in which we entered into the following three (3) promissory notes: (i) a
convertible promissory note, dated as of March 31, 2009 in the principal amount of $100,000; (ii) a convertible promissory note, dated as of March 31, 2009, in the principal amount of $50,000 and (iii) a convertible promissory
note, dated as of April 14, 2009, in the principal amount of $50,000. Of the total Bridge Financing, $1,600,000 was considered a related party transaction. See Item 8, Note 6. Bridge Financing in the accompanying notes to the
financial statements in this Form 10-K. Of the original Bridge Financing, $1,350,000 remained outstanding at September 30, 2013.
During the Fiscal Year Ended September 30, 2011, we entered into bridge financing transactions (the 2011 Bridge Financing)
where we entered into ten promissory notes, in the aggregate principal amount of $2,034,000 (the 2011 Bridge Notes), with various investors (the 2011 Lenders). We received the 2011 Bridge Financing in multiple
installments as follows: $674,400, $549,600, $360,000, and $100,000 in August, September, November and December of 2011 respectively and $350,000 in January 2012. Each bridge note has attached warrants to purchase an aggregate of 2,278,079 shares of
our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. Of the total 2011 Bridge Financing, $1,559,000 was considered a related party transaction. The warrants were issued January 1, 2014. See Note 6.
Bridge Financing in the accompanying notes to the financial statements in this Form 10-K. The 2011 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31,
2013, in installments of $420,000 and $1,614,000, respectively.
Beginning in February 2012, we entered into a staggered bridge financing
transaction (the 2012 Bridge Financing) whereby we entered into three promissory notes, in the aggregate principal amount of $1,279,000 (the 2012 Bridge Notes), with three investors (the 2012 Lenders) with
maturity dates of June 30, 2014. The 2012 Bridge Loans funded as follows; $340,000, $320,000, $390,000 and $229,000 in February, March, April, and May of 2012 respectively. Each bridge note has attached warrants to purchase an aggregate of
4,092,800 shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. The warrants were issued January 1, 2014. All of the 2012 Bridge Financing was considered a related party transaction. The 2012
Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31, 2013, in installments of $225,000 and $1,054,000, respectively.
Beginning in November 2013, we entered into a staggered bridge financing transaction (the 2013 Bridge Financing) whereby we
entered into four (4) promissory notes, with interest of 10% per annum, in the aggregate principal amount of $650,000 (the 2013 Bridge Notes), with 4 investors, each note maturing June 30, 2014. The 2013 Bridge Loans
funded as follows; $450,000 and $200,000 in November 2013 and January 2014, respectively. All of the 2013 Bridge Financing was considered a related party transaction.
In January 2014, the Company issued penny warrants to SMP Investments I, LLC for the purchase of up to 8,500,000 shares of Common
Stock at an initial exercise price of $0.01 per share and exercisable for a period of five years from the date of issuance. In March 2014, SMP exercised its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of
$85,000. The $85,000 proceeds were received by the company in Fiscal Year 2013, and were recorded as a liability until such time as the Company was able to accept the warrants.
In March 2014, we accepted two warrant exercises in the amount of 150,000 and 210,000 shares of Common Stock, at an exercise price of $0.625
and $0.50 per share respectively, for an aggregate purchase price of $198,000 from two investors. The $198,000 proceeds had been received by the company in Fiscal Year 2011, and were recorded as a liability until such time as the Company was able to
accept the warrants.
B-19
We are not aware of any trends, demands, events or uncertainties that will result in a material
change in our liquidity or capital resources, nor do we expect any changes in the cost of our capital resources or the mix and relative cost of our capital resources.
OFF-BALANCE SHEET ARRANGEMENTS
We do not
engage in any transactions or have relationships or other arrangements with unconsolidated entities. These include special purpose and similar entities or other off-balance sheet arrangements.
DISCLOSURE OF CONTRACTUAL OBLIGATIONS
Because we are a Smaller Reporting Company, we are not required to disclosure the information required by this item.
Item
7A.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
Because we are a
Smaller Reporting Company, we are not required to disclosure the information required by this item.
B-20
Item 8.
|
CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders
First Physicians
Capital Group, Inc.
We have audited the accompanying consolidated balance sheets of First Physicians Capital Group, Inc. (the Company), as of
September 30, 2013 and 2012, and the related consolidated statements of operations, stockholders deficit, and cash flows for the years then ended. The Companys management is responsible for these financial statements. Our
responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of
the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not
required to have, nor were we engaged to perform, an audit of their internal control over financial reporting. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Companys internal control over financial reporting. Accordingly, we express no such opinion. Our audits of the financial statements
included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to
above present fairly, in all material respects, the financial position of the Company, as of September 30, 2013 and 2012, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles
generally accepted in the United States of America.
/s/ Whitley Penn LLP
Dallas, Texas
April 4, 2014
B-21
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
September 30,
2013
|
|
|
September 30,
2012
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
982
|
|
|
$
|
1,389
|
|
Accounts receivable, net of allowance for uncollectible accounts
|
|
|
13,690
|
|
|
|
9,604
|
|
Prepaid expenses
|
|
|
66
|
|
|
|
51
|
|
Other current assets
|
|
|
14
|
|
|
|
7
|
|
Assets of discontinued operations
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
14,752
|
|
|
|
11,059
|
|
Property and equipment, net
|
|
|
2
|
|
|
|
11
|
|
Notes receivable
|
|
|
22,343
|
|
|
|
22,343
|
|
Other assets
|
|
|
249
|
|
|
|
268
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
37,346
|
|
|
$
|
33,681
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS DEFICIT
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,116
|
|
|
$
|
884
|
|
Accrued expenses
|
|
|
3,132
|
|
|
|
2,176
|
|
Income taxes payable
|
|
|
212
|
|
|
|
212
|
|
Current maturities of long term debt
|
|
|
1,857
|
|
|
|
5,041
|
|
Liabilities of discontinued operations
|
|
|
557
|
|
|
|
572
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
6,874
|
|
|
|
8,885
|
|
Long term debt, net of current portion
|
|
|
5,692
|
|
|
|
6,161
|
|
Deferred gain
|
|
|
15,496
|
|
|
|
15,698
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
28,062
|
|
|
|
30,744
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Non-redeemable preferred stock:
|
|
|
|
|
|
|
|
|
Preferred stock Series 1-A ($0.01 par value, 2,802,000 shares authorized; 67,600 shares issued and outstanding as of
September 30, 2013 and 2012)
|
|
|
166
|
|
|
|
166
|
|
Preferred stock Series 2-A ($0.01 par value, 1,672,328 shares authorized; 3,900 shares issued and outstanding as of
September 30, 2013 and 2012)
|
|
|
25
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Total non-redeemable preferred stock
|
|
|
191
|
|
|
|
191
|
|
Redeemable preferred stock:
|
|
|
|
|
|
|
|
|
Preferred stock Series 5-A ($0.01 par value, 5,000,000 shares authorized; 9,000 shares issued and outstanding as of
September 30, 2013 and 2012)
|
|
|
7,832
|
|
|
|
7,832
|
|
Preferred stock Series 6-A ($0.01 par value, 5,000 shares authorized; 4,875 shares issued and outstanding as of
September 30, 2013 and 2012)
|
|
|
4,381
|
|
|
|
4,381
|
|
|
|
|
|
|
|
|
|
|
Total redeemable preferred stock
|
|
|
12,213
|
|
|
|
12,213
|
|
Stockholders deficit:
|
|
|
|
|
|
|
|
|
Common stock ($0.01 par value, 100,000,000 shares authorized; 15,049,507 shares issued and outstanding as of September 30, 2013
and 2012)
|
|
|
153
|
|
|
|
153
|
|
Additional paid-in-capital
|
|
|
81,578
|
|
|
|
81,004
|
|
Accumulated deficit
|
|
|
(84,747
|
)
|
|
|
(90,520
|
)
|
Treasury stock, at cost (149,744 shares as of September 30, 2013 and 2012)
|
|
|
(104
|
)
|
|
|
(104
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders deficit
|
|
|
(3,120
|
)
|
|
|
(9,467
|
)
|
|
|
|
|
|
|
|
|
|
Total liabilities, preferred stock and stockholders deficit
|
|
$
|
37,346
|
|
|
$
|
33,681
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
B-22
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
Year
Ended
September 30,
2013
|
|
|
Year
Ended
September 30,
2012
|
|
Net revenue from services
|
|
$
|
19,392
|
|
|
$
|
16,194
|
|
Cost and expenses:
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
12,946
|
|
|
|
10,844
|
|
Depreciation and amortization
|
|
|
9
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
12,955
|
|
|
|
10,866
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
6,437
|
|
|
|
5,328
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(866
|
)
|
|
|
(1,126
|
)
|
Gain on retirement of note payable
|
|
|
|
|
|
|
1,447
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
(866
|
)
|
|
|
321
|
|
Net income from operations before taxation
|
|
|
5,571
|
|
|
|
5,649
|
|
Income tax
|
|
|
|
|
|
|
(212
|
)
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
|
5,571
|
|
|
|
5,437
|
|
Net income from discontinued operations, net of income taxes (including net gain on disposal of assets of $202 and $202, respectively.
See Note 3. Discontinued Operations)
|
|
|
202
|
|
|
|
181
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5,773
|
|
|
$
|
5,618
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share of common stock
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.37
|
|
|
$
|
0.36
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
Total basic earnings per share of common stock
|
|
$
|
0.38
|
|
|
$
|
0.37
|
|
Diluted earnings per share of common stock
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.09
|
|
|
$
|
0.09
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Total diluted earnings per share of common stock
|
|
$
|
0.10
|
|
|
$
|
0.09
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
B-23
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT
(in thousands, except for shares data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
|
|
|
Additional
Paid-in
Capital
|
|
|
Accumulated
Deficit
|
|
|
Treasury
Stock
|
|
|
Total
Stockholders
Deficit
|
|
|
|
Stock
|
|
|
Amount
|
|
|
|
|
|
Balance at Sept. 30, 2011
|
|
|
15,049,507
|
|
|
$
|
153
|
|
|
$
|
80,238
|
|
|
$
|
(96,138
|
)
|
|
$
|
(104
|
)
|
|
$
|
(15,851
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,618
|
|
|
|
|
|
|
|
5,618
|
|
Stock based compensation
|
|
|
|
|
|
|
|
|
|
|
766
|
|
|
|
|
|
|
|
|
|
|
|
766
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at Sept. 30, 2012
|
|
|
15,049,507
|
|
|
$
|
153
|
|
|
$
|
81,004
|
|
|
$
|
(90,520
|
)
|
|
$
|
(104
|
)
|
|
$
|
(9,467
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,773
|
|
|
|
|
|
|
|
5,773
|
|
Stock based compensation
|
|
|
|
|
|
|
|
|
|
|
574
|
|
|
|
|
|
|
|
|
|
|
|
574
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at Sept. 30, 2013
|
|
|
15,049,507
|
|
|
$
|
153
|
|
|
$
|
81,578
|
|
|
$
|
(84,747
|
)
|
|
$
|
(104
|
)
|
|
$
|
(3,120
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
B-24
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5,773
|
|
|
$
|
5,618
|
|
Net income from discontinued operations
|
|
|
202
|
|
|
|
181
|
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
|
5,571
|
|
|
|
5,437
|
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
|
|
|
|
|
|
|
|
|
Gain on retirement of note payable
|
|
|
|
|
|
|
(1,447
|
)
|
Depreciation and amortization
|
|
|
9
|
|
|
|
22
|
|
Bad debt provision
|
|
|
9,881
|
|
|
|
5,066
|
|
Amortization of stock-based compensation
|
|
|
574
|
|
|
|
766
|
|
Changes in working capital components:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(13,967
|
)
|
|
|
(10,615
|
)
|
Prepaid expenses
|
|
|
(15
|
)
|
|
|
9
|
|
Other assets
|
|
|
12
|
|
|
|
55
|
|
Accounts payable
|
|
|
232
|
|
|
|
(147
|
)
|
Accrued expenses
|
|
|
956
|
|
|
|
403
|
|
Income taxes payable
|
|
|
|
|
|
|
212
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
3,253
|
|
|
|
(239
|
)
|
Net cash provided by (used in) discontinued operations operating activities
|
|
|
(7
|
)
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
3,246
|
|
|
|
(219
|
)
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt
|
|
|
|
|
|
|
2,089
|
|
Payments on convertible debt
|
|
|
(3,313
|
)
|
|
|
(750
|
)
|
Payments on long term debt
|
|
|
(340
|
)
|
|
|
(732
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
(3,653
|
)
|
|
|
607
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(407
|
)
|
|
|
388
|
|
Cash and cash equivalents at beginning of year
|
|
|
1,389
|
|
|
|
1,001
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
982
|
|
|
$
|
1,389
|
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information:
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
562
|
|
|
$
|
855
|
|
Cash paid for taxes
|
|
$
|
|
|
|
$
|
|
|
Non-cash transactions:
|
|
|
|
|
|
|
|
|
Note receivable given as consideration for payment of note payable
|
|
$
|
|
|
|
$
|
2,150
|
|
Notes payable extinguished through assignment of notes receivable
|
|
$
|
|
|
|
$
|
1,500
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
B-25
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Company Background
We were originally incorporated in Nevada in October 1980 and re-incorporated in Delaware in November 2000.
During the fiscal year ended January 31, 2007 (the Fiscal Year Ended January 31, 2007), we resumed active operations
following the acquisition of two ambulatory surgical centers located in Southern California. On December 2, 2005, through newly created indirect subsidiaries, we entered into two separate purchase agreements to acquire from Surgical Ventures,
Inc., a California corporation, a controlling interest in two separate outpatient surgical centers in San Diego, California, Point Loma Surgical Center, L.P. and Outpatient Surgery of Del Mar, L.P., and we completed these acquisitions on
November 16, 2006.
On October 29, 2007, we acquired 51% of the issued and outstanding membership units of Rural Hospital
Acquisition, LLC, an Oklahoma limited liability company (RHA). Based in Oklahoma City, RHA owned and operated three critical access hospitals, one medical clinic and an ancillary support services unit, which were focused on the delivery
of healthcare services to rural communities in Oklahoma. On May 1, 2008, RHA Anadarko, LLC, a wholly owned subsidiary of RHA, purchased 100% of the issued and outstanding membership interests of Southern Plains Medical Center
(SPMC). Founded in 1915, SPMC is one of the oldest continuously operating multi-specialty physician practices in the United States. Beginning November 18, 2008, RHA began operating under the trade name Southern Plains Medical Group.
On December 11, 2008, we acquired the remaining 49% of the issued and outstanding membership units of RHA, making RHA an indirect wholly-owned subsidiary of ours.
On May 1, 2009, we purchased The Chandler Clinic (TCC), a family medical practice located in Chandler, Oklahoma. On
December 1, 2010, we sold the operations of The Chandler Clinic to the physician group from which it was originally purchased. The Company has no further obligations or interests in this facility and the buyer assumed the liabilities and leases
related to this facility in the transaction. The Company received no consideration at closing.
On September 29, 2009, at our Annual
Meeting of Stockholders, our stockholders voted to amend our Certificate of Incorporation to change our legal name from Tri-Isthmus Group, Inc. to First Physicians Capital Group, Inc. We became First Physicians Capital Group,
Inc. on September 29, 2009.
On January 13, 2010, Southern Plains Medical Center, Inc., our previously wholly-owned indirect
subsidiary (SPMC), entered into a sale/leaseback transaction pursuant to an asset purchase agreement dated January 13, 2010 whereby SPMC sold certain property to Southern Plains Associates, LLC (SPA). First Physicians
Realty Group, LLC, 50% of SPA and Capital Investors of Oklahoma, LLC, owned the other 50%. The purchase price for the sale/leaseback transaction was paid to SPMC as follows: (i) $1,500,000 was paid in the form of a promissory note, dated
January 13, 2010, and (ii) $4,500,000 was paid in cash at the closing. The $4,500,000 in cash proceeds was used to pay off short-term debt associated with the property sold in the amount of $3,700,942, plus related interest. SPMC received
net proceeds of $732,221 after retirement of the debt and other associated closing costs. Restricted cash on deposit with the debt holder and pledged as a security on the debt in the amount of $1,524,091 was released and returned to us. In
connection with the transaction, SPMC leased back from SPA the property sold, pursuant to a lease agreement dated December 16, 2009. The lease agreement provided for a 20-year term with an automatic 10-year renewal.
On January 10, 2011, RHA Tishomingo, LLC, an indirect subsidiary of ours, entered into an asset purchase agreement to sell the hospital
operations of Johnson Memorial Hospital in Tishomingo, Oklahoma to Mercy Tishomingo Hospital Corporation. Also on January 10, 2011, we entered into an agreement for purchase and sale
B-26
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
of real property to sell the real estate and equipment of Johnson Memorial Hospital to RSE Enterprises, Inc., (together with the sale to Mercy Tishomingo Hospital Corporation, the
Tishomingo Transaction).
As part of the Tishomingo Transaction, the $1.13 million in USDA mortgage debt related to the
facility was retired. The gross proceeds in the transaction were $1,687,000, consisting of $1,630,000 purchase price, $500,000 in cash and an additional $57,000 for medical supplies.
On January 31, 2011, RHA, and our wholly-owned subsidiaries, sold its owned hospital buildings and land in Stroud and Anadarko, Oklahoma
to First Physicians Realty Group for $10,324,000. As payment for the purchase, First Physicians Realty Group assumed the existing first mortgage debt of $6,625,000 and executed $3,699,000 of promissory notes payable to RHA.
Simultaneously with the sale of the land and buildings, RHA and its wholly-owned subsidiaries executed a twenty (20) year lease for the
hospital facilities. The leases have been accounted by First Physicians Realty Group as direct financing leases and reflected as notes receivable in the accompanying Consolidated Balance Sheet subsequent to the April 1, 2011 sale of the owned
hospitals. To date, no payments have been received on these notes, and no interest income has been recorded. The note receivables are collateralized by the hospital real estate. Upon completion of the transaction a deferred gain of $4.0 million was
recorded and is being amortized on a straight-line basis over the 20 year lease term. The Company recognized $0.2 million of amortization during the Fiscal Years Ended September 30, 2013 and 2012, which is included in net income from
discontinued operations on the accompanying Consolidated Statements of Operations.
On May 4, 2011 RHA entered into that certain
Stock Purchase Agreement, dated May 4, 2011 (the Cura SPA), by and between RHA and with One Cura Wellness Inc. (One Cura) for the sale of RHA Anadarko, LLC, and RHA Stroud, LLC to One Cura (the Cura
Transaction). Upon closing, RHA received two notes totaling $12,000,000 as consideration for the purchase. The notes have a term of ten (10) years and bear interest at a rate of ten percent (10%). To date, no payments have been received
on these notes, and no interest income has been recorded. A deferred gain of $12.0 million is recorded each year-end related to these notes and will be recognized upon cash payments received.
In conjunction with the Cura SPA, First Physicians Business Solutions, LLC (FPBS) a wholly owned direct subsidiary of the Company
entered into management services agreements with RHA Anadarko and RHA Stroud to provide management services for an initial period of six and one half (6.5) years. Further, First Physicians Resources, LLC (FPR) and wholly owned
direct subsidiary of the registrant entered into staff leasing agreements to provide staffing to RHA Anadarko and RHA Stroud for an initial term of one (1) year. Finally, First Physicians Realty Group, LLC (FPRG) a wholly owned
direct subsidiary of the registrant entered into an Amended and Restated lease with RHA Anadarko and RHA Stroud to continue the lease of real property associated with the hospitals owned by RHA Anadarko and RHA Stroud.
On July 13, 2011, Rural Hospital Acquisition, LLC (RHA) entered into a Stock Purchase Agreement, dated July 13, 2011
(the SPMC SPA), by and between RHA and Southern Plains Associates II, LLC (SPA II), and that certain Asset Purchase Agreement, dated July 13, 2011 (the SPMC APA), by and between RHA and SPA II, for the sale
of (i) SPMC and (ii) the medical records associated with SPMC, respectively. As consideration for the sale, RHA received two notes totaling $2,150,000. The notes have a term of ten (10) years and bear interest at a rate of five
percent (5%) per annum. In addition, SPA II delivered to RHA a buyers Members guarantee and a company guarantee.
In
conjunction with the stock sale/purchase agreement, SPA and Capital Investors of Oklahoma, LLC entered into a Real Estate Purchase Agreement with the SPMC buyer for the purchase/sale of the SPMC real
B-27
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
estate. As consideration for the purchase/sale of the SPMC real estate the buyer assumed the existing mortgage on the property and caused the lender to release all guarantees of the mortgage by
us. At closing the mortgage had a remaining principal balance of $4,560,982. The SPMC buyer also assumed four equipment loans from the company with a total remaining principal balance of $121,471 and bearing interest rates of 6.75%.
Following the SPMC real estate sale, all assets of SPA were liquidated and SPA immediately ceased operations.
On September 15, 2011, First Physicians Capital Group, Inc. (FPCG), entered into a Stock Purchase Agreement, dated
September 15, 2011 (the DEL MAR SPA) by and between Del Mar Gen Par, Inc. (DGP), Del Mar Acquisition, Inc. (DMA, and together with FPCG and DGP, the Seller), and Surgical Center Management, Inc.
(the Management Company), IHM Del Mar, LLC (IHM), and several individuals (together with IHM, each a Purchaser and collectively the Purchasers) for the sale of Outpatient Surgery of Del Mar, L.L.C.
(DEL MAR). Prior to the sale, FPCG held 53.54% of the member units of DEL MAR. As consideration for the sale, FPCG received two payments, consisting of $250,000, paid prior to closing as an initial deposit, and $500,000 paid at closing,
for total consideration of $750,000. An additional earnout payment of $243,735, payable upon meeting certain milestone was not received.
2. Summary of Significant Accounting Policies
We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The significant accounting policies which we believe are the most critical to aid in fully understanding and
evaluating our reported financial results include the following:
Principles of Consolidation and Basis of Presentation
The consolidated financial statements include our accounts and the accounts of our subsidiaries. All significant intercompany balances and
transactions have been eliminated.
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States
requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Our actual results could differ from estimates and assumptions made.
Cash and Cash Equivalents
Cash consists of cash on hand and amounts deposited with high quality financial institutions. Amounts on deposit at times exceeds the insurance
limits. Cash equivalents are highly liquid instruments including cash in money market current accounts that are interest-bearing, capital guaranteed and without any withdrawal restrictions. As of September 30, 2013, cash deposits exceeded the
federally insured limit of $250,000 by $732,000.
B-28
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
Accounts Receivable
The Company has contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed
revenues are then reduced by the Companys estimate of allowances based on expected collections, which includes the provision for doubtful accounts, to arrive at net revenues. Net revenues may not represent amounts ultimately collected.
Additions to the allowance for doubtful accounts are netted against revenue for the period See Revenue Recognition in this
Note to the financial statements in this Form 10-K. We write off uncollectible accounts against the allowance for doubtful accounts after exhausting collection efforts and adding subsequent recoveries. Net accounts receivable include only those
amounts we estimate we will collect.
We perform an analysis of our historical cash collection patterns and consider the impact of any
known material events in determining the allowance for doubtful accounts. In performing our analysis, we considered the impact of any adverse changes in general economic conditions, business office operations, payor mix, or trends in federal or
state governmental healthcare coverage.
Property and Equipment
Property and equipment are stated at cost. Depreciation for property and equipment is provided using the straight-line method over the
estimated useful lives of the respective assets as follows:
|
|
|
|
|
Computer hardware
|
|
|
2 to 5 years
|
|
Computer software
|
|
|
3 to 5 years
|
|
Office equipment, furniture and fixtures
|
|
|
5 years
|
|
Revenue Recognition
The Company has contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed
revenues are then reduced by the Companys estimate of allowances, which includes the provision for doubtful accounts, to arrive at net revenues. Net revenues may not represent amounts ultimately collected. The Company adjusts current period
revenue for differences in estimated revenue recorded in prior periods and actual cash collections.
The following table shows gross
revenues and allowances for the twelve months ended September 30, 2013 and 2012 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Fiscal year ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Revenue from services
|
|
$
|
29,273
|
|
|
$
|
21,260
|
|
Allowances
|
|
|
(9,881
|
)
|
|
|
(5,066
|
)
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
19,392
|
|
|
$
|
16,194
|
|
|
|
|
|
|
|
|
|
|
Allowances percentage
|
|
|
34
|
%
|
|
|
24
|
%
|
|
|
|
|
|
|
|
|
|
Income Taxes
The liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax
consequences of temporary differences between the carrying amounts and the tax
B-29
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
bases of assets and liabilities. We record a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized.
Accounting for Uncertainty in Income Taxes
Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 740 creates a single model to
address accounting for uncertainty in tax positions by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FASB ASC 740 also provides guidance on de-recognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated financial statements.
The Companys income tax returns are subject to examination by taxing authorities for a period of three years from the date they are
filed. As of September 30, 2013, the following tax years are subject to examination:
|
|
|
|
|
Jurisdiction
|
|
Open Years for Filed Returns
|
|
Return Filed in 2013
|
Federal
|
|
Fiscal years 2009 2011
|
|
|
California
|
|
Fiscal years 2009 2011
|
|
|
Stock-Based Compensation
The Company accounts for its stock options under the recognition and measurement principals of fair value set forth in FASB ASC Topic 718
Compensation Stock Compensation
.
Earnings Per Share
Basic earnings/(loss) per share is computed by dividing net income/(loss) by the weighted average shares of Common Stock outstanding during the
year. Diluted earnings per share is computed by dividing net income by the weighted average shares of Common Stock and potential common shares outstanding during the year. Potential common shares outstanding consist of dilutive shares issuable upon
the conversion of our preferred stock to Common Stock as computed using the if-converted method and the exercise of outstanding options and warrants to purchase Common Stock, computed using the treasury stock method.
Concentration of Credit Risk and Sales
Our operations are concentrated in one area rural critical access hospital management. For the Fiscal Years Ended
September 30, 2013 and 2012 100% of our revenue was derived from operations in the state of Oklahoma. For the Fiscal Years Ended September 30, 2013 and 2012, 100% and 99%, respectively, of our revenue was derived from our management
services and staff leasing contracts with one customer. At September 30, 2013 and 2012, 100% of our accounts receivable, respectively, was derived from our management services and staff leasing contracts with one customer.
Fair Value of Financial Instruments
Carrying amounts of certain of our financial instruments including accounts receivable, accounts payable and accrued expenses approximate fair
value due to their short maturities. Carrying value of notes receivable and long-term debt approximate fair values as they bear market rates of interest. None of our financial instruments are held for trading purposes.
B-30
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
3. Discontinued Operations
On January 10, 2011, RHA Tishomingo, LLC, an indirect subsidiary of ours, entered into an Asset Purchase Agreement to
sell the hospital operations of Johnson Memorial Hospital in Tishomingo, Oklahoma to Mercy Tishomingo Hospital Corporation. Also on January 10, 2011, we entered into an Agreement for Purchase and Sale of Real Property to sell the real estate
and equipment of Johnson Memorial Hospital to RSE Enterprises, Inc., (together with the sale to Mercy Tishomingo Hospital Corporation, the Tishomingo Transaction) (See Note 1 in this Form 10-K).
On May 4, 2011, we completed the RHA-One Cura transaction in which we sold RHA Anadarko LLC, and RHA Stroud LLC, and on
July 13, 2011, we completed the RHA SPA II transactions (See Note 1 in this Form 10-K) in which we sold SPMC and SPA.
On
September 15, 2011, we completed the DEL MAR SPA transaction in which we sold our 53% interest in Outpatient Surgery of Del Mar, L.L.C., a California limited liability company (DEL MAR) (See Note 1 in this Form 10-K).
As of September 30, 2013 and 2012, the operating assets of RHA Tishomingo, LLC, RHA Anadarko, RHA Stroud, SPMC, SPA, Del Mar, and
Point Loma, have been recorded as assets from discontinued operations and the liabilities as liabilities of discontinued operations. We have reclassified to discontinued operations, for all periods presented, the results of operations of RHA
Tishomingo, LLC, RHA Anadarko, RHA Stroud, SPMC, SPA, Del Mar, and Point Loma.
The results of discontinued operations for the twelve
months ended September 30, 2013 and 2012 are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Twelve months ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Net revenue from services
|
|
$
|
|
|
|
$
|
11
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
|
|
|
|
32
|
|
Loss before income taxes
|
|
|
|
|
|
|
(21
|
)
|
Taxation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total discontinued operations
|
|
$
|
|
|
|
$
|
(21
|
)
|
|
|
|
|
|
|
|
|
|
B-31
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
A summary of the assets and liabilities from discontinued operations as of September 30,
2013 and 2012 is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Assets
|
|
|
|
|
|
|
|
|
Other current assets
|
|
$
|
|
|
|
$
|
8
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
282
|
|
|
|
297
|
|
Accrued expenses
|
|
|
275
|
|
|
|
275
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
557
|
|
|
|
572
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
$
|
557
|
|
|
$
|
572
|
|
|
|
|
|
|
|
|
|
|
4. Earnings/(Loss) Per Share
The amounts in the table below are in thousands except for per share amounts.
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Numerator for basic earnings per share:
|
|
|
|
|
|
|
|
|
Net income attributable to continuing operations
|
|
$
|
5,571
|
|
|
$
|
5,437
|
|
Net income attributable to discontinued operations
|
|
|
202
|
|
|
|
181
|
|
Denominator for basic earnings per share weighted average shares
|
|
|
15,049,507
|
|
|
|
15,049,507
|
|
Numerator for diluted earnings per share:
|
|
|
|
|
|
|
|
|
Net income attributable to continuing operations
|
|
|
5,706
|
|
|
|
5,572
|
|
Net income attributable to discontinued operations
|
|
|
202
|
|
|
|
181
|
|
Denominator for diluted earnings per share weighted average shares
|
|
|
61,644,872
|
|
|
|
61,644,872
|
|
Basic earnings per share of common stock:
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.37
|
|
|
$
|
0.36
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
Total basic earnings per share of common stock
|
|
$
|
0.38
|
|
|
$
|
0.37
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share of common stock:
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.09
|
|
|
$
|
0.09
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Total diluted earnings per share of common stock
|
|
$
|
0.10
|
|
|
$
|
0.09
|
|
|
|
|
|
|
|
|
|
|
For the Fiscal Years Ended September 30, 2013 and 2012, stock options outstanding to purchase 6,760,000
common shares and warrants outstanding to purchase 360,000 and 796,250 common shares respectively, had strike prices above market value and are considered out-of-the-money, and were therefore excluded from the computation of diluted net
income (loss) per share.
B-32
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
For the Fiscal Years Ended September 30, 2013 and 2012, the following potential common
shares outstanding are included in the computation of diluted net income per share: 67,600 Series 1-A Convertible Preferred Stock convertible into 33,493 common shares, 3,900 Series 2-A Convertible Preferred Stock convertible into 1,872 common
shares, 9,000 Series 5-A Convertible Preferred Stock convertible into 28,800,000 common shares, 4,875 Series 6-A Convertible Preferred Stock convertible into 15,600,000 common shares, and $1,350,000 of 2009 Bridge Financing convertible into
2,160,000 common shares. For the Fiscal Years Ended September 31, 2013 and 2012, interest expense of $135,000 related to the convertible debt was added back to net income attributable to continuing operations for the computation of diluted net
income per share.
5. Accounts receivable
Accounts receivable consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Gross accounts receivable
|
|
$
|
32,875
|
|
|
$
|
18,908
|
|
Reserves for bad debt
|
|
|
(19,185
|
)
|
|
|
(9,304
|
)
|
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
$
|
13,690
|
|
|
$
|
9,604
|
|
|
|
|
|
|
|
|
|
|
6. Bridge Financing
During the Fiscal Year Ended September 30, 2009, we entered into a bridge financing transaction (the Bridge
Financing) which was consummated in three separate closings. On February 11, 2009, we completed the first closing of the Bridge Financing, a transaction in which we entered into the following two promissory notes, each dated as of
February 6, 2009: (i) a convertible promissory note with SMP Investments, LLC, a Michigan limited liability company (SMP), in the principal amount of $500,000 and (ii) a convertible promissory note with Anthony J.
Ciabattoni, Trustee of the Ciabattoni Living Trust, dated August 17, 2000 (Ciabattoni), in the principal amount of $1,000,000 (collectively, the Bridge Notes). SMP and Ciabattoni are each a Bridge Lender and
are collectively referred to herein as the Bridge Lenders.
On February 11, 2009, in addition to the issuance of the
Bridge Notes, we issued four warrants to purchase Common Stock to the Bridge Lenders as follows: (i) a warrant issued to SMP for the purchase of up to 375,000 shares of Common Stock at an initial exercise price of $0.50 per share and
exercisable for a period of three years from the date of issuance; (ii) a warrant issued to SMP for the purchase of up to 250,000 shares of Common Stock at an initial exercise price of $0.75 per share and exercisable for a period of three years
from the date of issuance; (iii) a warrant issued to Ciabattoni for the purchase of up to 750,000 shares of Common Stock at an initial exercise price of $0.50 per share and exercisable for a period of three years from the date of issuance and
(iv) a warrant issued to Ciabattoni for the purchase of up to 500,000 shares of Common Stock at an initial exercise price of $0.75 per share and exercisable for a period of three years from the date of issuance. These warrants were allowed to
expire, unexercised.
Each Bridge Note originally became due and payable on November 6, 2009. We extended these notes under the terms
of an extension option contained in the Bridge Notes. Pursuant to the terms of the extension option, we were required to issue warrants to the Bridge Lenders to purchase shares of Common Stock in the following amounts: (i) to SMP, 125,000
shares at a price of $0.50 per share, and 83,333 shares at a price of $0.75 per share and (ii) to Ciabattoni, 250,000 shares at a price of $0.50 per share, and 166,667 shares at a price of $0.75 per share. All of the warrants issued were
exercisable for a period of twenty six months from the date of issuance, and were allowed to expire unexercised. The new due date of the Bridge Notes pursuant to the extension option
B-33
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
was February 6, 2010. We were to repay the unpaid principal of each Bridge Note on this date, together with accrued and unpaid interest of 16%.
The Bridge Lenders initially agreed to extensions as follows: the maturity date of the promissory note held by SMP, in the principal amount of
$500,000, is extended to August 6, 2011; the maturity date of the promissory note held by Ciabattoni, in the principal amount of $1,000,000, is extended to February 6, 2013. Effective February 1, 2010, the interest rate was changed
from 16% to 10% per annum for the Bridge Notes. As further discussed in Note 15 to the financial statements in this Form 10-K, Subsequent Events, each 2009 Bridge Lender agreed to extend the maturity date(s) of their respective
Bridge Notes with the same terms and conditions contained in the originally executed Notes and related extensions until June of 2014.
The
Bridge Notes include a conversion feature allowing each Bridge Lender to convert all or any portion of the entire unpaid principal and any unpaid accrued interest at the date upon which the conversion is to be effected into a number of shares of
Common Stock, determined by dividing the sum of the unpaid principal and unpaid accrued interest at the conversion date by the conversion price in effect at the conversion date. The initial conversion price is $0.625, which price is adjustable as
set forth in the Notes. As of September 30, 2013, none of the Bridge Lenders has effected such a conversion.
On March 3, 2009,
we completed the second closing of the Bridge Financing, a transaction in which we entered into nine (9) promissory notes, each dated as of March 3, 2009, in the aggregate principal amount of $500,000 (the Second Bridge Notes),
with various investors (the Second Bridge Lenders). Subsequent to this second closing, Anthony J. Ciabattoni, holder of the $1,000,000 Bridge note from the first round of Bridge Financing, assumed three of the Second Bridge Notes, for a
total of $100,000.
Each Second Bridge Note originally became due and payable on December 3, 2009, unless the maturity date is
extended pursuant to the terms of an extension option. The Second Bridge Notes included a conversion feature allowing each Second Bridge Lender to convert all or any portion of the entire unpaid principal and any unpaid accrued interest at the date
upon which the conversion is to be effected into a number of shares of Common Stock, determined by dividing the sum of the unpaid principal and unpaid accrued interest at the conversion date by the conversion price in effect at the conversion date.
The initial conversion price is $0.625, which price is adjustable as set forth in the Second Bridge Notes. As of September 30, 2013, none of the Second Bridge Lenders has effected such a conversion.
We extended the Second Bridge Notes for an additional three months under the terms of the extension option contained in the Second Bridge
Notes. Upon exercising this option, we were required to issue warrants to the Second Bridge Lenders to purchase an aggregate of 208,333 shares of our Common Stock, 125,000 shares of which will be issued at an exercise price of $0.50 per share and
83,333 shares of which will be issued at an exercise price of $0.75 per share. These warrants were allowed to expire, unexercised. The new due date for the Second Bridge Notes pursuant to the extension option was March 3, 2010. The Second
Bridge Lenders agreed to an additional extension period for the Second Bridge Notes ranging from eighteen to thirty-six months from the March 3, 2010 due date and also agreed to a reduction in the annual interest rate from 16% to 10%. As
further discussed in Note 17 of the financial statements in this Form 10-K, Subsequent Events, each of the Second Bridge Lenders agreed to extend the maturity date(s) of their respective Notes with the same terms and conditions contained
in the originally executed Notes and related extensions until June of 2014.
On April 14, 2009, we completed the third closing of the
Bridge Financing, a transaction in which we entered into the following three (3) promissory notes: (i) a convertible promissory note, dated as of March 31, 2009, with Frank Darras, Trustee of the Darras Family Trust
(Darras), in the principal amount of $100,000 (the Darras Note); (ii) a convertible promissory note, dated as of March 31, 2009, with SFV, Inc., a California
B-34
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
corporation (SFV), in the principal amount of $50,000 (the SFV Note) and (iii) a convertible promissory note, dated as of April 14, 2009, with NFS LLC/FMTC Rol
IRA FBO Neal Katz (Katz), in the principal amount of $50,000 (the Katz Note) (each, a Third Bridge Note and collectively, the Third Bridge Notes). Darras, SFV and Katz are each a Third Bridge
Lender and are collectively referred to herein as the Third Bridge Lenders. Of the total Bridge Financing, $1,600,000 was considered a related party transaction.
The Darras Note and the SFV Note originally became due and payable on December 31, 2009 and the Katz Note originally became due and
payable on January 14, 2010. The terms of each of the Third Bridge Notes contained an extension option to extend such notes for an additional three months at our discretion. We extended the Darras Note and the SFV Note under the terms of the
respective options, and therefore were obligated to issue warrants to Darras and SFV as follows: (i) Darras 25,000 shares at an exercise price of $0.50 per share, and 16,667 shares at an exercise price of $0.75 per share; (ii) SFV
12,500 shares at an exercise price of $0.50 per share, and 8,333 shares at an exercise price of $0.75 per share. We extended the Katz Note under the terms of an extension option contained in the Katz Note. By exercising this option, we were
required to issue warrants to Katz to purchase an aggregate of 20,833 shares, 12,500 shares of which will be issued at an exercise price of $0.50 per share and 8,333 shares of which will be issued at an exercise price of $0.75 per share. All of the
Third Bridge Note extension warrants were allowed to expire, unexercised.
The new due dates for the Third Bridge Notes, pursuant to the
extension option, was March 31, 2010 for each of the Darras Note and the SFV Note and April 14, 2010 for the Katz Note. The Third Bridge Lenders agreed to an additional extension period for the notes ranging from eighteen to thirty-six
months from the March 31, 2010 and April 14, 2010 due dates and also agreed to a reduction in the annual interest rate from 16% to 10%. As further discussed in Note 17 of the financial statements in this Form 10-K, Subsequent
Events, each Third Bridge Lender agreed to extend the maturity date(s) of their respective Notes with the same terms and conditions contained in the originally executed Notes and related extensions until June of 2014.
The Third Bridge Notes include a conversion feature allowing each Third Bridge Lender to convert all or any portion of the entire unpaid
principal and any unpaid accrued interest at the date upon which the conversion is to be effected into a number of shares of Common Stock, determined by dividing the sum of the unpaid principal and unpaid accrued interest at the conversion date by
the conversion price in effect at the conversion date. The initial conversion price is $0.625, which price is adjustable as set forth in the Third Bridge Notes.
The fair value of the warrants issued in conjunction with the convertible notes issued under the Bridge Financing amounted to $932,000, and
the fair value of the warrants issued in conjunction with the extension of the Bridge Notes, the Second Bridge Notes, the Darras Note, the SFV Note and the Katz Note amounted to $291,000. The beneficial conversion feature associated with the
convertible notes issued in conjunction with the Bridge Financing totaled $253,000. Both the fair value of the warrants issued under the Bridge Financing and the subsequent extension of the Bridge Notes, the Second Bridge Notes the Darras Note, the
SFV Note and the Katz Note, as well as the beneficial conversion feature, were amortized over the term of the loans.
All of the
promissory notes under the Bridge Financing include a provision granting the lenders, to the extent that the lenders holding notes representing a majority of the aggregate outstanding principal amount of the notes agree, demand registration rights
with respect to the resale of the shares of Common Stock that would be issuable upon conversion of the notes, which rights vest thirty six (36) months after the date of issuance of the Bridge Financing notes. The registration statement would be
prepared by us at our expense and filed on Form S-1 or other appropriate form and, once declared effective, allow the registered securities to be sold on a continuous basis and we will keep the registration statement continuously effective until
certain conditions are met which would allow us to stop maintaining its effectiveness.
B-35
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
During the Fiscal Year Ended September 30, 2012, $750,000 of the 2009 Bridge Financing
was repaid. Of the $750,000 paid, $75,000 and $175,000 was paid to SMP Investments I, LLC, and Anthony J. Ciabattoni respectively, both of which are considered related party transactions. As of September 30, 2013, $1,350,000 of the 2009 Bridge
Financing remains outstanding.
During the Fiscal Year Ended September 30, 2011, we entered into bridge financing transactions (the
2011 Bridge Financing) where we entered into ten promissory notes, in the aggregate principal amount of $2,034,000 (the 2011 Bridge Notes), with various investors (the 2011 Lenders). We received the 2011
Bridge Financing in multiple installments as follows: $674,400, $549,600, $360,000, and $100,000 in August, September, November and December of 2011, respectively, and $350,000 in January 2012. Each bridge note has attached warrants to purchase an
aggregate of 2,278,079 shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. Of the total 2011 Bridge Financing, $1,559,000 was considered a related party transaction. The warrants were issued
January 1, 2014. The 2011 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31, 2013, in installments of $420,000 and $1,614,000, respectively.
Beginning in February 2012, we entered into a staggered bridge financing transaction (the 2012 Bridge Financing) whereby we
entered into three promissory notes, in the aggregate principal amount of $1,279,000 (the 2012 Bridge Notes), with three investors (the 2012 Lenders) with maturity dates of June 30, 2014. The 2012 Bridge Loans
funded as follows; $340,000, $320,000, $390,000 and $229,000 in February, March, April, and May of 2012 respectively. All of the 2012 Bridge Financing was considered a related party transaction. The 2012 Bridge Notes were paid in full, less
accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31, 2013, in installments of $225,000 and $1,054,000, respectively.
7. Long-term Debt
Long-term debt consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30,
2013
|
|
|
September 30,
2012
|
|
Note payable secured by real estate, $27,513 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted
quarterly, floor of 7%, rate is currently 7%, matures November 2028
|
|
$
|
3,059
|
|
|
$
|
3,170
|
|
Note payable secured by real estate, $34,144 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted
quarterly, floor of 7%, rate is currently 7%, matures November 2028
|
|
|
2,830
|
|
|
|
2,995
|
|
Bridge notes payable, 10% interest, matures on or before June 2014
|
|
|
1,350
|
|
|
|
4,663
|
|
Note payable, 9% interest per annum, matures in February 2016
|
|
|
210
|
|
|
|
274
|
|
Note payable, 10% interest per annum, matures in September 2014
|
|
|
100
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
7,549
|
|
|
|
11,202
|
|
|
|
|
|
|
|
|
|
|
Less current maturities of long term debt
|
|
|
(1,857
|
)
|
|
|
(5,041
|
)
|
|
|
|
|
|
|
|
|
|
Total long term debt
|
|
$
|
5,692
|
|
|
$
|
6,161
|
|
|
|
|
|
|
|
|
|
|
B-36
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
The following chart shows scheduled principal payments due as of September 30, 2013 on long-term debt
for the next five years and thereafter (in thousands):
|
|
|
|
|
Fiscal Year Ended September 30,
|
|
Payments
|
|
FY 2014
|
|
$
|
1,857
|
|
FY 2015
|
|
|
441
|
|
FY 2016
|
|
|
444
|
|
FY 2017
|
|
|
415
|
|
FY 2018
|
|
|
454
|
|
Thereafter
|
|
|
3,938
|
|
|
|
|
|
|
Total
|
|
$
|
7,549
|
|
|
|
|
|
|
8. Warrants
Outstanding exercisable warrants consisted of the following as of September 30, 2013:
|
|
|
|
|
|
|
|
|
|
|
|
|
Remaining
|
|
Exercise
|
|
|
|
|
Description
|
|
Life
|
|
Price
|
|
|
Warrants
|
|
June 8, 2009 Preferred Stock Series 6-A warrants issued to investor
|
|
6 months
|
|
|
0.50
|
|
|
|
210,000
|
|
June 10, 2009 warrants issued to Medical Advisory Board
|
|
6 months
|
|
|
0.63
|
|
|
|
150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
360,000
|
|
|
|
|
|
|
|
|
|
|
|
|
A summary of stock warrant activity and related information at September 30, 2013 and 2012 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
Number of Shares of Common Stock
|
|
|
Exercise Price Per Share
|
|
|
|
Fiscal year
Ended
September 30,
2013
|
|
|
Fiscal year
Ended
September 30,
2012
|
|
|
Fiscal year
Ended
September 30,
2013
|
|
|
Fiscal year
Ended
September 30,
2012
|
|
Warrants outstanding at beginning of the period
|
|
|
796,250
|
|
|
|
4,731,513
|
|
|
$
|
0.52
|
|
|
$
|
0.58
|
|
Issued
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancelled or expired
|
|
|
(436,250
|
)
|
|
|
(3,935,263
|
)
|
|
$
|
0.50
|
|
|
$
|
0.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding at end of the period
|
|
|
360,000
|
|
|
|
796,250
|
|
|
$
|
0.55
|
|
|
$
|
0.52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9. Commitments and Contingencies
The Company is party to various claims arising in the ordinary course of business. The Company has accrued
approximately $660,000 related to various claims based on managements assessment of the potential outcome. Actual settlement may be different from the accrued liability. However, in the opinion of the Companys management, the
ultimate liability in excess of the amounts accrued, if any, resulting from the disposition of these actions will not have a material effect on the consolidated financial position or results of operations.
B-37
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
In June 2011, the Company vacated office space in Oklahoma City, Oklahoma prior to the
expiration of the lease, at which time the landlord proceeded with litigation to collect outstanding lease payments. In December of 2013, both parties entered into a settlement agreement under which the Company agreed to make a one-time payment of
$65,000 in full satisfaction of all amounts due under the lease terms.
In August 2011, the holder of the $1.5 million note payable and
4.25 million of the Companys outstanding common stock, filed a law suit for performance and repayment of the loan. In December 2011, in full settlement of the lawsuit and satisfaction of the $1.5 million note payable, the lender accepted
assignment and receipt of the $2.15 million notes receivable the Company had received in July 2011 as consideration for the sale of the SPMC medical records, and cash totaling $91,000. Additionally, as part of the settlement, the lender agreed to
transfer the 4.25 million shares of common stock back to the Company.
We lease office space under non-cancelable operating leases
that expire at various dates through 2030. We also lease certain equipment under capital leases. Rent expense was $80,065 in the Fiscal Year Ended September 30, 2013 and $96,161 in the Fiscal Year Ended September 30, 2012.
Future minimum lease obligations at September 30, 2013 for those leases having an initial or remaining non-cancelable lease term in
excess of one year, are as follows (in thousands):
|
|
|
|
|
|
|
Operating
|
|
Year Ending September 30,
|
|
Leases
|
|
2014
|
|
$
|
54
|
|
2015
|
|
|
56
|
|
2016
|
|
|
58
|
|
2017
|
|
|
59
|
|
2018 and thereafter
|
|
|
20
|
|
|
|
|
|
|
|
|
$
|
247
|
|
|
|
|
|
|
10. Preferred Stock
Non-Redeemable Preferred Stock and Redeemable Preferred Stock
Effective February 24, 2000, we authorized 5,000,000 shares of preferred stock. The preferred stock is divided into several series. The
Series 1-A Convertible Preferred Stock consists of 2,802,000 shares, the
Series 2-A
Convertible Preferred Stock consists of 1,672,328 shares, the Series 3-A Convertible Preferred Stock consists
of 500,000 shares, the Series 4-A Preferred consists of 25,000 shares, the 5-A Preferred consists of 9,000 shares and the 6-A Preferred consists of 5,000 shares. Following completion of the sale of our BPO operations in Asia, no Series 3-A
Preferred Stock or Series 4-A Preferred Stock remained outstanding and no shares of Series 3-A Preferred Stock or Series 4-A Preferred Stock were subsequently issued. During the Fiscal Year Ended September 30, 2008, we began
issuing preferred stock designated as 6-A Preferred. Series 1-A Convertible Preferred Stock, Series 2-A Convertible Preferred Stock, 5-A Preferred and Series 6-A Preferred Stock outstanding as of end of the Fiscal Years Ended
September 30, 2013 and 2012 is described below.
Series 1-A Convertible Preferred Stock
As of the end of the Fiscal Years Ended September 30, 2013 and 2012, we had 67,600 shares of Series 1-A Convertible Preferred Stock,
convertible into 33,493 common shares with an aggregate liquidation value of $167,000. In the event of any liquidation or dissolution, either voluntary or involuntary, the holders of the Series 1-A Convertible Preferred Stock shall be entitled
to receive, prior and in preference to any distribution of
B-38
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
any of the assets or surplus funds, to the holders of the Common Stock by reason of their ownership thereof, a preference amount per share consisting of the sum of (A) $2.50 for each
outstanding share of Series 1-A Convertible Preferred Stock and (B) an amount equal to declared but unpaid dividends on such shares, if any. Each share of Series 1-A Convertible Preferred Stock shall be convertible at any time after
the date of issuance of such shares, into such number of fully paid shares of Common Stock as is determined by dividing the original issue price by the then-applicable conversion price in effect on the date the certificate evidencing such share is
surrendered for conversion. Each share of Series 1-A Convertible Preferred Stock, subject to the surrendering of the certificates of the Series 1-A Convertible Preferred Stock, shall be automatically converted into shares of Common Stock
at the then-effective conversion price, immediately upon closing of a public offering of our Common Stock with aggregate gross proceeds of at least $10.0 million and a per share price of at least $5.00, or at the election of the holders of a
majority of the outstanding shares of Series 1-A Convertible Preferred Stock. The holder of each share of Series 1-A Convertible Preferred Stock has the right to that number of votes equal to the number of shares of Common Stock which
would be issued upon conversion of the Series 1-A Convertible Preferred Stock. Holders of the Series 1-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by our Board of Directors, of $0.20 per share
annually. Under certain circumstances, such as stock splits or issuances of Common Stock at a price less than the issuance price of the Series 1-A Convertible Preferred Stock, these shares are subject to stated Series 1-A Convertible
Preferred Stock conversion price adjustments. There are currently three holders of Series 1-A Convertible Preferred Stock.
Series 2-A
Convertible Preferred Stock
As of the end of the Fiscal Years Ended September 30, 2013 and 2012, we had 3,900 shares of
Series 2-A Convertible Preferred Stock outstanding with an aggregate liquidation value of $24,000. In the event of any liquidation or dissolution, either voluntary or involuntary, the holders of the Series 2-A Convertible Preferred Stock
shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds, to the holders of the Common Stock by reason of their ownership thereof, a preference amount per share consisting of the sum of
(A) $6.41 for each outstanding share of Series 2-A Convertible Preferred Stock and (B) an amount equal to declared but unpaid dividends on such shares, if any. Each share of Series 2-A Convertible Preferred Stock shall be
convertible at any time after the date of issuance of such shares, into such number of fully paid shares of Common Stock as is determined by dividing the original issue price by the then-applicable conversion price in effect on the date the
certificate evidencing such share is surrendered for conversion. Each share of Series 2-A Convertible Preferred Stock, subject to the surrendering of the certificates of the Series 2-A Convertible Preferred Stock, shall be automatically
converted into shares of Common Stock at the then-effective conversion price, immediately upon closing of a public offering of our Common Stock with aggregate gross proceeds of at least $20.0 million and a per share price of at least $13.00, or
at the election of the holders of a majority of the outstanding shares of Series 2-A Convertible Preferred Stock. The holder of each share of Series 2-A Convertible Preferred Stock has the right to that number of votes equal to the number of
shares of Common Stock which would be issued upon conversion of the Series 2-A Convertible Preferred Stock. Holders of the Series 2-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by our Board of
Directors, of $0.20 per share annually. Under certain circumstances, such as stock splits or issuances of Common Stock at a price less than the issuance price of the Series 2-A Convertible Preferred Stock, these shares are subject to stated
Series 2-A Convertible Preferred Stock conversion price adjustments. There is currently one holder of Series 2-A Convertible Preferred Stock.
Series 5-A Convertible Preferred Stock
Under the terms of the Series 5-A Preferred Stock and Warrant Purchase Agreement, in the event of any liquidation or dissolution, either
voluntary or involuntary, the holders of the 5-A Preferred shall be entitled to receive,
pari passu
with the 6-A Preferred, after distribution of all amounts due to the holders of the Series 1-A
B-39
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
Convertible Preferred Stock and Series 2-A Convertible Preferred Stock, but prior and in preference to any distribution of any of the assets or surplus funds to the holders of the Common
Stock by reason of their ownership thereof, a preference amount per share consisting of the sum of (A) the original issue price, which initially is $1,000 (as adjusted for stock splits, stock dividends, combinations and the like) plus
(B) an amount equal to all declared but unpaid dividends on such shares, if any. Each share of 5-A Preferred shall be convertible at any time after the date of issuance of such shares, into such number of fully paid shares of Common Stock as is
determined by dividing the original issue price by the then-applicable conversion price in effect on the date the certificate evidencing such share is surrendered for conversion. Each share of 5-A Preferred, subject to the surrendering of the
certificates of the 5-A Preferred, shall be automatically converted into shares of Common Stock at the then-applicable conversion price, upon the election of the holders of not less than a majority of the outstanding shares of 5-A Preferred electing
to effect such conversion. The holder of each share of 5-A Preferred shall have the right to that number of votes equal to the number of shares of Common Stock which would be issued upon conversion of the 5-A Preferred. Holders of the 5-A Preferred
are entitled to non-cumulative dividends, if declared by our Board of Directors, of $40 per share annually. Under certain circumstances, such as stock splits or issuances of Common Stock at a price less than the issuance price of the Series 5-A
Convertible Preferred Stock, these shares are subject to stated Series 5-A Convertible Preferred Stock conversion price adjustments. Shares of 5-A Preferred had an initial conversion price of $0.3125 per share.
Shares of 5-A Preferred Stock are subject to redemption at our option or if required by a majority of the outstanding 5-A Preferred shares
after certain events have occurred (Triggering Events). Triggering Events include our failure to honor a properly tendered request for conversion and if our Common Stock is not eligible for quotation on certain public stock exchanges
including the OTC Bulletin Board and the Nasdaq Small Cap Market. During the Fiscal Year ended September 30, 2011, our Common Stock became ineligible for quotation on any public stock exchange, resulting in the occurrence of a Triggering Event.
As of September 30, 2013 and 2012 neither we nor a majority of the outstanding 5-A Preferred shares had required redemption. In February 2014, a majority of the Series 5-A Convertible Preferred Stock holders consented to waive their rights
to demand registration. As a result of the majority consent, demand registration rights for all of the stockholders of the Series 5-A Convertible Preferred Stock were waived.
As of September 30, 2013 and 2012, there were 9,000 shares of 5-A Preferred outstanding, convertible into 28,800,000 common shares with
an aggregate liquidation value of $9.01 million and an aggregate redemption value of $9.4 million. There are currently 61 holders of 5-A Preferred.
Series 6-A Convertible Preferred Stock
On March 31, 2008, we entered into a Series 6-A Preferred Stock and Warrant Purchase Agreement (the
6-A
Purchase Agreement), pursuant to which we issued and sold 3,585 shares of newly created class of convertible preferred stock, known as the 6-A Preferred and warrants to purchase an aggregate of
2,151,000 shares of Common Stock to a group of investors. Net proceeds from the issuance totaled $3.3 million. As of September 30, 2013, all of the warrants from the March 31, 2008 issuance have expired.
Under the terms of the 6-A Purchase Agreement, in the event of any liquidation or dissolution, either voluntary or involuntary, the holders of
the 6-A Preferred shall be entitled to receive,
pari passu
with the 5-A Preferred, after distribution of all amounts due to the holders of the Series 1-A Convertible Preferred Stock and Series 2-A Convertible Preferred Stock, but
prior and in preference to any distribution of any of the assets or surplus funds to the holders of the Common Stock by reason of their ownership thereof, a preference amount per share consisting of the sum of (A) the original issue price,
which initially is $1,000 (as adjusted for stock splits, stock dividends, combinations and the like) plus (B) an amount equal to all declared but unpaid dividends on such shares, if any. The holders of 6-A Preferred shall be entitled to receive
dividends
pari passu
with the 5-A
B-40
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
Preferred stockholders. Each share of 6-A Preferred shall be convertible at any time after the date of issuance of such shares, into such number of fully paid shares of Common Stock as is
determined by dividing the original issue price by the then-applicable conversion price in effect on the date the certificate evidencing such share is surrendered for conversion. Each share of 6-A Preferred, subject to the surrendering of the
certificates of the 6-A Preferred, shall be automatically converted into shares of Common Stock at the then-applicable conversion price, upon the election of the holders of not less than a majority of the outstanding shares 6-A Preferred electing to
effect such conversion. The holder of each share of 6-A Preferred shall have the right to that number of votes equal to the number of shares of Common Stock, which would be issued upon conversion of the 6-A Preferred. Holders of the 6-A Preferred
are entitled to non-cumulative dividends, if declared by our Board of Directors, of $40 per share annually. Under certain circumstances, such as stock splits or issuances of Common Stock at a price less than the issuance price of the Series 6-A
Convertible Preferred Stock, these shares are subject to stated Series 6-A Convertible Preferred Stock conversion price adjustments. Shares of 6-A Preferred have an initial conversion price of $0.3125 per share.
Shares of 6-A Preferred Stock are subject to redemption at our option or if required by a majority of the outstanding 6-A Preferred shares
after certain events have occurred (Triggering Events). Triggering Events include our failure to honor a properly tendered request for conversion and if our Common Stock is not eligible for quotation on certain public stock exchanges
including the OTC Bulletin Board and the Nasdaq Small Cap Market. During the Fiscal Year ended September 30, 2011, our Common Stock became ineligible for quotation on any public stock exchange, resulting in the occurrence of a Triggering Event.
As of September 30, 2013 neither we nor a majority of the outstanding 6-A Preferred shares had required redemption. In February 2014, a majority of the Series 6-A Convertible Preferred Stock holders consented to waive their rights to
demand registration. As a result of the majority consent, demand registration rights for all of the stockholders of the Series 6-A Convertible Preferred Stock were waived.
As of September 30, 2013 and 2012, there were 4,875 shares of 6-A Preferred outstanding, convertible into 15,600,000 common shares with
an aggregate liquidation value of $4.9 million and an aggregate redemption value of $5.3 million. There are currently 37 holders of 6-A Preferred.
Related Party Interests in Preferred Stock
Our executive officers and affiliates held no shares of either Series 1-A Convertible Preferred Stock or Series 2-A Convertible
Preferred Stock as of September 30, 2013 and 2012. They held 2,373 shares of 5-A Preferred and 1,643 shares of 6-A Preferred as of September 30, 2013 and 2012.
11. Stock Options
Stock-Based Compensation
There were no options to purchase shares of our Common Stock granted in the Fiscal Years Ended September 30, 2013 and 2012.
Stock Option Plans
In 2001, at our 2001
Annual Meeting, our stockholders approved two equity compensation plans: (a) our 2001 Stock Options/Stock Issuance Plan (the 2001 Plan) and (b) our Employee Stock Purchase Plan (ESPP). The maximum number of shares
of Common Stock that may be issued under the 2001 Plan cannot exceed 20% of the total shares of Common Stock outstanding at the time the calculation is made (including, on an as-converted basis, all convertible preferred stock, convertible debt
securities, warrants, options and other
B-41
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
convertible securities that are exercisable), but in no event will the maximum number of shares of Common Stock which may be issued under the 2001 Plan as incentive stock options exceed
20,000,000. As of September 30, 2013 based on the 20% calculation, the maximum number of shares issuable under the 2001 Plan was 14,264,477. As of September 30, 2013, we have discontinued offering the ESPP. Since its inception, a total of
22,940 shares of Common Stock have been purchased pursuant to the ESPP. We granted options to purchase 650,000 shares of our common stock during the Fiscal Years ended September 30, 2010. No options were granted during the Fiscal Year Ended
September 30, 2013. Amortization of stock-based compensation expense was $574,000 and $766,000 for the Fiscal Years Ended September 30, 2013 and 2012 respectively.
The following summarizes activities under the stock option plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Options
|
|
|
Weighted-Average
Exercise Price Per Share
|
|
|
|
Fiscal
Year
Ended
September 30,
2013
|
|
|
Fiscal
Year
Ended
September 30,
2012
|
|
|
Fiscal
Year
Ended
September 30,
2013
|
|
|
Fiscal
Year
Ended
September 30,
2012
|
|
Options outstanding at beginning of the period
|
|
|
6,760,000
|
|
|
|
7,260,000
|
|
|
$
|
0.61
|
|
|
$
|
0.61
|
|
Granted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at above fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at below fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
|
|
|
|
(500,000
|
)
|
|
|
|
|
|
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at end of the period
|
|
|
6,760,000
|
|
|
|
6,760,000
|
|
|
$
|
0.61
|
|
|
$
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options vested/exercisable at end of the period
|
|
|
6,730,000
|
|
|
|
5,450,000
|
|
|
$
|
0.61
|
|
|
$
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following summarizes information for stock options outstanding as of September 30, 2013:
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price
|
|
Number of options
|
|
|
Weighted-average
exercise price
|
|
|
Weighted-average
remaining
contractual life
|
|
$0.40
|
|
|
360,000
|
|
|
$
|
0.40
|
|
|
|
0.25
|
|
$0.63
|
|
|
6,400,000
|
|
|
$
|
0.63
|
|
|
|
1.80
|
|
As of September 30, 2013, there was $89,294 in unrecognized compensation cost related to outstanding
options, net of forecasted forfeitures. This amount is expected to be recognized over a weighted average of 9 months. As all options outstanding as of September 30, 2013 had strike prices above the market value, the shares are considered
out-of-the-money, and they have no intrinsic value.
Employee Stock Purchase Plan
In November 2001, our stockholders approved the Employee Stock Purchase Plan (the ESPP), which provides (after adjustment to
reflect our November 20, 2002 reverse stock split) for the issuance of a maximum of 350,000 shares of Common Stock. Eligible employees can have up to 10% of their earnings withheld, up to certain maximum limits, to be used to purchase shares of
Common Stock at certain plan-defined dates. The price
B-42
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
of Common Stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the Common Stock on the commencement date and specified purchase date of each six-month offering
period. We have discontinued offering the ESPP and no shares have been issued subsequent to the original issuance, and we have no current intention to issue any more shares under the ESPP.
12. 401(k) Plan
We sponsor a 401(k) employee savings plan (401(k) Plan) under which eligible U.S. employees may choose to defer
a portion of their eligible compensation on a pre-tax basis, subject to certain IRS limitations.
13. Income Taxes
Rate reconciliation:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Statutory federal income tax rate
|
|
$
|
1,962,869
|
|
|
$
|
1,910,377
|
|
Increase (reduction) in taxes resulting from:
|
|
|
|
|
|
|
|
|
State income taxes, net of federal benefit
|
|
|
251,347
|
|
|
|
261,228
|
|
Permanent differences
|
|
|
195,158
|
|
|
|
260,382
|
|
Change in valuation allowance
|
|
|
(2,409,374
|
)
|
|
|
(2,292,014
|
)
|
Other
|
|
|
|
|
|
|
72,107
|
|
|
|
|
|
|
|
|
|
|
Income tax provision
|
|
$
|
|
|
|
$
|
212,080
|
|
|
|
|
|
|
|
|
|
|
The deferred tax assets and liabilities were comprised of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Net operating loss carry forward
|
|
$
|
7,562
|
|
|
$
|
13,646
|
|
Accounts receivable reserves
|
|
|
7,560
|
|
|
|
3,808
|
|
Deferred gain
|
|
|
1,327
|
|
|
|
1,404
|
|
AMT carry forward
|
|
|
221
|
|
|
|
221
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
|
16,670
|
|
|
|
19,079
|
|
Valuation allowance
|
|
|
16,670
|
|
|
|
19,079
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
The valuation allowance at September 30, 2013 principally applies to federal tax loss carry-forwards
that, in the opinion of the management, are more likely than not to expire before we can use them.
As of September 30, 2013, we had
net operating loss carry-forwards of approximately $19.9 million, available to offset future regular, alternative minimum and foreign taxable income, if any. Change of ownership of more than 50% occurred on June 22, 2001 and according to
applicable U.S. tax laws, losses that occurred before that date are limited to $0.3 million per year for up to 20 years, totaling approximately $6.5 million. The loss carryovers will expire between 2012 and 2030. Changes in our
ownership may lead to further restrictions in respect of the availability and use of these tax losses.
B-43
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
FASB ASC 740 creates a single model to address accounting for uncertainty in tax positions by
prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FASB ASC 740 also provides guidance on de-recognition, measurement, classification, interest and penalties,
accounting in interim periods, disclosure and transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated financial statements. Additionally, there were no tax penalties or interest recorded in the Fiscal Years
Ended September 31, 2013 and 2012.
14. Related Party Transactions
Bridge Financing
During the
Fiscal Year Ended September 30, 2012, $750,000 of the original 2009 Bridge Financing was repaid. Of the $750,000 paid, $75,000 and $175,000 was paid to SMP Investments I, LLC, and Anthony J. Ciabattoni respectively, both of which are considered
related party transactions.
The 2011 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the
Fiscal Year Ended September 31, 2013, in installments of $420,000 and $1,614,000, respectively. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold 10% or greater voting interests, are considered
related parties, and received $759,000, $380,000, and $420,000 respectively of the total payments.
During the Fiscal Year Ended
September 30, 2012, we entered into 2012 Bridge Financing in the aggregate principal amount of $1,279,000 (see Note 6 in the Notes to the financial statements in this Form 10-K) . The three lenders, SMP, Anthony J. Ciabattoni, and William A.
Houlihan, each hold 10% or greater voting interests and are considered related parties.
The 2012 Bridge Notes were paid in full, less
accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31, 2013, in installments of $225,000 and $1,054,000, respectively. The three 2012 bridge lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan,
each hold 10% or greater voting interests and are considered related parties. They received total payments of $620,000, $434,000, and 225,000 respectively.
15. Subsequent Events
In preparing these financial statements, the Company has evaluated events and transactions for potential recognition or
disclosure through March 28, 2014, the date on which the financial statements became available to be issued. The Company noted the following items for disclosure.
Litigation
In June 2011, the Company vacated
office space in Oklahoma City, Oklahoma prior to the expiration of the lease, at which time the landlord proceeded with litigation to collect outstanding lease payments. In December of 2013, both parties entered into a settlement agreement under
which the Company agreed to make a one-time payment of $65,000 in full satisfaction of all amounts due under the lease terms.
Change in Management
Effective November 18, 2013, David Hirschhorn resigned (i) as Chief Executive Officer, Chairman of the Board of Directors (the
Board) and as a member of the Board of First Physicians Capital Group, Inc., a
B-44
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
Delaware corporation (the Registrant) and (ii) from any and all other positions and in all other capacities in which he served as an officer or director of the Registrant or any
of the Registrants subsidiaries. Mr. Hirschhorn had no disagreements with the Registrant on any matter related to the Registrants operations, policies or practices. Upon his departure, Mr. Hirschhorn was paid $699,000 in
accrued salary.
On November 21, 2013, the Board appointed Sean J. Kirrane to the position of Chief Executive Officer of the
Registrant, to serve until his successor is duly appointed and qualified or until his earlier resignation or removal. Mr. Kirrane has no family relationship with any officer or director of the Registrant or any of its subsidiaries.
2013 Bridge Financing
Beginning in November
2013, we entered into a staggered bridge financing transaction (the 2013 Bridge Financing) whereby we entered into four (4) promissory notes, with interest of 10% per annum, in the aggregate principal amount of $650,000 (the
2013 Bridge Notes), with 4 investors, each note maturing June 30, 2014. The 2013 Bridge Loans funded as follows; $450,000 and $200,000 in November 2013 and January 2014, respectively. Three of the investors, SMP Investments I, LLC
(SMP), Anthony J. Ciabottoni, and William Houlihan each hold a 10% or greater voting interest and are considered related parties. The fourth investor, Blue Ridge Investments, LLC is wholly owned by Richardson Sells, a member of the Board, and is
therefore also considered a related party. The four lenders contributed $300,000, $125,000, $125,000, and $100,000, respectively.
Bridge Note Extensions
In January 2014, each 2011 Bridge Lender (see Note 6 to the financial statements in this Form 10-K Bridge Financing) agreed to
extend the maturity date(s) of their respective Notes with the same terms and conditions contained in the originally executed Notes and related extensions until June 2014. Also in January 2014, each 2009 Bridge Lender (see Note 6 to the financial
statements in this Form 10-K Bridge Financing) agreed to extend the maturity date(s) of their respective Notes with the same terms and conditions contained in the originally executed Notes and related extensions until June of 2014. Three
of the Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan each hold a 10% or greater voting interest and are considered related parties to this transaction.
In addition, as part of the 2009 Bridge Notes extensions, in January 2014 the Company issued penny warrants to SMP for the
purchase of up to 8,500,000 shares of Common Stock at an initial exercise price of $0.01 per share and exercisable for a period of five years from the date of issuance. SMP was one of the original 2009 Bridge Financing lenders. SMP, holds a 10% or
greater voting interest and is considered a related party. In March 2014, SMP exercised its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of $85,000. The $85,000 proceeds were received by the company in Fiscal
Year 2013, and were recorded as a liability until such time as the Company was able to accept the warrants.
Series 5-A and 6-A Convertible Preferred
Stock Waiver
In February 2014, a majority of the Series 5-A Convertible Preferred Stock and Series 6-A Convertible Preferred
Stock holders consented to waive their rights to demand registration. As a result of the majority consent, demand registration rights for all of the stockholders of the two classes of stock, were waived.
B-45
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
Warrant Exercise
In March 2014, we accepted two warrant exercises in the amount of 150,000 and 210,000 shares of Common Stock, at an exercise price of $0.625
and $0.50 per share respectively, for an aggregate purchase price of $198,000 from two investors. The $198,000 proceeds had been received by the company in Fiscal Year 2011, and were recorded as a liability until such time as the Company was able to
accept the warrants.
Warrant Issuance
The
2011 Bridge Financing had attached warrants to purchase an aggregate of 2,278,079 shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. These warrants were issued January 1, 2014. Three of the
2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10% or greater voting interest and are considered related parties to this transaction and received in aggregate 1,746,080 of the warrants.
The 2012 Bridge Financing had attached warrants to purchase an aggregate of 4,092,800 shares of our Common Stock with an exercise price of
$0.3125, maturing five years from date of issuance. These warrants were issued January 1, 2014. The 2012 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan each hold a 10% or greater voting interest and are considered related
parties to this transaction.
Series 7-A Convertible Preferred Stock
On December 5, 2013, the Company filed a Certificate of Designation of Rights and Preferences of
Series 7-A
Convertible Preferred Stock authorizing the issuance of up to 7,000 Series 7-A Convertible Preferred Stock (see Exhibit 3.15). As part of the consideration for entering into the 2011 Bridge
Financing, all of the 2011 Bridge Lenders were granted the option to convert their current holdings if any, of Series 5-A Preferred Convertible Stock, 6-A Preferred Convertible Stock and Common Stock (collectively the Exchanged
Securities), into Series 7-A Convertible Preferred Stock. Upon election to convert, each lender would receive the number of Series 7-A Convertible Preferred Stock equal to the initial consideration paid for their Exchanged Securities divided
by $1,000. In connection with the conversion, each 2011 Bridge Lender shall receive warrants to purchase a number of shares of Common Stock of the Company in an amount equal to 1,120 multiplied by the aggregate number of shares of Series 7-A
Preferred issued. Such issued warrants shall have an exercise price of $0.3125, and shall expire five years from date of issuance. The Company has received notification from all the 2011 Bridge Lenders of their intent to convert, as appropriate,
their holdings of Exchanged Securities to
Series 7-A
Convertible Preferred Stock, which will result in the issuance of an aggregate of 5,998 Series 7-A Preferred Stock and warrants to purchase 6,717,760
shares of Common Stock. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10% or greater voting interest and will be considered related parties to this transaction.
B-46
Item 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|
None.
Item 9A.
|
CONTROLS AND PROCEDURES
|
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and Principal Accounting Officer has evaluated the effectiveness of our disclosure controls and procedures (as such
term is defined in Rules 13a-15(e) under the Exchange Act), as of September 30, 2013. Based on such evaluation, our Chief Executive Officer and Principal Accounting Officer determined that, as of September 30, 2013, our disclosure controls
and procedures were not effective to provide reasonable assurance that information required to be included in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported with the time periods specified in
the rules and forms of the SEC and such information is accumulated and communicated to our management, including our principal executive and financial officers or persons performing similar functions, as appropriate, to allow timely decisions
regarding required disclosure.
Changes in Internal Controls
There were no changes in our internal controls over financial reporting that occurred during the quarter ended September 30, 2013, that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Managements Assessment
of Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control
over financial reporting, as defined in Exchange Act Rule 13a-15(f). Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2013. The criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission in Internal Control Integrated Framework 1992 were used to make this assessment. Management believes that our internal control over financial reporting as of September 30, 2013
contained evidence of a material weakness based on those criteria. Specifically, a material weakness regarding the effectiveness of managements financial reporting close process controls, specifically those relating to adequate oversight by
management, adequate segregation of duties, adequate review and approval of journal entries and adequate review and approval of consolidating financial statements
This Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial
reporting. Managements report was not subject to attestation by our registered public accounting firm pursuant section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act, which exempts smaller reporting companies from the
auditor attestation requirement.
Item 9B.
|
OTHER INFORMATION
|
None.
B-47
PART III
Item 10.
|
DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
The following table sets
forth the names, ages and certain information regarding each of our current directors and executive officers as of March 28, 2014. There are no family relationships among our directors or executive officers.
|
|
|
|
|
|
|
Name
|
|
Age
|
|
|
Position
|
Sean Kirrane
|
|
|
33
|
|
|
Chief Executive Officer and Chief Financial Officer
|
Robert N. Schwartz, PhD.(1)
|
|
|
71
|
|
|
Director
|
Richardson E. Sells(1)
|
|
|
64
|
|
|
Director
|
William Houlihan(1)
|
|
|
55
|
|
|
Director
|
(1)
|
Member of the Audit Committee and Compensation Committee.
|
David Hirschhorn.
Since September 2005,
Mr. Hirschhorn, age 41, served as our Chairman and CEO. Effective November 18, 2013, 2013, Mr. Hirschorn resigned as Chairman and CEO of the Company. Previously, Mr. Hirschhorn served on our Board of Directors and as Co-Chairman,
Co-Chief Executive Officer and Co-Chief Financial Officer from July 2005 through September 2007, when he was appointed as sole Chairman and Chief Executive Officer. Prior to that, Mr. Hirschhorn co-managed a private equity firm from
July 2001 through July 2005. During his career, he has been CEO and chairman of a number of turnarounds and start-ups. He was a managing director at Cruttenden Roth (now Roth Capital Partners) from May 1994 to March 1997.
Mr. Hirschhorn also worked for The Nikko Securities Co. International, Inc. as an investment banker in their New York office from 1991 to 1994, where as part of a team he built a new department that provided financial advice and raised capital
for domestic and international clients. He began his career as a consultant for KPMG Peat Marwick and later worked as a senior consultant for Deloitte & Touche from 1997 to 2000. Mr. Hirschhorn earned a BA from the University of
Michigan in Political Science. See Subsequent Events Note 17 in this Form 10-K for details regarding his resignation.
Sean Kirrane.
On
August 23, 2010 Mr. Kirrane, who has served as the Companys Vice President of Finance and Controller since June 14, 2010, was appointed to serve as the Companys Principal Accounting Officer following
Mr. Parkersons departure. On November 21, 2013, Mr. Kirrane was appointed to serve as the Companys Chief Executive Officer and Chief Financial Officer following Mr. Hirschorns departure. Mr. Kirrane brings
over 10 years of experience in senior finance and accounting roles for large publicly traded companies, including large financial services and insurance firms. From September 2007 to March 2010, Mr. Kirrane served as Assistant
Vice President, Head of Global Treasury for Endurance Specialty Holdings, Ltd., where he designed and implemented, staffed and managed global treasury functions for the property and casualty insurer. From March 2004 to March 2007,
Mr. Kirrane served in various finance and investment roles at New York Mortgage Trust, Inc. (New York Mortgage), where he was responsible for treasury, budgeting & forecasting, debt management and covenant compliance
activities. He assisted New York Mortgage through a successful IPO in June 2004 and was eventually appointed Vice President and Treasurer in 2005. From January 2000 to March 2004, Mr. Kirrane held various positions in the
accounting and treasury departments of Hudson United Bancorp. (Hudson United), including Assistant Vice President, Investment Officer and Treasury Cash Manager. In his positions at Hudson United, he was responsible for managing treasury
operations and the derivatives and traded fixed income portfolio. Mr. Kirrane received a B.S. in Finance in 2000 from St. Josephs University in Philadelphia, PA and is a candidate for the Chartered Financial Analyst designation.
Robert N. Schwartz, Ph.D.
Dr. Schwartz has served on our Board of Directors since January 1998. Since 1979, Dr. Schwartz has been a
visiting professor at U.C.L.A. and, since December 2000, the owner of a scientific consulting company, Channel Islands Scientific Consulting. From 1981 to 2000, Dr. Schwartz was a Senior
Research Scientist at HRL Laboratories, LLC, Malibu, California. Prior to joining HRL Laboratories he was a Professor of Physical Chemistry at the University
of Illinois, Chicago from 1968 until 1981. Since 2006
B-48
Dr. Schwartz has served as a Senior Scientist at the Aerospace Corporation in El Segundo, California. He has a B.A. in Mathematics, Chemistry and Physics, an M.S. in Chemical Physics from
the University of Connecticut and a Ph.D. in Chemical Physics from the University of Colorado. Based on Mr. Schwartz technical expertise and prior executive management experience, the Company believes that Mr. Schwartz has the
requisite set of skills to serve as a Board member of the Company.
Richardson E. Sells.
Mr. Sells has served on our Board of Directors since
April 2005. Mr. Sells served as Vice President Global Sales, Cargo, of Northwest Airlines, Inc. from January 29, 2001 until his retirement at the end of calendar year 2006. Mr. Sells is currently the Managing Partner of
Transition Management, LLC, a transportation-related consulting firm. Prior to joining Northwest Airlines, Mr. Sells was Managing Director, Hong Kong and China, for CV Transportation Services, LDC, from 1995 through December 31, 2000.
Mr. Sells has a Bachelors of Science degree in Business Management from East Tennessee State University. Based upon Mr. Sells extensive experience as an executive officer and director, together with his educational experience
and his extensive operational, corporate governance, financial and transactional expertise, the Company believes that Mr. Schiller has the requisite set of skills to serve as a Board member of the Company.
William A. Houlihan.
Mr. Houlihan has served on our Board of Directors since September 29, 2009. Mr. Houlihan has more than
30 years of business and financial experience. For the periods from February 2006 to July 2006, February 2007 to May 2007 and December 2008 through present, Mr. Houlihan was a private investor while he evaluated
opportunities to be the Chief Financial Officer of certain companies. Mr. Houlihan has served as Chief Financial Officer for several companies, which were Sixth Gear, Inc. from October 2007 to November 2008, Sedgwick Claims Management
Services in Memphis, Tennessee from August 2006 until January 2007, Metris Companies from August 2004 to January 2006, and Hudson United Bancorp from January 2001 to November 2003. He also worked as an investment banker
at UBS in New York, New York from June 2007 to September 2007, at J.P. Morgan Securities from November 2003 to July 2004, KBW, Inc. from October 1996 to January 2001, Bear, Stearns & Co., Inc. from April 1991
to October 1996, and Goldman Sachs & Co. from June 1981 to April 1991. Mr. Houlihan received a B.S. in Accounting in 1977 from Manhattan College, became licensed as a C.P.A. in 1979, and received his M.B.A. in Finance in
1983 from New York University Graduate School of Business. Based upon Mr. Houlihans prior experience as an executive officer of companies in a variety of industries, financial expertise, the Company believes that Mr. Houlihan has the
requisite set of skills to serve as a Board and Board committee member of the Company.
Board Meetings and Committees
During the fiscal year ended September 30, 2013, the Board of Directors met via teleconference 8 times.
The Audit Committee, which held one meeting during the fiscal year ended September 30, 2013, assists in the Board of Directors
oversight of our financial statements and compliance with legal and regulatory requirements and the qualifications and performance of our independent auditor. The Audit Committee currently has two members: Mr. Houlihan and Mr. Sells. Each
of Mr. Houlihan and Mr. Sells is an independent director in accordance with the NASDAQ listing standards. None of Mr. Houlihan and Mr. Sells is considered an audit committee financial expert, as that term is currently
defined under the applicable rules and regulations of the SEC. The Audit Committee does not have an audit committee financial expert because it has not been able to identify a qualified candidate.
The Compensation Committee, held one meeting during the fiscal year ended September 30, 2013, is comprised of Dr. Schwartz,
Mr. Houlihan and Mr. Sells. The primary purpose of the Compensation Committee is to determine, or recommend to the Board of Directors for its determination, the compensation of our Chief Executive Officer and our other executive officers
to ensure that our executive officers are fairly compensated based upon their performance and contribution to us. In addition, the Compensation Committee will produce an annual report on executive compensation for inclusion in our annual proxy
statement filed with the SEC, in accordance with applicable rules and regulations.
B-49
We do not currently have a nominating committee or a committee performing the functions of a
nominating committee. Our Board of Directors fulfills the roles of this committee. It is the position of our Board of Directors that it is appropriate for us not to have a separate nominating committees at this time in light of our size and our
level of operations. Moreover, at present we are not required to have a nominating committee until such time as we are listed on a national stock exchange, in which event we would have to abide by the applicable rules and regulations of such stock
exchange. We do not currently consider director nominations from shareholders. In selecting director nominees, we consider various criteria, such as the recommendations of the independent directors, the candidates relevant business skills and
experience, commitment to enhancing shareholder value and professional ethics and values.
Stockholder Communications with the Board of Directors
Our stockholders may communicate with the members of our Board of Directors and may recommend nominees to our Board of Directors by
writing directly to our Board of Directors or specified individual directors at the following address:
First Physicians Capital Group,
Inc.
Attn: Corporate Secretary
9663 Santa Monica Boulevard, #959
Beverly Hills, California 90210
Our Secretary will deliver stockholder communications to the specified individual director, if so addressed, or to one of our directors who
can address the matter.
Compensation of Directors
Mr. Hirschhorn was the only director also serving as a full-time employee of ours as of September 30, 2013. He received no additional
compensation for serving as a director. With respect to non-employee, independent directors, our philosophy is to provide competitive compensation necessary to attract and retain qualified non-employee, independent directors.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors and officers and persons who beneficially own more than ten percent of our Common
Stock to file with the SEC reports of beneficial ownership on Forms 3 and changes in beneficial ownership of our Common Stock and other equity securities on Form 4s or Forms 5. SEC regulations require all officers, directors and greater than
10% stockholders to furnish us with copies of all Section 16(a) forms they file.
Based solely upon a review of Forms 3 and 4 and
amendments thereto furnished to us during, and Forms 5 and amendments thereto furnished to us with respect to, the Fiscal Year Ended September 30, 2013, and any written representations from reporting persons that no Form 5 is required,
there were no untimely reports required by Section 16(a) of the Exchange Act during the Fiscal Year Ended September 30, 2013.
Code of Ethics
On April 22, 2008, we adopted a Corporate Code of Business Conduct and Ethics for Directors, executive officers and Employees
(the
Code of Ethics
). The Code of Ethics applies to the Board, the Chief Executive Officer, the President, the Chief Operations Officer (should one be appointed), the Chief Financial Officer, each financial or accounting officer
at the level of the principal accounting officer or controller and all other Section 16 reporting executive officers and all of our employees. A copy of the Code of Ethics is attached as an exhibit to the Form 10-K for the Fiscal Year Ended
September 30, 2008.
B-50
Item 11.
|
EXECUTIVE COMPENSATION
|
THE FISCAL YEARS ENDED SEPTEMBER 30, 2013 AND 2012 SUMMARY EXECUTIVE
COMPENSATION TABLE
The following table sets forth information concerning total compensation paid or earned during the Fiscal Years
Ended September 30, 2013, and 2012 for the persons who served during the Fiscal Years Ended September 30, 2013 and 2012.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Total
|
|
Name and Principal Position
|
|
Year
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
David Hirschhorn
|
|
September 30, 2012
|
|
$
|
635,000
|
|
|
$
|
|
|
|
$
|
635,000
|
|
Chief Executive Officer
(formerly Co-Chief Executive Officer and
Co-Chief Financial Officer)
|
|
September 30, 2013
|
|
$
|
661,500
|
|
|
$
|
|
(1)
|
|
$
|
661,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sean Kirrane
|
|
September 30, 2012
|
|
$
|
165,000
|
|
|
$
|
|
|
|
$
|
165,000
|
|
Chief Executive Officer and Chief Financial Officer(2)
|
|
September 30, 2013
|
|
$
|
202,500
|
|
|
$
|
480,000
|
|
|
$
|
682,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Mr. Hirschhorns employment agreement terminated in July 2013. The agreement was extended for three months, with a based compensation of $30,000 monthly, or $360,000 annually. Mr. Hirschorn resigned as
Chairman and CEO of the Company November 18, 2013. See Subsequent Events Note 17 for details regarding his resignation and the payout of his accrued compensation.
|
(2)
|
During 2012 and 2013, Mr. Kirrane served as VP Finance, and Principal Accounting Officer. In June, 2013, Mr. Kirrane was appointed Chief Financial Officer. In November 2013, Mr. Kirrane was appointed
Chief Executive Officer. Mr. Kirannes bonuses were accrued for, but were not paid, as of September 30, 2013.
|
EMPLOYMENT
AGREEMENTS
Mr. Hirschorn
Mr. Hirschhorn was party to an employment agreement with us dated effective as of July 1, 2008 and approved by our Compensation
Committee. The employment agreement expires on July 1, 2013. Under the employment agreement, Mr. Hirschhorn receives annual base salaries for the years Ended July 1, 2009, 2010, 2011, 2012 and 2013 of $480,000, $540,000, $600,000,
$630,000 and $661,500, respectively, and is eligible for an annual incentive bonus as determined by the Compensation Committee in an amount not to exceed three times his base salary for that fiscal year or 10% of our EBITDA for the immediately
preceding fiscal year. Mr. Hirschhorn entered into an Option Grant Agreement pursuant to the 2001 Plan, effective July 1, 2008, pursuant to which Mr. Hirschhorn was granted the option to acquire 6,250,000 shares of our Common Stock at
an exercise price of $0.625. The shares underlying this option vest according to the following schedule: 1,250,000 vested on July 1, 2009, 1,250,000 on July 1, 2010, 1,250,000 on July 1, 2011, 1,250,000 on July 1, 2012, and the
remaining 1,250,000 on July 1, 2013. Pursuant to the plan, Mr. Hirschhorns stock options expired three months after his departure from the Company on November 18, 2013.
The employment agreement with Mr. Hirschhorn also stated that Mr. Hirschhorn shall receive a term life insurance policy with a death
benefit of $1.0 million for the first year of the agreement, $1.5 million for the second and third years of the agreement and $2.0 million for each of the fourth and fifth years of the agreement. The premiums for this policy were to
be paid by us as long as Mr. Hirschhorn remains employed by us pursuant to the Agreement.
Mr. Hirschorn resigned as Chairman
and CEO of the Company November 18, 2013. See Subsequent Events Note 17 for details regarding his resignation and the payout of his accrued compensation package.
B-51
Mr. Kirrane
Prior to his appointment as Chief Executive Officer, Mr. Kirrane entered into a Consulting Agreement, dated as of June 30, 2013, with
the Company. Pursuant to the Consulting Agreement, Mr. Kirrane served as the Registrants Chief Financial Officer for a period of twelve months from the effective date thereof, or the expiration of such twelve-month term in accordance with
the terms of the Consulting Agreement. In return for past services rendered to the Registrant prior to June 30, 2013, and upon the occurrence of certain events specified in the Consulting Agreement, Mr. Kirrane may also receive two earned
bonus payments in the amount of $177,500 per payment. Mr. Kirranes base salary under the Consulting Agreement is $20,000 per month. Upon meeting certain performance milestones, Mr. Kirrane may also receive bonuses totaling up to
$475,000. In event that Mr. Kirrane is terminated without cause, the agreement requires the Company pay to Mr. Kirrane the amount of any bonuses which have been earned and not paid, in addition to 12 months base salary.
THE FISCAL YEAR ENDED SEPTEMBER 30, 2013 OUTSTANDING EQUITY AWARDS
The following table summarizes information with respect to our outstanding equity awards held by executive officers at September 30, 2013.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
|
|
|
|
Options
|
|
|
Options
|
|
|
Exercise
|
|
|
Option
|
|
|
|
(#)
|
|
|
(3)
|
|
|
Price
|
|
|
Expiration
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
($)
|
|
|
Date
|
|
David Hirschhorn
|
|
|
6,250,000
|
|
|
|
0
|
|
|
$
|
0.63
|
|
|
|
7/1/2015
|
|
Chief Executive Officer
(formerly Co-Chief Executive Officer and Co-Chief Financial Officer)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sean Kirrane,
|
|
|
120,000
|
|
|
|
30,000
|
|
|
$
|
0.63
|
|
|
|
6/14/2017
|
|
VP of Finance & Chief Accounting Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
On July 1, 2008, our Compensation Committee approved the issuance of options to purchase 6,250,000 shares of our Common Stock pursuant to the 2001 Plan to David Hirschhorn. These options are exercisable for a
period of seven years at an exercise price of $0.625 per share. See Note 17. Subsequent Events in the accompanying notes to the financial statements in this Form 10-K, regarding Mr. Hirschorns departure from the Company on
November 18, 2013. Pursuant to the plan, Mr. Hirschhorns stock options expired three months after his departure from the Company on November 18, 2013.
|
(2)
|
On June 14, 2010, our Compensation Committee approved the issuance of options to purchase 150,000 shares of our Common Stock pursuant to the 2001 Plan to Sean Kirrane. These options are exercisable for a period of
seven years at an exercise price of $0.625 per share.
|
THE FISCAL YEAR ENDED SEPTEMBER 30, 2013 POTENTIAL PAYMENTS UPON
TERMINATION OR A CHANGE IN CONTROL
The following tables show the estimated amount of potential payments, as well as estimated value of
continuing benefits, assuming the executive officers employment terminated effective September 30, 2013, and based on compensation and benefit levels in effect on September 30, 2013. Due to the numerous factors involved in estimating
these amounts, the actual benefits and amounts payable can only be determined at the time of an executive officers termination.
B-52
DAVID HIRSCHHORN, CHIEF EXECUTIVE OFFICER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination
|
|
|
|
|
|
|
Voluntary
|
|
|
Involuntary Not
|
|
|
|
|
|
Without Cause
|
|
|
|
|
|
|
Termination
|
|
|
For
|
|
|
|
|
|
or Termination
|
|
|
|
|
Benefits/Payments
|
|
(including
|
|
|
Cause
|
|
|
For Cause
|
|
|
for Good
|
|
|
Death or
|
|
Upon Termination
|
|
Retirement)
|
|
|
Termination
|
|
|
Termination
|
|
|
Reason
|
|
|
Disability
|
|
Salary(1)
|
|
$
|
120,000
|
|
|
$
|
120,000
|
|
|
$
|
120,000
|
|
|
$
|
1,620,000
|
|
|
$
|
120,000
|
|
Accelerated Vesting of Deferred Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
(3)
|
(1)
|
In the event of Mr. Hirschhorns voluntary termination, we were required to pay Mr. Hirschhorn any amount of base salary earned by, but not yet paid to, Mr. Hirschhorn through the effective date of
termination.
|
(2)
|
In the event of Mr. Hirschhorns voluntary termination, we would have been required to pay to Mr. Hirschhorn (i) all benefits that have been earned by or vested in, and are payable to,
Mr. Hirschhorn under and subject to the terms (including all eligibility requirements) of, the compensation and benefit plans in which Mr. Hirschhorn participated through the effective date of termination; (ii) all reimbursable
expenses due, but not yet paid, to Mr. Hirschhorn as of the effective date of termination and (iii) an amount equal to all accrued and unused paid vacation or time off, calculated in accordance with our paid vacation or time off policies,
practices and procedures (including authorized deductions and the deductions required by law), as of the effective date of termination.
|
(3)
|
Mr. Hirschhorns employment agreement provided that he was entitled to receive a term life insurance policy with a death benefit of $1,000,000 for the first year of the agreement; $1,500,000 for the second and
third years of the agreement and $2,000,000 for each of the fourth and fifth years of the agreement.
|
Mr. Hirschorn
resigned as Chairman and CEO of the Company November 18, 2013. See Item 8, Footnote 15 Subsequent Events for details regarding his resignation and the payout of his accrued compensation package.
SEAN KIRRANE, VP of FINANCE AND PRINCIPAL ACCOUNTING OFFICER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination
|
|
|
|
Voluntary
|
|
|
Involuntary Not
|
|
|
|
|
|
Without Cause
|
|
|
|
Termination
|
|
|
For
|
|
|
|
|
|
or Termination
|
|
Benefits/Payments
|
|
(including
|
|
|
Cause
|
|
|
For Cause
|
|
|
for Good
|
|
Upon Termination
|
|
Retirement)
|
|
|
Termination
|
|
|
Termination
|
|
|
Reason
|
|
Salary(1)
|
|
$
|
37,500
|
|
|
$
|
37,500
|
|
|
$
|
37,500
|
|
|
$
|
37,500
|
|
Salary(2)
|
|
$
|
82,500
|
|
|
$
|
82,500
|
|
|
$
|
82,500
|
|
|
$
|
82,500
|
|
Salary(3)
|
|
$
|
165,000
|
|
|
$
|
165,000
|
|
|
$
|
165,000
|
|
|
$
|
165,000
|
|
(1)
|
In the event Mr. Kirranes employment is terminated in the first six months of employment, he shall receive the continued payment of his base salary for three months.
|
(2)
|
In the event Mr. Kirranes employment is terminated between six and twenty four months of employment, he shall receive the continued payment of his base salary for six months.
|
(3)
|
In the event Mr. Kirranes employment is terminated after two years of employment, he shall receive the continued payment of his base salary for twelve months.
|
THE FISCAL YEAR ENDED SEPTEMBER 30, 2013 DIRECTOR COMPENSATION
We did not compensate non-employee members of our Board of Directors during the Fiscal Year Ended September 30, 2013.
B-53
Item 12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
|
Common Stock, Series 1-A Convertible Preferred Stock, Series 2-A Convertible Preferred Stock, Series 5-A Convertible Preferred Stock and
Series 6-A Convertible Preferred Stock
The following table sets forth certain information, as of March 28, 2014, regarding
the beneficial ownership of our Common Stock, including Common Stock issuable upon conversion of all preferred convertible securities, options, warrants and other convertible securities, by (i) all persons or entities who beneficially own 5% or
more of our Common Stock, (ii) each of our current directors, (iii) the executive officers listed in the Summary Compensation Table herein and (iv) all of our current executive officers and directors as a group, in each case, to the
best of our knowledge. As of March 28, 2014, there were (i) 23,909,507 shares of Common Stock outstanding, (ii) 75,353,951 shares of Common Stock on a fully as-converted basis and (iii) on a fully as-converted basis, 51,294,700
shares of Preferred Stock, options, warrants and other securities convertible into Common Stock currently exercisable within 60 days of March 28, 2014, with each share of Common Stock being entitled to one vote. Unless otherwise noted
below, the address of the persons and entities listed in the table is c/o First Physicians Capital Group, Inc., 433 North Camden Drive, #810, Beverly Hills, California 90210
|
|
|
|
|
|
|
|
|
|
|
Title of Class
|
|
Name of Beneficial Owner(1)
|
|
Amount and Nature of
Beneficial Ownership
|
|
|
Percent of
Class
|
|
|
|
5% Holders or Potential 5% Holders of Common Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Common(2)
|
|
SMP Investments I, LLC
|
|
|
16,797,618
|
|
|
|
51
|
%
|
|
|
c/o HSP Group, LLC
|
|
|
|
|
|
|
|
|
|
|
875 Prospect Street, Suite 220
|
|
|
|
|
|
|
|
|
|
|
La Jolla, CA 92037(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
Ciabattoni Living Trust 8/17/2000
|
|
|
11,822,917
|
|
|
|
36
|
%
|
|
|
16 Lagunita Drive
|
|
|
|
|
|
|
|
|
|
|
Laguna Beach, CA 92561(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
The Kupfer Family Trust UTD May 3, 2009
|
|
|
2,384,250
|
|
|
|
16
|
%
|
|
|
P.O. Box 9330
|
|
|
7
|
%
|
|
|
|
|
|
|
Rancho Santa Fe, CA 92067
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Directors and former directors
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
Robert N. Schwartz, Ph.D(7)
|
|
|
185,857
|
|
|
|
0.6
|
%
|
|
|
|
|
Common
|
|
David Hirschhorn(3)
|
|
|
5,482,800
|
|
|
|
17
|
%
|
|
|
|
|
Common
|
|
Richardson E. Sells(8)
|
|
|
380,000
|
|
|
|
1.2
|
%
|
|
|
|
|
Common
|
|
William Houlihan(11)
|
|
|
1,100,000
|
|
|
|
3.3
|
%
|
|
|
|
|
|
|
Current Officers
|
|
|
|
|
|
|
|
|
|
|
Sean Kirrane
|
|
|
93,750
|
|
|
|
|
|
|
|
|
|
Common
|
|
Current directors and officers as a group
(7 persons)(10)
|
|
|
7,212,171
|
|
|
|
22
|
%
|
|
|
|
|
|
|
5% Holders of Series 1-A Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 1-A Preferred
|
|
Ron Soderling
|
|
|
40,000
|
|
|
|
59
|
%
|
|
|
901 Dove Street, Suite 270
|
|
|
|
|
|
|
|
|
|
|
Newport Beach, CA 92660
|
|
|
|
|
|
|
|
|
B-54
|
|
|
|
|
|
|
|
|
|
|
Title of Class
|
|
Name of Beneficial Owner(1)
|
|
Amount and Nature of
Beneficial Ownership
|
|
|
Percent of
Class
|
|
Series 1-A Preferred
|
|
First Clearing Corporation
|
|
|
20,000
|
|
|
|
30
|
%
|
|
|
PO Box 6570
|
|
|
|
|
|
|
|
|
|
|
Glen Allen, VA 23058
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 1-A Preferred
|
|
Steven Tingey Jt Ten
|
|
|
7,600
|
|
|
|
11
|
%
|
|
|
C/O Jeffries & Co Inc.
|
|
|
|
|
|
|
|
|
|
|
650 California Street
|
|
|
|
|
|
|
|
|
|
|
San Francisco, CA 94108
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5% Holders of Series 2-A Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 2-A Preferred
|
|
Gretchen K. Musey
|
|
|
3,900
|
|
|
|
100
|
%
|
|
|
2312 Naples
|
|
|
|
|
|
|
|
|
|
|
Newport Beach, CA 92660
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5% Holders of Series 5-A Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Ciabattoni Living Trust 8/17/2000
|
|
|
600
|
|
|
|
6.7
|
%
|
|
|
16 Lagunita Drive
|
|
|
|
|
|
|
|
|
|
|
Laguna Beach, CA 92561
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Richard Sambora Living Trust 4/13/00
|
|
|
500
|
|
|
|
5.6
|
%
|
|
|
c/o Gelfand Rennert & Feldman LLP
|
|
|
|
|
|
|
|
|
|
|
360 Hamilton Avenue, Suite 100
|
|
|
|
|
|
|
|
|
|
|
White Plains, New York 10601
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
SMP Investments I, LLC
|
|
|
1,250
|
|
|
|
14
|
%
|
|
|
c/o HSP Group, LLC
|
|
|
|
|
|
|
|
|
|
|
875 Prospect Street, Suite 220
|
|
|
|
|
|
|
|
|
|
|
La Jolla, CA 92037
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
South Bay Capital LLC
|
|
|
500
|
|
|
|
5.6
|
%
|
|
|
c/o Keith Lehman, Managing Member
|
|
|
|
|
|
|
|
|
|
|
960 Third Street, Apt. 204
|
|
|
|
|
|
|
|
|
|
|
Santa Monica, CA 90403
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Directors
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
David Hirschhorn
|
|
|
131
|
|
|
|
1.5
|
%
|
|
|
|
|
Series 5-A Preferred
|
|
Todd Parker
|
|
|
135
|
|
|
|
1.5
|
%
|
|
|
|
|
Series 5-A Preferred
|
|
William Houlihan
|
|
|
250
|
|
|
|
2.8
|
%
|
|
|
|
|
Series 5-A Preferred
|
|
Richardson E. Sells
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Robert N. Schwartz, Ph.D
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Former Officers
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
David Hirschhorn
|
|
|
131
|
|
|
|
1.4
|
%
|
|
|
|
|
Series 5-A Preferred
|
|
Current directors and officers as a group
(7 persons)(10)
|
|
|
516
|
|
|
|
5.8
|
%
|
|
|
|
|
|
|
5% Holders of Series 6-A Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Ciabattoni Living Trust 8/17/2000
|
|
|
600
|
|
|
|
12
|
%
|
|
|
16 Lagunita Drive
|
|
|
|
|
|
|
|
|
|
|
Laguna Beach, CA 92561
|
|
|
|
|
|
|
|
|
B-55
|
|
|
|
|
|
|
|
|
|
|
Title of Class
|
|
Name of Beneficial Owner(1)
|
|
Amount and Nature of
Beneficial Ownership
|
|
|
Percent of
Class
|
|
Series 6-A Preferred
|
|
Darras Revocable Trust dated 9/2/94
|
|
|
250
|
|
|
|
5.1
|
%
|
|
|
600 South Indian Hill Boulevard
|
|
|
|
|
|
|
|
|
|
|
Claremont, CA 91711
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
SMP Investments I, LLC
|
|
|
1,000
|
|
|
|
21
|
%
|
|
|
c/o HSP Group, LLC
|
|
|
|
|
|
|
|
|
|
|
875 Prospect Street, Suite 220
|
|
|
|
|
|
|
|
|
|
|
La Jolla, CA 92037
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Hector S. Torres
|
|
|
300
|
|
|
|
6.2
|
%
|
|
|
c/o Joseph Apuzzo, CPA
|
|
|
|
|
|
|
|
|
|
|
150 Airport Road, Suite 1000
|
|
|
|
|
|
|
|
|
|
|
Lakewood, NJ 08701
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
James Chao
|
|
|
350
|
|
|
|
7.2
|
%
|
|
|
5471 Kearny Villa Road, # 200
|
|
|
|
|
|
|
|
|
|
|
San Diego, CA 92123
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Directors
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
David Hirschhorn
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Todd Parker
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
William Houlihan
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Richardson E. Sells
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Robert N. Schwartz, Ph.D
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Former Officers
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
David Hirschhorn
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Current directors and officers as a group
(7 persons)(10)
|
|
|
|
|
|
|
|
|
(1)
|
Except as otherwise indicated, we believe that the beneficial owners of the securities listed have sole investment and voting power with respect to their shares.
|
(2)
|
The number of shares of Common Stock shown as beneficially owned by any person or entity includes all Preferred Stock, options, warrants and other convertible securities currently exercisable by that person or entity
within 60 days of March 28, 2014. The percentages of beneficial ownership of Common Stock shown assume the exercise or conversion of all preferred stock, options, warrants and other securities convertible into Common Stock held by such
person or entity currently exercisable within 60 days of March 28, 2014, but not the exercise or conversion of preferred stock, options, warrants and other convertible securities held by other holders of such securities.
|
(3)
|
Consists of (a) 1,250,000 restricted shares of Common Stock granted in connection with Mr. Hirschhorns Employment Agreement, dated as of July 18, 2005; (b) 419,200 shares beneficially owned by
Mr. Hirschhorn in his capacity as President of Hope & Abel Investments, LLC, which directly holds 125 shares of 5-A Preferred and 6 shares of 5-A Preferred owned by him individually, which are convertible into 400,000 shares of Common
Stock; (c) 60,000 shares of Common Stock issued to Mr. Hirschhorn in his capacity as President of Hope & Abel Investments, LLC, pursuant to the exercise of a warrant dated July 18, 2005; (d) 2,500,000 vested options
convertible into shares of Common Stock and (e) 3,600 warrants dated January 7, 2011. Mr. Hirschhorn resigned from the Company effective November 18, 2013.
|
(4)
|
Consists of (a) 1,250 shares of 5-A Preferred, which are convertible into 4,000,000 shares of Common Stock; (b) 1,000 shares of 6-A
Preferred which are convertible into 3,200,000 shares of Common Stock;
|
B-56
|
(c) 1,014,285 shares of Common Stock at $0.45 per share; (d) a warrant to purchase 1,200,000 shares of Common Stock at a price of $0.3125 per share; (e) warrants to purchase an
aggregate of 1,250,000 shares of Common Stock at a price of $0.50 per share; (f) warrants to purchase an aggregate of 333,333 shares of Common Stock at a price of $0.75 per share and (g) $500,000 of debt convertible at $0.625 per share
into 800,000 shares of Common Stock.
|
(5)
|
Consists of (a) 600 shares of 5-A Preferred, which are convertible into 1,920,000 shares of Common Stock; (b) 600 shares of 6-A Preferred, which are convertible into 1,920,000 shares of Common Stock;
(c) a warrant to purchase 600,000 shares of Common Stock at a price of $0.3125 per share; (d) warrants to purchase an aggregate of 1,556,250 shares of Common Stock at a price of $0.50 per share; (e) warrants to purchase an aggregate
of 666,667 shares of Common Stock at a price of $0.75 per share and (f) $1,000,000 of debt convertible at $0.625 per share into 1,600,000 shares of Common Stock.
|
(6)
|
Consists of (a) 361,389 shares of Common Stock, of which (i) 350,000 restricted shares were granted in connection with Mr. Parkers employment agreement, dated as of July 18, 2005, of which
48,611 have been cancelled pursuant to termination of Mr. Parkers employment agreement, and (ii) 60,000 were issued pursuant to the exercise of a warrant dated July 18, 2005, and (b) 135 shares of 5-A Preferred, which are
convertible into 432,000 shares of Common Stock.
|
(7)
|
Consists of (a) 982 shares directly owned by Dr. Schwartz; (b) 1,125 shares owned in a trust on behalf of Dr. Schwartz and (c) 183,750 shares of Common Stock issuable upon exercise of
Dr. Schwartzs stock options.
|
(8)
|
Consists of (a) 180,000 shares of Common Stock issuable upon exercise of Mr. Sells stock options; (b) 200,000 shares of Common Stock and which are currently vested; (c) warrants to purchase
60,000 shares of Common Stock at a price of $0.50 per share.
|
(9)
|
Consists of (a) 125 shares of 5-A Preferred which are convertible into 400,000 shares of Common Stock; (b) 60,000 shares of Common Stock issued pursuant to the exercise of a warrant dated July 18, 2005
and (c) 15,000 shares of Common Stock granted pursuant to the exercise of a warrant dated September 18, 2006.
|
(10)
|
Includes shares held directly, as well as shares held jointly with family members, held in retirement accounts, held in a fiduciary capacity, held by certain of the group members families, or held by trusts of
which the group member is a trustee or substantial beneficiary, with respect to which shares the group member may be deemed to have sole or shared voting or investment powers.
|
(11)
|
Consists of (a) 250 shares of 5-A Preferred, which are convertible into 800,000 shares of Common Stock and (b) 300,000 shares of Common Stock.
|
Item 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
|
Since we are
not listed on a national securities exchange, we have decided to use the independence standards of the NYSE Amex (formerly known as the American Stock Exchange or AMEX). We believe that the Board of Directors would determine that Richardson E.
Sells, Robert N. Schwartz and William Houlihan would be independent directors under the rules of the NYSE Amex if we were listed on the NYSE Amex and asked to make such a determination.
Related Party Transactions
During the Fiscal
Year Ended September 30, 2012, $750,000 of the original 2009 Bridge Financing was repaid. Of the $750,000 paid, $75,000 and $175,000 was paid to SMP, and Anthony J. Ciabattoni respectively, both of which are considered related party
transactions.
The 2011 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year
Ended September 31, 2013, in installments of $420,000 and $1,614,000, respectively. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold 10% or greater voting interests, are considered related
parties, and received $759,000, $380,000, and $420,000 respectively of the total payments.
B-57
The 2011 Bridge Financing had attached warrants to purchase an aggregate of 2,278,079 shares of
our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. These warrants were issued January 1, 2014. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10% or
greater voting interest and are considered related parties to this transaction and received 850,080, 425,600, and 470,400 of the total warrants.
During the Fiscal Year Ended September 30, 2012, we entered into 2012 Bridge Financing in the aggregate principal amount of $1,279,000
(see Note 6 in the Notes to the financial statements in this Form 10-K). The three lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold 10% or greater voting interests and are considered related parties, and held $620,000,
$434,000, and $225,000 of the notes respectively.
The 2012 Bridge Notes were paid in full, less accumulated interest, in the second and
third quarters of the Fiscal Year Ended September 31, 2013, in installments of $225,000 and $1,054,000, respectively. The three 2012 bridge lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold 10% or greater voting interests
and are considered related parties.
The 2012 Bridge Financing had attached warrants to purchase an aggregate of 4,092,800 shares of our
Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. These warrants were issued January 1, 2014. The 2012 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan each hold a 10% or greater
voting interest and are considered related parties to this transaction and received 1,984,000, 1,388,800, and 720,000 warrants respectively.
As part of the 2009 Bridge Notes extensions, in January 2014 the Company issued penny warrants to SMP for the purchase of up to
8,500,000 shares of Common Stock at an initial exercise price of $0.01 per share and exercisable for a period of five years from the date of issuance. SMP was one of the original 2009 Bridge Financing lenders. SMP, holds a 10% or greater voting
interest and is considered a related party. In March 2014, SMP exercised its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of $85,000.
Advisory Board
On August 22, 2005,
we announced the creation of an Advisory Board with seven initial members. We issued warrants to purchase up to 900,000 shares of Common Stock to Advisory Board members as compensation for their service. On November 9, 2005, we delivered
727,500 of such warrants to our seven initial Advisory Board members, with an effective issuance date of August 2, 2005. All such warrants were issued with Black-Scholes assumptions of 99% volatility, $0.35 share price, risk-free interest rates
of 4.1% and an exercise price of $0.35. The warrants become one-third vested upon issuance and vest an additional third after each calendar year. The shares underlying these warrants became fully vested in August 2007. In December 2006,
our Board of Directors approved the issuance of a warrant to purchase 50,000 shares of our Common Stock at an exercise price of $0.45 per share to Steven Spector, upon his addition as a member to the Advisory Board. The shares underlying the warrant
issued to Mr. Spector became fully vested on December 12, 2008 and are currently in the process of being exercised. On September 11, 2007, our Board of Directors approved the issuance of warrants to purchase an aggregate of 350,000
shares of our Common Stock at an exercise price of $0.45 per share to six new members of our Advisory Board. The shares underlying these warrants become fully vested on September 13, 2009. 125,000 of these warrants expired and 225,000 are in
the process of being exercised. On February 15, 2008, our Board of Directors approved the issuance of a warrant to purchase a total of 714,285 shares of our Common Stock at an exercise price of $0.45 per share to Brian Potiker, in consideration
for his continued service as a member of our Advisory Board. The shares underlying the warrant issued to Mr. Potiker became fully vested on October 30, 2008 and expired on October 30, 2009.
In March 2009, in consideration for their strategic advice and assistance, Messrs. Jay Beaghan, Rod Rivera, I. Bobby Majumder and
Dr. Harley Liker, as members of our Advisory Board, were issued Advisory Board warrants to purchase an aggregate of 125,000 shares of Common Stock at an exercise price of $0.625 per share. These warrants will expire on March 16, 2012 and
were issued in the following individual amounts: (i) 25,000
B-58
warrants to Mr. Beaghan; (ii) 25,000 warrants to Mr. Rivera; (iii) 25,000 warrants to Mr. Majumder and (iv) 50,000 warrants to Dr. Liker. One-third of the
warrants vested immediately, one-third vest on March 16, 2010 and one-third vest on March 16, 2011. These warrants expired on March 16, 2012.
In June 2009, we issued warrants to purchase 150,000 shares of Common Stock to a member of the newly created Medical Advisory Board.
These warrants were issued an exercise price of $0.625. One-third of the warrants vested immediately upon issuance on June 10, 2009 and the remaining two-thirds vest on June 10, 2010. These warrants expired on June 10, 2012.
Sub-Lease from HSP, Inc.
We are
subleasing office space located at 433 N. Camden, Suite 810, Beverly Hills, California 90210 from HSP, Inc. which is a related entity to SMP, an affiliate of ours. The sub-lease is for a term of 5 years at a monthly rental of $4,800 per
month, subject to adjustment downward based on other subtenants occupying space at the same location
Item 14.
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES
|
We have engaged Whitley Penn LLP to audit our
financial statements for the Fiscal Years Ended September 30, 2013 and September 30, 2012. The decision to engage Whitley Penn LLP as our independent auditors for Fiscal Year Ended September 30, 2013 has been approved by the Board of
Directors, the Audit Committee and our stockholders.
Fees
Aggregate fees for professional services rendered to us by Whitley Penn LLP as of or for the Fiscal Year Ended September 30, 2013 and
2012, respectively, were:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
|
|
|
Year
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
|
2011
|
|
Audit Fees
|
|
$
|
110,126
|
|
|
$
|
141,070
|
|
|
$
|
188,464
|
|
Audit-Related Fees
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Tax Fees
|
|
$
|
30,000
|
|
|
$
|
32,450
|
|
|
$
|
27,315
|
|
All Other Fees
|
|
$
|
|
|
|
$
|
|
|
|
$
|
9,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
140,126
|
|
|
$
|
173,520
|
|
|
$
|
224,979
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Audit
fees for the Fiscal Year Ended September 30, 2013 and 2012 were for professional services
rendered for the audits of our consolidated financial statements and the reviews of certain subsidiary companies and the quarterly reviews of the financial statements included in our Forms 10-Q.
Audit Related
fees for the Fiscal Year Ended September 30, 2013, and 2012 would have been for accounting consultations, capital
issuances and review of responses to various SEC comment letters.
Tax fees
for the Fiscal Year Ended September 30, 2013, and
2012 were for services related to tax compliance and advisory services including assistance with review of tax returns, advice on goods and services taxes and duties in various jurisdictions and ad hoc corporate tax planning and advice.
We had no other fees for professional services rendered by our independent auditors during the Fiscal Years Ended September 30, 2013 and
2012 respectively.
Audit Committee Pre-Approval Policies and Procedures
Our Audit Committee pre-approves audit and non-audit services provided by our independent auditors at its quarterly meetings.
B-59
PART IV
Item 15.
|
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
|
The following documents are filed as part of
this Form 10-K:
(1)
|
Consolidated Financial Statements
|
(2)
|
Financial Statement Schedules
|
All schedules have been omitted because they are not required or
the required information is shown in the financial statements or notes thereto.
(3)
|
See exhibit index for documents that are filed as exhibits to this Form 10-K (exhibits marked with an asterisk (*) have been previously filed with the SEC as indicated and are incorporated herein by reference).
|
B-60
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
First Physicians Capital Group, Inc.
|
|
|
|
|
Date: April 4, 2014
|
|
|
|
By:
|
|
/s/ Sean Kirrane
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
/s/ Sean Kirrane
|
|
Chief Executive Officer
|
|
April 4, 2014
|
|
|
|
/s/ Sean Kirrane
|
|
Principal Accounting Officer
|
|
April 4, 2014
|
Sean Kirrane
|
|
|
|
|
|
|
|
/s/ Robert N. Schwartz
|
|
Director
|
|
April 4, 2014
|
Robert N. Schwartz
|
|
|
|
|
|
|
|
/s/ Richardson E. Sells
|
|
Director
|
|
April 4, 2014
|
Richardson E. Sells
|
|
|
|
|
|
|
|
/s/ William Houlihan
|
|
Chairman of the Board, Director
|
|
April 4, 2014
|
William Houlihan
|
|
|
|
|
B-61
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
3.1 *
|
|
Certificate of Incorporation (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on November 14, 2000)
|
|
|
3.2 *
|
|
Amended and Restated Bylaws dated October 25, 2002 (filed as Exhibit 3.2 to the Form 8-K, as filed with the SEC on October 28, 2002)
|
|
|
3.3 *
|
|
Certificate of Designation of Rights and Preferences of Series 2-A Convertible Preferred Stock filed November 8, 2000 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on November 14, 2000)
|
|
|
3.4 *
|
|
Certificate of Merger filed November 8, 2000, merging Vsource, Inc. (a Nevada corporation) with and into the Vsource, Inc. (a Delaware corporation) (filed as Exhibit 4.2 to the Form 8-K, as filed with the SEC on
November 14, 2000)
|
|
|
3.5 *
|
|
Agreement and Plan of Merger dated as of December 14, 2000, among the Registrant, OTT Acquisition Corp., Online Transaction Technologies, Inc. and its Shareholders (filed as Exhibit 10.11 to the Form 10-Q, as
filed with the SEC on December 15, 2000)
|
|
|
3.6 *
|
|
Amendment to Certificate of Incorporation, dated January 16, 2002 (filed as Exhibit 3.3 to the Form 8-K, as filed with the SEC on January 23, 2002)
|
|
|
3.7 *
|
|
Amendment to Certificate of Incorporation, dated November 20, 2002 (filed as Exhibit 3.1 to the Form 10-Q for the period Ended October 31, 2002, as filed with the SEC on December 5, 2002)
|
|
|
3.8 *
|
|
Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on July 21, 2005)
|
|
|
3.9 *
|
|
Amendment to Certificate of Incorporation, dated December 16, 2005 (filed as Exhibit 3.5 to the Form 10-Q for the period Ended October 31, 2005, as filed with the SEC on December 20, 2005)
|
|
|
3.10 *
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences Series 5-A Convertible Preferred Stock filed January 10, 2008 (filed as Exhibit B to the Form of Series 5-A Preferred Stock and
Warrant Purchase Agreement, filed as Exhibit 10.52 herein)
|
|
|
3.11 *
|
|
Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred Stock filed April 2, 2008 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
3.12 *
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 5-A
Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit 4.2 to the
Form 10-Q, as filed with the SEC on May 20, 2008)
|
|
|
3.13 *
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 6-A
Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit B to the Form
of Series 6-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.54 herein)
|
|
|
3.14 *
|
|
Amendment to Certificate of Incorporation, dated September 29, 2009 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on October 1, 2009)
|
|
|
3.15 *
|
|
Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on December 12, 2013)
|
|
|
4.1 *
|
|
Certificate of Decrease of Shares Designated as Series 1-A Convertible Preferred Stock (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
4.2 *
|
|
Certificate of Decrease of Shares Designated as Series 2-A Convertible Preferred Stock (filed as Exhibit 4.2 to the Form 8-K, as filed with the SEC on July 13,
2005)
|
B-62
|
|
|
Exhibit No.
|
|
Description
|
10.1 *
|
|
Form of Limited Guaranty by Tri-Isthmus Group, Inc. (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on November 5, 2007)
|
|
|
10.2 *
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of July 7, 2005, by and among Vsource, Inc. and the investors listed therein (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on
July 21, 2005)
|
|
|
10.3 *
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of September, 18, 2006, by and among First Physicians Capital Group, Inc. and certain Series 5-A Preferred Stock Investors (filed as Exhibit 4.1 to
the Form 8-K, as filed with the SEC on September 22, 2006)
|
|
|
10.4 *
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated January 14, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on January 22, 2008)
|
|
|
10.5 *
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated March 31, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
10.6 *
|
|
Form of Waveland Warrant (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
10.7 *
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
10.8 *
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated May 29, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on June 4, 2008)
|
|
|
10.9 *
|
|
Employment Agreement of David Hirschhorn, dated as of July 1, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on July 7, 2008)
|
|
|
10.10 *
|
|
Form of Option Grant Agreement of David Hirschhorn, dated as of July 1, 2008 (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on July 7, 2008)
|
|
|
10.11 *
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated September 8, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on September 12, 2008)
|
|
|
10.12 *
|
|
Employment Agreement of Thomas Rice, dated effective as of November 10, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on November 14, 2008)
|
|
|
10.13 *
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Anadarko, LLC, Tri-Isthmus Group, Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services, Inc., RHA Stroud, LLC, RHA Tishomingo, LLC,
TSG Physicians Group, LLC, and Canadian State Bank (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.14 *
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Tishomingo, LLC,
Tri-Isthmus
Group, Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services,
Inc., RHA Stroud, LLC, RHA Anadarko, LLC, TSG Physicians Group, LLC, and Canadian State Bank (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.15 *
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Anadarko, LLC, in favor of Canadian State Bank (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.16 *
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Stroud, LLC, in favor of Valliance Bank (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on December 17,
2008)
|
B-63
|
|
|
Exhibit No.
|
|
Description
|
10.17 *
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Tishomingo, LLC, in favor of Canadian State Bank (filed as Exhibit 10.7 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.18 *
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Anadarko, LLC, in favor of Canadian State Bank (filed as Exhibit 10.8 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.19 *
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Stroud, LLC, in favor of Valliance Bank (filed as Exhibit 10.9 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.20 *
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Anadarko, LLC, in favor of Canadian State Bank (filed as Exhibit 10.10 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.21 *
|
|
Form of Guaranty of Tri-Isthmus Group, Inc., dated December 11, 2008, in favor of Carol Schuster (filed as Exhibit 10.12 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
10.22 *
|
|
Convertible Promissory Note Issued in Favor of SMP Investments I, LLC (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
10.23 *
|
|
Convertible Promissory Note Issued in Favor of Anthony J. Ciabattoni, Trustee of the Ciabattoni Living Trust dated August 17, 2000 (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
10.24 *
|
|
Form of Warrant No. 108 (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
10.25 *
|
|
Form of Warrant No. 109 (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
10.26 *
|
|
Form of Warrant No. 110 (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
10.27 *
|
|
Form of Warrant No. 111 (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
10.28 *
|
|
Form of Convertible Promissory Note (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on March 5, 2009)
|
|
|
10.29 *
|
|
Form of Warrant (exercisable at $0.50 per share) issued to each of Michael Ciabattoni, Scott Casey, Jean Heaton, Stephanie Heaton, Jennifer Heaton, Cobea Associates, LLC, William Wallace, Trustee of the Wallace Family Revocable
Trust dated April 23, 2001, Otto J. Claricurzio, and Phillip J. Ciabattoni (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on March 5, 2009)
|
|
|
10.30 *
|
|
Form of Warrant (exercisable at $0.75 per share) issued to each of Michael Ciabattoni, Scott Casey, Jean Heaton, Stephanie Heaton, Jennifer Heaton, Cobea Associates, LLC, William Wallace, Trustee of the Wallace Family Revocable
Trust dated April 23, 2001, Otto J. Claricurzio, and Phillip J. Ciabattoni (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on March 5, 2009)
|
|
|
10.31 *
|
|
Form of Convertible Promissory Note issued to each of Frank Darras, Trustee of the Darras Family Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit 10.1 to the Form 8-K, as
filed with the SEC on April 20, 2009)
|
B-64
|
|
|
Exhibit No.
|
|
Description
|
10.32 *
|
|
Form of Warrant (exercisable at $0.50 per share) Frank Darras, Trustee of the Darras Family Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit 10.2 to the Form 8-K, as filed with the
SEC on April 20, 2009)
|
|
|
10.33 *
|
|
Form of Warrant (exercisable at $0.75 per share) Frank Darras, Trustee of the Darras Family Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit 10.3 to the Form 8-K, as filed with the
SEC on April 20, 2009)
|
|
|
10.34 *
|
|
Form of Warrant (exercisable at $0.75 per share) Frank Darras, Trustee of the Darras Family Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit 10.3 to the Form 8-K, as filed with the
SEC on April 20, 2009)
|
|
|
10.35 *
|
|
Form of Series 6-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on June 12, 2009)
|
|
|
10.36 *
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on June 12, 2009)
|
|
|
10.37 *
|
|
Form of Medical Advisory Board Warrant (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on June 12, 2009)
|
|
|
10.38 *
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement, dated October 19, 2009 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
10.39 *
|
|
Form of Warrant issued in connection with 5-A (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
10.40 *
|
|
Form of Series 6-A Preferred Stock and Warrant Purchase Agreement, dated October 19, 2009 (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
10.41 *
|
|
Form of Warrant issued in connection with 6-A (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
10.42 *
|
|
Form Subscription Agreement, dated December 3, 2009 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on December 14, 2009)
|
|
|
10.43 *
|
|
Form of Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on December 14, 2009)
|
|
|
10.44 *
|
|
Form of Asset Purchase Agreement (filed as Exhibit 10.1 to Form 8-K as filed with the SEC on January 14, 2011)
|
|
|
10.45 *
|
|
Form of Agreement for Purchase and Sale of Real Property (filed as Exhibit 10.2 to Form 8-K as filed with the SEC on January 14, 2011)
|
|
|
10.46 *
|
|
Form of Transition Services Agreement (filed as Exhibit 10.3 to Form 8-K as filed with the SEC on January 14, 2011)
|
|
|
10.47 *
|
|
Form of Corporate Guaranty (filed as Exhibit 10.4 to Form 8-K as filed with the SEC on January 14, 2011)
|
|
|
10.48 *
|
|
Form of Stock Purchase Agreement (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
|
|
10.49 *
|
|
Form of Asset Purchase Agreement (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
|
|
10.50 *
|
|
Form of Promissory Note (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
B-65
|
|
|
Exhibit No.
|
|
Description
|
|
|
10.51 *
|
|
Form of Promissory Note (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
|
|
10.52 *
|
|
Form of Guaranty (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
|
|
10.53 *
|
|
Form of Guaranty (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
|
|
10.54 *
|
|
Form of Real Estate Purchase Agreement (filed as Exhibit 10.7 to the Form 8-K, as filed with the SEC on July 26, 2011)
|
|
|
10.55 *
|
|
Form of 2011 Promissory Note (filed as Exhibit 10.58 to the 2011 Form 10-K, as filed with the SEC on April 2, 2014)
|
|
|
10.56 *
|
|
Form of 2012 Promissory Note (filed as Exhibit 10.1 to the Form 10-Q for the Quarter ended March 31, 2012, as filed with the SEC on April 2,
2014)
|
|
|
10.57
|
|
Form of 2013 Promissory Note
|
|
|
10.58
|
|
Form of Warrant issued in connection with 2011 and 2012 Promissory Notes
|
|
|
10.59
|
|
Form of Waiver Agreement
|
|
|
10.60
|
|
Form of Subordination Agreement
|
|
|
14.1 *
|
|
Corporate Code of Business Conduct and Ethics for Directors, Executive Officers, and Employees, dated effective as of April 22, 2008 (filed as Exhibit 14.1 to the Form 10-K, as filed with the SEC on January 13,
2009)
|
|
|
21.1
|
|
Subsidiaries of First Physicians Capital Group, Inc. (f/k/a Tri-Isthmus Group, Inc.)
|
|
|
23.1
|
|
Consent of Whitley Penn LLP.
|
|
|
31.1
|
|
Certification Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
32.1
|
|
Certification Pursuant to 18 U.S.C. 1350
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
*
|
Previously filed with the SEC as indicated, and hereby incorporated herein by reference.
|
B-66
Annex C
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2014
OR
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from
to
Commission File Number: 000-30326
FIRST
PHYSICIANS CAPITAL GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
DELAWARE
|
|
77-0557617
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
433 North Camden Drive #810
|
|
|
Beverly Hills, California
|
|
90210
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(310) 860-2501
(Registrants Telephone Number, Including Area Code)
N/A
(Former Name, Former
Address and Former Fiscal Year, if Changed Since Last Report)
Indicate by
check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
¨
Yes
x
No
Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).
x
Yes
¨
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
¨
|
|
|
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).
¨
Yes
x
No
|
|
|
|
|
Number of shares of common stock outstanding as of May 9, 2014
|
|
|
23,909,507
|
|
C-1
TABLE OF CONTENTS
C-2
PART I
FINANCIAL INFORMATION
I
tem 1. FINANCIAL STATEMENTS
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and per share data)
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
September 30,
|
|
|
|
2014
|
|
|
2013
|
|
|
|
(Unaudited)
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
4,109
|
|
|
$
|
982
|
|
Accounts receivable, net of allowance for uncollectible accounts
|
|
|
15,286
|
|
|
|
13,690
|
|
Prepaid expenses
|
|
|
334
|
|
|
|
66
|
|
Other current assets
|
|
|
13
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
19,742
|
|
|
|
14,752
|
|
Property and equipment, net
|
|
|
|
|
|
|
2
|
|
Notes receivable
|
|
|
22,343
|
|
|
|
22,343
|
|
Other assets
|
|
|
239
|
|
|
|
249
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
42,324
|
|
|
$
|
37,346
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS EQUITY (DEFICIT)
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,036
|
|
|
$
|
1,116
|
|
Accrued expenses
|
|
|
2,021
|
|
|
|
3,132
|
|
Income taxes payable
|
|
|
427
|
|
|
|
212
|
|
Current maturities of long term debt
|
|
|
2,524
|
|
|
|
1,857
|
|
Liabilities of discontinued operations
|
|
|
557
|
|
|
|
557
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
6,565
|
|
|
|
6,874
|
|
Long term debt, net of current portion
|
|
|
5,491
|
|
|
|
5,692
|
|
Deferred gain
|
|
|
15,395
|
|
|
|
15,496
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
27,451
|
|
|
|
28,062
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Non-redeemable preferred stock:
|
|
|
|
|
|
|
|
|
Preferred stock Series 1-A ($0.01 par value, 2,802,000 shares authorized; 67,600 shares issued and outstanding as of March 31,
2014 and September 30, 2013)
|
|
|
166
|
|
|
|
166
|
|
Preferred stock Series 2-A ($0.01 par value, 1,672,328 shares authorized; 3,900 shares issued and outstanding as of March 31,
2014 and September 30, 2013)
|
|
|
25
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Total non-redeemable preferred stock
|
|
|
191
|
|
|
|
191
|
|
Redeemable preferred stock:
|
|
|
|
|
|
|
|
|
Preferred stock Series 5-A ($0.01 par value, 9,000 shares authorized; 9,000 shares issued and outstanding as of March 31, 2014
and September 30, 2013)
|
|
|
7,832
|
|
|
|
7,832
|
|
Preferred stock Series 6-A ($0.01 par value, 5,000 shares authorized; 4,875 shares issued and outstanding as of March 31, 2014
and September 30, 2013)
|
|
|
4,381
|
|
|
|
4,381
|
|
|
|
|
|
|
|
|
|
|
Total redeemable preferred stock
|
|
|
12,213
|
|
|
|
12,213
|
|
Stockholders equity (deficit):
|
|
|
|
|
|
|
|
|
Common stock ($0.01 par value, 100,000,000 shares authorized; 23,549,507 and 15,049,047 shares issued and outstanding as of
March 31, 2014 and September 30, 2013, respectively)
|
|
|
238
|
|
|
|
153
|
|
Additional paid-in-capital
|
|
|
81,588
|
|
|
|
81,578
|
|
Accumulated deficit
|
|
|
(79,253
|
)
|
|
|
(84,747
|
)
|
Treasury stock, at cost (149,744 shares as of March 31, 2014 and September 30, 2013)
|
|
|
(104
|
)
|
|
|
(104
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity (deficit)
|
|
|
2,469
|
|
|
|
(3,120
|
)
|
|
|
|
|
|
|
|
|
|
Total liabilities, preferred stock and stockholders equity (deficit)
|
|
$
|
42,324
|
|
|
$
|
37,346
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
C-3
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
Net revenue from services
|
|
$
|
6,934
|
|
|
$
|
6,062
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
3,028
|
|
|
|
3,166
|
|
Depreciation and amortization
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
3,028
|
|
|
|
3,168
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
3,906
|
|
|
|
2,894
|
|
Other expense:
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(154
|
)
|
|
|
(223
|
)
|
|
|
|
|
|
|
|
|
|
Total other expense
|
|
|
(154
|
)
|
|
|
(223
|
)
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxation
|
|
|
3,752
|
|
|
|
2,671
|
|
Income tax expense
|
|
|
(141
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
3,611
|
|
|
$
|
2,671
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of income taxes (including net gain from disposal of assets of $51 and $51, respectively. See
Note 2. Discontinued Operations)
|
|
|
51
|
|
|
|
51
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
3,662
|
|
|
$
|
2,722
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share of common stock:
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.23
|
|
|
$
|
0.18
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Total basic earnings per share of common stock
|
|
$
|
0.24
|
|
|
$
|
0.18
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share of common stock:
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.06
|
|
|
$
|
0.04
|
|
Discontinued operations
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Total diluted earnings per share of common stock
|
|
$
|
0.06
|
|
|
$
|
0.04
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
C-4
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
Net revenue from services
|
|
$
|
11,833
|
|
|
$
|
9,639
|
|
Cost and expenses:
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
5,920
|
|
|
|
6,102
|
|
Depreciation and amortization
|
|
|
2
|
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
5,922
|
|
|
|
6,107
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
5,911
|
|
|
|
3,532
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(303
|
)
|
|
|
(518
|
)
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
(303
|
)
|
|
|
(518
|
)
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxation
|
|
$
|
5,608
|
|
|
$
|
3,014
|
|
Income tax expense
|
|
|
(215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
5,393
|
|
|
|
3,014
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of income taxes (including net gain from disposal of assets of $101 and $101, respectively.
See Note 2. Discontinued Operations)
|
|
|
101
|
|
|
|
101
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5,494
|
|
|
$
|
3,115
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share of common stock:
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.35
|
|
|
$
|
0.20
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
Total basic earnings per share of common stock
|
|
$
|
0.36
|
|
|
$
|
0.21
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share of common stock:
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.09
|
|
|
$
|
0.05
|
|
Discontinued operations
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
Total diluted earnings per share of common stock
|
|
$
|
0.09
|
|
|
$
|
0.05
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
C-5
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5,494
|
|
|
$
|
3,115
|
|
Net income from discontinued operations
|
|
|
101
|
|
|
|
101
|
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
|
5,393
|
|
|
|
3,014
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
2
|
|
|
|
5
|
|
Amortization of stock-based compensation
|
|
|
10
|
|
|
|
380
|
|
Bad debt provision
|
|
|
5,328
|
|
|
|
4,904
|
|
Changes in working capital components:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(6,924
|
)
|
|
|
(5,558
|
)
|
Prepaid expenses
|
|
|
(268
|
)
|
|
|
(102
|
)
|
Other assets
|
|
|
11
|
|
|
|
3
|
|
Accounts payable
|
|
|
(80
|
)
|
|
|
(240
|
)
|
Accrued expenses
|
|
|
(1,026
|
)
|
|
|
780
|
|
Income taxes payable
|
|
|
215
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by continuing operations operating activities
|
|
|
2,661
|
|
|
|
3,186
|
|
Net cash used in discontinued operations operating activities
|
|
|
|
|
|
|
(7
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
2,661
|
|
|
|
3,179
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from long term debt
|
|
|
650
|
|
|
|
|
|
Payments on long term debt
|
|
|
(184
|
)
|
|
|
(817
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
466
|
|
|
|
(817
|
)
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents
|
|
|
3,127
|
|
|
|
2,362
|
|
Cash and cash equivalents at beginning of period
|
|
|
982
|
|
|
|
1,389
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
4,109
|
|
|
$
|
3,751
|
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information:
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
281
|
|
|
$
|
282
|
|
|
|
|
|
|
|
|
|
|
Cash paid for taxes
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash transactions:
|
|
|
|
|
|
|
|
|
Warrants related to 2009 Bridge financing exercised for common stock, cash proceeds of $85,000 received in Fiscal 2013
|
|
$
|
85
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
C-6
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of First Physicians Capital Group, Inc., f/k/a Tri-Isthmus Group, Inc.,
a Delaware corporation (the Company, we, us, or our, depending on the context), as of March 31, 2014 and for the three and six month periods ended March 31, 2014 and March 31, 2013, have
been prepared on substantially the same basis as our annual consolidated financial statements and should be read in conjunction with our Annual Report on Form 10-K (the Form 10-K), filed with the United States Securities and
Exchange Commission (the SEC) on April 4, 2014, and any amendments thereto, for the Fiscal Year Ended September 30, 2013 (the Fiscal Year Ended September 30, 2013). In the opinion of management, the
accompanying condensed consolidated financial statements reflect all adjustments of a normal recurring nature considered necessary to present fairly the financial information included herein.
The consolidated financial statements include our accounts and the accounts of our subsidiaries. All significant inter-company balances and
transactions have been eliminated.
The results as of September 30, 2013 have been derived from our audited consolidated financial
statements for the fiscal year ended as of such date.
The unaudited consolidated results for interim periods are not necessarily
indicative of expected results for the full fiscal year.
Future Funding
We have an accumulated deficit of approximately $79.3 million as of March 31, 2014. This deficit has been funded primarily through
the issuance of promissory notes, the sale of preferred and common stock, and cash generated from operations.
At March 31, 2014, we
had current liabilities of $6.6 million and current assets of $19.7 million.
Critical Accounting Policies
For critical accounting policies affecting us, see Item 7, Managements Discussion and Analysis of Financial Condition and
Results of Operations, of our Annual Report on Form 10-K for the Fiscal Year Ended September 30, 2013. Critical accounting policies affecting us have not changed materially since September 30, 2013.
Fair Value of Financial Instruments
Carrying amounts of certain of our financial instruments, including accounts receivable, accounts payable and accrued expenses approximate fair
value due to their short maturities. Carrying value of notes receivable and long-term debt approximate fair values as they bear market rates of interest. None of our financial instruments are held for trading purposes.
Revenue Recognition
The Company has
contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed revenues are then reduced by the Companys estimate of allowances based on expected collections, which includes the
provision for doubtful accounts, to arrive at net revenues. Net revenues
C-7
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
may not represent amounts ultimately collected. The Company adjusts current period revenue for differences in estimated revenue recorded in prior periods and actual cash collections.
The following table shows gross revenues and allowances for the three and six months ended March 31, 2014 and 2013 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Six months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2014
|
|
|
2013
|
|
|
2014
|
|
|
2013
|
|
Revenue from services
|
|
$
|
10,314
|
|
|
$
|
9,144
|
|
|
$
|
17,161
|
|
|
$
|
14,543
|
|
Allowances
|
|
|
(3,380
|
)
|
|
|
(3,082
|
)
|
|
|
(5,328
|
)
|
|
|
(4,904
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
6,934
|
|
|
$
|
6,062
|
|
|
$
|
11,833
|
|
|
$
|
9,639
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowances percentage
|
|
|
33
|
%
|
|
|
34
|
%
|
|
|
31
|
%
|
|
|
34
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company computes its estimate of bad debt by taking into account collections received for the services
performed and also estimating amounts collectible for the services performed within the last twelve months.
2. Discontinued Operations
As of March 31, 2014 and September 30, 2013, the remaining operating liabilities of RHA Tishomingo, RHA Anadarko,
RHA Stroud, SPMC, Del Mar, Point Loma, and SPA, have been recorded as liabilities of discontinued operations. We have reclassified the results of operations of RHA Tishomingo, RHA Anadarko, RHA Stroud, SPMC, Del Mar, Point Loma, and SPA for all
periods presented, to discontinued operations. As of March 31, 2014 and September 30, 2013, there was $557,000 of current liabilities classified as liabilities of discontinued operations. In fiscal year 2011, a deferred gain of $4.0
million was recorded related to the sale-leaseback of the RHA Anadarko and RHA Stroud assets, and is being amortized on a straight-line basis over the 20 year lease term. The Company recognized $51,000 and $101,000 of gain during each of the three
and six month periods, respectively, ended March 31, 2014 and 2013, which is included in income from discontinued operations on the accompanying Consolidated Statements of Operations.
C-8
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
3. Income Per Share
The following table shows the calculation of income per share for the three and six month periods ended March 31, 2014
and 2013 (in thousands, except for per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Six months ended
|
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
March 31,
|
|
|
March 31,
|
|
|
2014
|
|
|
2013
|
|
|
2014
|
|
|
2013
|
|
Numerator for basic and diluted earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to continuing operations
|
|
$
|
3,611
|
|
|
$
|
2,671
|
|
|
$
|
5,393
|
|
|
$
|
3,014
|
|
Net income attributable to discontinued operations
|
|
|
51
|
|
|
|
51
|
|
|
|
101
|
|
|
|
101
|
|
Denominator for basic earnings per share weighted average shares
|
|
|
15,522
|
|
|
|
15,050
|
|
|
|
15,283
|
|
|
|
15,050
|
|
Numerator for diluted earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to continuing operations
|
|
|
3,645
|
|
|
|
2,705
|
|
|
|
5,461
|
|
|
|
3,082
|
|
Net income attributable to discontinued operations
|
|
|
51
|
|
|
|
51
|
|
|
|
101
|
|
|
|
101
|
|
Denominator for diluted earnings per share weighted average shares
|
|
|
62,117
|
|
|
|
61,645
|
|
|
|
61,878
|
|
|
|
61,645
|
|
Basic earnings per share of common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.23
|
|
|
$
|
0.18
|
|
|
$
|
0.35
|
|
|
$
|
0.20
|
|
Discontinued operations
|
|
|
0.01
|
|
|
|
0.00
|
|
|
|
0.01
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total basic earnings per share of common stock
|
|
$
|
0.24
|
|
|
$
|
0.18
|
|
|
$
|
0.36
|
|
|
$
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share of common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.06
|
|
|
$
|
0.04
|
|
|
$
|
0.09
|
|
|
$
|
0.05
|
|
Discontinued operations
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
0.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total diluted earnings per share of common stock
|
|
$
|
0.06
|
|
|
$
|
0.04
|
|
|
$
|
0.09
|
|
|
$
|
0.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three and six month periods ended March 31, 2014 and 2013, the Company had stock options
outstanding to purchase up to 150,000 and 6,760,000 shares of common stock, respectively, and warrants outstanding to purchase up to 6,730,879 and 360,000 shares of common stock, respectively, which had strike prices above market value and so are
considered out-of-the-money. As a result, they were excluded from the computation of diluted earnings per share.
For the
three and six month periods ended March 31, 2014 and 2013, the following potential shares of common stock outstanding were included in the computation of diluted earnings per share: 67,600 Series 1-A Convertible Preferred Stock convertible into
33,493 shares of common stock, 3,900 Series 2-A Convertible Preferred Stock convertible into 1,872 shares of common stock, 9,000 Series 5-A Convertible Preferred Stock convertible into 28,800,000 shares of common stock and 4,875 Series 6-A
Convertible Preferred Stock convertible into 15,600,000 shares of common stock, and $1,350,000 of convertible debt from our bridge financings convertible into 2,160,000 shares of common stock.
For the three month periods ended March 31, 2014 and 2013, interest expense of $34,000 related to the convertible debt was added back to
net income attributable to continuing operations for the computation of diluted earnings per share. For the six month periods ended March 31, 2014 and 2013, interest expense of $68,000 related to the convertible debt was added back to net
income attributable to continuing operations for the computation of diluted earnings per share.
C-9
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
4. Accounts Receivable
Accounts receivable consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
|
September 30,
|
|
|
|
2014
|
|
|
2013
|
|
Gross accounts receivable
|
|
$
|
39,799
|
|
|
$
|
32,875
|
|
Reserves for bad debt
|
|
|
(24,513
|
)
|
|
|
(19,185
|
)
|
|
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
$
|
15,286
|
|
|
$
|
13,690
|
|
|
|
|
|
|
|
|
|
|
5. Long Term Debt
Beginning in November 2013, we entered into a staggered bridge financing transaction (the 2013 Bridge Financing)
whereby we entered into four promissory notes, with interest of 10% per annum, in the aggregate principal amount of $650,000 (the 2013 Bridge Notes). The 2013 Bridge Notes mature June 30, 2014. The 2013 Bridge Loans funded
as follows: $450,000 and $200,000 in November 2013 and January 2014, respectively. Three of the investors, SMP Investments I, LLC (SMP), Anthony J. Ciabottoni, and William A. Houlihan each hold a 10% or greater voting interest and are
considered related parties. The fourth investor, Blue Ridge Investments, LLC is wholly owned by Richardson Sells, a member of the Board, and is therefore also considered a related party. SMP, Anthony J. Ciabottoni, William A. Houlihan and Blue Ridge
Investments, LLC contributed $300,000, $125,000, $125,000, and $100,000, respectively.
In January 2014, each 2009 Bridge Lender agreed to
extend the maturity of their respective notes with the same terms and conditions contained in the originally executed notes and related extensions until June 30, 2014. In April 2014, the Company paid all outstanding principal and accrued
interest related to these notes. For additional information, see Note 9. Three of the 2009 Bridge Lenders, SMP, Anthony Ciabattoni, and William A. Houlihan, each hold a 10% or greater voting interest and are considered related parties to this
transaction.
Long-term debt consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, 2014
|
|
|
September 30, 2013
|
|
Note payable secured by real estate, $27,513 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted
quarterly, floor of 7% rate is currently 7% matures November 2028
|
|
$
|
3,001
|
|
|
$
|
3,059
|
|
Note payable secured by real estate, $34,144 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted
quarterly, floor of 7% rate is currently 7% matures November 2028
|
|
|
2,739
|
|
|
|
2,830
|
|
Bridge notes payable. 10% interest, matures on or before June 2014
|
|
|
2,000
|
|
|
|
1,350
|
|
Note payable, 9% interest per annum and matures in February 2016
|
|
|
175
|
|
|
|
210
|
|
Note payable, 10% interest per annum and matures in September 2014
|
|
|
100
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
8,015
|
|
|
|
7,549
|
|
|
|
|
|
|
|
|
|
|
Less current maturities of long term debt
|
|
|
(2,524
|
)
|
|
|
(1,857
|
)
|
|
|
|
|
|
|
|
|
|
Total long terms debt
|
|
$
|
5,491
|
|
|
$
|
5,692
|
|
|
|
|
|
|
|
|
|
|
C-10
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
The following chart shows scheduled principal payments due as of March 31, 2014 on
long-term debt for the next five years and thereafter (in thousands):
|
|
|
|
|
March 31,
|
|
Payments
|
|
2015
|
|
$
|
2,524
|
|
2016
|
|
|
469
|
|
2017
|
|
|
401
|
|
2018
|
|
|
433
|
|
2019
|
|
|
462
|
|
Thereafter
|
|
|
3,726
|
|
|
|
|
|
|
Total
|
|
$
|
8,015
|
|
|
|
|
|
|
6. Warrants
On January 17, 2014, the Company issued warrants to SMP for the purchase of up to 8,500,000 shares of common stock at
an initial exercise price of $0.01 per share. The warrants are exercisable for a period of five years from the date of issuance and were issued as consideration for the extension of the maturity date of the SMP promissory note associated with the
2009 Bridge Lenders (see Note 5). SMP holds a 10% or greater voting interest and is considered a related party. On March 27, 2014, SMP exercised its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of
$85,000. The $85,000 proceeds were received previously by the company in fiscal year 2013, and were recorded as a liability until such time as the Company was able to accept the warrants.
On January 1, 2014, the Company issued warrants to purchase an aggregate of 2,278,079 shares of common stock with an exercise price of
$0.3125. These warrants are exercisable for a period of five years from date of issuance. SMP, Anthony J. Ciabattoni, and William A. Houlihan received warrants to purchase up to 850,080, 425,600 and 470,400 shares of common stock, respectively. The
warrant issuance was related to the 2011 Bridge Financing and the warrants were issued at such time as the Company was able to legally issue warrants. Three of the warrant recipients, SMP, Anthony J. Ciabattoni, and William A. Houlihan, a member of
the Companys Board, each hold a 10% or greater voting interest and are considered related parties and received in aggregate 1,746,080 of the warrants.
On January 1, 2014, the Company issued warrants to purchase an aggregate of 4,092,800 shares of common stock with an exercise price of
$0.3125. These warrants are exercisable for a period of five years from date of issuance. SMP, Anthony J. Ciabattoni, and William A. Houlihan received warrants to purchase up to 1,984,400, 1,388,800 and 720,000 shares of common stock, respectively.
The warrant issuance was related to the 2012 Bridge Financing and the warrants were issued at such time as the Company was able to legally issue warrants. The warrant recipients, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10%
or greater voting interest and are considered related parties.
C-11
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
The following warrants were outstanding and exercisable as of the following as of
March 31, 2014:
|
|
|
|
|
|
|
|
|
|
|
Description
|
|
Remaining
Life
|
|
Exercise
Price
|
|
|
Warrants
|
|
June 8, 2009 Preferred Stock Series 6-A warrants issued to investor
|
|
1 month
|
|
$
|
0.5000
|
|
|
|
210,000
|
|
June 10, 2009 warrants issued to Medical Advisory Board
|
|
1 month
|
|
$
|
0.6250
|
|
|
|
150,000
|
|
January 1, 2014 warrants issued in connection with the 2011 bridge financing
|
|
4.75 years
|
|
$
|
0.3125
|
|
|
|
2,278,079
|
|
January 1, 2014 warrants issued in connection with the 2012 bridge financing
|
|
4.75 years
|
|
$
|
0.3125
|
|
|
|
4,092,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,730,879
|
|
|
|
|
|
|
|
|
|
|
|
|
A summary of our stock warrant activity and related information at March 31, 2014 and September 30,
2013 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares of Common Stock
|
|
|
Weighted-Average
Exercise Price Per Share
|
|
|
|
Six months
ended
March 31,
2014
|
|
|
Fiscal year
ended
September 30,
2013
|
|
|
Six months
ended
March 31,
2014
|
|
|
Fiscal year
ended
September 30,
2013
|
|
Warrants outstanding at beginning of the period
|
|
|
360,000
|
|
|
|
796,250
|
|
|
$
|
0.55
|
|
|
$
|
0.52
|
|
|
|
|
|
|
Issued
|
|
|
14,870,879
|
|
|
|
|
|
|
$
|
0.14
|
|
|
|
|
|
Exercised
|
|
|
(8,500,000
|
)
|
|
|
|
|
|
$
|
0.01
|
|
|
|
|
|
Cancelled or expired
|
|
|
|
|
|
|
(436,250
|
)
|
|
|
|
|
|
$
|
0.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding at end of the period
|
|
|
6,730,879
|
|
|
|
360,000
|
|
|
$
|
0.33
|
|
|
$
|
0.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7. Stock Options
A summary of our options activity and related information at March 31, 2014 and September 30, 2013 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Options
|
|
|
Weighted-Average
Exercise Price Per Share
|
|
|
|
Six months ended
March 31,
2014
|
|
|
Fiscal year ended
September 30,
2013
|
|
|
Six months ended
March 31,
2014
|
|
|
Fiscal year ended
September 30,
2013
|
|
Options outstanding at beginning of the period
|
|
|
6,760,000
|
|
|
|
6,760,000
|
|
|
$
|
0.61
|
|
|
$
|
0.61
|
|
Granted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at above fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at below fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(6,610,000
|
)
|
|
|
|
|
|
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at end of the period
|
|
|
150,000
|
|
|
|
6,760,000
|
|
|
$
|
0.63
|
|
|
$
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options vested/exercisable at end of the period
|
|
|
120,000
|
|
|
|
6,730,000
|
|
|
$
|
0.63
|
|
|
$
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
C-12
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
The following options were outstanding as of March 31, 2014:
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price
|
|
Number of options
|
|
|
Weighted-average
exercise price
|
|
|
Weighted-average
remaining
contractual life
|
|
$0.63
|
|
|
150,000
|
|
|
$
|
0.63
|
|
|
|
3.21
|
|
8. Preferred Stock
Series 7-A Convertible Preferred Stock
On December 5, 2013, the Company filed a Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock
(the 7-A Certificate) authorizing the issuance of up to 7,000 Series 7-A Convertible Preferred Stock (7-A Preferred).
Under the terms of the 7-A Certificate, in the event of any liquidation or dissolution, either voluntary or involuntary, the holders of the
7-A Preferred shall be entitled to receive, pari passu with the Series 6-A Convertible Preferred Stock (6-A Preferred) and the Series 5-A Convertible Preferred Stock (5-A Preferred), after distribution of all amounts due to
the holders of the Series 1-A Convertible Preferred Stock (1-A Preferred) and Series 2-A Convertible Preferred Stock (2-A Preferred), but prior and in preference to any distribution of any of the assets or surplus
funds to the holders of the Common Stock by reason of their ownership thereof, a preference amount per share consisting of the sum of (A) the original issue price, which initially is $1,000 (as adjusted for stock splits, stock dividends,
combinations and the like), plus (B) an amount equal to all declared but unpaid dividends on such shares, if any.
Each share of 7-A
Preferred shall be convertible at any time after the date of issuance of such shares, into such number of fully paid shares of Common Stock as is determined by dividing the original issue price by the then-applicable conversion price in effect on
the date the certificate evidencing such share is surrendered for conversion. Each share of 7-A Preferred, subject to the surrendering of the certificates of the 7-A Preferred, shall be automatically converted into shares of Common Stock at the
then-applicable conversion price, upon the election of the holders of not less than a majority of the outstanding shares 7-A Preferred electing to effect such conversion. Under certain circumstances, such as the sale of the Company or the sale of
the Companys shares in a public offering, each at a valuation of greater than $100,000,000, the Company can elect to convert all Series 7-A into Common Stock. The initial conversion price per share is $0.3125. The holder of each share of 7-A
Preferred shall have the right to that number of votes equal to the number of shares of Common Stock, which would be issued upon conversion of the 7-A Preferred.
The Company, at its option and upon the approval of a majority of the holders of the shares of Series 7-A Preferred Stock then-outstanding,
may redeem any or all of the outstanding shares of Series 7-A Preferred Stock at any time upon five (5) business days prior written notice to each holder of shares of Series 7-A Preferred Stock, at a price per share equal to the
(i) redemption price (as provided in the Certificate of Designation) then in effect plus (ii) an amount equal to any declared but unpaid dividends on such share. In the event the Company elects to redeem less than all of the outstanding
shares of Series 7-A Preferred Stock, the Company shall redeem shares of Series 7-A Preferred Stock on a pro rata basis among all holders of Series 7-A Preferred Stock, based on the number of shares of Series 7-A Preferred Stock held by each holder
relative to the total number of shares of Series 7-A Preferred Stock outstanding as of the time of such redemption.
The holders of 7-A
Preferred shall be entitled to receive (out of any assets legally available), if declared by our Board of Directors, noncumulative dividends pari passu with the 6-A Preferred and the 5-A Preferred stockholders, of $100 per share annually. No
dividend may be declared and paid upon shares of 7-A Preferred in any fiscal year of the Company unless dividends have first been paid upon or declared and set aside for payment
C-13
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTINUED
to the holders of shares of the Companys 1-A Preferred and 2-A Preferred. Under certain circumstances, such as stock splits or issuances of Common Stock at a price less than the issuance
price of the 7-A Preferred, the 7-A Preferred is entitled to conversion price adjustments. Shares of 7-A Preferred have an initial conversion price of $0.3125 per share. Shares of 7-A Preferred Stock are subject to redemption at our option and upon
approval of the majority of the holders of the outstanding 7-A Preferred.
As part of the consideration for entering into the 2011 Bridge
Financing, all of the 2011 Bridge Lenders were granted the option to exchange their current holdings if any, of 5-A Preferred, 6-A Preferred and common stock (collectively the Exchanged Securities), into 7-A Preferred. Upon election to
exchange, each lender would receive the number of 7-A Preferred equal to the initial consideration paid for their Exchanged Securities divided by $1,000. In connection with the exchange, each 2011 Bridge Lender shall receive warrants to purchase a
number of shares of common stock of the Company in an amount equal to 1,120 multiplied by the aggregate number of shares of 7-A Preferred issued. Such issued warrants shall have an exercise price of $0.3125, and shall expire five years from date of
issuance. The Company has received notification from all the 2011 Bridge Lenders of their intent to exchange, as appropriate, their holdings of Exchanged Securities to 7-A Preferred, which will result in the issuance of an aggregate of 5,998 shares
of 7-A Preferred and warrants to purchase up to 6,717,760 shares of common stock. The Company expects to complete the exchange during the fiscal quarter ending June 30, 2014. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and
William A. Houlihan, a member of the Companys Board each hold a 10% or greater voting interest and are considered related parties. SMP, Anthony J. Ciabattoni, and William A. Houlihan will receive 2,713, 1,560 and 317 shares of 7-A Preferred,
respectively, and warrants to purchase up to 3,038,560, 1,747,200 and 415,520 shares of common stock, respectively.
9. Subsequent Events
Bridge Financing
On
April 7, 2014, the Company paid all outstanding principal and accrued interest related to the 2009 and 2013 Bridge Financing notes, and the outstanding accrued interest related to the 2011 and 2012 Bridge Financing notes. The total amount paid
was $2,463,874 consisting of $2,000,000 on principal and $463,874 of interest. Three of the bridge lenders, SMP, Anthony J. Ciabottoni, and William A. Houlihan (a member of the board) each hold a 10% or greater voting interest and are considered
related parties. A fourth lender, Blue Ridge Investments, LLC is wholly owned by Richardson Sells, a member of the Board, and is therefore also considered a related party. SMP, Anthony J. Ciabottoni, William A. Houlihan and Blue Ridge Investments,
LLC received payments of $930,059, $1,187,701, $209,024, and $101,056, respectively. The Company also paid an outstanding note payable in the amount of $100,000 plus interest of $28,812, to Anthony Ciabottoni who holds a 10% or greater voting
interest and is considered a related party.
Warrant Exercise
In April 2014, we accepted two warrant exercises in the amount of 150,000 and 210,000 shares of Common Stock, at an exercise price of $0.625
and $0.50 per share, respectively, for an aggregate purchase price of $198,000 from two investors. The $198,000 proceeds, consisting of $138,000 cash and $60,750 in consulting fees owed, had been received by the Company in fiscal year 2012, and were
recorded as a liability until the Company accepted the warrants in April 2014.
Change in Management
On March 24, 2014, the Board appointed Adrian B. Reeder to the position of Chief Financial Officer of the Company effective April 7,
2014 to serve until his successor is duly appointed and qualified or until his earlier resignation or removal.
C-14
Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in
conjunction with the condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this Form 10-Q).
FORWARD LOOKING STATEMENTS
The
discussion in this Form 10-Q contains forward-looking statements that may be subject to protection under the Private Securities Litigation Reform Act of 1995 and such statements should not be unduly relied upon. Forward-looking statements can be
identified by the use of words such as may, will, could, should, anticipates, believes, estimates, expects, intends, plans and
variations thereof or of similar expressions. All forward-looking statements included in this Form 10-Q are based on information available to us on the date hereof. We assume no obligation to update any such forward-looking statements. Our actual
results in future periods could differ materially from those indicated in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to:
|
|
|
our ability to obtain ongoing financing, manage our cash resources, control expenses and continue as a going concern;
|
|
|
|
impact of our indebtedness on our ability to invest in the ongoing needs and growth of our business;
|
|
|
|
significant past operating losses, potential future losses and limited ongoing revenue;
|
|
|
|
changes in government regulation, particularly healthcare laws;
|
|
|
|
possession of significant voting control over us by the holders of our Series 5-A Convertible Preferred Stock, Series 6-A Convertible Preferred Stock and Series 7-A Convertible Preferred Stock;
|
|
|
|
increased competition in the industry, geography and the segments in which we compete;
|
|
|
|
our ability to attract and retain employees and key members of management;
|
|
|
|
changes in economic and industry conditions;
|
|
|
|
reliance on third parties to provide services critical to our operations;
|
|
|
|
potential dilution of existing stockholders if we raise capital by issuing additional capital stock;
|
|
|
|
availability of appropriate prospective acquisitions or investment opportunities;
|
|
|
|
significant costs and obligations as a result of being a public company;
|
|
|
|
continued positive relationships with our customers;
|
|
|
|
deterioration in the collectability of our accounts;
|
|
|
|
major man-made or natural disasters;
|
|
|
|
compliance with applicable laws and regulations and cost of potential legal actions such as litigation or investigations;
|
|
|
|
inadequacy of our insurance coverage and fluctuating insurance requirements and costs;
|
|
|
|
impact of a potential requirement to record asset impairment charges in the future;
|
|
|
|
failure of our information technology system or the breach of our network security;
|
|
|
|
impact on our disclosure of use the scaled disclosure option available to smaller reporting companies; and
|
|
|
|
volatility in the price of our common stock.
|
C-15
OVERVIEW
References to we, us, our, FPCG or the Company refer to First Physicians Capital
Group, Inc. and its subsidiaries. We maintain our executive offices at 433 North Camden Drive, #810, Beverly Hills, California 90210. Our telephone number is +1 (310) 860-2501.
We invest in and provide financial and managerial services to healthcare facilities in non-urban markets. We promote quality medical care by
offering improved access and breadth of services. We unlock the value of our investments by developing strong, long-term and mutually-beneficial relationships with our physicians and the communities they serve.
STRATEGY
During the Fiscal Year Ended
September 30, 2010, we shifted our strategy away from majority ownership in healthcare delivery companies to a focus on the provision of management, financial, and ancillary healthcare and IT services to the rural and community hospital market.
We expect to maintain and/or acquire minority ownership in selected healthcare delivery companies that complement our management services and financing activities. We may also invest in, acquire or partner with other companies that provide similar
services in our markets.
In pursuit of this reorganization, we undertook an initiative to divest ourselves of underperforming facilities
and reduce or outsource administrative functions to better align cost structures and business volume. As a result of the initiative, during the Fiscal Year Ended September 30, 2011, we successfully divested ourselves of our majority owned
hospitals, and obtained contracts to provide the healthcare management services to several hospital clients.
We currently have four
operating subsidiaries which are First Physicians Business Solutions, LLC First Physicians Resources, LLC, First Physicians Services, LLC and First Physicians Realty Group. First Physicians Business Solutions, LLC provides an array of
management services to include hospital operations management, revenue cycle management, IT, finance and human resources. First Physicians Services provides ancillary service oversight and management solutions for lab, pharmacy, and emergency
departments in rural hospital settings. First Physicians Resources, LLC provides medical and back office staffing solutions to our hospital clientele. First Physicians Realty Group is our real estate subsidiary that owns healthcare related
properties and leases them to clients. We currently have contracts to provide financial and back office services to two hospital clients.
RECENT
DEVELOPMENTS
SERIES 5-A AND 6-A CONVERTIBLE PREFERRED STOCK WAIVER
In February 2014, holders of a majority of the outstanding shares of Series 5-A Convertible Preferred Stock and Series 6-A Convertible
Preferred Stock consented to waive their rights to demand registration. As a result of the majority consent, demand registration rights for all of the stockholders of the two classes of stock were waived.
MATERIAL CHANGES IN RESULTS OF OPERATIONS
NET REVENUE
Net revenue from services was $6.9 million for the three month period ended March 31, 2014, compared to $6.1 million for the three
month period ended March 31, 2013, representing an increase of $0.8 million, or 13.1%. A portion of the Companys management fee revenue is based on successful collection of client accounts receivable. In March 2014, the Company
successfully collected $4.3 million in accounts receivable related to fiscal years 2012 and 2013. The increase in net revenue for the quarter was primarily the result of these
C-16
collections. Net revenue from services was $11.8 million for the six month period ended March 31, 2014, compared to $9.6 million for the six month period ended March 31, 2013,
representing an increase of $2.2 million, or 22.9%. This increase was primarily attributable to the increase in accounts receivable collections for the period, and an increase in the scope and price of services provided by the Company under the
contracts to provide healthcare management.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses remained consistent at $3.0 million and $3.2 million for the three month periods ended
March 31, 2014 and 2013, respectively, and $5.9 million and $6.1 million for the six month periods ended March 31, 2014 and 2013, respectively. Amortization of stock-based compensation is included in selling, general and administrative
expense.
INTEREST EXPENSE
Interest expense
decreased $69,000 from $223,000 for the three month period ended March 31, 2013 to $154,000 for the three month period ended March 31, 2014, and decreased $215,000 from $518,000 for the six month period ended March 31, 2013 to
$303,000 for the six month period ended March 31, 2014. The decreases for the periods resulted from the decrease in outstanding bridge financing debt due to payments of $3,313,000 million paid against the bridge financing in the second and
third quarters of fiscal year 2013.
MATERIAL CHANGES IN FINANCIAL CONDITION AT MARCH 31, 2014 COMPARED TO SEPTEMBER 30, 2013:
CASH AND CASH EQUIVALENTS
Our cash and cash
equivalents totaled $4.1 million as of March 31, 2014, compared to $1.0 million at September 30, 2013, an increase of $3.1 million. This represents an increase of 310%, which was primarily the result of net cash provided by operating
activities of $2.7 million, plus net proceeds from financing of $0.5 million.
ACCOUNTS RECEIVABLE
As of March 31, 2014, accounts receivables, net of allowances for uncollectible accounts totaled $15.3 million, an increase of $1.6
million from $13.7 million at September 30, 2013. This 11.7% increase was primarily due to the increased billings generated from an increase in the scope and price of healthcare management services provided by the Company.
LONG-TERM DEBT
Long-term debt (including
current maturities) increased $0.5 million to $8.0 million at March 31, 2014 from $7.5 million at September 30, 2013. This 6.7% increase reflects cash proceeds from debt of $0.7 million, offset by routine payments on long-term debt of $0.2
million.
LIQUIDITY AND CAPITAL RESOURCES
We have funded operations primarily through cash flows from operations and short-term bridge financing. We estimate that, based on current
plans and assumptions, our available cash and cash flows from operations will be sufficient to satisfy our cash requirements under our present operating expectations, without further financing, for the next 12 months.
As of March 31, 2014, we had working capital of $13.2 million compared with working capital of $7.9 million at September 30, 2013,
an increase of $5.3 million. The working capital increase was primarily the result
C-17
of a $3.1 million increase in cash, a $1.6 million increase in trade accounts receivable and a $1.1 million reduction in accrued expenses.
As of March 31, 2014, we had a stockholders equity of $2.5 million, as compared to a stockholders deficit of $3.1 million as
of September 30, 2013. The decrease in the stockholders deficit arose primarily from net income for the six month period ended March 31, 2014.
During the six month period ended March 31, 2014, there was $2.7 million in cash provided by operating activities compared to $3.2
million in cash provided by operating activities during the six month period ended March 31, 2013. The $0.5 million decrease in cash provided by operating activities was primarily the result of a $2.4 million increase in net income, plus a $0.2
million increase in income taxes payable, offset by a $1.4 million decrease in cash from accounts receivable and a $1.8 million increase in cash used to pay accrued expenses.
Cash provided by financing activities totaled $0.5 million for the six month period ended March 31, 2014, which was primarily the result
of cash proceeds from long term debt of $0.7 million, partially offset by cash payments on long term debt of $0.2 million. Cash used in financing activities of $0.8 million during the six month period ended March 31, 2013 was the result of cash
payments on long-term debt.
Beginning in November 2013, we entered into a staggered bridge financing transaction (the 2013 Bridge
Financing) whereby we entered into four promissory notes, with interest of 10% per annum, in the aggregate principal amount of $650,000 (the 2013 Bridge Notes). The 2013 Bridge Notes mature June 30, 2014. The 2013 Bridge
Loans funded as follows: $450,000 and $200,000 in November 2013 and January 2014, respectively. Three of the investors, SMP Investments I, LLC (SMP), Anthony J. Ciabottoni, and William Houlihan, a member of the Board, each hold a 10% or greater
voting interest and are considered related parties. The fourth investor, Blue Ridge Investments, LLC is wholly owned by Richardson Sells, a member of the Board, and is therefore also considered a related party. SMP, Anthony J. Ciabottoni, William A.
Houlihan and Blue Ridge Investments, LLC contributed $300,000, $125,000, $125,000, and $100,000, respectively.
On January 17, 2014,
the Company issued warrants to SMP for the purchase of up to 8,500,000 shares of common stock at an initial exercise price of $0.01 per share. The warrants are exercisable for a period of five years from the date of issuance and were issued as
consideration for the extension of the maturity date of the SMP promissory note associated with the 2009 Bridge Lenders (see Note 5). SMP holds a 10% or greater voting interest and is considered a related party. On March 27, 2014, SMP exercised
its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of $85,000. The $85,000 proceeds were received previously by the company in fiscal year 2013, and were recorded as a liability until such time as the Company
was able to accept the warrants.
On January 1, 2014, the Company issued warrants to purchase an aggregate of 2,278,079 shares of
common stock with an exercise price of $0.3125. These warrants are exercisable for a period of five years from date of issuance. SMP, Anthony J. Ciabattoni, and William A. Houlihan received warrants to purchase up to 850,080, 425,600 and 470,400
shares of common stock, respectively. The warrant issuance was related to the 2011 Bridge Financing and were issued at such time as the Company was able to legally issue warrants. Three of the warrant recipients, SMP, Anthony J. Ciabattoni, and
William A. Houlihan, a member of the Companys Board, each hold a 10% or greater voting interest and are considered related parties and received in aggregate 1,746,080 of the warrants.
On January 1, 2014, the Company issued warrants to purchase an aggregate of 4,092,800 shares of common stock with an exercise price of
$0.3125. These warrants are exercisable for a period of five years from date of issuance. SMP, Anthony J. Ciabattoni, and William A. Houlihan received warrants to purchase up to 1,984,400, 1,388,800 and 720,000 shares of common stock, respectively.
The warrant issuance was related to the 2012 Bridge Financing and were issued at such time as the Company was able to legally issue warrants. The warrant recipients, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10% or greater
voting interest and are considered related parties.
C-18
In April 2014, we accepted two warrant exercises in the amount of 150,000 and 210,000 shares of
Common Stock, at an exercise price of $0.625 and $0.50 per share, respectively, for an aggregate purchase price of $198,000 from two investors. The $198,000 proceeds, consisting of $138,000 cash and $60,750 in consulting fees owed, had been received
by the Company in Fiscal Year 2012, and were recorded as a liability until the Company accepted the warrants in April 2014.
We are not
aware of any trends, demands, events or uncertainties that will result in a material change in our liquidity or capital resources, nor do we expect any changes in the cost of our capital resources or the mix and relative cost of our capital
resources.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
Item 4. CONTROLS AND
PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
As of the end of the period covered by this report an evaluation was carried out by our management, including our Chief Executive Officer and
Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as defined in
Rules 13a-15(e)
and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on this
evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our controls and procedures are ineffective as they contained evidence of a material weakness as of the end of the fiscal quarter ended March 31, 2014.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2014 that had a material
effect on our internal control over financial reporting.
C-19
PART II
OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
None.
Item 1A. RISK FACTORS
Because we are a Smaller Reporting Company, we are not required to disclose the information required by this item.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On January 17, 2014, the Company issued warrants to SMP for the purchase of up to 8,500,000 shares of common stock at an initial exercise
price of $0.01 per share. The warrants are exercisable for a period of five years from the date of issuance and were issued as consideration for the extension of the maturity date of the SMP promissory note associated with the 2009 Bridge Lenders
(see Note 5). SMP holds a 10% or greater voting interest and is considered a related party. On March 27, 2014, SMP exercised its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of $85,000. The $85,000
proceeds were received previously by the company in fiscal year 2013, and were recorded as a liability until such time as the Company was able to accept the warrants.
The shares of common stock were issued pursuant to the exemption set forth in Section 4(a)(2) of the Securities Act of 1933 and the
regulations promulgated thereunder. We believe that each investor is an accredited investor, acquired the shares of common stock for investment purposes and had access to sufficient information concerning the Company. The certificates representing
the shares of common stock issued bear a restrictive legend.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4.
MINE SAFETY DISCLOSURES
None.
Item 5. OTHER INFORMATION
None.
Item 6. EXHIBITS
See Exhibit index following the Signatures page.
C-20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
|
|
Date: May 9, 2014
|
|
First Physicians Capital Group, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
By:
|
|
/s/ Sean Kirrane
|
|
|
|
|
Sean Kirrane
|
|
|
|
|
Chief Executive Officer and authorized signatory.
(Principal Executive Officer)
|
|
|
|
|
|
By:
|
|
/s/ Adrian Reeder
|
|
|
|
|
Adrian Reeder
|
|
|
|
|
Chief Financial Officer and authorized signatory. (Principle Accounting Officer)
|
C-21
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
2.1*
|
|
Membership Interest Purchase Agreement (filed as Exhibit 2.1 to the Form 8-K, as filed with the SEC on November 5, 2007)
|
|
|
3.1*
|
|
Certificate of Incorporation (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on November 14, 2000)
|
|
|
3.2*
|
|
Certificate of Designation of Rights and Preferences of Series 2-A Convertible Preferred Stock filed November 8, 2000 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on November 14, 2000)
|
|
|
3.3*
|
|
Certificate of Merger filed November 8, 2000, merging Vsource, Inc. (a Nevada corporation) with and into the Vsource, Inc. (a Delaware corporation) (filed as Exhibit 4.2 to the Form 8-K, as filed with the SEC on
November 14, 2000)
|
|
|
3.4*
|
|
Amendment to Certificate of Incorporation, dated January 16, 2002 (filed as Exhibit 3.3 to the Form 8-K, as filed with the SEC on January 23, 2002)
|
|
|
3.5*
|
|
Amended and Restated Bylaws dated October 25, 2002 (filed as Exhibit 3.2 to the Form 8-K, as filed with the SEC on October 28, 2002)
|
|
|
3.6*
|
|
Amendment to Certificate of Incorporation, dated November 20, 2002 (filed as Exhibit 3.1 to the Form 10-Q for the period ended October 31, 2002, as filed with the SEC on December 5, 2002)
|
|
|
3.7*
|
|
Certificate of Decrease of Shares Designated as Series 1-A Convertible Preferred Stock (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
3.8*
|
|
Certificate of Decrease of Shares Designated as Series 2-A Convertible Preferred Stock (filed as Exhibit 4.2 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
3.9*
|
|
Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on July 21, 2005)
|
|
|
3.10*
|
|
Amendment to Certificate of Incorporation, dated December 16, 2005 (filed as Exhibit 3.5 to the Form 10-Q for the period ended October 31, 2005, as filed with the SEC on December 20, 2005)
|
|
|
3.11*
|
|
Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred Stock filed April 2, 2008 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
3.12*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 5-A
Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit 4.2 to the Form 10-Q,
as filed with the SEC on May 20, 2008)
|
|
|
3.13*
|
|
Amendment to Certificate of Incorporation, dated September 29, 2009 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on October 1, 2009)
|
|
|
3.14*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences Series 5-A Convertible Preferred Stock filed January 10, 2008 (filed as Exhibit B to Exhibit 10.1 to the Form 8-K, as filed with the SEC on
October 23, 2009)
|
|
|
3.15*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 6-A
Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit B to Exhibit 10.3 to
the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
3.16*
|
|
Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on December 12, 2013)
|
|
|
4.1*
|
|
Certificate of Incorporation (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on November 14, 2000)
|
C-22
|
|
|
4.2*
|
|
Certificate of Designation of Rights and Preferences of Series 2-A Convertible Preferred Stock filed November 8, 2000 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on November 14, 2000)
|
|
|
4.3*
|
|
Certificate of Decrease of Shares Designated as Series 1-A Convertible Preferred Stock (filed as Exhibit 4.1 to the
Form 8-K,
as filed with the SEC on July 13, 2005)
|
|
|
4.4*
|
|
Certificate of Decrease of Shares Designated as Series 2-A Convertible Preferred Stock (filed as Exhibit 4.2 to the
Form 8-K,
as filed with the SEC on July 13,
2005)
|
|
|
4.5*
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of July 7, 2005, by and among Vsource, Inc. and the investors listed therein (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 21,
2005)
|
|
|
4.6*
|
|
Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on July 21, 2005)
|
|
|
4.7*
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of September 18, 2006, by and among First Physicians Capital Group, Inc. and certain Series 5-A Preferred Stock Investors (filed as Exhibit 4.1 to the Form 8-K, as
filed with the SEC on September 22, 2006)
|
|
|
4.8*
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated January 14, 2008 (filed as Exhibit 10.1 to the
Form 8-K,
as filed with the SEC on January 22, 2008)
|
|
|
4.9*
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated March 31, 2008 (filed as Exhibit 10.1 to the
Form 8-K,
as filed with the SEC on April 3, 2008)
|
|
|
4.10*
|
|
Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred Stock filed April 2, 2008 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
4.11*
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
4.12*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit 4.2 to the Form 10-Q, as filed with the SEC on May 20,
2008)
|
|
|
4.13*
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated May 29, 2008 (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on June 4, 2008)
|
|
|
4.14*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences Series 5-A Convertible Preferred Stock filed January 10, 2008 (filed as Exhibit B to Exhibit 10.1 to the Form 8-K, as filed with the SEC on October
23, 2009)
|
|
|
4.15*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit B to Exhibit 10.3 to the Form 8-K, as filed with the SEC on October
23, 2009)
|
|
|
4.16*
|
|
Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on December 12, 2013)
|
|
|
10.1*
|
|
Form of 2013 Promissory Note (filed as Exhibit 10.57 to the 2013 Form 10-K as filed with the SEC on April 2, 2014)
|
|
|
10.2*+
|
|
Employment Agreement, dated March 24, 2014, between the Company and Adrian Reeder (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on March 27, 2014)
|
|
|
10.3*+
|
|
Consulting Agreement Addendum, dated March 21, 2014, between the Company and Sean Kirrane (filed as Exhibit 10.2 to the Form 10-K, as filed with the SEC on March 27, 2014)
|
C-23
|
|
|
31.1
|
|
Certification of the Chief Executive Officer Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
31.2
|
|
Certification of the Chief Financial Officer Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
32.1
|
|
Certification of the Chief Executive Officer Pursuant to 18 U.S.C. 1350
|
|
|
32.2
|
|
Certification of the Chief Financial Officer Pursuant to 18 U.S.C. 1350
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
+
|
Management contract, compensatory plan or arrangement.
|
*
|
Previously filed with the SEC as indicated, and hereby incorporated herein by reference.
|
C-24
Annex D
Common Stock Independent Appraisal for First Physicians Capital Group, Inc. Valuation Date as of May 27, 2014
Prepared as of June 16, 2014 Cabrillo Advisors, LLC This report is limited only by the agreed upon procedures, and contains our unbiased professional analysis and calculations of fair market value. To the best of our knowledge or belief, all
statements and information contained in this report are true and correct, and no important facts have been knowingly withheld. This report is to be used only for the purpose stated herein, and it is invalid for any other purpose.
|
|
1 | P a g e C o n f i d e n t i a l June 16 2014 First Physicians Capital Group, Inc. 433 North Camden Drive #810 Beverly Hills, CA 90210 In response to the engagement letter,
Cabrillo Advisors, LLC (Cabrillo Advisors) has completed an analysis of First Physicians Capital Group, Inc. (FPCG or the Company) as of May 27, 2014 (the Valuation Date), to provide Company
management with a calculation of a range of fair market value (FMV) of the Companys common stock (Common Stock) on a minority, marketable interest basis. The objective of the valuation is to provide a calculation of the
range of FMV (as defined herein) of the Company as of the Valuation Date for the Companys planning purposes. No other uses are intended or should be inferred. Please see our Exhibits for limiting conditions. For purposes of this report, FMV is
defined as the price, expressed in terms of cash equivalents, at which such property would change hands between a hypothetical willing and able buyer and a hypothetical willing and able seller, acting at arms length in an open and
unrestricted market, when neither is under compulsion to buy or to sell, and when both have reasonable knowledge of relevant facts. 1 Based on our analysis, Cabrillo Advisors calculated the FMV of the Common Stock on a marketable, minority
interest basis is in a range of $0.54 to $0.64 (FIFTY FOUR CENTS TO SIXTY FOUR CENTS) per share as of the Valuation Date. For purposes of performing our analysis, the management of FPCG (Management) provided us with financial data and
other records and documents pertaining to the Companys operations and assets. This information has been accepted as a proper representation of the Companys operations and condition. In addition, discussions were held with Management
about the history and nature of the Companys operations, reasonableness of financial projections, economic and competitive conditions, markets served, future prospects, and other relevant factors. Cabrillo Advisors did not independently verify
the information provided to us and in that regard, the validity of the valuation depends on the completeness and accuracy of the information provided to Cabrillo Advisors by the Company. 1. Internal Revenue Service (IRS) Revenue Ruling
5960, 19591 C.B. 237 (Rev. Rul. 5960).
2 | P
a g e C o n f i d e n t i a l This report is subject to the terms and conditions of the Agreement as outlined in the engagement letter between Cabrillo Advisors, LLC and the Company. Our fee for this service is not contingent upon the results of the
Opinion expressed herein. This Opinion is subject to the terms and conditions of the engagement letter between Cabrillo Advisors and FPCG. CABRILLO ADVISORS, LLC Principal Appraiser Dean Colvin Managing Director Cabrillo Advisors, LLC Contributing
Appraiser Daren Mesrobian Cabrillo Advisors, LLC
3 | P
a g e C o n f i d e n t i a l Company Overview Overview: FPCG is a provider of operational and capital solutions to the rural and community hospital market. The Company promotes quality medical care by offering improved access and breadth of
services. The Company expects to maintain and/or acquire minority ownership in selected healthcare delivery companies that complement its management services and financing activities The Company has contracts to provide financial and backoffice
services to two hospital clients. History: The Company was original incorporated in Nevada in 1980 and reincorporated in Delaware in November 2000. In 2010, the Company shifted its strategy away from ownership in healthcare delivery companies to a
focus on the provision of management, financial, and ancillary healthcare and IT services to the rural and community hospital market. In pursuit of this reorganization, The Company undertook an initiative to divest itself of underperforming
facilities and reduce or outsource administrative functions to better align cost structures and business volume. In 2011, the Company divested its majority owned hospitals, and obtained contracts to provide the healthcare management services to
several hospital clients. Ownership: The Companys common stock is traded in the over-the-counter market under the symbol FPCG.OB. As of March 28, 2014, there were approximately 349 stockholders of record.
4 | P
a g e C o n f i d e n t i a l Company Overview (continued) Corporate Structure: The Company has the following operating subsidiaries: Subsidiary Description First Physicians Business Solutions, LLC (FPBS) First Physicians Business Solutions provides
the following management services: Hospital Administration Billing and Revenue Cycle Management Finance, Accounting, and Tax Insurance Medical Supplies First Physicians Services, LLC (FPPS) FPPS provides ancillary healthcare and IT services;
provided in collaboration with joint venture and other strategic partners: Electronic Health and Medical Records Solutions Radiology and Diagnostic Imaging Pathology and Laboratory Services Emergency Room Care Physical Therapy and Rehabilitation
First Physicians Realty Group (FPRG) FPRG invests in, manages and develops properties associated with the delivery of healthcare services. Our longterm strategy is focused on providing real estate ownership, property management, leasing and
development services to health system operators and physicians. FPRG also provides medical equipment financing and leasing services to health system operators and physicians. FPRG maintains a conservative investment risk profile by focusing
primarily on real estate and equipment associated with rural and community hospitals. These include: Critical access hospitals Physician owned hospitals Federal & state funded clinics, including Federally Qualified Health Centers (FQHCs)
and Community Health Centers (CHCs) Outpatient facilities, including ambulatory surgery centers, outpatient surgical centers, and ancillary services facilities Medical office buildings Medical equipment, including CT, MRI, Xray, Ultrasound, and
surgical equipment First Physicians Resources, LLC (FPR) FPR provides staff leasing services to hospitals and other healthcare facilities, including the following contract labor services: Physician and nurse staffing Administrative staffing
(including hospital administrator, billing and coding, and nonhealthcare provider personnel)
5 | P
a g e C o n f i d e n t i a l Company Overview (continued) Employees: The Company has two employees: o Sean Kirrane (Chief Executive Officer) Mr. Kirrane brings over 10 years of experience in senior finance and accounting roles for large
publicly traded companies, including large financial services and insurance firms. From September 2007 to March 2010, Mr. Kirrane served as Assistant Vice President, Head of Global Treasury for Endurance Specialty Holdings, Ltd., where he
designed and implemented, staffed and managed global treasury functions for the property and casualty insurer. From March 2004 to March 2007, Mr. Kirrane served in various finance and investment roles at New York Mortgage Trust, Inc., where he
was responsible for treasury, budgeting & forecasting, debt management and covenant compliance activities. He assisted New York Mortgage through a successful IPO in June 2004 and was eventually appointed Vice President and Treasurer in
2005. From January 2000 to March 2004, Mr. Kirrane held various positions in the accounting and treasury departments of Hudson United Bancorp., including Assistant Vice President, Investment Officer and Treasury Cash Manager. In his positions
at Hudson United, he was responsible for managing treasury operations and the derivatives and traded fixed income portfolio. Mr. Kirrane received a B.S. in Finance in 2000 from St. Josephs University in Philadelphia, PA. o Adrian Reeder
(Chief Financial Officer) Mr. Reeder brings over 14 years of experience in finance and accounting. Since 2013, Mr. Reeder served as a senior consultant for NowCFO, a professional services firm providing outsourced CFO services. From 2010
until 2013, Mr. Reeder served as audit manager and consultant for Kezos & Dunlavy, LLC, an accounting firm serving the Southern Utah market. Prior to 2010, Mr. Reeder was involved in several ventures, including founding Old
Cobblestone Road, LLC, an online retail company, and serving as director of finance for Elim Valley Planning & Development, LLC, a 2,400 acre master planned real estate development in Southern Utah where he helped raise over $24,000,000 in
real estate financing. Mr. Reeder began his career with KPMG, LLP and held the position of manager at his departure. Mr. Reeder received a B.S. and Masters in Accountancy in 2000 from Brigham Young University and is a Certified Public
Accountant, licensed in the State of Utah. Employees of FPR, a subsidiary of the Company, are part of a staff leasing/contract labor operation and leased under staff leasing agreements to two hospital clients. As of March 28, 2014, FPR had 170
employees.
6 | P
a g e C o n f i d e n t i a l Company Overview (continued) Locations: The following principal facilities are leased by the Company: o Office sublease from HSP, Inc. (headquarters Beverly Hills, CA) o Office sublease from Praxis Health Group,
LLC (Oklahoma City, OK) The company (through a subsidiary) leases the following medical facilities to a third party: o Physicians Hospital of Anadarko (Anadarko, Oklahoma) o Stroud Regional Medical Center (Stroud, Oklahoma) Accounting: The Company
has contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed revenues are then reduced by the Companys estimate of allowances, which includes the provision for doubtful
accounts, to arrive at net service revenues. Net patient service revenues may not represent amounts ultimately collected, as the Company adjusts current period revenue for differences in estimated revenue recorded in prior periods and actual cash
collections.
Capital Structure
The Companys capital
structure is composed of the following securities:
Preferred Stock
Series 1-A
67,600 shares outstanding.
Liquidation Preference
of $2.50 per share.
Convertible into 654,292 shares of common stock (implied conversion price of $0.26 per
share).
Series 2-A
3,900 shares outstanding. Non-redeemable.
Liquidation Preference of $6.41 per share.
Convertible into 168,954 shares of common stock (implied conversion price of $0.15 per share).
Series 5-A
9,000 shares issued, 6,370 estimated
outstanding after conversion to Series 7-A. Redeemable by the Company.
Liquidation Preference of $1,000.00 per
share.
Convertible into 28,800,000 shares of common stock (implied conversion price of $0.3125 per share)
prior to Series 7-A conversion, and 20,384,000 shares after Series 7-A conversion.
Series 6-A
4,875 shares issued, 2,495 estimated outstanding after conversion to Series 7-A. Redeemable by the Company.
Liquidation Preference of $1,000.00 per share.
Convertible into 15,600,000 shares of common stock (implied conversion price of $0.3125 per share) prior to Series 7-A conversion, and 7,984,000 shares after Series 7-A conversion.
Pari passu with Series 5-A Convertible Preferred Stock.
Series 7-A
On December 5, 2013, the Company filed a Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock authorizing the issuance of up to 7,000 shares
of Series 7-A.
As part of the consideration for entering into the 2011 Bridge Financing, all of the 2011
Bridge Lenders were granted the option to convert their current holdings if any, of Series 5-A, Series 6-A and Common Stock into Series 7-A.
The Company estimates there will be 5,998 Series 7-A shares outstanding following the exchange.
Liquidation Preference of $1,000.00 per share.
Convertible into approximately 19,193,600 shares of Common Stock (implied conversion price of $0.3125 per share).
Pari passu with Series 5-A and Series 6-A.
Common Stock
Common Stock
Approximately 17.5 million
basic shares outstanding as of the Valuation Date
Warrants for approximately 13.1 million additional
shares with a strike price of $0.3125 per share.
Options for 150,000 shares with a strike price of $0.63 per
share.
7 | P a g e
CARBILLO ADVISORS
Confidential
8 | P
a g e C o n f i d e n t i a l Industry Overview Health Care Sector Industry Overview2 Health care in the United States is provided by many distinct organizations. Health care facilities are largely owned and operated by private sector businesses. o
62% of the approximately 6,500 hospitals are nonprofit, 20% are government owned, and 18% are forprofit.3 o 6065% of healthcare provision and spending comes from programs such as Medicare, Medicaid, TRICARE, the Childrens Health
Insurance Program, and the Veterans Health Administration. Most of the population under 67 is insured by their or a family members employer, some buy health insurance on their own, and the remainder are uninsured. Health insurance for public
sector employees is primarily provided by the government. Companies in this industry provide a wide range of health care and social services through hospitals, doctors offices, nursing homes, outpatient surgery centers, and other facilities.
Competitive Landscape Demand for health care services is driven by demographics and advances in medical care and technology. The profitability of individual companies depends on efficient operations and, in the case of many nonprofit health care
providers, obtaining grants and federal funds. Large companies have advantages in accessing the latest medical research, buying supplies, offering a wide range of services, and negotiating contracts with health insurers. Small institutions can
compete successfully by serving a limited geographical area, offering specialized services, or building a local reputation for quality care. The U.S. health care sector is highly fragmented: the top 50 organizations generate about 15% of revenue. o
Major companies include Ascension Health, HCA, Kaiser Permanente, and Tenet Healthcare (all based in the US). Products, Operations & Technology Major services include hospital medical care (45% of industry revenue) and outpatient care
provided by physicians (20%). Other services include dental work, urgent care, elderly and hospice care, and social assistance. Leading health care entities in the U.S. include a number of forprofit entities, an exception to the global norm of
nationalized medicine. Sources: SunLink_Health_Systems_Inc__Form_10K (Sep272013) and IPC The Hospitalist Comp Form_10K (Feb262014). Rosenthal, Elisabeth (December 21, 2013). News Analysis Health Cares Road to Ruin. New York
Times.
9 | P a g e C o n f i d e n t i a l Industry Overview (continued) Managed Care4 Each hospital is affected by its ability
to negotiate service contracts with purchasers of group healthcare services. HMOs and PPOs attempt to direct and control the use of hospital services through managed care programs. In addition, employers and traditional health insurers increasingly
are seeking to contain costs through negotiations with hospitals for managed care programs and discounts from established charges. Generally, hospitals compete for service contracts with group healthcare service purchasers on the basis of market
reputation, geographic location, quality and range of services, quality of medical staff, convenience and price. The importance of obtaining contracts with managed care organizations varies from market to market, depending on the market strength of
such organizations. The healthcare industry as a whole faces the challenge of continuing to provide quality patient care while managing rising costs, facing strong competition for patients, and adjusting to a continued general reduction of
reimbursement rates by both private and government payors. Both private and government payors continually seek to reduce the nature and scope of services which may be reimbursed. Healthcare reform at both the federal and state level generally has
created pressure to reduce reimbursement rates. Changes in medical technology, existing and future legislation, regulations and interpretations, and competitive contracting for provider services by private and government payors, may require changes
in our facilities, equipment, personnel, rates and/or services in the future. Efforts to Control Healthcare Costs The hospital industry continues to have significant unused capacity. Inpatient utilization, average lengths of stay and average
inpatient occupancy rates continue to be affected negatively by payorrequired preadmission authorization, utilization review, and payment mechanisms designed to maximize outpatient and alternative healthcare delivery services for less acutely ill
patients and to limit the cost of treating inpatients. Admissions constraints, payor pressures, and increased competition are likely to continue. Historically, hospitals have responded to such trends by adding and expanding outpatient services,
upgrading facilities and equipment, offering new programs and adding or expanding certain inpatient and ancillary services. Sources: SunLink_Health_Systems_Inc__Form_10K (Sep272013) and IPC The Hospitalist Comp Form_10K (Feb262014).
10 | P a g e C o n f i d e n t i a l Industry Overview (continued) Health Care Reform5 The Patient Protection and
Affordable Care Act and the Health Care Education Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA) were signed into law by President Obama on March 23, 2010, and March 30, 2010,
respectively. The ACA alters the U.S. healthcare system and is intended to decrease the number of uninsured Americans and reduce overall health care costs. The ACA attempts to achieve these goals by, among other things, requiring most Americans to
obtain health insurance or pay a tax penalty, expanding Medicare and Medicaid eligibility, reducing Medicare and Medicaid payments including disproportionate share payments, expanding the Medicare programs use of value based purchasing
programs, tying hospital payments to the satisfaction of certain quality criteria, and bundling payments to hospitals and other providers. The ACA also contains a number of measures intended to reduce fraud and abuse in the Medicare and Medicaid
programs, such as requiring the use of recovery audit contractors in the Medicaid program and generally prohibiting physician owned hospitals from adding new physicianowners or increasing the number of beds or operating rooms for which they are
licensed. Because a majority of the measures contained in the ACA are taking effect in 2013, 2014 or 2015 and many of the rules and regulations that implement the provisions of the ACA have not been finalized, it is difficult to predict the impact
the ACA will have on the hospital facilities. Government Reimbursement Programs A significant portion of the Companys net revenues are dependent upon reimbursement from Medicare and Medicaid. The Centers for Medicare and Medicaid Services or
CMS is the federal agency which administers Medicare, Medicaid and the Childrens Health Insurance Program (CHIP). Although the federal government generally reviews payment rates under its various programs annually,
changes in reimbursement rates under such programs, including Medicare and Medicaid, generally occur based on the fiscal year of the federal government which currently begins on October 1 and ends on September 30 of each year. Sources:
SunLink_Health_Systems_Inc__Form_10K (Sep272013) and IPC The Hospitalist Comp Form_10K (Feb262014).
11 | P a g e C o n f i d e n t i a l Industry Overview (continued) Medicare Inpatient Reimbursement6 The Medicare program
currently pays hospitals under the provisions of a prospective payment system for most inpatient services. Under the inpatient prospective payment system, a hospital receives a fixed amount for inpatient hospital services based on the established
fixed payment amount per discharge for categories of hospital treatment, known as diagnosis related groups (DRGs). Each patient admitted for care is assigned to a DRG based upon his or her primary admitting diagnosis. Every DRG is
assigned a payment rate by the government based upon the estimated intensity of hospital resources necessary to treat the average patient with that particular diagnosis. DRG payments do not consider a specific hospitals costs, but are national
rates adjusted for area wage differentials and case mix indices. DRG rates are usually adjusted by an update factor each federal fiscal year (FFY). The percentage increases to DRG payment rates for the last several years have been lower
than the percentage increases in the related cost of goods and services provided by general hospitals. The index used to adjust the DRG payment rates is based on a price statistic, known as the CMS Market Basket Index, reduced by congressionally
mandated reduction factors and other factors imposed by CMS. DRG rate increases were 1.1% and 2.8% for FFY 2012 and 2013, respectively, and currently is 0.7% for FFY 2014. The Balanced Budget Act of 1997 originally set the increase in DRG payment
rates for future FFYs at rates that would be based on the market basket index, which in certain years have been, and in the future may be, subject to reduction factors. Beginning in FFY 2012 the market basket rate began to be reduced by two such
reduction factors. First as required by the ACA, the market basket rate is reduced by 0.25%. Second, CMS is applying a documentation and coding adjustment to recoup a portion of perceived excess aggregate payments. Sources:
SunLink_Health_Systems_Inc__Form_10K (Sep272013) and IPC The Hospitalist Comp Form_10K (Feb262014). Congressional Budget Office (CBO) www.cbo.gov/publication/44521
12 | P a g e C o n f i d e n t i a l Economic Overview7 The U.S. economy continued to grow in the fourth quarter of 2013
(Q4 2013). The output of goods and services produced by labor and property located in the U.S., increased at an annual rate of 3.2% in Q4 2013, according to the advance estimate released by the Bureau of Economic Analysis
(BEA). In the third quarter of 2013 (Q3 2013), the real gross domestic product (GDP) increased 4.1%. The increase in the real GDP in Q4 2013 primarily reflected positive contributions from personal consumption
expenditures (PCE), exports, nonresidential fixed investment, private inventory investment, and state and local government spending that were partly offset by negative contributions from federal government spending and residential fixed
investment. Imports, which are a subtraction in the calculation of GDP, increased. Real PCE increased 3.3% in Q4 2013, compared with an increase of 2.0% in Q3 2013. Durable goods increased 5.9%, compared with an increase of 7.9%. Nondurable goods
increased 4.4%, compared with an increase of 2.9%. Services increased 2.5%, compared with an increase of 0.7%. Real exports of goods and services increased 11.4% in Q4 2013, compared with an increase of 3.9% in Q3 2013. Real imports of goods and
services increased 0.9%, compared with an increase of 2.4%. U.S. import prices recorded no change in December 2013, the U.S. Bureau of Labor Statistics reported, following declines of 0.9% in November 2013 and 0.6% in October 2013. In December 2013,
higher fuel prices offset declining nonfuel prices. U.S. export prices advanced 0.4% in December 2013, after edging up 0.1% the previous month. Import prices were unchanged in December 2013, after falling 1.6% over the previous two months.
Decreasing fuel prices drove the overall declines in import prices in November 2013 and October 2013. The price index for U.S. imports decreased 1.3% in 2013 following a 2.0% decline in 2012. Falling fuel and nonfuel prices contributed to the 2013
decline in overall import price. Export prices rose 0.4% in December 2013 following a 0.1% advance in November 2013. Higher agricultural and nonagricultural prices contributed to the December 2013 increase in overall export prices. Despite rising in
3 of the past 4 months, the price index for U.S. exports fell 1.0% over the past year, after increasing 1.1% in 2012. Sources: News: Gross Domestic Product, 4th quarter and annual 2013 (advance estimate),
http://www.bea.gov/newsreleases/national/gdp/gdpnewsrelease.htm News: U.S. Import and Export Prices Indexes December 2013, http://www.bls.gov/news.release/pdf/ximpim.pdf News: Press Release, January 2014, http://www.federalreserve.gov/news
events/press/monetary/20140129a.htm News: Employment Situation News Release, January 2014, http://www.bls.gov/news.release/empsit.htm News: U.S. Consumer Confidence Rebounds in December, http://www.conference board.org/press/press
detail.cfmpressid=5047 News: January 2014, Kiplinger, Kiplingers Economic Outlooks, http://www.kiplinger.com/tool/business/T019S000kiplingerseconomicoutlooks/
13 | P a g e C o n f i d e n t i a l Economic Overview8(continued) The price index for gross domestic purchases, which
measures prices paid by the U.S. residents, increased 1.2% in Q4 2013, compared with an increase of 1.8% in Q3 2013. Excluding food and energy prices, the price index for gross domestic purchases increased 1.7% in Q4 2013, compared with an increase
of 1.5% in Q3 2013. The Committee also reaffirmed its expectation that the current exceptionally low target range for the federal funds rate of 0 to 0.25% will be appropriate at least as long as the unemployment rate remains above 6.5%, inflation
between one and two years ahead is projected to be no more than a half percentage point above the Committees 2.0% longerrun goal, and longerterm inflation expectations continue to be well anchored. The Feds announced tapering of its
longterm bond buying in 2014 is likely to push up longterm rates. Kiplinger expects 10 year Treasury rates to rise to about 3.5% by the end of 2014. Further, shortterm interest rates will remain low through 2014 in any case. Inflation is likely to
remain below 2.0% in 2014. The Consumer Price Index in 2014 is expected to post an increase of about 1.8%, measuring from December 2013 to December 2014, up from just a 1.5% hike from December 2012 to December 2013. Sources: News: Gross Domestic
Product, 4th quarter and annual 2013 (advance estimate), http://www.bea.gov/newsreleases/national/gdp/gdpnewsrelease.htm News: U.S. Import and Export Prices Indexes December 2013, http://www.bls.gov/news.release/pdf/ximpim.pdf News: Press
Release, January 2014, http://www.federal reserve.gov/news events/press/monetary/20140129a.htm News: Employment Situation News Release, January 2014, http://www.bls.gov/news.release/empsit.htm News: U.S. Consumer Confidence Rebounds in December,
http://www.conferenceboard.org/press/pressdetail.cfmpressid=5047 News: January 2014, Kiplinger, Kiplingers Economic Outlooks, http://www.kiplinger.com/tool/business/T019S000kiplingerseconomicoutlooks/
14 |
P a g e C o n f i d e n t i a l Valuation Approaches Market Approach: The three general methodologies of the Market Approach are: o Guideline Company Method: This method involves the identification and analysis of publicly traded companies that are
comparable to the subject company. Pricing multiples of the publicly traded companies are applied to representative financial metrics of the subject company. o Guideline Transaction Method: This method includes the identification of transactions in
which the targets are comparable to the subject company. This method can also include identification of transactions completed by the most likely buyers in the subject companys industry. Transaction multiples from the identified transactions
are applied to the representative financial metrics of the subject company. o Precedent Transaction Method: By considering the sale price of shares in a recent financing, the enterprise value can be backsolved using an option pricing
model that gives consideration to the Companys capitalization structure and rights of the preferred and Common Stock shareholders. Income Approach: The Discounted Cash Flow (DCF) Method assumes: o A business is worth today what it
can generate in future cash to its owners; o Cash received today is worth more than an equal amount of cash received in the future; and o Future cash flows can be reasonably estimated. The DCF analysis is comprised of the sum of the present value of
two components: discrete period projected cash flows and a residual or terminal value. Cost Approach: Identifies the market value of the Companys significant tangible assets. o The price at which a business entity changes hands can be
influenced by the values of the assets employed in the business, net of its liabilities.
15 |
P a g e C o n f i d e n t i a l Valuation Approaches (continued) Selected Approach: We selected the Market Approach; specifically the Guideline Company Method and Guideline Transaction Method, and the Income Approach. o We placed a greater degree of
weight on the Income Approach (45%) given the relative dearth of highly comparable companies and transactions in each of the Market Approaches. o We weighted the Guideline Company Method at 30% versus the Guideline Transaction Method at 25%
given the higher relevance of comparable companies in the Guideline Company Method relative to the Guideline Transaction Method. o We did not utilize the Cost Approach, as the Company has substantial operating earnings relative to the value of its
underlying assets. As a result, the residual equity value resulting from the cost approach may not accurately reflect the value inherent in the Companys cashgenerating capabilities. Key Considerations: The Valuation is based on a number of key
considerations, including the following: o The Companys: historical and projected financial performance; size (including number of facilities); and operating risk (including payor mix and customer concentration risk) o Rights and privileges of
the Companys classes of preferred stock, including an estimate of the Companys time to liquidity. o Anticipated changes in the Companys outstanding Common Stock as a result of the anticipated Series 7A Preferred Stock exchange and
cancellation of 4.25 million shares of Common Stock acquired from a stockholder in 2011.
16 |
P a g e C o n f i d e n t i a l Equity Allocation Methods Current Value Method (CVM): o Once the fair market value of the enterprise is established, the CVM allocates equity by subtracting the liquidation preference of any preferred
stock considering all rights and assumed conversion behavior associated with those shares. Option Pricing Method (OPM): o Once the fair market value of the enterprise is established, shares are valued by creating a series of call options
with exercise prices based on the liquidation preference and conversion behavior of the different classes of equity. Pursuant to the AICPA Guidelines, the OPM values the common by creating a series of call options with exercise prices based on the
liquidation preference of the preferred stock. The value of the common stock can then be inferred by analyzing these options and allocating the full equity value to the common stock of the subject company. Probability Weighted Expected Return
Method(PWERM): o Shares are valued upon the probability weighted present value of expected future investment returns, considering various future outcomes available to the company, as well as the rights of each share class. The PWERM
requires the projection of several likely scenarios and the determination of the future value of equity within the different scenarios. Selected Method: We relied on the option pricing method rather than the probability weighted expected return
method because specific future outcomes were difficult to predict for the Company. Additionally, the terms of the Companys preferred stock are such that there is no difference in value for an IPO relative to a sale or redemption. The current
value method was not appropriate to use as this method assumes a current liquidation which is presently not contemplated by the Company.
17 |
P a g e C o n f i d e n t i a l Discount for Lack of Marketability & Control Discount for Lack of Marketability (DLOM): o Since the Companys shares are publicly traded, a DLOM was not applied to the value of the
Companys common stock. Discount for Lack of Control (DLOC): o To identify lack of control discounts, which are referenced by the inverse of premiums paid by control acquirers, we researched available databases for control
acquisitions of public companies, considered general sources of control premiums, and considered the specifics of FPCG. o General industry premium information was available from Capital IQ and Mergerstats Control Premium Study, an online
database of Business Valuation Resources, LLC. o For the purpose of this analysis, we considered observed control premiums in recent similar transactions and concluded on 25.0% as control premium. o Accordingly, the determined control premium for
the Company indicates a DLOC of 20.0%. Summary and Conclusion The value created under the Option Pricing Method resulted in a calculation of range of FMV per share of FPCGs Common Stock, as of the Valuation Date, of: $0.54 to $0.64 (FIFTY FOUR
CENTS TO SIXTY FOUR CENTS) per share This Opinion of value is contingent upon the terms and conditions attached to the accompanying report. It is our pleasure to be of service to you on this engagement. Please do not hesitate to call or email me
with any questions or comments.
18 |
P a g e C o n f i d e n t i a l Appraisers Bio and Credentials Dean Colvin (Senior Director Valuation Services) Dean Colvin has nearly 20 years of valuation and transaction advisory service experience with both public and private companies, on
matters relating to mergers and acquisitions, fairness opinions, strategic planning, corporate tax planning, estate and gift tax, financial reporting and restructuring, portfolio valuation, employee stock ownership plans and litigation. Prior to
joining Cabrillo Advisors, Mr. Colvin was a Senior Vice President at FMV Opinions, where he was a leader in the firms Southern California Valuation and Advisory Services practice. Prior to FMV Opinions, Mr. Colvin was a Vice
President with Houlihan Lokey, a specialty investment banking firm, where he managed valuation and transaction advisory assignments for a variety of purposes. Mr. Colvin began his career as a Manager in the Corporate Finance and Transaction
Advisory Services groups of Ernst & Young and Deloitte. Mr. Colvin earned his Bachelors Degree in Business Administration at the University of Southern California and an MBA at the University of Southern Californias
Marshall School of Business. He is registered with FINRA as a General Securities Representative (Series 7, 63 and 79). Daren Mesrobian (Valuation Services) Daren Mesrobian has nearly 10 years of experience providing valuations, solvency and fairness
opinions, and other advisory services to public and private clients in connection with strategic alternative assessments, mergers and acquisitions, recapitalizations, leveraged buyouts, going private transactions and capitalraising activities to
over 100 clients in a wide range of industries. Prior to joining Cabrillo Advisors, Mr. Mesrobian was an Associate with Houlihan Lokey, a specialty investment banking firm. Prior to Houlihan Lokey, Mr. Mesrobian worked as a Senior Analyst
for Maxim Integrated Products, a leading analog and mixedsignal semiconductor company. At Maxim, he managed the companys worldwide cost reduction efforts. Mr. Mesrobians previous experience includes roles at a midsized hedge fund,
and semiconductor companies Intel Corporation and Conexant Systems. Mr. Mesrobian received a B.S. in Industrial Engineering from California Polytechnic State University, San Luis Obispo and an MBA at the University of Southern Californias
Marshall School of Business. He is a board member of the American Society of Appraisers (ASA) Los Angeles Chapter and was previously registered with FINRA as a General Securities Representative (Series 7, 63 and 79).
19 |
P a g e C o n f i d e n t i a l Scope of Analysis Cabrillo Advisors has based this Opinion on information provided and represented by the Management of the Company. Our review and analysis included, but was not necessarily limited to, the following
steps: o Had discussions with the Companys management concerning the Companys operations, financial condition, future prospects and financial forecast. o Reviewed the Companys Annual Reports on Form 10 K and related financial
information for the years ended September 30, 2010, 2011, 2012 and 2013 as filed with the SEC. o Reviewed the Companys Quarterly Reports on Form 10 Q and the related unaudited financial information for the periods ended March 31,
2013 and March 31, 2014 as filed with the SEC. o Reviewed the reported current and historical market prices and trading activity of the Companys publicly traded securities. o Analyzed the Company, its financial and operating history, the
nature of its offerings, and its competitive position. o Reviewed the industry in which the Company competes and the state of development of the Companys target markets. o Reviewed the current economic conditions and outlook for the U.S.
economy. o Reviewed prior transactions in the Companys Common Stock by related parties. o Reviewed and analyzed certain publicly available information, including information from Capital IQ and analyst reports regarding the guideline public
companies, and information from Capital IQ regarding transactions of comparable companies for which financial data was disclosed. o Conducted such other financial studies, analyses and investigations and considered such other historical information
as it deemed necessary or appropriate for purposes of its presentation. We did not independently verify the information provided to us and in that regard, the validity of the valuation depends on the completeness and accuracy of the information
provided to Cabrillo Advisors by the Company. This report is subject to the terms and conditions of the Agreement as outlined in the engagement letter between Cabrillo Advisors, LLC and the Company. This report is to be used only for the sole
purpose of the Companys planning purposes, and it is invalid for any other purpose. This opinion should not be considered, in whole or in part, as investment advice by anyone. Our fee for this service is not contingent upon the Opinion
expressed herein.
20 |
P a g e C o n f i d e n t i a l Background These materials and their conclusions (the Valuation or the Opinion) are intended to be used by the Board of Directors of the Company for the Companys planning purposes. The
Opinion is directed to the Board of Directors of the Company (the Board), relates only to the FMV of the shares of the Common Stock and does not address any other aspect of the Companys contemplated reverse stock split or any
related transaction, and does not constitute a recommendation to the Board or any stockholder with respect to the contemplated reverse stock split, or any other matter being voted upon by the stockholders. The Opinion and its analyses must be
considered as a whole. Selecting portions of the Valuation and Cabrillo Advisors analyses and factors considered by it, without considering all of its analyses and factors, or attempting to ascribe relative weights to some or all its analyses
and factors, could create an incomplete view of the evaluation process underlying the Valuation. None of the information provided by the Company was verified by Cabrillo Advisors as part of its engagement. The Opinion and related analysis reflect
Cabrillo Advisors best judgment in light of the information available as of the Valuation Date. We make no representation as to the accuracy of this Valuation Opinion if it is used for any other purpose without the written consent of Cabrillo
Advisors.
21 |
P a g e C o n f i d e n t i a l Assumptions and Limiting Opinions Purpose and Distribution of Report The report prepared by Cabrillo Advisors is prepared solely for the purpose stated in the Engagement Letter and should not be used for any other
purpose. Except as specifically stated in the report, the Cabrillo Advisors report and its contents may not be quoted or referred to, in whole or in part, in any registration statement, prospectus, public filing, loan agreement, or other agreement
or document without the prior written approval of Cabrillo Advisors. Except as set forth in Cabrillo Advisors report, the Cabrillo Advisors report is prepared for Client use only and may not be reproduced or distributed to any third parties
without Cabrillo Advisors prior written consent. Scope of Analysis The appraisal of any financial instrument or business is a matter of informed judgment. The accompanying appraisal has been prepared on the basis of information and assumptions
set forth in the attached report, its appendices, our underlying work papers, and these limiting conditions and assumptions. Nature of Opinion Neither the opinion nor the report provided or prepared by Cabrillo Advisors are to be construed as a
fairness opinion as to the fairness of an actual or proposed transaction, a solvency opinion, or an investment recommendation, but, instead, are the expression of Cabrillo Advisors calculation of a range of fair market value for the assets
between a hypothetical willing buyer and a hypothetical willing seller in an assumed transaction on an assumed Valuation Date. For various reasons, the price at which the assets might be sold in a specific transaction between specific parties on a
specific date might be significantly different from the fair market value as expressed in our report. Going Concern Assumption, No Undisclosed Contingencies Cabrillo Advisors analysis: (a) is based on the past and present financial
condition of the Client and its assets as of the Valuation Date; (b) assumes that as of the Valuation Date the Client and its assets will continue to operate as configured as a going concern; (c) assumes that the current level of
management expertise and effectiveness would continue to be maintained and that the character and integrity of the enterprise through any sale, reorganization, exchange, or diminution of the owners participation would not be materially or
significantly changed; and (d) assumes that the Company had no undisclosed real or contingent assets or liabilities, no unusual obligations or substantial commitments, other than in the ordinary course of business, nor had any litigation
pending or threatened that would have a material effect on our analysis.
22 |
P a g e C o n f i d e n t i a l Lack of Verification of Information Provided Cabrillo Advisors has relied on information supplied by the Client without audit or verification. Cabrillo Advisors has assumed that all information furnished is complete,
accurate and reflects Clients managements good faith efforts to describe the status and prospects of the Client at the Valuation Date from an operating and a financial point of view. As part of this engagement, Cabrillo Advisors has
relied upon publicly available data from recognized sources of financial, industry, or statistical information, which have not been verified. Reliance on Forecasted Data Cabrillo Advisors use of Clients managements projections or
forecasts in any analysis does not constitute an examination or compilation of prospective financial statements in accordance with standards established by the American Institute of Certified Public Accountants (AICPA). Cabrillo Advisors
does not express an opinion or any other form of assurance on the reasonableness of the underlying assumptions or whether any of the prospective financial statements, if used, are presented in conformity with AICPA presentation guidelines. Further,
there will usually be differences between prospective and actual results because events and circumstances frequently do not occur as expected and these differences may be material. Achievement of the forecasted results is dependent on action, plans,
and assumptions of management. Subsequent Events The terms of Cabrillo Advisors engagement are such that Cabrillo Advisors has no obligation to update this report or to revise the valuation because of events and transactions occurring
subsequent to the date of the valuation unless Cabrillo Advisors is engaged to provide valuations in the future. Legal Matters Cabrillo Advisors assumes no responsibility for legal matters including interpretations of either the law or contracts.
Cabrillo Advisors has made no investigation of legal title and has assumed that all owners claims to property are valid. Cabrillo Advisors has given no consideration to liens or encumbrances except as specifically stated in financial
statements provided to Cabrillo Advisors. Cabrillo Advisors has assumed that all required licenses, permits, etc. are in full force and effect. Cabrillo Advisors assumes that all applicable federal, state, local zoning, environmental and similar
laws and regulations have and continue to be complied with by Client. Cabrillo Advisors assumes no responsibility for the acceptability of the valuation approaches used in our report as legal evidence in any particular court or jurisdiction. The
suitability of Cabrillo Advisors report and opinion for any legal forum is a matter for Client and Clients legal advisor to determine. Cabrillo Advisors assumes that any Employee Agreement provided by Clients management is legally
enforceable and is the most recent document available.
23 |
P a g e C o n f i d e n t i a l Testimony Cabrillo Advisors and its employees, consultants and agents shall not provide any testimony or appear in any legal proceeding unless Cabrillo Advisors coordinates such testimony. Verification of Hazardous
Conditions Cabrillo Advisors will not investigate the extent of any hazardous substances or environmental conditions that may exist and takes no responsibility for investigating or having knowledge of them. The presence of hazardous substances, such
as asbestos or environmental conditions may affect the value of Clients property. Cabrillo Advisors valuation report will be based on the assumption that there are no hazardous substances or environmental conditions on, in or near the
Clients property. Any person entitled to rely on this report wishing to know whether such liabilities exist, or their scope, and the effect on the value of the property is encouraged to obtain a professional environmental assessment. Cabrillo
Advisors does not conduct or provide environmental assessments and has not performed one for the subject property. Cabrillo Advisors has not determined independently whether the Company is subject to any present or future liability relating to
environmental matters (including but not limited to CERCLA/Superfund liability), nor the scope of any such liabilities. Cabrillo Advisors valuation takes no such liabilities into account except as they have been reported expressly to Cabrillo
Advisors by the Company, or by an environmental consultant working for the Company, and then only to the extent that the liability was reported to us in an actual or estimated dollar amount. Such matters are noted in the report. To the extent such
information has been reported to us, Cabrillo Advisors has relied on it without verification and offers no warranty or representation as to its accuracy or completeness. Condition, Zoning and Other Regulatory Compliance of Clients Property or
Locations Cabrillo Advisors assumes no knowledge or liability whatsoever with respect to the condition of the Clients property or locations at which Client and its employees and operations are located, or for hidden or unapparent conditions,
if any, of the subject property, subsoil or structures, and further assume no liability or responsibility whatsoever with respect to the correction of any defects which may now exist or which may develop in the future. Equipment components
considered, if any, were assumed to be adequate for the needs of the propertys improvements, and in good working condition, unless otherwise reported. Cabrillo Advisors assumes that Client has complied with all public and private zoning and
use restrictions and regulations, unless nonconformity was stated, defined and considered in Cabrillo Advisors report. Cabrillo Advisors will not make a specific compliance survey or analysis of this property to determine whether or not it is
in conformity with the various detailed requirements of the Americans with Disabilities Act (ADA). Any failure of compliance with the ADA of Clients properties and could have a negative effect upon the value of the property.
Cabrillo Advisors has no direct evidence relating to compliance or noncompliance with the ADA and will not consider possible noncompliance with the requirements of the ADA in preparing its valuation report.
24 |
P a g e C o n f i d e n t i a l EXHIBITS
Valuation Summary First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Valuation Summary ($ in millions) Market
Approach Income Approach Guideline Public Company Analysis Guideline Transaction Analysis Discounted Cash Flow Analysis Enterprise Value (Indicated Range) $43.000$52.000 $39.000$45.000 $32.000$41.000 x Weighting 1 Weighted
Indication $12.900$15.600 $9.750$11.250 $14.400$18.450 Enterprise Value (Implied Range) $37.100$45.300 Add: Implied Value of Catch-Up Payments2 $4.200$4.200 Enterprise Value (Implied Range) $41.300$49.500
Non-operating Assets/Liabilities: Add: Cash and Cash Equivalents Balance as of 3/31/14 $4.109$4.109 Add: Net Operating Loss 3 2.3002.300 Less: Cash Used for Paydown of Certain Interest-Bearing Debt 4 (2.100)(2.100) Total
Nonoperating Assets/Liabilities $4.309$4.309 Total Enterprise Value $45.600$53.800 Less: Interest-Bearing Debt 5 (5.915)(5.915) Less: Preferred Stock 6 0.0000.000 Total Equity Value (Marketable Minority Interest Basis)
(rounded) $40.000$48.000 Results Summary 7 Value of Common Stock (Marketable Minority Interest Basis) $0.54$0.64 1. Cabrillo Advisors estimate. Discounts the market approaches given the lack of pure-play comparable companies 2. Based on
discussions with Management, represents an estimate of the present value of future proceeds (partial recovery of valuation allowance) 3. See Net Operating Loss Analysis for details 4. Per Management, reflects cash used in April 2014 to paydown the
remainder of the 2009 and 2013 Bridge Financings, and a $0.1 million note payable 5. See Debt Summary for details 6. For purposes of this analysis, Preferred Stock is considered to be a component of equity. See Equity Allocation Summary for detail
7. See Equity Allocation Summary for details Overall 30.0% 25.0% 45.0% Cabrillo Advisors | 2
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Net Operating Loss Analysis ($ in millions)
Assumptions: Market Value of Equity (midpoint) $44.000 Applicable Federal Rate 3.270% Projected FYE September 30, Pretax Income 2014 1 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Total Pretax Income / (Loss) 2 $7.213 $7.623 $8.140
$8.682 $9.251 $9.806 $10.296 $10.708 $11.029 $11.360 $11.701 $12.052 29.5% 6.8% 6.7% 6.5% 6.0% 5.0% 4.0% 3.0% 3.0% 3.0% 3.0% Tax Liability Before Tax Asset Usage 40.0% $2.885 $3.049 $3.256 $3.473 $3.700 $3.922 $4.118 $4.283 $4.412 $4.544
$4.680 $4.821 NOL Carryforward Pretax Income Subject to NOL Usage 3 90.0% $6.492 $6.860 $7.326 $7.814 $8.326 $8.825 $9.267 $9.637 $9.926 $10.224 $10.531 $10.847 Annual Restriced NOL Limitation: 4 $0.300 $0.300 $0.300 $0.300 $0.300 $0.300 $0.300
$0.300 $0.300 $0.300 $0.300 $0.300 Beginning Restricted NOL 5,6 13.000 12.700 12.400 12.100 11.800 11.500 11.200 10.900 0.000 0.000 0.000 0.000 Less: Expirations 4 0.000 0.000 0.000 0.000 0.000 0.000 0.000 10.600 0.000 0.000 0.000 0.000 Less: NOL
Usage 4 0.300 0.300 0.300 0.300 0.300 0.300 0.300 0.300 0.000 0.000 0.000 0.000 Ending Restriced NOL 12.700 12.400 12.100 11.800 11.500 11.200 10.900 0.000 0.000 0.000 0.000 0.000 Annual Additional NOL Limitation: 7 $1.139 $1.139 $1.139 $1.139
$1.139 $1.139 $0.067 $0.000 $0.000 $0.000 $0.000 $0.000 Beginning Additional NOL 1,8 6.900 5.761 4.622 3.484 2.345 1.206 0.067 0.000 0.000 0.000 0.000 0.000 Less: Expirations 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Less: NOL Usage 7 1.139 1.139 1.139 1.139 1.139 1.139 0.067 0.000 0.000 0.000 0.000 0.000 Ending Additional NOL 5.761 4.622 3.484 2.345 1.206 0.067 0.000 0.000 0.000 0.000 0.000 0.000 Total Annual Tax Savings Total NOL Usage $1.439 $1.439 $1.439
$1.439 $1.439 $1.439 $0.367 $0.300 $0.000 $0.000 $0.000 $0.000 Tax Relief from NOL Usage $0.576 $0.576 $0.576 $0.576 $0.576 $0.576 $0.147 $0.120 $0.000 $0.000 $0.000 $0.000 Discount Period 0.30 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10 9.10 10.10
11.10 Discount Factor 9 20.25% 0.95 0.82 0.68 0.56 0.47 0.39 0.32 0.27 0.22 0.19 0.16 0.13 Present Value of Tax Savings $0.545 $0.470 $0.391 $0.325 $0.270 $0.225 $0.048 $0.032 $0.000 $0.000 $0.000 $0.000 Total Federal Tax Savings (Rounded) $2.300 1.
Represents a 7.2-month stub period. 2. Projections per Management. Projected pretax income for tax purposes has been assumed to equal pretax income for book purposes. 3. Due to restrictions imposed by the alternative minimum tax (AMT), only 90.0% of
total pretax income is subject to tax relief from NOL carryforwards. 4. Per Management, losses that occurred before June 22, 2001 are limited to $0.3 million per year an expire in 2021. 5. Per Management, as of September 30, 2013. 6.
Represents the balance of restricted NOLs as a result of a change of ownership of more than 50% that occurred on June 22, 2001. 6. Per Management, losses that occurred before June 22, 2001 are limited to $0.3 million per year and expire in
2021. 7. Calculated pursuant to Section 382 as the product of the market value of equity and the applicable federal rate, less the portion of the Restricted NOL utilized. 8. Represents NOLs incurred subsequent to the June 22, 2001
transaction, and are currently unrestricted. 9. Consideration was given to the companys cost of equity capital. See Derivation of WACCSummary and Reconciliation for details. Note: Mid-year convention applied. Cabrillo Advisors | 3
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Debt Summary ($ in millions) Issue Maturity
Initial Current Date Date Stated Effective Shares Conv. Price Exer. Date 2009 Bridge Financing 1 Bridge Notes (SMP) $0.500 $0.000 2/6/2009 0.625 NA NA Bridge Notes (Ciabattoni) 1.000 0.000 2/6/2009 1.250 NA
NA Second Bridge Notes 0.500 0.000 3/3/2009 0.208 NA NA Third Bridge Notes 0.200 0.000 4/14/2009 0.083 NA NA Total 2009 Bridge Financing $2.200 $0.000 2.167 $0.6000 expired 2011 Bridge Financing Installment
1 (Aug 11) $0.674 $0.000 Aug 2011 NA NA NA Installment 2 (Sep 11) 0.550 0.000 Sep 2011 NA NA NA Installment 3 (Nov 11) 0.360 0.000 Nov 2011 NA NA NA Installment 4 (Dec
11) 0.100 0.000 Dec 2011 NA NA NA Installment 5 (Jan 12) 0.350 0.000 Jan 2012 NA NA NA Total 2011 Bridge Financing $2.034 $0.000 2.278 $0.3125 5 years 2012 Bridge Financing Installment 1 (Feb
12) $0.340 $0.000 Feb 2012 NA NA NA Installment 2 (Mar 12) 0.320 0.000 Mar 2012 NA NA NA Installment 3 (Apr 12) 0.390 0.000 Apr 2012 NA NA NA Installment 4 (May
12) 0.229 0.000 May 2012 NA NA NA Total 2012 Bridge Financing $1.279 $0.000 4.093 $0.3125 5 years 2013 Bridge Financing 2 Installment 1 (Nov 13) $0.450 $0.000 Nov 2013 NA NA NA Installment 2 (Jan
14) 0.200 0.000 Jan 2014 NA NA NA Total 2013 Bridge Financing $0.650 $0.000 Long-Term Debt 3 Note Payable (Real Estate) $3.001 NA Nov 2028 P+2% (7% Min) 7.00% Note Payable (Real Estate) 2.739 NA Nov 2028 P+2% (7% Min)
7.00% Bridge Notes Payable 0.000 see above see above see above see above Note Payable 0.175 NA Feb 2016 9.00% 9.00% Note Payable 4 0.000 NA Total Debt $5.915 7.06% Less: Cash & Cash Equivalents 4.109 Net Debt $1.806
Adjusted EBITDA (LTM) $7.822 Net Debt / EBITDA 0.2x Other Warrants: Series 7-A Convertible Preferred Stock Warrants 6.718 $0.3125 Dec 2017 EBITDAEarnings Before Interest, Taxes, Depreciation & Amortization; LTM refers to Latest Twelve
Months; P refers to Prime Rate 1. Per Management, the 2009 Bridge Financings, which had a balance of $1.35 million, were paid off in April 2014. An adjustment has been made to the Companys cash balance to reflect the paydown. 2. Per
Management, the 2013 Bridge Financings, which had a balance of $0.65 million, were paid off in April 2014. An adjustment has been made to the Companys cash balance to reflect the paydown. 3. Balances as of March 31, 2014. 4. Per
Management, the $0.1 million Note Payable was paid off in April 2014. An adjustment has been made to the Companys cash balance to reflect the paydown. Sources: Companys audited annual 10-K and interim 10-Q filings, and Managment. Balance
Interest Rate Warrants Cabrillo Advisors | 4
First Physicians Capital Group Valuation Analysis as of May 27, 2014 FPCG Stock Price ($ in millions) Date Price
Change Volume Date Price Change Volume 5/27/2014 $0.540 0.0% 70 4/14/2014 $0.260 0.0% 8,570 5/23/2014 $0.540 0.1% 60,530 4/11/2014 $0.260 0.0% 10 5/22/2014 $0.539 11.2% 6,100 4/10/2014 $0.260 -16.1% 26,790 5/21/2014 $0.485 1.0% 10,560 4/9/2014
$0.310 -3.1% 161,500 5/20/2014 $0.480 -12.1% 9,770 4/8/2014 $0.320 23.1% 144,120 5/19/2014 $0.546 -0.7% 22,920 4/7/2014 (2) $0.260 1290.4% 227,780 5/16/2014 $0.550 12.0% 510 4/4/2014 $0.019 0.0% 0 5/15/2014 $0.491 -3.9% 37,820 4/3/2014 $0.019
-1.1% 3,000 5/14/2014 $0.511 24.6% 81,470 4/2/2014 $0.019 0.0% 0 5/13/2014 $0.410 -4.7% 7,390 4/1/2014 $0.019 0.0% 30 5/12/2014 $0.430 65.4% 249,870 3/31/2014 $0.019 0.0% 20 5/9/2014 (1) $0.260 0.0% 7,000 3/28/2014 $0.019 372.5% 7,000 5/8/2014
$0.260 0.0% 100 3/27/2014 $0.004 0.0% 0 5/7/2014 $0.260 4.0% 1,000 3/26/2014 $0.004 0.0% 10 5/6/2014 $0.250 4.2% 9,000 3/25/2014 $0.004 0.0% 20 5/5/2014 $0.240 37.1% 3,500 3/24/2014 $0.004 0.0% 0 5/2/2014 $0.175 0.0% 150 3/21/2014 $0.004 0.0% 1,000
5/1/2014 $0.175 8.7% 710 3/20/2014 $0.004 0.0% 0 4/30/2014 $0.161 0.0% 10 3/19/2014 $0.004 0.0% 0 4/29/2014 $0.161 0.0% 0 3/18/2014 $0.004 0.0% 0 4/28/2014 $0.161 -32.9% 2,500 3/17/2014 $0.004 0.0% 0 4/25/2014 $0.240 0.0% 0 3/14/2014 $0.004 0.0% 10
4/24/2014 $0.240 0.0% 0 3/13/2014 $0.004 0.0% 0 4/23/2014 $0.240 0.0% 80 3/12/2014 $0.004 0.0% 0 4/22/2014 $0.240 0.0% 8,330 3/11/2014 $0.004 0.0% 0 4/21/2014 $0.240 9.1% 5,000 3/10/2014 $0.004 0.0% 0 4/18/2014 $0.220 0.0% 0 3/7/2014 $0.004 0.0%
2,470 4/17/2014 $0.220 0.0% 10 3/6/2014 $0.004 0.0% 15,190 4/16/2014 $0.220 -15.1% 8,070 3/5/2014 $0.004 0.0% 0 4/15/2014 $0.259 -0.4% 6,050 3/4/2014 $0.004 0 1-day $0.540 70 5-day $0.517 17,406 10-day $0.509 23,714 30-day $0.325 17,951
60-day $0.193 18,934 Implied Equity Value at $0.54/share: 3 $40.000 Cabrillo Midpoint Total Equity Value $44.000 Total Equity Value vs. Implied Equity Value 10.0% 1. On May 8, 2014 a large shareholder (SMP Investments I, LLC) filed a Schedule
13D/A, stating, among other items, that the Reporting Persons are evaluating potential transactions that could allow the Issuer 1. to become eligible to terminate its registration under Section 12(g)(4) of the Act. As of the date of this
Statement, the Issuer has approximately 353 stockholders, a significant portion of which hold small 1. positions in the Issuers Common Stock. The Reporting Persons intend to support a reverse stock split by the Issuer, which would result in
the Issuer having fewer than 300 stockholders and becoming 1. eligible to terminate the Issuers registration. 2. On May 4, 2014, the Company filed their delinquent financial results dating from Q3 2011 to Q1 2014. 3. Implied Market
Value of Equity based on a backsolve of the Equity Allocation Model using a common stock price of $0.54 per share. Source: Capital IQ. OTCPK:FPCG OTCPK:FPCG OTCK:FPCG Historical Price and Volume 0 50,000 100,000 150,000 200,000 250,000 300,000
$0.000 $0.100 $0.200 $0.300 $0.400 $0.500 $0.600 Cabrillo Advisors | 5
Company Financial Information First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Representative Levels ($ in millions) Fiscal
Year Ended September 30, LTM Projected Fiscal Year Ended September 30, CAGR 2010 2011 2012 2013 3/31/14 2014 2015 2016 2017 2018 5-year Total Revenue (gross) 1 $1.081 $10.630 $21.260 $29.273 $31.891 $32.369 $33.340 $34.341 $35.371 $36.432
Revenue Growth % 883.3% 100.0% 37.7% 1.5% 3.0% 3.0% 3.0% 3.0% Allowances (unadjusted) 0.000 (3.916) (5.066) (9.881) (10.305) (10.829) (11.336) (11.332) (11.319) (11.294) Add: Adjustments 2
0.000 0.000 0.000 0.000 (1.000) (0.500) 0.000 0.000 0.000 0.000 Allowances (adjusted) 0.000 (3.916) (5.066) (9.881) (11.305) (11.329) (11.336) (11.332) (11.319) (11.294) % of Revenue 0.0% 36.8% 23.8%
33.8% 35.4% 35.0% 34.0% 33.0% 32.0% 31.0% Total Revenue (net) $1.081 $6.714 $16.194 $19.392 $20.586 $21.040 $22.005 $23.008 $24.052 $25.138 5.3% Revenue Growth % 521.1% 141.2% 19.7% 8.5% 4.6% 4.6% 4.5% 4.5% Less: Total Operating
Expenses 6.853 8.820 10.866 12.955 12.770 13.166 13.701 14.167 14.648 15.144 as a % of Revenue 634.0% 131.4% 67.1% 66.8% 62.0% 62.6% 62.3% 61.6% 60.9% 60.2% Add: Depreciation & Amortization 0.028 0.025 0.022 0.009 0.006 0.013 0.054 0.110
0.169 0.230 EBITDA ($5.744) ($2.081) $5.350 $6.446 $7.822 $7.887 $8.357 $8.951 $9.573 $10.225 9.7% EBITDA Margin % -531.4% -31.0% 33.0% 33.2% 38.0% 37.5% 38.0% 38.9% 39.8% 40.7% Less: Depreciation & Amortization 0.028 0.025 0.022 0.009
0.006 0.013 0.054 0.110 0.169 0.230 EBIT ($5.772) ($2.106) $5.328 $6.437 $7.816 $7.874 $8.303 $8.841 $9.404 $9.994 9.2% EBIT Margin % -534.0% -31.4% 32.9% 33.2% 38.0% 37.4% 37.7% 38.4% 39.1% 39.8% Less: Other Expenses/(Income), net 0.048 0.000
(1.447) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 Less: Interest Expense, net 0.869 0.561 1.126 0.866 0.651 0.661 0.681 0.701 0.722 0.744 Adjusted Pre-tax Income ($6.689) ($2.667) $5.649 $5.571 $7.165 $7.213 $7.623 $8.140 $8.682 $9.251 Less:
Taxes @ 40.0% (2.676) (1.067) 2.260 2.228 2.866 2.885 3.049 3.256 3.473 3.700 Net Income ($4.013) ($1.600) $3.389 $3.343 $4.299 $4.328 $4.574 $4.884 $5.209 $5.550 10.7% Net Income Margin % -371.3% -23.8% 20.9% 17.2% 20.9% 20.6% 20.8% 21.2%
21.7% 22.1% Additional Financial Information: Capital Expenditures 3 $0.000 $0.000 $0.000 $0.000 $0.000 $0.158 $0.330 $0.345 $0.361 $0.377 Net Working Capital 4 ($1.297) $1.401 $6.390 $9.310 $12.348 $12.416 $12.561 $12.711 $12.868 $13.031 as a % of
Revenue (net) -120.0% 20.9% 39.5% 48.0% 60.0% 59.0% 57.1% 55.2% 53.5% 51.8% Adjusted as a % of Revenue (net) 5 51.4% 32.5% 20.3% 17.7% 17.6% Net Working Capital Inflow/(Outflow) ($2.698) ($4.989) ($2.920)
($0.068) ($0.145) ($0.151) ($0.157) ($0.163) LTM refers to Latest Twelve Months; CAGR refers to Compound Annual Growth Rate. EBITDAEarnings Before Interest, Taxes, Depreciation & Amortization; EBITEarnings Before Interest
and Taxes 1. Excludes income from First Physicians Realty Group, which is recorded as Other Income, and equal to $0 after a valuation allowance 2. Management estimate of allowance run-rate, after adjusting for a higher rate of collections
received in the LTM and 2014 period 3. Represents corporate level overhead, plus an allocation for hospital level maintenance expenditures, estimated at 1.5% of revenue annually per Management 3. Hospital-level capital expenditures are incurred by
the hospital rather than the Company, but impact the Companys cashflows through lower collections from the hospita 3. As a result, Capital Expenditures are being used as a proxy for such lower collections from hospital-level capital
expenditures 4. Working Capital is estimate to grow at 15.0% of revenue in the projected period 5. Reflects working capital adjusted for the timing of certain catch-up payments in the projected period Cabrillo Advisors | 7
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Historical and Projected Income Statements ($ in
millions) FYE September 30, LTM Projected FYE September 30, 2010 2011 2012 2013 3/31/14 2014 2015 2016 2017 2018 Revenue from Services (gross) $1.081 $10.630 $21.260 $29.273 $31.891 $32.369 $33.340 $34.341 $35.371 $36.432 Allowances 0.000
(3.916) (5.066) (9.881) (10.305) (10.829) (11.336) (11.332) (11.319) (11.294) Revenue from Services (net) $1.081 $6.714 $16.194 $19.392 $21.586 $21.540 $22.005 $23.008 $24.052 $25.138 Total Operating
Expenses: Selling, General & Administrative 6.825 8.795 10.844 12.946 12.764 13.153 13.648 14.057 14.479 14.913 Depreciation & Amortization 0.028 0.025 0.022 0.009 0.006 0.013 0.054 0.110 0.169 0.230 Total Operating Expenses 6.853
8.820 10.866 12.955 12.770 13.166 13.701 14.167 14.648 15.144 Operating Income (5.772) (2.106) 5.328 6.437 8.816 8.374 8.303 8.841 9.404 9.994 Interest Expense (Income) 0.869 0.561 1.126 0.866 0.651 0.661 0.681 0.701 0.722 0.744 Other
Expenses (Income) 0.048 0.000 (1.447) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 Pre-tax Income (Loss) (6.689) (2.667) 5.649 5.571 8.165 7.713 7.623 8.140 8.682 9.251 Income Taxes (Credit) 0.000 0.000 0.212 0.000 0.215 0.218 0.225
0.232 0.238 0.246 Net Income (Loss) (6.689) (2.667) 5.437 5.571 7.950 7.495 7.398 7.909 8.444 9.005 Income (net of taxes) from Discontinued Operations (2.855) 2.195 0.181 0.202 0.202 0.205 0.211 0.218 0.224 0.231 Net Income (Loss)
from Continuing Operations ($9.544) ($0.472) $5.618 $5.773 $8.152 $7.700 $7.609 $8.126 $8.668 $9.236 Additional Information: Capital Expenditures $0.000 $0.000 $0.000 $0.000 $0.000 $0.158 $0.330 $0.345 $0.361 $0.377 EBITDA (unadjusted) ($5.744)
($2.081) $5.350 $6.446 $8.822 $8.387 $8.357 $8.951 $9.573 $10.225 EBIT (unadjusted) ($5.772) ($2.106) $5.328 $6.437 $8.816 $8.374 $8.303 $8.841 $9.404 $9.994 FYE refers to fiscal year end; LTM refers to latest twelve months EBITDA refers to Earnings
Before Interest, Taxes, Depreciation and Amortization; EBIT refers to Earnings Before Interest and Taxes Sources: Historical financials per the Companys audited annual 10-K and preliminary 10-Q filing. Projections per Management Cabrillo
Advisors | 8
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Historical and Projected Common-Size Income
Statements FYE September 30, LTM Projected FYE September 30, 2010 2011 2012 2013 3/31/14 2014 2015 2016 2017 2018 Revenue from Services (gross) 100.0% 158.3% 131.3% 151.0% 147.7% 150.3% 151.5% 149.3% 147.1% 144.9% Allowances 0.0% -58.3%
-31.3% -51.0% -47.7% -50.3% -51.5% -49.3% -47.1% -44.9% Revenue from Services (net) 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% Total Operating Expenses: Selling, General & Administrative 631.4% 131.0% 67.0% 66.8%
59.1% 61.1% 62.0% 61.1% 60.2% 59.3% Depreciation & Amortization 2.6% 0.4% 0.1% 0.0% 0.0% 0.1% 0.2% 0.5% 0.7% 0.9% Total Operating Expenses 634.0% 131.4% 67.1% 66.8% 59.2% 61.1% 62.3% 61.6% 60.9% 60.2% Operating Income -534.0% -31.4% 32.9%
33.2% 40.8% 38.9% 37.7% 38.4% 39.1% 39.8% Interest Expense (Income) 80.4% 8.4% 7.0% 4.5% 3.0% 3.1% 3.1% 3.0% 3.0% 3.0% Other Expenses (Income) 4.4% 0.0% -8.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Pre-tax Income (Loss) -618.8% -39.7% 34.9% 28.7% 37.8%
35.8% 34.6% 35.4% 36.1% 36.8% Income Taxes (Credit) 0.0% 0.0% 1.3% 0.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% Net Income (Loss) -618.8% -39.7% 33.6% 28.7% 36.8% 34.8% 33.6% 34.4% 35.1% 35.8% Income (net of taxes) from Discontinued Operations -264.1% 32.7%
1.1% 1.0% 0.9% 1.0% 1.0% 0.9% 0.9% 0.9% Net Income (Loss) from Continuing Operations -882.9% -7.0% 34.7% 29.8% 37.8% 35.7% 34.6% 35.3% 36.0% 36.7% Additional Information: Capital Expenditures 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 1.5% 1.5% 1.5% 1.5% EBITDA
(unadjusted) -531.4% -31.0% 33.0% 33.2% 40.9% 38.9% 38.0% 38.9% 39.8% 40.7% EBIT (unadjusted) -534.0% -31.4% 32.9% 33.2% 40.8% 38.9% 37.7% 38.4% 39.1% 39.8% FYE refers to fiscal year end; LTM refers to latest twelve months EBITDA refers to Earnings
Before Interest, Taxes, Depreciation and Amortization; EBIT refers to Earnings Before Interest and Taxes Sources: Historical financials per the Companys audited annual 10-K and preliminary 10-Q filing. Projections per Management Cabrillo
Advisors | 9
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Historical and Balance Sheets ($ in millions)
Fiscal Year Ended September 30, As of 2010 2011 2012 2013 3/31/14 Assets Current Assets: Cash & Cash Equivalents 1 $0.535 $1.001 $1.389 $0.982 $4.109 Accounts Receivable 0.038 4.055 9.604 13.690 15.286 Prepaid Expenses 0.047 0.060
0.051 0.066 0.334 Other Current Assets 0.186 0.037 0.007 0.014 0.013 Assets from Discont. Operations 5.738 0.012 0.008 0.000 0.000 Total Current Assets 6.544 5.165 11.059 14.752 19.742 Net Fixed Assets 0.058 0.033 0.011 0.002 0.000 Notes Receivable
0.000 24.493 22.343 22.343 22.343 Other Assets 0.332 0.293 0.268 0.249 0.239 Assets from Discont. Operations 18.796 0.041 0.000 0.000 0.000 Total Assets $25.730 $30.025 $33.681 $37.346 $42.324 Liabilities & Stockholders Equity Current
Liabilities: Accounts Payable $0.418 $1.031 $0.884 $1.116 $1.036 Accrued Expenses 1.150 1.720 2.176 3.132 1.822 Taxes Payable 0.000 0.000 0.212 0.212 0.427 Current Maturities 1 1.022 4.102 5.041 1.857 2.524 Liabilities from Discont. Operations 7.671
0.576 0.572 0.557 0.557 Total Current Liabilities 10.261 7.429 8.885 6.874 6.366 Long-Term Debt 9.391 7.993 6.161 5.692 5.491 Deferred Gain 0.000 18.050 15.698 15.496 15.395 Long-Term Liabilities from Discont. Ops 10.056 0.000 0.000 0.000 0.000
Total Liabilities 29.708 33.472 30.744 28.062 27.252 Commitments and Contingencies: Preferred StockSeries 1-A 0.166 0.166 0.166 0.166 0.166 Preferred StockSeries 2-A 0.025 0.025 0.025 0.025 0.025 Preferred StockSeries 5-A 2 7.832
7.832 7.832 7.832 7.832 Preferred StockSeries 6-A 2 4.381 4.381 4.381 4.381 4.381 Preferred StockSeries 7-A 2 0.000 0.000 0.000 0.000 0.000 Total Preferred Stock 12.404 12.404 12.404 12.404 12.404 Net Stockholders Equity
(16.382) (15.851) (9.467) (3.120) 2.668 Total Liabilities & Stockholders Equity $25.730 $30.025 $33.681 $37.346 $42.324 Working Capital (net) 3 ($1.297) $1.401 $6.390 $9.310 $12.348 % of revenue -120.0% 20.9% 39.5%
48.0% 57.2% Total Debt $10.413 $12.095 $11.202 $7.549 $8.015 Total Debt (incl. Preferred Stock) $22.817 $24.499 $23.606 $19.953 $20.419 1. Subsequent to March 31, 2014 the Company redeemed the remaining balance of the 2009 Bridge Financing
notes. The impact of this transaction is not reflected in the balance sheet. 2. The Company is in the proces of issuing Series 7-A Preferred Stock. Such final issuance is expected to occur subsequent to the Valuation Date. For purposes of this
analysis, 1. we have assumed the Series 7-A issuance, which includes the conversion of certain Series 5-A, 6-A and common shareholders into Series 7-A, will have occurred as of 1. the Valuation Date. The balance sheet figures shown for Series 5-A,
6-A, 7-A, however, reflect balances prior to issuance/conversion. 3. Excludes current assets and liabilities from discontinued operations. Sources: Historical financials per the Companys audited annual 10-K and preliminary 10-Q filing.
March 31, 2013 Balance Sheet is preliminary and provided by Management. Cabrillo Advisors | 10
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Historical Common-Size Balance Sheets Fiscal
Year Ended September 30, As of 2010 2011 2012 2013 3/31/14 Assets Current Assets: Cash & Cash Equivalents 2.1% 3.9% 5.4% 3.8% 16.0% Accounts Receivable 0.1% 15.8% 37.3% 53.2% 59.4% Prepaid Expenses 0.2% 0.2% 0.2% 0.3% 1.3% Other
Current Assets 0.7% 0.1% 0.0% 0.1% 0.1% Assets from Discont. Operations 22.3% 0.0% 0.0% 0.0% 0.0% Total Current Assets 25.4% 20.1% 43.0% 57.3% 76.7% Net Fixed Assets 0.2% 0.1% 0.0% 0.0% 0.0% Notes Receivable 0.0% 95.2% 86.8% 86.8% 86.8% Other Assets
1.3% 1.1% 1.0% 1.0% 0.9% Assets from Discont. Operations 73.1% 0.2% 0.0% 0.0% 0.0% Total Assets 100.0% 116.7% 130.9% 145.1% 164.5% Liabilities & Stockholders Equity Current Liabilities: Accounts Payable 1.6% 4.0% 3.4% 4.3% 4.0%
Accrued Expenses 4.5% 6.7% 8.5% 12.2% 7.1% Taxes Payable 0.0% 0.0% 0.8% 0.8% 1.7% Current Maturities 1 4.0% 15.9% 19.6% 7.2% 9.8% Liabilities from Discont. Operations 29.8% 2.2% 2.2% 2.2% 2.2% Total Current Liabilities 39.9% 28.9% 34.5% 26.7% 24.7%
Long-Term Debt 36.5% 31.1% 23.9% 22.1% 21.3% Deferred Gain 0.0% 70.2% 61.0% 60.2% 59.8% Long-Term Liabilities from Discont. Ops 39.1% 0.0% 0.0% 0.0% 0.0% Total Liabilities 115.5% 130.1% 119.5% 109.1% 105.9% Commitments and Contingencies: Preferred
StockSeries 1-A 0.6% 0.6% 0.6% 0.6% 0.6% Preferred StockSeries 2-A 0.1% 0.1% 0.1% 0.1% 0.1% Preferred StockSeries 5-A 2 30.4% 30.4% 30.4% 30.4% 30.4% Preferred StockSeries 6-A 2 17.0% 17.0% 17.0% 17.0% 17.0% Preferred
StockSeries 7-A 2 0.0% 0.0% 0.0% 0.0% 0.0% Total Preferred Stock 48.2% 48.2% 48.2% 48.2% 48.2% Net Stockholders Equity -63.7% -61.6% -36.8% -12.1% 10.4% Total Liabilities & Stockholders Equity 100.0% 116.7% 130.9% 145.1%
164.5% Working Capital (net) 3 -5.0% 4.7% 19.0% 24.9% 29.2% Total Debt 40.5% 40.3% 33.3% 20.2% 18.9% Total Debt (incl. Preferred Stock) 88.7% 81.6% 70.1% 53.4% 48.2% 1. Subsequent to March 31, 2014 the Company redeemed the remaining balance of
the 2009 Bridge Financing notes. The impact of this transaction is not reflected in the balance sheet. 2. The Company is in the proces of issuing Series 7-A Preferred Stock. Such final issuance is expected to occur subsequent to the Valuation Date.
For purposes of this analysis, 1. we have assumed the Series 7-A issuance, which includes the conversion of certain Series 5-A, 6-A and common shareholders into Series 7-A, will have occurred as of 1. the Valuation Date. The balance sheet figures
shown for Series 5-A, 6-A, 7-A, however, reflect balances prior to issuance/conversion. 3. Excludes current assets and liabilities from discontinued operations. Sources: Historical financials per the Companys audited annual 10-K and
preliminary 10-Q filing. March 31, 2013 Balance Sheet is preliminary and provided by Management. Cabrillo Advisors | 11
Guideline Public Company Analysis First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Public Company Analysis Summary ($ in
millions) Representative Selected Indicated Level Multiple Range Enterprise Value Range LTM Ended (3/31/14) Revenues $20.586 2.00 x 2.50 x $41.170 $51.470 EBITDA $7.822 6.0 x 7.0 x $46.930 $54.750 NFY
(2014) Revenues $21.040 2.00 x 2.50 x $42.080 $52.600 EBITDA $7.887 5.5 x 6.5 x $43.380 $51.270 Selected Enterprise Value Range, on a Minority Interest Basis $43.000 $52.000 LTM refers to Latest Twelve Months;
NFYNext Fiscal Yea Cabrillo Advisors | 13
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Public Company Multiples ($ in
millions) Guideline Company FYE (2013) LTM NFY (2014) NFY+1 (2015) AmSurg Corp. $42.96 $1,382.6 $2,461.6 6.7x 6.8x 6.4x 5.7x First Choice Healthcare Solutions, Inc. $1.74 29.7 42.2 NMF F NMF F NAA NA NA Foundation Healthcare, Inc.
$0.31 53.1 81.7 NMF F 25.8x 11.6x 7.2x IPC The Hospitalist Company, Inc. $44.23 780.4 842.2 12.7x 12.5x 11.0x 9.8x Northstar Healthcare Inc. $1.05 45.6 49.3 9.5x 7.8x 5.2x 2.4x Providence Service Corp. $39.97 616.3 640.9 11.9x 11.6x 9.6x 8.1x
SunLink Health Systems Inc. $1.16 11.0 24.8 6.6x 5.7x NAA NA NA Surgical Care Affiliates, Inc. $29.04 1,159.5 1,981.2 14.6x 14.8x 12.9x 11.4x Team Health Holdings, Inc. $49.71 3,570.7 4,013.2 17.0x 16.2x 14.0x 12.1x USMD Holdings, Inc. $11.93 121.0
158.6 15.0x NMF F NAA NA NA Low 6.6x 5.7x 5.2x 5.7x High 17.0x 25.8x 14.0x 12.1x Median 12.3x 12.1x 11.0x 8.9x Mean 11.7x 12.6x 10.1x 9.0x Guideline Company FYE (2013) LTM NFY (2014) NFY+1 (2015) AmSurg Corp. $42.96 $1,382.6 $2,461.6
2.28x 2.27x 2.17x 1.99x First Choice Healthcare Solutions, Inc. $1.74 29.7 42.2 6.48x 5.72x NAA NA NA Foundation Healthcare, Inc. $0.31 53.1 81.7 0.94x 0.90x 0.83x 0.78x IPC The Hospitalist Company, Inc. $44.23 780.4 842.2 1.38x 1.34x 1.18x 1.07x
Northstar Healthcare Inc. $1.05 45.6 49.3 1.58x 1.26x 1.00x 0.54x Providence Service Corp. $39.97 616.3 640.9 0.57x 0.57x 0.51x 0.46x SunLink Health Systems Inc. $1.16 11.0 24.8 0.23x 0.23x NAA NA NA Surgical Care Affiliates, Inc. $29.04 1,159.5
1,981.2 2.52x 2.51x 2.37x 2.29x Team Health Holdings, Inc. $49.71 3,570.7 4,013.2 1.68x 1.64x 1.50x 1.36x USMD Holdings, Inc. $11.93 121.0 158.6 0.68x 0.65x NAA NA NA Low 0.57x 0.57x 0.51x 0.46x High 2.52x 2.51x 2.37x 2.29x Median 1.38x 1.26x 1.09x
0.93x Mean 1.42x 1.36x 1.34x 1.19x *Excluded from high, low, mean and median data. NA refers to not available; NMF refers to not meaningful figure. FYE refers to the most recently completed fiscal year end (FYE), latest twelve months (LTM) or next
fiscal year (NFY) for which financial information has been made public. Adjusted EBITDAEarnings Before Interest, Taxes, Depreciation and Amortization adjusted for certain non-recurring items. 1. Based on reported diluted shares. Enterprise
Value calculated as equity market value + debt outstanding + preferred stock cash and cash equivalents. Note: No company used in this analysis for comparative purposes is identical to the Company. Sources: Public filings, Capital IQ and
analyst reports. Share Price Share Price Equity Market Value 1 Equity Market Value 1 Enterprise Value 1 Enterprise Value 1 EV to Revenue EV to Adjusted EBITDA Cabrillo Advisors | 14
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Benchmarking Analysis Size Size Historical
Growth Historical Growth Projected Growth (LTM Revenue, $mm) (Enterprise Value, $mm) (2-Fiscal Year Revenue) (1-Fiscal Year Revenue) (2-Fiscal Year Revenue) Team Health Holdings, Inc. $2,449.3 Team Health Holdings, Inc. $4,013.2 First Choice
Healthcare Solutions, Inc. 123.3% USMD Holdings, Inc. 122.2% Northstar Healthcare Inc. 70.6% Providence Service Corp. $1,130.6 AmSurg Corp. $2,461.6 First Physicians Capital Group 69.9% Foundation Healthcare, Inc. 87.8% IPC The Hospitalist Company,
Inc. 13.6% AmSurg Corp. $1,084.3 Surgical Care Affiliates, Inc. $1,981.2 Foundation Healthcare, Inc. 54.3% First Choice Healthcare Solutions, Inc. 71.0% Providence Service Corp. 12.0% Surgical Care Affiliates, Inc. $790.8 IPC The Hospitalist
Company, Inc. $842.2 Northstar Healthcare Inc. 52.0% Northstar Healthcare Inc. 50.0% Team Health Holdings, Inc. 11.5% IPC The Hospitalist Company, Inc. $629.2 Providence Service Corp. $640.9 Industry Average 32.3% Industry Average 38.4% Foundation
Healthcare, Inc. 9.9% USMD Holdings, Inc. $245.8 USMD Holdings, Inc. $158.6 AmSurg Corp. 18.2% First Physicians Capital Group 19.7% Industry Average * 9.8% SunLink Health Systems Inc. $105.5 Foundation Healthcare, Inc. $81.7 Team Health Holdings,
Inc. 16.9% AmSurg Corp. 16.9% AmSurg Corp. 7.2% Foundation Healthcare, Inc. $90.6 FPCG (implied) $49.7 IPC The Hospitalist Company, Inc. 15.4% IPC The Hospitalist Company, Inc. 16.4% First Physicians Capital Group 6.5% Northstar Healthcare Inc.
$39.1 Northstar Healthcare Inc. $49.3 Providence Service Corp. 9.1% Team Health Holdings, Inc. 15.2% Surgical Care Affiliates, Inc. 4.8% First Physicians Capital Group $20.6 First Choice Healthcare Solutions, Inc. $42.2 Surgical Care Affiliates,
Inc. 6.1% Surgical Care Affiliates, Inc. 7.6% SunLink Health Systems Inc. NA First Choice Healthcare Solutions, Inc. $7.4 SunLink Health Systems Inc. $24.8 SunLink Health Systems Inc. (4.9%) Providence Service Corp. 1.5% First Choice Healthcare
Solutions, Inc. NA USMD Holdings, Inc. NA SunLink Health Systems Inc. (4.3%) USMD Holdings, Inc. NA Historical Growth Historical Growth Projected Growth Profitability Profitability (2-Fiscal Year EBITDA) (1-Fiscal Year EBITDA) (2-Fiscal Year
EBITDA) (SG&A to Revenue) (EBIT to Revenue) SunLink Health Systems Inc. 120.3% Foundation Healthcare, Inc. 201.2% Foundation Healthcare, Inc. 116.9% Providence Service Corp. 5.5% First Physicians Capital Group 38.0% AmSurg Corp. 17.1% Providence
Service Corp. 29.4% Northstar Healthcare Inc. 97.0% Team Health Holdings, Inc. 10.9% AmSurg Corp. 30.6% IPC The Hospitalist Company, Inc. 16.3% First Physicians Capital Group 20.5% Industry Average * 44.6% SunLink Health Systems Inc. 12.9% Northstar
Healthcare Inc. 14.0% Team Health Holdings, Inc. 16.1% AmSurg Corp. 18.2% Providence Service Corp. 21.0% IPC The Hospitalist Company, Inc. 17.1% IPC The Hospitalist Company, Inc. 9.9% Industry Average * 13.3% Team Health Holdings, Inc. 17.4% Team
Health Holdings, Inc. 18.2% USMD Holdings, Inc. 20.5% Surgical Care Affiliates, Inc. 8.0% Surgical Care Affiliates, Inc. 8.6% IPC The Hospitalist Company, Inc. 17.0% First Physicians Capital Group 13.9% AmSurg Corp. 23.8% Team Health Holdings, Inc.
7.8% Providence Service Corp. 3.6% Industry Average * 12.0% IPC The Hospitalist Company, Inc. 13.7% Surgical Care Affiliates, Inc. 23.9% Industry Average 6.5% First Physicians Capital Group NMF Surgical Care Affiliates, Inc. 4.8% Surgical Care
Affiliates, Inc. 13.2% Industry Average 27.3% Providence Service Corp. 3.6% Foundation Healthcare, Inc. NMF Northstar Healthcare Inc. (14.7%) AmSurg Corp. 8.7% Foundation Healthcare, Inc. 43.8% SunLink Health Systems Inc. 0.6% First Choice
Healthcare Solutions, Inc. NMF USMD Holdings, Inc. (35.7%) First Choice Healthcare Solutions, Inc. NMF Northstar Healthcare Inc. 56.5% USMD Holdings, Inc. (1.0%) Northstar Healthcare Inc. NMF SunLink Health Systems Inc.
(49.8%) SunLink Health Systems Inc. NA First Choice Healthcare Solutions, Inc. 57.8% Foundation Healthcare, Inc. (2.5%) USMD Holdings, Inc. NA First Choice Healthcare Solutions, Inc. NMF USMD Holdings, Inc. NA First Physicians Capital
Group 62.0% First Choice Healthcare Solutions, Inc. (5.8%) Profitability Relative Depreciation Internal Investment Liquidity Leverage1 (EBITDA to Revenue) (Depreciation to EBITDA) (Capital Expenditures to Revenue) (Current Ratio) (Debt to EV)
First Physicians Capital Group 38.0% First Physicians Capital Group 0.1% First Choice Healthcare Solutions, Inc. 5.5% First Physicians Capital Group 3.1 Northstar Healthcare Inc. 7.0% AmSurg Corp. 33.6% IPC The Hospitalist Company, Inc. 7.1%
Surgical Care Affiliates, Inc. 4.7% AmSurg Corp. 2.5 IPC The Hospitalist Company, Inc. 10.1% Surgical Care Affiliates, Inc. 17.0% AmSurg Corp. 9.2% Northstar Healthcare Inc. 4.1% Northstar Healthcare Inc. 2.1 FPCG (implied) 11.9% Northstar
Healthcare Inc. 16.1% Northstar Healthcare Inc. 13.1% SunLink Health Systems Inc. 3.8% IPC The Hospitalist Company, Inc. 1.9 Team Health Holdings, Inc. 12.4% IPC The Hospitalist Company, Inc. 10.7% Team Health Holdings, Inc. 23.1% AmSurg Corp. 2.7%
Industry Average 1.4 Providence Service Corp. 19.3% Industry Average 10.3% Providence Service Corp. 26.9% Industry Average 2.6% Surgical Care Affiliates, Inc. 1.3 Industry Average * 18.9% Team Health Holdings, Inc. 10.1% Industry Average * 46.5%
Foundation Healthcare, Inc. 1.7% Providence Service Corp. 1.3 AmSurg Corp. 23.8% Providence Service Corp. 4.9% Surgical Care Affiliates, Inc. 53.1% FPCG (projected) 1.5% Team Health Holdings, Inc. 1.2 Foundation Healthcare, Inc. 27.9% SunLink Health
Systems Inc. 4.1% SunLink Health Systems Inc. 86.5% Providence Service Corp. 1.0% USMD Holdings, Inc. 1.2 USMD Holdings, Inc. 28.3% Foundation Healthcare, Inc. 3.5% USMD Holdings, Inc. 152.8% Team Health Holdings, Inc. 1.0% SunLink Health Systems
Inc. 1.2 First Choice Healthcare Solutions, Inc. 30.3% USMD Holdings, Inc. 1.9% Foundation Healthcare, Inc. 172.1% USMD Holdings, Inc. 0.9% First Choice Healthcare Solutions, Inc. 0.9 Surgical Care Affiliates, Inc. 34.2% First Choice Healthcare
Solutions, Inc. 1.3% First Choice Healthcare Solutions, Inc. 535.2% IPC The Hospitalist Company, Inc. 0.6% Foundation Healthcare, Inc. 0.6 SunLink Health Systems Inc. 71.2% Industry Metric Industry Metric Industry Metric Industry Metric
(Medicare/Medicaid Payor Mix) (Uninsured Mix) (Uncollectible Accounts to Revenue) (# of Facilities) Northstar Healthcare Inc. 3.1% USMD Holdings, Inc. 2.4% USMD Holdings, Inc. 1.5% AmSurg Corp. 242 Surgical Care Affiliates, Inc. 23.0% Surgical Care
Affiliates, Inc. 6.0% Surgical Care Affiliates, Inc. 1.9% Surgical Care Affiliates, Inc. 187 AmSurg Corp. 25.0% Industry Average 8.0% AmSurg Corp. 2.5% Team Health Holdings, Inc. 185 Foundation Healthcare, Inc. 27.0% Foundation Healthcare, Inc.
10.0% IPC The Hospitalist Company, Inc. 3.5% USMD Holdings, Inc. 29 USMD Holdings, Inc. 30.0% First Physicians Capital Group 12.5% Foundation Healthcare, Inc. 3.9% Foundation Healthcare, Inc. 14 First Choice Healthcare Solutions, Inc. 38.0% SunLink
Health Systems Inc. 13.7% Industry Average 9.8% Northstar Healthcare Inc. 6 Industry Average 38.6% AmSurg Corp. NA SunLink Health Systems Inc. 11.0% SunLink Health Systems Inc. 6 Team Health Holdings, Inc. 49.9% Team Health Holdings, Inc. NA First
Physicians Capital Group 33.8% First Physicians Capital Group 2 IPC The Hospitalist Company, Inc. 53.0% Northstar Healthcare Inc. NA Team Health Holdings, Inc. 44.7% First Choice Healthcare Solutions, Inc. 1 SunLink Health Systems Inc. 56.6% First
Choice Healthcare Solutions, Inc. NA First Choice Healthcare Solutions, Inc. NA IPC The Hospitalist Company, Inc. NA First Physicians Capital Group 57.0% IPC The Hospitalist Company, Inc. NA Northstar Healthcare Inc. NA Providence Service Corp. NA
Providence Service Corp. 80.0% Providence Service Corp. NA Providence Service Corp. NA FPCG refers to First Physicians Capital Group; NA refers to not available; NMF refers to not meaningful figure. * Excludes outliers. Note: No company used for
comparative purposes is identical to the Company. Sources: Public filings, investor presentations, Capital IQ and analyst reports. Cabrillo Advisors | 15
Guideline Transactions Analysis First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Transactions Analysis Summary ($ in
millions) Representative Selected Indicated Level Multiple Range Enterprise Value Range LTM Ended (3/31/14) EBITDA $7.822 6.0 x 7.0 x $46.930 $54.750 Selected Enterprise Value Range, on a Controlling Interest Basis $47.000
$55.000 Less: Total Interest-Bearing Debt (5.915) (5.915) Less: Preferred Stock 1 0.000 0.000 Equity Value, on a Control Basis $41.085 $49.085 Less: Minority Discount @ 20.0% (8.217) (9.817) Total
Equity Value, on a Marketable Minority Interest Basis $32.868 $39.268 Add: Total Interest-Bearing Debt 5.915 5.915 Add: Preferred Stock 1 0.000 0.000 Implied Enterprise Value Range, on a Minority Interest Basis $39.000
$45.000 1. For purposes of this analysis, Preferred Stock is considered to be a component of equity. See Equity Allocation Summary for details Cabrillo Advisors | 17
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Transaction StatisticsOutsourced
Medical Service Providers ($ in millions) OUTSOURCED MEDICAL SERVICE PROVIDERS Transaction Transaction Value / EBITDA Announced Target Target Business Description Acquiror Value1 Revenue EBITDA Revenue2 EBITDA2 Margin %2 12/02/2013 Allied Healthcare
Staffing Division On Assignment, Inc., Allied Healthcare Staffing Division comprises staffing division which provides nurse, allied, and physician (locum tenens) staffing services. Local Staff, LLC $28.7 $39.5 NA 0.73x NA N A NA NA 10/09/2013 Novia
CareClinics, LLC Novia CareClinics, LLC creates and manages employer sponsored on-site clinics that provide primary care health services to employees, their families, or others. QuadMed, LLC $13.5 $15.0 NA 0.90x NA N A NA NA 09/30/2013 TherEX, Inc.
TherEX, Inc. provides rehabilitation management and consulting services for hospital. Kindred Healthcare Inc. (NYSE:KND) $14.0 $20.0 NA 0.70x NA N A NA NA 06/03/2013 Health Inventures, LLC Health Inventures, LLC operates as a surgical and physician
services company in the United States. Surgical Care Affiliates, LLC $18.5 $41.5 $4.3 0.45x 4.27x 10.4% 07/16/2012 Conmed Healthcare Management, Inc Conmed Healthcare Management, Inc. provides correctional healthcare services to county and municipal
detention centers in the United States. Correct Care Solutions, LLC $59.5 $75.1 $4.6 0.79x 13.02x 6.1% 11/07/2011 American Dental Partners, Inc. American Dental Partners, Inc. provides business services, dental facilities, and support staff to
multidisciplinary dental group practices in the United States. JLL Partners $396.2 $289.3 $48.9 1.37x 8.10x 16.9% 08/01/2011 Healthcare Partners, Inc. Healthcare Partners, Inc. operates as a physician and healthcare recruitment company in the United
States. VISTA Staffing Solutions, Inc. $19.4 $20.0 NA 0.97x NA N A NA NA 07/29/2011 Allied Healthcare International Inc. Allied Healthcare International Inc., together with its subsidiaries, provides healthcare staffing services to the healthcare
and social care industry in the United Kingdom. Saga Group Ltd. $180.5 $283.6 $18.2 0.64x 9.91x 6.4% Low 0.45x 4.3x 6.1% High 1.37x 13.0x 16.9% Median 0.76x 9.0x 8.4% Mean 0.82x 8.8x 10.0% NA refers to not available. 1. Transaction Value refers to
the implied enterprise value of target company, based on the announced transaction price and other public information available 2. Based on reported metric for the most recent LTM period prior to the announcement of the transaction Notes:
Transaction study based on announced and completed, controlling interest acquisitions greater than $1.0 million Notes: No company used in this analysis for comparative purposes is identical to the Company. Cabrillo Advisors | 18
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Transaction
StatisticsHospital & Other Medical Facilities ($ in millions) HOSPITAL & OTHER MEDICAL FACILITIES Transaction Transaction Value / EBITDA Announced Target Target Business Description Acquiror Value1 Revenue EBITDA Revenue2
EBITDA2 Margin %2 12/30/2013 Casa Grande Community Hospital Casa Grande Regional Medical Center operates as a community healthcare system in Arizona. Banner Health $87.0 $138.6 NA 0.63x NA N A NA NA 12/02/2013 Ambulatory Surgery Center in Great
Falls Comprises an ambulatory surgery centre services spread over an area of 12,636 sqft. Physicians Realty Trust (NYSE:DOC) $4.0 $0.3 NA 11.76x NA N A NA NA 09/30/2013 Crescent City Surgical Centre, LLC Crescent City Surgical Centre, L.L.C operates
a hospital in New Orleans. Physicians Realty L.P. $37.5 $2.3 NA 16.45x NA N A NA NA 08/08/2013 GRMC, MVMC and Southeast Texas Hospital IASIS Healthcare LLC, 3 facilities in LA, AZ and TX represent the combined operations of Iasis Glenwood Regional
Medical Center, LP, Mountain Vista Medical Center, LP, and The Medical Center of Southeast Texas, LP. MPT Operating Partnership, L.P. $283.3 $2,400.0 NA 0.12x NA N A NA NA 07/29/2013 Health Management Associates Inc. Health Management Associates,
Inc., through its subsidiaries, engages in the operation of general acute care hospitals and other health care facilities in non-urban communities in the US. Community Health Systems, Inc. (NYSE:CYH) $7,715.9 $5,868.3 $880.1 1.31x 8.77x 15.0%
07/23/2013 Wilson Medical Center, Inc. Wilson Medical Center, Inc. provides healthcare services to the residents of Wilson County and surrounding communities. DLP Healthcare, LLC $56.0 $150.0 NA 0.37x NA N A NA NA 06/24/2013 Vanguard Health Systems
Inc. Vanguard Health Systems, Inc. owns and operates general acute care and specialty hospitals, and outpatient facilities in urban and suburban markets in the United States. Tenet Healthcare Corp. (NYSE:THC) $4,818.4 $5,936.7 $523.9 0.81x 9.20x
8.8% 03/07/2013 Cleveland County Healthcare System Cleveland County Healthcare System, a three hospital system, provides health care services. The Charlotte- Mecklenburg Hospital Authority $100.0 $243.5 NA 0.41x NA N A NA NA 01/02/2013 North Valley
Orthopedic Surgery North Valley Orthopedic Surgery Center, Phoenix comprises ambulatory surgery center. American Realty Capital Healthcare Trust, Inc. ( ) $9.0 $0.8 NA 11.39x NA N A NA NA 12/11/2012 LifeCare Holdings, Inc. LifeCare Holdings, Inc.
develops, acquires, and operates acute long-term acute care (LTAC) hospitals in the United States.$801.4 $483.2 $59.7 1.66x 13.42x 12.4% 11/14/2012 Arkansas Surgical Hospital LLC Arkansas Surgical Hospital, LLC operates a surgical acute care
hospital in North Little Rock, Arkansas. Medical Facilities Holdings, Inc. $39.0 $53.8 $9.9 0.72x 3.93x 18.4% 06/04/2012 Woods Memorial Hospital, LLC Woods Memorial Hospital, LLC, doing business as Woods Memorial Hospital, operates a hospital that
provides various healthcare services to patients in Tennessee. Lifepoint Hospitals Inc. (LPNT) $17.7 $74.3 NA 0.24x NA N A NA NA 03/23/2012 Univ. of Maryland St. Joseph Medical Center LLC Operates as a Catholic acute care hospital that provides
healthcare services in Towson. University Of Maryland Medical System Corp. $158.1 $409.2 NA 0.39x NA N A NA NA 03/23/2012 Cheboygan Memorial Hospital Cheboygan Memorial Hospital operates as a hospital. McLaren Health Care Corporation $5.0 $44.1 NA
0.11x NA N A NA NA 07/01/2011 Tennova Healthcare Owns and operates hospitals, surgery centers, assisted living and home health centers, and rehabilitation centers in East Tennessee. Health Management Associates Inc. $532.4 $600.0 NA 0.89x NA N A NA
NA 06/27/2011 Continucare Corp. Continucare Corporation provides primary care physician services on an outpatient basis in Florida, the United States. Metropolitan Health Networks Inc. $413.2 $324.2 $42.7 1.27x 9.68x 13.2% 05/13/2011 Smith Of
Georgia, LLC Smith Northview Hospital provides health care services to Valdosta community and the surrounding region of Southern Georgia. South Georgia Medical Center $55.0 $52.0 NA 1.06x NA N A NA NA Represents transactions for which both
RevenueAND EBITDA figures were made available Low 0.72x 3.9x 8.8% High 1.66x 13.4x 18.4% Median 1.27x 9.2x 13.2% Mean 1.16x 9.0x 13.6% Refer to footnotes on prior page. Cabrillo Advisors | 19
Discounted Cash Flow Analysis First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Discounted Cash Flow Analysis Summary ($ in
millions) Projected Fiscal Year Ending September 30, 2014 1 2015 2016 2017 2018 2019 2020 DCF Assumptions Revenue (adjusted) $12.566 $22.005 $23.008 $24.052 $25.138 $26.144 $27.189 Discount Rate 16.0% Revenue Growth % 8.5% 9.4% 4.5% 4.5%
4.0% 4.0% Tax Rate 40.0% Less: Operating Expenses 7.856 13.648 14.057 14.479 14.913 15.510 16.130 Less: Depreciation & Amortization 0.008 0.054 0.110 0.169 0.230 0.294 0.348 Adjusted EBIT $4.703 $8.303 $8.841 $9.404 $9.994 $10.339 $10.711
Distribution of Value EBIT Margin % 37.4% 37.7% 38.4% 39.1% 39.8% 39.5% 39.4% Period Cash Flow 50.0% Less: Taxes 2 1.881 3.321 3.536 3.762 3.998 4.136 4.284 Terminal Cash Flow 50.0% Unlevered Earnings $2.822 $4.982 $5.305 $5.643 $5.997 $6.204 $6.427
Total 100.0% Less: Capital Expenditures 0.094 0.330 0.345 0.361 0.377 0.392 0.408 Less: Increase/(Decrease) in W/C 0.068 0.145 0.151 0.157 0.163 0.151 0.157 Terminal Value Assumptions Add: Depreciation and Amortization 0.008 0.054 0.110 0.169 0.230
0.294 0.348 2021 Cash Flow $6.458 Total Net Investment ($0.155) ($0.421) ($0.386) ($0.348) ($0.310) ($0.248) ($0.217) ÷ (Discount RateGrowth Rate) 12.0% Net Unlevered Cash Flows $2.667 $4.561 $4.919 $5.294 $5.687 $5.955 $6.210 Terminal
Value $53.820 Discount Period 0.30 1.10 2.10 3.10 4.10 5.10 6.10 Discount Period 6.10 Discount Factor @ 16.0% 0.96 0.85 0.73 0.63 0.54 0.47 0.40 Discount Factor @ 16.0% 0.40 Present Value of Net Unlevered Cash Flows $2.551 $3.876 $3.603 $3.343
$3.096 $2.795 $2.512 PV of Terminal Value $21.774 Sensitivity Analysis: Enterprise Value 0.01 1.0% Perpetual Growth Rate $43.550 2.0% 3.0% 4.0% 5.0% 6.0% 14.0% $46.696 $49.108 $52.003 $55.541 $59.964 15.0% $43.132 $45.084 $47.392 $50.160 $53.545
16.0% $40.081 $41.682 $43.550 $45.758 $48.407 17.0% $37.440 $38.768 $40.301 $42.089 $44.202 18.0% $35.132 $36.245 $37.517 $38.984 $40.696 Selected Enterprise Value Range $38.800 $50.200 Less: Total Interest-Bearing Debt (5.915)
(5.915) Less: Preferred Stock 3 0.000 0.000 Equity Value, on a Control Basis $32.885 $44.285 Less: Minority Discount @ 20.0% (6.577) (8.857) Total Equity Value, on a Marketable Minority Interest Basis $26.308
$35.428 Add: Total Interest-Bearing Debt 5.915 5.915 Add: Preferred Stock 3 0.000 0.000 Implied Enterprise Value Range, on a Minority Interest Basis $32.000 $41.000 W/CWorking Capital 1. Represents a 7.2-month stub
period. 2. Tax estimated at 40.0%, per Management. 3. For purposes of this analysis, Preferred Stock is considered to be a component of equity. See Equity Allocation Summary for details. Note: Mid-year convention applied. Refer to WACC
calculation in the Appendices for derivation of discount rate. Note: Projections beyond 2018 assume a 4.0% annual growth rate and margins consistent with 2018 levels, in order to develop a stable terminal period. Discount Rate Cabrillo Advisors | 21
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Derivation of WACCSummary and
Reconciliation Cost of Equity Result Weighting Indication CAPM (Ibbotson Size Risk Premia Data) 19.75% 1 33.33% 4 6.58% CAPM (Duff & Phelps Size Risk Premia Data) 20.50% 2 33.33% 4 6.83% Buildup Method 20.50% 3 33.33% 4 6.83% Concluded Cost
of Equity (rounded) 20.25% Cost of Debt Pre-Tax Cost of Debt 5 7.00% Tax Rate 6 40.00% Concluded After-Tax Cost of Debt (rounded) 4.25% Concluded Cost Capital Structure Weighted Cost WACC Calculation of Capital (rounded) 5 of Capital Equity 20.25%
75.00% 15.19% Debt (After-Tax) 4.25% 25.00% 1.06% Preferred 0.00% 0.00% 0.00% Indicated WACC 16.25% Concluded WACC (rounded) 16.00% WACCWeighted Average Cost of Capital CAPMCapital Asset Pricing Model. 1. See Cost of EquityCAPM
(Ibbotson Size Risk Premia Data) for details. 2. See Cost of EquityCAPM (Duff & Phelps Size Risk Premia Data) for details 3. See Cost of EquityBuildup Method for details. 4. Cabrillo Advisors estimate. 5. Cabrillo Advisors
estimate. Gives consideration to the comparable companies cost of debt (Weighted Average Cost of Capital (WACC)Statistics 5. and the Companys cost of debt (Debt Summary) 6. Estimate per Management. Cabrillo Advisors | 22
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Cost of EquityCAPM (Ibbotson Size Risk
Premia Data) Levered Beta Cost of Equity Selected Unlevered Beta 1 0.97 20-Year Treasury Bond Yield 3 3.09% Normalized Corporate Tax Rate 40.00% U.S. Equity Risk Premium4 5.75% Debt to Total Capitalization (rounded) 2 25.00% x Levered Beta 1.17
Preferred Stock to Total Capitalization 1 0.00% Add: Levered Equity Risk Premium 6.72% 6.72% Levered Beta 1.17 Add: Size Premium 5 5.99% Add: Nonsystematic Risk Premium 6 4.00% Indicated Cost of EquityCAPM 19.80% Selected Cost of
EquityCAPM (rounded) 19.75% Sources: Capital IQ. CAPMCapital Asset Pricing Model. Levered Beta = Selected Unlevered Beta * (1 + ((Debt / Equity Market Value) * (1 Tax Rate)) + (Preferred Stock / Equity Market Value) 1. See
Guideline Public Company WACC Analysis for details 2. Reflects Cabrillo Advisors estimate. See Weighted Average Cost of Capital (WACC)Statistics page for further detail. 3. Risk Free Rate of Return as of May 27, 2014, based on
20-year U.S. Treasury Bond Yield 4. Cabrillo Advisors estimate, based on review of studies measuring historical returns between stocks and bonds, theoretical models and other materials 5. Duff & Phelps 2014 Valuation Handbook. 6. Cabrillo
Advisors estimate. Nonsystematic Risk Premium is used to adjust for issues such as key man risk, key supplier or customer risk, etc Cabrillo Advisors | 23
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Cost of EquityCAPM (Duff & Phelps
Size Risk Premia Data) Risk Premia over CAPM Representative Level Rank Smoothed Premium over CAPM Market Value of Equity NA 25 7.42% Tangible Book Value of Equity $2.668 25 5.96% 5-Year Average Net Income 1 $0.280 25 6.90% Market Value of Invested
Capital NA 25 7.09% Total Assets $42.324 25 6.45% 5-Year EBITDA 1 $0.993 25 6.66% Total Revenue $20.586 25 6.14% Number of Employees 2 25 6.48% Average 6.64% Median 6.57% Concluded Size Risk Premium 2 6.60% Cost of Equity 20-Year Treasury Bond Yield
3 3.09% Equity Risk Premium 4 5.75% x Levered Beta 1.17 Add: Levered Equity Risk Premium 6.72% 6.72% Add: Size Risk Premium 6.60% Add: Nonsystematic Risk Premium 5 4.00% Indicated Cost of EquityCAPM 20.41% Selected Cost of EquityCAPM
(rounded) 20.50% Sources: Capital IQ. CAPMCapital Asset Pricing Model. EBITDAEarnings Before Interest, Taxes, Depreciation and Amortization 1. Representative level indicates 4-year averages for the Company 2. Assumed equal distribution
between the average and median. 3. Risk Free Rate of Return as of May 27, 2014, based on 20-year U.S. Treasury Bond Yield 4. Cabrillo Advisors estimate, based on review of studies measuring historical returns between stocks and bonds,
theoretical models and other materials 5. Cabrillo Advisors estimate. Nonsystematic Risk Premium is used to adjust for issues such as key man risk, key supplier or customer risk, etc Cabrillo Advisors | 24
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Cost of EquityBuildup Method Assumptions
20-Year Treasury Bond Yield 1 3.09% Equity Risk Premium 2 5.75% Size Risk Premium 3 5.99% Industry Risk Premium 4 1.77% Nonsystematic Risk Premium 5 4.00% Indicated Cost of EquityBuildup Method 20.60% Selected Cost of EquityBuildup
Method (rounded) 20.50% Industry SIC Code Industry Classification Premium 80 Health Services 0.66% 806 Hospitals 2.87% Average 1.77% SIC = Standard Industrial Classification 1. Risk Free Rate of Return as of May 27, 2014, based on 20-year U.S.
Treasury Bond Yield 2. Cabrillo Advisors estimate, based on review of studies measuring historical returns between stocks and bonds, theoretical models and other materials 3. Duff & Phelps 2014 Valuation Handbook. 4. Duff & Phelps
2014 Valuation Handbook; Average industry risk premium for SIC code 80 and 806. 5. Cabrillo Advisors estimate. Nonsystematic Risk Premium is used to adjust for issues such as key man risk, key supplier or customer risk, etc Cabrillo Advisors | 25
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Weighted Average Cost of Capital
(WACC)Statistics ($ in millions) Preferred Total Debt to Debt to Preferred to MVE to Total Guideline Company Debt 1 Stock 1 MVE 2 Capitalization 3 MVE Capitalization Capitalization Capitalization AmSurg Corp. $585.2 $0.0 $1,382.6 $1,967.8
42.3% 29.7% 0.0% 70.3% First Choice Healthcare Solutions, Inc. 12.8 0.0 29.7 42.5 43.0% 30.1% 0.0% 69.9% Foundation Healthcare, Inc. 22.8 0.0 53.1 75.9 42.9% 30.0% 0.0% 70.0% IPC The Hospitalist Company, Inc. 85.0 0.0 780.4 865.4 10.9% 9.8% 0.0%
90.2% Northstar Healthcare Inc. 3.5 0.0 45.6 49.0 7.6% 7.0% 0.0% 93.0% Providence Service Corp. 123.5 0.0 616.3 739.8 20.0% 16.7% 0.0% 83.3% SunLink Health Systems Inc. 17.7 0.0 11.0 28.6 161.1% 61.7% 0.0% 38.3% Surgical Care Affiliates, Inc. 678.1
0.0 1,159.5 1,837.6 58.5% 36.9% 0.0% 63.1% Team Health Holdings, Inc. 497.5 0.0 3,570.7 4,068.2 13.9% 12.2% 0.0% 87.8% USMD Holdings, Inc. 44.8 0.0 121.0 165.9 37.0% 27.0% 0.0% 73.0% Median $64.9 $0.0 $368.6 $452.8 37.0% 27.0% 0.0% 73.0% Mean $207.1
$0.0 $777.0 $984.1 30.7% 22.2% 0.0% 77.8% Levered Unlevered Equity Risk Size Cost of Cost of Cost of Guideline Company Beta 4 Beta 5 Premium 6 Premium 7 Equity 8 Debt 9 Preferred 10 WACC 11 AmSurg Corp. 0.86 0.68 5.75% 5.99% 14.0% 4.4% 0.0% 9.8%
First Choice Healthcare Solutions, Inc. 1.15 0.91 5.75% 5.99% 15.7% 7.2% 0.0% 12.3% Foundation Healthcare, Inc. NA N NA N 5.75% 2.36% NA N 6.9% 0.0% NA NA IPC The Hospitalist Company, Inc. 1.51 1.42 5.75% 5.99% 17.8% 0.9% 0.0% 16.0% Northstar
Healthcare Inc. (0.42) (0.40) 5.75% 2.81% 3.5% 5.3% 0.0% 3.5% Providence Service Corp. 1.16 1.03 5.75% 5.99% 15.7% 4.2% 0.0% 13.1% SunLink Health Systems Inc. 1.27 0.65 5.75% 1.94% 12.3% 5.6% 0.0% 6.8% Surgical Care Affiliates, Inc. NA N NA N 5.75%
1.94% NA N 4.3% 0.0% NA NA Team Health Holdings, Inc. 1.17 1.08 5.75% 1.75% 11.6% 3.2% 0.0% 10.4% USMD Holdings, Inc. NA N NA N 5.75% 5.99% NA N 4.3% 0.0% NA NA Median 1.16 0.97 14.0% 5.6% 0.0% 10.4% Mean 1.19 0.96 12.9% 5.9% 0.0% 10.3% *Excluded
from high, low, mean and median data. MVEmarket value of equity. 1. Based on most recent public filing as of May 27, 2014. 2. Equity market value based on closing price and reported fully-diluted shares as of May 27, 2014 3. Total
capitalization equal to equity market value + debt outstanding + preferred stock 4. Based on 5-year actual beta per Capital IQ as of May 27, 2014. 5. Unlevered Beta = Levered Beta / (1 + ((1 Tax Rate) * (Debt / MVE)) + (Preferred Stock /
MVE) 6. Cabrillo Advisors estimate, based on review of studies measuring the historical returns between stocks and bonds, theoretical models and other materials 7. Duff & Phelps 2014 Valuation Handbook. 8. Cost of Equity = Risk Free Rate of
Return + (Levered Beta * Equity Risk Premium) + Size Premium 9. Based on selected company weighted average interest rate per most recent public filings 10. Based on selected company weighted average preferred dividend per most recent public filings
11. Weighted Average Cost of Capital (WACC) = (Cost of Debt * (1 Tax Rate) * Debt to Total Capitalization) + (Cost of Equity * MVE to Total Capitalization Sources: Capital IQ and Duff & Phelps. Cabrillo Advisors | 26
Supporting Exhibits First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Public Company Operating Performance
Parameters ($ in millions) LTM Operating Indications LTM Margins 2-Year Historical CAGR Guideline Company AmSurg Corp. $1,084.3 $589.6 $364.6 $331.2 $70.7 54.4% 33.6% 30.6% 6.5% 18.2% 17.1% 17.4% 14.9% 14.9% First Choice Healthcare Solutions, Inc.
7.4 3.8 0.1 (0.4) (2.4) 52.0% 1.3% -5.8% -32.8% 123.3% NMF N NMF N NMF NMF Foundation Healthcare, Inc. 90.6 37.4 3.2 (2.3) (4.8) 41.3% 3.5% -2.5% -5.3% 54.3% NMF N NMF N NMF NMF IPC The Hospitalist Company, Inc. 629.2 169.7 67.2 62.4
36.1 27.0% 10.7% 9.9% 5.7% 15.4% 16.3% 15.9% 12.3% 12.3% Northstar Healthcare Inc. 39.1 27.6 6.3 5.5 (3.1) 70.5% 16.1% 14.0% -8.0% 52.0% NMF N NMF N NMF NMF Providence Service Corp. 1,130.6 102.8 55.3 40.4 22.4 9.1% 4.9% 3.6% 2.0% 9.1% 3.6%
3.3% 10.7% 10.7% SunLink Health Systems Inc. 105.5 14.2 4.4 0.6 (0.4) 13.5% 4.1% 0.6% -0.4% -4.9% 120.3% NMF N NMF NMF Surgical Care Affiliates, Inc. 790.8 327.2 134.2 62.9 (34.0) 41.4% 17.0% 8.0% -4.3% 6.1% 8.6% 1.8% NMF NMF Team Health
Holdings, Inc. 2,449.3 457.1 248.0 190.7 119.5 18.7% 10.1% 7.8% 4.9% 16.9% 16.1% 11.8% 13.5% 13.5% USMD Holdings, Inc. 245.8 47.9 4.7 (2.5) (1.8) 19.5% 1.9% -1.0% -0.8% NA N NA N NA N NA NA Low 9.1% 1.3% -5.8% -32.8% -4.9% 3.6% 1.8% 10.7%
High 70.5% 33.6% 30.6% 6.5% 123.3% 120.3% 17.4% 14.9% Median 34.1% 7.5% 5.7% -0.6% 16.9% 16.2% 11.8% 12.9% Mean 34.7% 10.3% 6.5% -3.2% 32.3% 30.3% 10.1% 12.9% First Physicians Capital Group $20.6 NA $7.8 $7.8 $4.3 NA 38.0% 38.0% 20.9% 69.9% NA NA NA
CAGR refers to compound annual growth rate; NMF refers to not meaningful figure; LTM refers to latest 12 months. EBIT refers to earnings before interest and taxes; EBITDA refers to earnings before interest, taxes, depreciation and amortization.
Source: Capital IQ. Revenue Gross Profit Adj. Net Income Adj. EBIT Adj. Revenue EBITDA Adj. Net Income Adj. EBIT Adj. EBITDA Gross Profit Adj. Net Income Adj. EBIT Adj. EBITDA Cabrillo Advisors | 28
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Public Company Balance Sheet
Statistics ($ in millions) Net Income Activity Ratios Leverage Total Current Quick A/R A/P Net Other Debt/ Debt/ Debt/ Interest Guideline Company Assets ROA ROE Ratio Ratio Days Days W/C LT Liab/EV EBITDA MVE1 EV Coverage2 AmSurg Corp. $2,184.1 3.3%
9.5% 2.5 1.8 35.0 16.6 $98.9 8.6% 1.6x 42.3% 23.8% 12.6x # First Choice Healthcare Solutions, Inc. 11.8 -22.0% 463.4% 0.9 0.7 59.5 61.2 1.5 0.2% 130.0x 43.0% 30.3% 0.0x # Foundation Healthcare, Inc. 53.8 -17.9% 28.7% 0.6 0.4 25.5 36.5
(4.0) 18.5% 7.2x 42.9% 27.9% 1.4x # IPC The Hospitalist Company, Inc. 562.5 7.5% 12.0% 1.9 1.6 60.7 7.1 54.4 6.8% 1.3x 10.9% 10.1% 91.0x Northstar Healthcare Inc. 24.6 -17.6% -15.4% 2.1 1.9 46.2 48.8 3.4 0.0% 0.5x 7.6% 7.0% NMF NM Providence
Service Corp. 434.7 5.3% 16.6% 1.3 1.1 31.1 1.8 (11.3) 3.5% 2.2x 20.0% 19.3% 8.1x # SunLink Health Systems Inc. 66.6 -0.5% -1.5% 1.2 0.7 45.4 23.2 9.5 9.5% 4.1x 161.1% 71.2% 3.6x # Surgical Care Affiliates, Inc. 1,424.5 -2.4% -10.0% 1.3 0.9
38.3 19.3 (12.1) 6.9% 5.1x 58.5% 34.2% 2.5x # Team Health Holdings, Inc. 1,390.4 9.1% 53.4% 1.2 1.1 58.0 4.4 65.3 5.0% 2.0x 13.9% 12.4% 17.1x # USMD Holdings, Inc. 278.6 -0.7% -1.2% 1.2 0.9 35.8 5.0 8.1 19.2% 9.6x 37.0% 28.3% 2.0x # Low $11.8
-22.0% -15.4% 0.6 0.4 25.5 1.8 ($12.1) 0.0% 0.5x 7.6% 7.0% 0.0x High $2,184.1 9.1% 53.4% 2.5 1.9 60.7 61.2 $98.9 19.2% 130.0x 58.5% 34.2% 17.1x Median $356.6 -0.6% 9.5% 1.3 1.0 41.8 18.0 $5.7 6.8% 3.1x 37.0% 23.8% 3.0x Mean $643.2 -3.6% 10.2% 1.4
1.1 43.6 22.4 $21.4 7.8% 16.4x 30.7% 21.5% 5.9x First Physicians Capital Group $42.3 10.2% 161.1% 3.1 3.0 256.9 29.6 $12.3 31.0% 1.0x 18.2% 16.1% 12.0x *Excluded from high, low, mean and median data. EV refers to enterprise value; MVE refers to
market value of equity EBITDA refers to earnings before interest, taxes, depreciation and amortization ROA refers to return on assets; ROE refers to return on equity A/R refers to accounts receivable; A/P refers to accounts payable; W/C refers to
working capital; LT Liab refers to long term liabilities 1. Represents Total Interest-Bearing Debt to Market Value of Equity 2. Represents EBITDA to Interest Expense Source: Capital IQ. Cabrillo Advisors | 29
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Company Market Analysis (figures in
millions, except per share values) AmSurg Corp. First Choice Healthcare Solutions Foundation Healthcare, Inc. IPC The Hospitalist Company, Inc. Northstar Healthcare Inc. Providence Service Corp. SunLink Health Systems Inc. Surgical Care Affiliates,
Inc. Team Health Holdings, Inc. USMD Holdings, Inc. General Market Information Ticker Symbol AMSG FCHS FDNH IPCM NHC PRSC SSY SCAI TMH USMD Exchange NasdaqGS OTCPK OTCPK OTCPK TSX NasdaqGS AMEX NasdaqGS NYSE NasdaqCM Fiscal Year End 12/31/13
12/31/13 12/31/13 12/31/13 12/31/13 12/31/13 6/30/13 12/31/13 12/31/13 12/31/13 Latest Financial Information 3/31/14 3/31/14 3/31/14 3/31/14 3/31/14 3/31/14 3/31/14 3/31/14 3/31/14 3/31/14 Closing Price: May 27, 2014 $42.96 $1.74 $0.31 $44.23
$1.05 $39.97 $1.16 $29.04 $49.71 $11.93 20-Day Average Stock Price $41.65 $2.25 $0.38 $42.82 $1.04 $39.50 $1.35 $28.00 $48.42 $11.89 52-Week Price Range High $49.84 $3.70 $0.75 $63.70 $1.64 $43.35 $2.94 $37.69 $50.33 $43.99 Low $34.12 $0.40 $0.07
$39.66 $0.28 $23.91 $0.62 $25.50 $36.41 $11.52 52-Week Return 19.5% 83.2% NA -7.3% 262.1% 62.6% 45.0% 45.0% 28.9% -10.9% Market Valuation Information Diluted Shares Outstanding 32.183 17.081 171.248 17.645 43.411 15.418 9.443 39.927 71.831 10.146
Closing Price: May 27, 2014 $42.96 $1.74 $0.31 $44.23 $1.05 $39.97 $1.16 $29.04 $49.71 $11.93 Market Value of Equity (MVE) $1,382.6 $29.7 $53.1 $780.4 $45.6 $616.3 $11.0 $1,159.5 $3,570.7 $121.0 plus: Total Debt (book) 585.2 12.8 22.8 85.0 3.5
123.5 17.7 678.1 497.5 44.8 less: Converted Debt 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 plus: Preferred Stock Redemption 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 less: Converted Preferred 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 less: Cash &
Cash Equivalents 47.1 0.3 4.0 23.3 5.9 105.8 3.8 90.4 56.6 10.2 plus: Minority Interest Subsidiaries 540.9 0.0 9.8 0.0 6.2 7.0 0.0 234.0 1.6 3.0 Enterprise Value $2,461.6 $42.2 $81.7 $842.2 $49.3 $640.9 $24.8 $1,981.2 $4,013.2 $158.6 Source: Capital
IQ. Cabrillo Advisors | 30
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Guideline Public Company Cash and Working
Capital Analysis ($ in millions) Latest Twelve Months Cash & Net Cash to W/C to Net W/C to Cash to 1-month Guideline Company Equivalents W/C W/C 1 Revenues Revenues Revenue Revenue1 Op. Expenses 2 AmSurg Corp. $47.1 $125.7 $98.9 $1,084.3
4.3% 11.6% 9.1% 218.9% 218.9% First Choice Healthcare Solutions, Inc. 0.3 (0.4) 1.5 7.4 4.2% -6.0% 20.8% 47.4% 47.4% Foundation Healthcare, Inc. 4.0 (16.8) (4.0) 90.6 4.4% -18.5% -4.4% 119.8% 119.8% IPC The Hospitalist Company, Inc. 23.3
77.7 54.4 629.2 3.7% 12.3% 8.6% 260.3% 260.3% Northstar Healthcare Inc. 5.9 7.6 3.4 39.1 15.2% 19.4% 8.7% 322.2% 322.2% Providence Service Corp. 105.8 45.5 (11.3) 1,130.6 9.4% 4.0% -1.0% 2037.7% SunLink Health Systems Inc. 3.8 4.1 9.5 105.5
3.6% 3.9% 9.0% 336.5% 336.5% Surgical Care Affiliates, Inc. 1,981.2 54.9 (12.1) 790.8 250.5% 6.9% -1.5% 174386.5% Team Health Holdings, Inc. 65.3 102.2 65.3 2,449.3 2.7% 4.2% 2.7% 5744.2% USMD Holdings, Inc. 10.2 8.2 8.1 245.8 4.2% 3.3% 3.3%
243.9% 243.9% Median 4.2% 4.1% 6.0% 243.9% Mean 5.7% 4.1% 5.5% 221.3% First Physicians Capital Group $4.1 $13.4 $12.3 $20.6 20.0% 65.0% 60.0% 386.1% *Excluded from high, low, mean and median data. 1. Net Working Capital equals current assets less
cash less current liabilities less current debt 2. One Month Operating Expense equals LTM operating expenses divided by 12. W/C refers to Working Capita Source: Capital IQ. Cabrillo Advisors | 31
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Control Premium Q4 2012 Q1 2013 Q2 2013 Q3 2013
Latest Twelve Months Domestic Only 10/1/2012 ####### 1/1/2013 3/31/2013 4/1/2013 6/30/2013 7/1/2013 9/30/2013 # of Transactions 63 43 44 45 195 Range -7.2%189.5% 0.1%139.1% -8.5%194.1% -27.4%1020.6% -27.4%1020.6% Median
42.5% 35.1% 32.5% 32.7% NA Mean 47.4% 42.7% 40.0% 69.6% 49.9% All # of Transactions 157 110 103 108 478 Range -86.6%700.0% -91.3%343.6% -44.6%238.8% -72.0%1020.6% -91.3%1020.6% Median 37.1% 34.7% 30.4% 33.1% 33.3% Mean
50.4% 43.2% 42.3% 56.1% 48.0% 12-Month Summary (All) # of Transactions 518 498 492 478 478 Range -99.9%1775.1% -91.3%1775.1% -91.3%700.0% -91.3%1020.6% -91.3%1020.6% Median 37.1% 34.2% 34.0% 33.3% 33.3% Mean 55.8% 49.1%
45.7% 48.0% 48.0% Comparable Industries1 Date Sun Healthcare Group, Inc. 12/3/2012 43.1% Metropolitan Health Networks, Inc. 12/21/2012 3.7% Sunrise Senior Living, Inc. 1/9/2013 62.4%
Assisted Living Concepts, Inc. 7/11/2013 24.5% # of Transactions 2 1 0 1 4 Range 3.7%43.1% 62.4%62.4% NA 24.5%24.5% 3.7%62.4% Median 23.4% 62.4% NA 24.5% 33.8% Mean 23.4% 62.4% NA 24.5% 33.4% Concluded
Control Premium 25.0% Note: Control Premium Study median/mean figures exclude negative premiums. 1. SIC 8049 (Offices of Health Practicitioners) and 8051 (Skilled Nursing Care Facilities). Source: Mergerstat Control Premium Study Cabrillo Advisors |
32
Equity Allocation Analysis First Physicians Capital Group
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Equity Allocation Summary (figures in millions,
except per unit values) Low High Security Type Aggregate Per Share Per CSE Aggregate Per Share Per CSE Series 1-A $0.437 $6.47 $0.67 $0.499 $7.39 $0.76 Series 2-A 0.103 $26.43 $0.61 0.120 $30.72 $0.71 Series 5-A 12.363 $1,940.85 $0.61 14.447
$2,268.02 $0.71 Series 6-A 4.842 $1,940.85 $0.61 5.659 $2,268.02 $0.71 Series 7-A 11.641 $1,940.85 $0.61 13.604 $2,268.02 $0.71 Common Stock 9.409 $0.54 $0.54 11.244 $0.64 $0.64 Warrants 5.357 $0.41 $0.41 6.568 $0.50 $0.50 Options 0.047 $0.31 $0.31
0.059 $0.39 $0.39 Total Equity Value 1 $44.200 $51.200 Results Summary Value of Common Stock (Marketable Minority Interest) (rounded) $9.400 $0.54 $11.200 $0.64 CSE refers to Common Stock Equivalents Note: See Valuation of Securities for details.
Valuation of Securities is based on the midpoint Equity Value rather than the low or high Equity Value. Note: Valuation of Securities is based on the midpoint Equity Value rather than the low or high Equity Value. 1. Equal to the low and high range
of Equity Value of $40.0 million to $48.0 million, including approximately $4.2 million in proceeds from the exercise of outstanding 1. warrants ($0.31/share) and options ($0.63/share), which are assumed converted for purposes of our analysis. See
Preferred Stock Summary for details. 2. See Discount for Lack of Marketability for details. Cabrillo Advisors | 34
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Valuation of Securities (Low Indication) ($ in
millions, except per unit figures) Allocation of Value (by Percent) Series 1-A Series 2-A Series 5-A Series 6-A Series 7-A Common Stock Add: Series 2-A Converting Add: Series 1-A Converting Add: 5-7 Convert + Warrants Add: Options Shares $0.000
$0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 Security Outstanding CSE $0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 & Greater Series 1-A 0.068 0.654 100.00% 0.00% 0.00% 0.00% 0.00% 3.57% 0.83% 0.83% Series 2-A 0.004 0.169
0.00% 100.00% 0.00% 0.00% 0.95% 0.92% 0.21% 0.21% Series 5-A 0.006 20.384 0.00% 0.00% 42.86% 0.00% 0.00% 0.00% 25.80% 25.75% Series 6-A 0.002 7.984 0.00% 0.00% 16.79% 0.00% 0.00% 0.00% 10.11% 10.09% Series 7-A 0.006 19.194 0.00% 0.00% 40.36% 0.00%
0.00% 0.00% 24.30% 24.25% Common Stock 17.527 17.527 0.00% 0.00% 0.00% 100.00% 99.05% 95.51% 22.19% 22.14% Warrants 13.089 13.089 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.57% 16.54% Options 0.150 0.150 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.19%
Total Units 79.151 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% Concluded Values Allocation of Value (by Value) Per Per Total $0.000 $0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 Security Share CSE Value $0.169 $0.194
$15.057 $17.650 $19.603 $20.598 $49.770 & Greater Series 1-A $6.47 $0.67 $0.437 $0.156 $0.000 $0.000 $0.000 $0.000 $0.013 $0.064 $0.203 Series 2-A $26.43 $0.61 0.103 0.000 0.023 0.000 0.000 0.007 0.003 0.017 0.053 Series 5-A $1,940.85 $0.61
12.363 0.000 0.000 4.020 0.000 0.000 0.000 2.004 6.340 Series 6-A $1,940.85 $0.61 4.842 0.000 0.000 1.575 0.000 0.000 0.000 0.785 2.483 Series 7-A $1,940.85 $0.61 11.641 0.000 0.000 3.785 0.000 0.000 0.000 1.887 5.969 Common Stock $0.54 $0.54 9.409
0.000 0.000 0.000 1.108 0.767 0.360 1.723 5.451 Warrants $0.41 $0.41 5.357 0.000 0.000 0.000 0.000 0.000 0.000 1.286 4.071 Options $0.31 $0.31 0.047 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.047 Total Value $44.200 $0.156 $0.023 $9.380 $1.108
$0.774 $0.377 $7.765 $24.616 Black-Scholes Option Value Exercise Price of Option $0.000 $0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 Value of Equity (rounded) 1 $44.200 $44.200 $44.200 $44.200 $44.200 $44.200 $44.200 $44.200 Volatility 2
70.0% 70.0% 70.0% 70.0% 70.0% 70.0% 70.0% 70.0% Time to Liquidity 3 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Risk-Free Rate 4 1.56% 1.56% 1.56% 1.56% 1.56% 1.56% 1.56% 1.56% Black-Scholes Option Value $44.200 $44.044 $44.021 $34.641 $33.533 $32.758
$32.381 $24.616 Differential in Black-Scholes Option Value $0.156 $0.023 $9.380 $1.108 $0.774 $0.377 $7.765 $24.616 CSE refers to Common Stock Equivalents 1. Equal to the low indication of the range of Equity Value of $40.0 million plus
approximately $4.2 million in proceeds from the exercise of outstanding warrants ($0.31/share) 1. and options ($0.63/share), which are assumed converted for purposes of our analysis. See Preferred Stock Summary for details 2. See Selected Volatility
for details. 3. Based on discussions with Management. 4. Based on the 5-year U.S. Treasury Note yield as of May 27, 2014. Cabrillo Advisors | 35
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Valuation of Securities (High Indication) ($ in
millions, except per unit figures) Allocation of Value (by Percent) Series 1-A Series 2-A Series 5-A Series 6-A Series 7-A Common Stock Add: Series 2-A Converting Add: Series 1-A Converting Add: 5-7 Convert + Warrants Add: Options Shares $0.000
$0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 Security Outstanding CSE $0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 & Greater Series 1-A 0.068 0.654 100.00% 0.00% 0.00% 0.00% 0.00% 3.57% 0.83% 0.83% Series 2-A 0.004 0.169
0.00% 100.00% 0.00% 0.00% 0.95% 0.92% 0.21% 0.21% Series 5-A 0.006 20.384 0.00% 0.00% 42.86% 0.00% 0.00% 0.00% 25.80% 25.75% Series 6-A 0.002 7.984 0.00% 0.00% 16.79% 0.00% 0.00% 0.00% 10.11% 10.09% Series 7-A 0.006 19.194 0.00% 0.00% 40.36% 0.00%
0.00% 0.00% 24.30% 24.25% Common Stock 17.527 17.527 0.00% 0.00% 0.00% 100.00% 99.05% 95.51% 22.19% 22.14% Warrants 13.089 13.089 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.57% 16.54% Options 0.150 0.150 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.19%
Total Units 79.151 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% Concluded Values Allocation of Value (by Value) Per Per Total $0.000 $0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 Security Share CSE Value $0.169 $0.194
$15.057 $17.650 $19.603 $20.598 $49.770 & Greater Series 1-A $7.39 $0.76 $0.499 $0.156 $0.000 $0.000 $0.000 $0.000 $0.015 $0.073 $0.256 Series 2-A $30.72 $0.71 0.120 0.000 0.023 0.000 0.000 0.008 0.004 0.019 0.066 Series 5-A $2,268.02 $0.71
14.447 0.000 0.000 4.218 0.000 0.000 0.000 2.260 7.969 Series 6-A $2,268.02 $0.71 5.659 0.000 0.000 1.652 0.000 0.000 0.000 0.885 3.121 Series 7-A $2,268.02 $0.71 13.604 0.000 0.000 3.972 0.000 0.000 0.000 2.128 7.504 Common Stock $0.64 $0.64 11.244
0.000 0.000 0.000 1.210 0.842 0.397 1.943 6.852 Warrants $0.50 $0.50 6.568 0.000 0.000 0.000 0.000 0.000 0.000 1.451 5.117 Options $0.39 $0.39 0.059 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.059 Total Value $52.200 $0.156 $0.023 $9.842 $1.210
$0.850 $0.415 $8.758 $30.945 Black-Scholes Option Value Exercise Price of Option $0.000 $0.169 $0.194 $15.057 $17.650 $19.603 $20.598 $49.770 Value of Equity (rounded) 1 $52.200 $52.200 $52.200 $52.200 $52.200 $52.200 $52.200 $52.200 Volatility 2
70.0% 70.0% 70.0% 70.0% 70.0% 70.0% 70.0% 70.0% Time to Liquidity 3 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Risk-Free Rate 4 1.56% 1.56% 1.56% 1.56% 1.56% 1.56% 1.56% 1.56% Black-Scholes Option Value $52.200 $52.044 $52.021 $42.179 $40.969 $40.119
$39.703 $30.945 Differential in Black-Scholes Option Value $0.156 $0.023 $9.842 $1.210 $0.850 $0.415 $8.758 $30.945 CSE refers to Common Stock Equivalents 1. Equal to the high indication of the range of Equity Value of $48.0 million plus
approximately $4.2 million in proceeds from the exercise of outstanding warrants ($0.31/share) 1. and options ($0.63/share), which are assumed converted for purposes of our analysis. See Preferred Stock Summary for details 2. See Selected Volatility
for details. 3. Based on discussions with Management. 4. Based on the 5-year U.S. Treasury Note yield as of May 27, 2014. Cabrillo Advisors | 36
First Physicians Capital Group Valuation Analysis as of May 27, 2014 Preferred Stock Summary Shares Liquidation
Preference Conversion Dividends (if declared) Initial Outstanding Per Share Total Rate 1 Shares Per Share Cumulative? Non-Redeemable Preferred Stock Series 1-A Convertible Preferred Stock 67,600 67,600 $2.50 $169,000 9.679:1 654,292 $0.20 No Series
2-A Convertible Preferred Stock 3,900 3,900 $6.41 $25,000 43.322:1 168,954 8.0% No Redeemable Preferred Stock 2 Series 5-A Convertible Preferred Stock 9,000 6,370 $1,000.00 $6,370,000 3,200:1 20,384,000 $40.00 No Series 6-A Convertible Preferred
Stock 4,875 2,495 $1,000.00 $2,495,000 3,200:1 7,984,000 $40.00 No Series 7-A Convertible Preferred Stock 2 from Series 5-A (2011 Bridge Lenders) 2,630 2,630 from Series 6-A (2011 Bridge Lenders) 2,380 2,380
from Common Stock 988 988 Total Series 7-A 5,998 5,998 $1,000.00 $5,998,000 3,200:1 19,193,600 $100.00 No Total 86,363 $15,057,000 48,384,846 Common Stock and Common
Stock Equivalents Common Stock 1 Shares Conversion/ Exercise CSE Proceeds Basic Shares Outstanding (less treasury) 23,909,507 Less: Carol Schuster Retired Shares 3 (4,250,000) Less: Common Stock Exchanged for Series 7-A 1 (2,132,285) Basic
Shares Outstanding (adjusted) 17,527,222 1:1 17,527,222 Preferred Stock Series 1-A Convertible Preferred Stock 67,600 9.679:1 654,292 Series 2-A Convertible Preferred Stock 3,900 43.322:1 168,954 Series 5-A Convertible Preferred Stock 6,370 3,200:1
20,384,000 Series 6-A Convertible Preferred Stock 2,495 3,200:1 7,984,000 Series 7-A Convertible Preferred Stock 5,998 3,200:1 19,193,600 Total Preferred Stock 86,363 48,384,846 $0 Warrants 2011 Bridge Financing 2,278,079 $0.3125 2,278,079 $711,900
2012 Bridge Financing 4,092,800 $0.3125 4,092,800 1,279,000 Series 7-A Preferred Stock 6,717,760 $0.3125 6,717,760 2,099,300 Total Warrants 13,088,639 13,088,639 $4,090,200 Options 2011 Bridge Financing 150,000 $0.630 150,000 $94,500 Total Diluted
Common Share Equivalents 79,150,707 $4,184,700 CSECommon Share Equivalents 1. Per Management. 2. The Company is in the process of issuing Series 7-A Preferred Stock. Such final issuance is expected to occur subsequent to the Valuation Date.
For purposes of this analysis, we have assumed 2. the Series 7-A issuance, which includes the conversion of certain Series 5-A, 6-A and common shareholders into Series 7-A, will have occurred as of the Valuation Date. As a result, 2. the figures
shown for Series 5-A, 6-A, 7-A and basic shares outstanding are adjusted to reflect the Series 7-A issuance/conversion. 3. In August 2011, the holder of a $1.5 million note payable and 4.25 million of the Companys outstanding common
stock, filed a lawsuit for performance and repayment of the loan. 3. In December 2011, in full settlement of the lawsuit and satisfaction of the $1.5 million note payable, the lender accepted assignment and receipt of the $2.15 million notes
receivable. 3. As of the Valuation Date, the Company has received, but is unable to find the transferred stock certificates, and as a result, the stock certificates have not been cancelled with the transfer agent. Source: Per file titled
Adjusted Cap Table 4.10.2014 Post 7A.xlsx and 7A Exchange CALC SK.xlsx as provided by Management. Cabrillo Advisors | 37
First
Physicians Capital Group Valuation Analysis as of May 27, 2014 Selected Volatility ($ in millions) Guideline Company Ticker 13 26 52 104 260 AmSurg Corp. NasdaqGS:AMSG $1,382.6 28.0% 24.9% 20.4% 21.8% 25.2% First Choice Healthcare Solutions,
Inc. OTCPK:FCHS $29.7 122.9% 114.5% 124.1% 114.3% NA Foundation Healthcare, Inc. OTCPK:FDNH $53.1 169.1% 207.9% 194.5% 174.2% 131.2% IPC The Hospitalist Company, Inc. NasdaqGS:IPCM $780.4 33.6% 28.6% 26.1% 30.9% 39.0% Northstar Healthcare Inc.
TSX:NHC $45.6 49.8% 66.2% 91.0% 125.2% 113.1% Providence Service Corp. NasdaqGS:PRSC $616.3 73.0% 56.3% 48.6% 50.9% 47.6% SunLink Health Systems Inc. AMEX:SSY $11.0 113.6% 111.6% 73.7% 78.3% 76.7% Surgical Care Affiliates, Inc. NasdaqGS:SCAI
$1,159.5 25.5% NA N NA N NA N NA Team Health Holdings, Inc. NYSE:TMH $3,570.7 27.1% 25.0% 24.7% 22.7% NA USMD Holdings, Inc. NasdaqCM:USMD $121.0 33.1% 42.2% 72.6% NA N NA Equity Value Below $100.0 million Median 118.2% 113.1% 107.6% 119.8% 113.1%
Mean 113.8% 125.1% 120.8% 123.0% 107.0% All Guideline Companies Median 41.7% 56.3% 72.6% 64.6% 62.2% Mean 67.6% 75.3% 75.1% 77.3% 72.1% First Physicians Capital Group OTCPK:FPCG $12.9 866.6% 992.2% 433.8% 419.0% 365.7% Selected Volatility 70.0% NA
refers to not available. Source: Capital IQ. Equity Value Volatility (weeks) Cabrillo Advisors | 38
PRELIMINARY COPY
|
|
|
FIRST PHYSICIANS CAPITAL GROUP, INC.
433 North Camden Drive # 810
Beverly Hills,
California 90210
|
|
VOTE BY MAIL
Mark, sign and date your
proxy card and return it in the postage-paid envelope.
|
|
|
VOTE BY INTERNET www.edocumentview.com/FPCG
Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off
date or meeting date. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form.
|
|
|
VOTE BY PHONE 1-800-VOTE (8683)
Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your
proxy card in hand when you call and then following the instructions.
|
|
|
|
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
|
|
KEEP THIS PORTION FOR YOUR RECORDS
|
DETACH AND RETURN THIS PORTION ONLY
|
|
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Board of Directors recommends you vote
FOR proposals 1, 2, 4 and 5 and EVERY
THREE YEARS for
proposal 3:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
1. Approve the Amendment to the Certificate of Incorporation to authorize a 1-for-2,000 reverse stock split of the common stock, as
further described in the accompanying proxy statement.
|
|
|
|
|
|
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|
2. Election of Directors.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
FOR all nominees listed below (except as marked to the contrary)
|
|
|
|
|
|
|
|
|
|
|
¨
WITHHOLD AUTHORITY to vote for all nominees listed below
|
|
|
|
|
|
|
|
|
|
|
¨
ABSTAIN
|
|
|
|
|
|
|
|
|
|
|
|
|
Election of the following nominees as directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01 William A.
Houlihan 02 Sean
Kirrane 03 Brian Potiker
04 Robert N. Schwartz, Ph.D. 05
Richardson E. Sells
|
|
|
|
|
|
|
|
|
|
|
(Instructions: To withhold authority to vote for any nominee, strike out the name of such nominee.)
|
|
|
|
|
|
|
|
|
|
|
3. Approve the frequency of executive compensation votes by non-binding vote.
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
EVERY YEAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
EVERY OTHER YEAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
EVERY THREE YEARS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
ABSTAIN
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
|
|
|
|
|
|
4. Approve executive compensation by non-binding vote.
|
|
|
|
|
|
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
|
|
|
5. Ratify the selection of Whitley Penn LLP as the Companys independent registered public accounting firm for the fiscal year ending September 30, 2014.
|
|
|
|
|
|
|
|
¨
|
|
¨
|
|
¨
|
|
|
|
|
THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED BY THE STOCKHOLDER.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For address change/comments, mark here (see reverse for instructions)
|
|
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Please sign your name exactly as it appears hereon. Executors, administrators, guardians, officers of corporations and others signing in a fiduciary capacity should state their full titles as such.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Signature of Stockholder)
|
|
Date
|
|
|
|
(Signature of Joint Owner)
|
|
Date
|
|
|
|
FIRST PHYSICIANS CAPITAL GROUP, INC.
Annual Meeting of Stockholders
, 2014 9:00 a.m.,
Central Standard Time
This proxy is solicited by the Board of Directors
|
The undersigned hereby appoints Sean Kirrane and Adrian Reeder, with power to act without the other and with power of substitution, as proxies
and attorneys-in-fact and hereby authorizes them to represent and vote, as provided on the other side, all of the shares of
First Physicians Capital Group, Inc.
common stock that the undersigned is entitled to vote and, in their discretion,
to vote upon such other business as may properly come before the annual meeting of stockholders of the Company to be held at 9:00 a.m., Central Standard Time, on
, 2014 or any postponement or adjournment thereof, with all powers that the undersigned would possess if present at the
meeting.
This proxy, when properly executed, will be voted in the manner directed
herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors recommendations.
|
Address
change/comments:
|
|
|
|
|
|
|
|
|
(If you noted any Address Changes and/or Comments above, please mark corresponding box on the reverse side.)
|
Continued and to be signed on reverse side
|
First Physicians Capital (CE) (USOTC:FPCG)
Historical Stock Chart
From Nov 2024 to Dec 2024
First Physicians Capital (CE) (USOTC:FPCG)
Historical Stock Chart
From Dec 2023 to Dec 2024